0001213900-24-028218.txt : 20240401 0001213900-24-028218.hdr.sgml : 20240401 20240401074930 ACCESSION NUMBER: 0001213900-24-028218 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41845 FILM NUMBER: 24805588 BUSINESS ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 393-4540 MAIL ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 10-K 1 ea0202511-10k_domin.htm ANNUAL REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark one)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission file number 001-41845

 

DOMINARI HOLDINGS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   52-0849320
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

725 5th Avenue, 22nd Floor

New York, NY 10022

(Address of principal executive offices)

 

(212) 393-4540

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock ($0.0001 par value per share)   DOMH   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

 

The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter ended June 30, 2023: $12,149,343 based upon the closing sale price of our common stock of $2.91 on that date. Common stock held by each officer and director and by each person known to own in excess of 5% of outstanding shares of our common stock has been excluded in that such persons may be deemed to be affiliates. The determination of affiliate status is not necessarily a conclusive determination for other purposes.

 

There were 5,934,917 shares of the registrant’s common stock outstanding as of March 26, 2024.

 

 

 

 

 

 

DOMINARI HOLDINGS INC.

TABLE OF CONTENTS 

 

    Page
Special Cautionary Notice Regarding Forward Looking Statements   ii
Part I    
  Item 1. Business   1
  Item 1A. Risk Factors   6
  Item 1B. Unresolved Staff Comments   19
  Item 1C. Cybersecurity   20
  Item 2. Properties   20
  Item 3. Legal Proceedings   20
  Item 4. Mine Safety Disclosures   20
Part II    
  Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   21
  Item 6. [Reserved]   22
  Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations   22
  Item 7A. Quantitative and Qualitative Disclosures about Market Risk   26
  Item 8. Consolidated Financial Statements and Supplementary Data Index to Financial Statements   F-1
  Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure   27
  Item 9A. Controls and Procedures   27
  Item 9B. Other Information   27
  Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections   27
Part III      
  Item 10. Directors, Executive Officers and Corporate Governance   28
  Item 11. Executive Compensation   32
  Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   40
  Item 13. Certain Relationships and Related Transactions and Director Independence   42
  Item 14. Principal Accountant Fees and Services   43
Part IV    
  Item 15. Exhibits and Consolidated Financial Statement Schedules   44
  Item 16. Form 10-K Summary   46
  Signatures   47

 

i

 

 

EXPLANATORY NOTE

 

All references in this Annual Report on Form 10-K (“Annual Report”) to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation, and its consolidated subsidiaries unless the context requires otherwise.

 

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS AND
RISK FACTOR SUMMARY

 

This Annual Report contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this in this Annual Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

 

You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ are described in greater detail in Item 1A of Part I, “Risk Factors.”

 

ii

 

 

PART I

 

Item 1. BUSINESS

 

Overview

 

Dominari Holdings Inc. (“Dominari”) is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management.  In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as “Company,” “we,” “our” or “us.”

 

Dominari Financial Inc. (“Dominari Financial”), a wholly-owned subsidiary of Dominari Holdings Inc., executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually-registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust (“Fieldpoint”), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities LLC (“Dominari Securities”) and is a wholly-owned subsidiary of Dominari Financial.

 

The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. These biotechnology assets consist of patented technology from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, SARS-CoV-2 and acute lymphoblastic leukemia.  

 

History

 

The Company was founded in 1967 as Spherix Incorporated. In 2017, the Company changed its name to AIkido Pharma Inc. From 2017 to 2022, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. During the second half of 2022, in an effort to enhance stockholder value, the Company shifted its primary focus away from biotechnology to a new line of business in the financial services industry.  In furtherance of this new focus, in June of 2022, the Company formed Dominari Financial Inc., with the purpose of making strategic acquisitions across the financial services industry. On December 22, 2022, the Company changed its name to Dominari Holdings Inc. 

 

On September 9, 2022, we entered into a membership interest purchase agreement (the “FPS Purchase Agreement”) with Fieldpoint, a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”) and dually-registered broker-dealer and investment advisor registered with the Financial Industry Regulatory Authority (“FINRA”) and the Securities and Exchange Commission (“SEC”). Pursuant to the terms of the FPS Purchase Agreement, we purchased from Fieldpoint 100% of the membership interests in FPS (the “Membership Interests”) and, as a result thereof, operate the newly acquired dual registered broker-dealer and investment adviser as a wholly owned subsidiary of Dominari Financial Inc.  The FPS Purchase Agreement provided for Dominari’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022, at which Dominari paid Fieldpoint $2,000,000 in consideration for a transfer by Fieldpoint to Dominari of 20% of the Membership Interests.   Following FINRA’s approval of the Continuing Membership Application pursuant to FINRA Rule 1017 (the “Rule 1017 Application”) on March 20, 2023, the second closing occurred on March 27, 2023, at which time Dominari paid Fieldpoint an additional $1.4 million in consideration for a transfer by Fieldpoint to Dominari of the remaining 80% of the Membership Interests.

 

Dominari Securities

 

Dominari Securities offers, and plans to offer, a broad range of broker-dealer and registered investment adviser services. Those services are discussed below and include wealth management, investment banking, sales and trading, asset management and insurance products.

  

1

 

 

Wealth Management Services

 

Dominari Securities provides a comprehensive array of financial services to high-net-worth individuals and families, corporate executives, and public and private businesses. Clients are able to choose a variety of ways to establish a relationship and conduct business, including by establishing brokerage accounts with transaction-based pricing and/or investment advisory accounts with asset-based fee pricing. Dominari Securities also provides the following private client services:

 

Full-Service Brokerage.  Dominari Securities offers full-service brokerage services covering investment alternatives, including exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts.

 

Wealth Planning. Dominari Securities offers financial and wealth planning services, which include asset management, individual and corporate retirement solutions, insurance and annuity products, IRAs and 401(k) plans, U.S. stock plan services to corporate executives and businesses, education savings programs, and trust and fiduciary services to individual and corporate clients through third-party trust companies.

 

Margin Lending. Dominari Securities, through its clearing partnerships, extends credit to its customers, collateralized by securities and cash in the customer’s account, for a portion of the purchase price, and receives income from interest on such extensions of credit at interest rates derived from Dominari Securities’ posted rate as adjusted, from time to time.

   

Investment Banking

 

Dominari Securities’ investment banking division provides strategic advisory services and capital markets products to emerging growth and middle market businesses. The investment banking groups focus on the consumer and retail, energy, financial institutions, healthcare, rental services, technology, education, and transportation and logistics sectors. Investment banking services include:

 

Financial Advisory. Dominari Securities advises buyers and sellers on sales, divestitures, mergers, acquisitions, tender offers, privatizations, spin-offs, joint ventures, restructurings and liability management.

 

Equities Capital Markets. Dominari Securities provides capital raising solutions for corporate clients through initial public offerings, follow-on offerings, confidentially marketed public offerings, registered directs, private investments in public equity, private placements, at-the-market offerings, and equity-linked offerings.

 

Debt Capital Markets. Dominari Securities plans to offer debt capital markets solutions for emerging growth and middle market companies. Dominari Securities will focus on structuring and distributing public and private debt through financing transactions, including leveraged buyouts, acquisitions, growth capital financings, recapitalizations and Chapter 11 exit financings. Dominari Securities expects to also participate in high yield debt and fixed and floating-rate senior and subordinated debt offerings in the future.

 

Fund Placement. Dominari Securities expects to provide alternative investment firms with a broad and deep portfolio of value-added services. Services may include bespoke strategic and tactical advisory as well as primary fundraises, co-investments and direct transactions.

 

Debt Advisory & Restructuring. Dominari Securities expects to offer creative solutions to leveraged corporate issuers and credit investors. We will evaluate a full range of strategic alternatives, identify the appropriate structure and source of funds to provide our clients the ability to pursue an optimal and value maximizing outcome.

 

2

 

 

Sales and Trading

 

Dominari Securities provides a broad range of sales and trading services to our clients. Sales and trading services include:

 

Institutional Equity Sales and Trading. Dominari Securities acts as an agent in the execution of its customers’ orders through our strategic clearing partners.

 

Equity Derivatives and Index Options. Dominari Securities offers listed equity and index options strategies for investors seeking to manage risk and optimize returns within the equities market.

 

Institutional Fixed Income Sales and Trading. Dominari Securities offers trading in public and private debt (including sovereign debt) securities, including investment and non-investment grade, distressed and convertible corporate securities through our clearing partners.

 

Securities Lending. In connection with both its trading and brokerage activities, Dominari Securities, through its clearing relationships, expects to borrow securities to cover short sales and to complete transactions in which customers have failed to deliver securities by the required settlement date and lend securities to other brokers and dealers for similar purposes. Dominari Securities expects to earn interest on its cash collateral provided and pay interest on the cash collateral received less a rebate earned for lending securities.

 

Asset Management

 

Dominari Securities offers discretionary and non-discretionary fee-based programs to provide tailored investment management solutions and services to high-net-worth private clients, institutions and corporations and/or plans sponsored by them. These include, but are not limited to, portfolio management, manager research and due diligence through third party partners, asset allocation advice and financial planning. Dominari Securities offers portfolio management strategies and third-party investment management capabilities through separately managed accounts, alternative investments and discretionary and non-discretionary portfolio management programs as well as managed portfolios of mutual funds. Platform support functions can include sales and marketing along with administrative services such as trade execution, client services, records management and client reporting and performance monitoring. Dominari Securities generates revenues through the receipt of investment advisory and transactional fees for advisory services and from fees earned through sharing arrangements with registered and private alternative investment vehicles. Dominari Securities also earns investment advisory fees on assets held in discretionary and non-discretionary asset-based programs. These fees are billed monthly in advance and are calculated based on all fee-based assets under management balances at the end of the prior month. Dominari Securities also earns income from revenue-sharing arrangements that are derived from management and incentive fees on alternative investments and calculates these on a pre-determined basis with registered and private investment companies. The Company’s asset management services include:

 

Separately Managed Accounts. Dominari Securities provides clients with fee-based programs: (i) a unified managed account which allows multiple investment managers, mutual funds and exchange-traded funds to be combined in a single custodial account; and (ii) an asset review dual contract program designed for clients seeking a direct contractual relationship with investment managers.

 

Discretionary Advisory Accounts.  Dominari Securities offers client-focused discretionary fee-based investment programs managed by Dominari Securities advisors.

 

Non-Discretionary Advisory Accounts. Dominari Securities provides fee-based non-discretionary investment advisory services and consultation to clients.

 

Alternative Investments. Dominari Securities offers high net worth and institutional investors the opportunity to participate in a wide range of non-traditional investment strategies. Strategies include single manager hedge funds, fund of funds, diversified private equity funds and single investment late stage private equity funds.

 

Private Market Platform. Through a collaborative effort among the Company’s business units, Dominari’s private market platform focuses on sourcing private investments across various sectors. Transactions are expected to cover the full spectrum of private investments, including early stage, late stage, direct, co-investments, funds and secondary market transactions in debt, equity and hybrid securities.

 

3

 

 

Regulation

 

Regulation in the United States

 

The financial services industry in which we operate is subject to extensive regulation. In the U.S., the SEC is the federal agency responsible for the administration of federal securities laws. In addition, the Financial Industry Regulatory Authority, Inc. (“FINRA”) is a self-regulatory organization (“SRO”) that is actively involved in the regulation of securities businesses. In addition to federal regulation, we are subject to state securities regulations in each state and U.S. territory in which we conduct securities or investment advisory activities. The SEC, FINRA, and state securities regulators conduct periodic examinations of broker-dealers and investment advisors. The designated examining authority under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) for Dominari Securities’ activities as a broker-dealer is FINRA. Financial services businesses are also subject to regulation and examination by state securities regulators and attorneys general in those states in which they do business. In addition, broker-dealers and investment advisors must also comply with the rules and regulation of clearing houses, exchanges, and trading platforms of which they are a member.

 

Broker-dealers are subject to SEC, FINRA, and state securities regulations that cover all aspects of the securities business, including sales and trading methods, trade practices among broker-dealers, use and safekeeping of customers’ funds and securities, capital structure and requirements, anti-money laundering efforts, recordkeeping and the conduct of broker-dealer personnel including officers and employees (although state securities regulations are, in a number of cases, more limited). Registered investment advisors are subject to, among other requirements, SEC regulations concerning marketing, transactions with affiliates, custody of client assets, disclosures to clients, conflict of interest, insider trading and recordkeeping. Additional legislation, changes in rules promulgated by the SEC, FINRA, and other SROs of which the broker-dealer is a member, and state securities regulators, or changes in the interpretation or enforcement of existing laws or rules may directly affect the operations and profitability of broker-dealers and investment advisors. The SEC, FINRA, and state securities regulators and state attorneys general may conduct administrative proceedings or initiate civil litigation that can result in adverse consequences for Dominari Securities, its affiliates, including affiliated investment advisors, as well as its and their officers and employees (including, without limitation, injunctions, censures, fines, suspensions, directives that impact business operations (including proposed expansions), membership expulsions, or revocations of licenses and registrations).

 

SEC Regulation Best Interest (“Reg BI”) requires that a broker-dealer and its associated persons act in a retail customer’s best interest and not place their own financial or other interests ahead of a retail customer’s interests when recommending securities transactions or investment strategies, including recommendations of types of accounts. To meet this best interest standard, a broker-dealer must satisfy four component obligations including a disclosure obligation, a care obligation, a conflict of interest obligation, and a compliance obligation and both broker-dealers and investment advisors are required to provide disclosures about their standard of conduct and conflicts of interest.

 

In addition, certain states, have proposed or adopted measures that would make broker-dealers, sales agents and investment advisors and their representatives subject to a fiduciary duty when providing products and services to customers. The SEC did not indicate an intent to pre-empt state regulation in this area, and some of the state proposals would allow for a private right of action. In the event our wealth management division makes recommendations to retail customers, it will be required to comply with the obligations imposed under Reg BI and applicable state laws.

 

Regulatory Capital Requirements 

 

Dominari Securities is subject to financial capital requirements that are set by regulation. Dominari Securities is a registered broker-dealer and is required to maintain net capital in an amount equal to SEC minimum financial requirements. As a broker-dealer, Dominari Securities is subject to the SEC’s Uniform Net Capital Rule 15c3-1 (the “Net Capital Rule”). Compliance with the Net Capital Rule could limit Dominari Securities’ operations, such as underwriting and trading activities and financing customers’ prime brokerage or other margin activities, in each case, that could require the use of significant amounts of capital, limit its ability to engage in certain financing transactions, such as repurchase agreements, and may also restrict its ability (i) to make payments of dividends, withdrawals or similar distributions or payments to a stockholder/parent or other affiliate, (ii) to make a redemption or repurchase of shares of stock, or (iii) to make an unsecured loan or advance to such stockholders or affiliates.

 

4

 

 

Under the Exchange Act, state securities regulators are not permitted to impose capital, margin, custody, financial responsibility, making and keeping records, bonding, or financial or operational reporting requirements on registered broker-dealers that differ from, or are in addition to, the requirements in those areas established under the Exchange Act, including the rules and regulations promulgated thereunder.

 

Regulation outside the United States

 

In the event Dominari Securities provides financial services internationally, it will be subject to extensive regulations proposed, promulgated and enforced by, among other regulatory bodies, the European Commission and European Supervisory Authorities (including the European Banking Authority and European Securities and Market Authority), U.K. Financial Conduct Authority, German Federal Financial Supervisory Authority (“BaFin”), Investment Industry Regulatory Organization of Canada, Hong Kong Securities and Futures Commission, the Japan Financial Services Agency, the Monetary Authority of Singapore, and the Australian Securities and Investments Commission. Every country in which we may do business will impose upon us laws, rules and regulations similar to those in the U.S., including with respect to some form of capital adequacy rules, customer protection rules, data protection regulations, anti-money laundering and anti-bribery rules, compliance with other applicable trading and investment banking regulations and similar regulatory reform.

 

Competition

 

All aspects of our business are, and are expected to be, intensely competitive. We compete primarily with small to mid-size bank holding companies that engage in wealth management, investment banking and capital markets activities as one of their lines of business and that have greater capital and resources than we do. We will also compete against other broker-dealers, asset managers and boutique firms. We believe the principal factors that will drive our competitiveness in the future will include our ability to: provide differentiated insights to our clients that lead to better business outcomes; attract, retain and develop skilled professionals; deliver a competitive breadth of high-quality service offerings; and to maintain a flat, nimble and entrepreneurial culture built on immediacy and client service.

 

Employees

 

As of December 31, 2023, we had 26 full-time employees and 2 part-time employees, none of which are represented by a labor union or covered by a collective bargaining agreement. The Company offers health insurance benefits to eligible employees. Additional benefits offered by the Company depend on the employee position and title, but may include a 401(k) retirement plan, short-term disability, Workers’ Compensation for qualifying illness or injury, sick leave and paid vacation. The Company also provides certain training for employees, such as New York State Harassment Prevention Training, Cyber Security Awareness Training and some continuing education training. 

 

5

 

 

Item 1A. RISK FACTORS

 

The Company’s business and operations are subject to numerous risks. The material risks and uncertainties that management believes affect the Company are described below. The risks and uncertainties described below are not the only ones facing the Company. Additional risks and uncertainties that are presently unknown, management is not aware of or focused on or that management currently deems immaterial may also impair the Company’s business operations. If any of the following risks actually occur, the Company’s financial condition and results of operations may be materially and adversely affected. We may amend or supplement these risk factors from time to time in other reports we file with the SEC.

 

Business Risks

 

Because we have a limited operating history to evaluate our company, the likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by an early-stage financial services company.

 

Since we have a limited operating history in our current financial services business, it will make it difficult for investors and securities analysts to evaluate our business and prospects. You must consider our prospects in light of the risks, expenses, and difficulties we face as an early-stage financial services company with a limited operating history. Investors should evaluate an investment in our securities in light of the uncertainties encountered by early-stage companies in an intensely competitive industry. There can be no assurance that our efforts will be successful or that we will be able to become profitable.

 

Accordingly, you should consider the Company’s prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in their start-up stages, particularly those in the financial services industry. Stockholders should carefully consider the risks and uncertainties that a business with no operating history will face. In particular, stockholders should consider that there is a significant risk that we will not be able to:

 

  implement or execute our current business plan, or that our current business plan is sound;

 

  raise sufficient funds in the capital markets or otherwise to fully effectuate our business plan;

 

  maintain our management team; and/or

 

  attract clients.

 

Any of the foregoing risks may adversely affect the Company and result in the failure of our business. In addition, we expect to encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.

 

We continue to incur operating losses and may not achieve profitability.

 

Our net loss for the year ended December 31, 2023 was $22.9 million. Our accumulated deficit was $208.8 million as of December 31, 2023. Our ability to become profitable depends upon our ability to generate revenue from our financial products and services. We do not know when, or if, we will generate significant revenue from such financial services and products. Even though our revenue may increase, we expect to incur significant additional losses while we grow and expand our business. We cannot predict if and when we will achieve profitability. Our failure to achieve and sustain profitability could negatively impact the market price of our common stock.

 

If we cannot meet our future capital requirements, we may be unable to develop and enhance our services, take advantage of business opportunities and respond to competitive pressures.

 

We may need to raise additional funds in the future to grow our business internally, invest in new businesses, expand through acquisitions, enhance our current services or respond to changes in our target markets. If we raise additional capital through the sale of equity or equity derivative securities, the issuance of these securities could result in dilution to our existing stockholders. If additional funds are raised through the issuance of debt securities, the terms of that debt could impose additional restrictions on our operations or harm our financial condition. Additional financing may be unavailable on acceptable terms.

 

6

 

  

If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.

 

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and to effectively prevent fraud. Any inability to provide reliable financial reports or to prevent fraud could harm our business. The Sarbanes-Oxley Act of 2002 requires management to evaluate and assess the effectiveness of our internal control over financial reporting. In order to continue to comply with the requirements of the Sarbanes-Oxley Act, we are required to continuously evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of our internal controls over financial reporting, we could be subject to litigation or regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. We cannot assure you that in the future we will be able to fully comply with the requirements of the Sarbanes-Oxley Act or that management will conclude that our internal control over financial reporting is effective. If we fail to fully comply with the requirements of the Sarbanes-Oxley Act, our business may be harmed and our stock price may decline.

  

Our assessment, testing and evaluation of the design and operating effectiveness of our internal control over financial reporting resulted in our conclusion that, as of December 31, 2023, our internal control over financial reporting was not effective, due to the design and maintenance of fair value reporting relating to certain notes receivable. We can provide no assurance as to conclusions of management with respect to the effectiveness of our internal control over financial reporting in the future.

 

Developments in market and economic conditions may adversely affect the Company’s business and profitability.

 

Performance in the financial services industry is heavily influenced by the overall strength of economic conditions and financial market activity, which generally have a direct and material impact on the Company’s results of operations and financial condition. These conditions are a product of many factors, which are mostly unpredictable and beyond the Company’s control, and may affect the decisions made by financial market participants.

 

Changes in economic and political conditions, including economic output levels, interest and inflation rates, employment levels, prices of commodities including oil and gas, exogenous market events, consumer confidence levels, and fiscal and monetary policy can affect market conditions. For example, the Federal Reserve’s policies determine, in large part, the cost of funds for lending and investing and the return earned on those loans and investments. Changes in the Federal Reserve’s policies are beyond our control and, consequently, the impact of these changes on our activities and results of our operations are difficult to predict. While global financial markets have shown signs of improvement in recent years, uncertainty remains. A period of sustained downturns and/or volatility in the securities markets, and/or prolonged levels of increasing interest rates, could lead to a return to increased credit market dislocations, reductions in the value of real estate, and other negative market factors which could significantly impair our revenues and profitability.

 

U.S. markets may also be impacted by political and civil unrest occurring in the Middle East, Eastern Europe, Russia, Venezuela and Asia. Continued uncertainties loom over the outcome of the EU’s financial support programs. It is possible that other EU member states may choose to follow Britain’s lead and leave the EU. Any negative impact on economic conditions and global markets from these developments could adversely affect our business, financial condition and liquidity.

 

Uncertain or unfavorable market or economic conditions could result in reduced transaction volumes, reduced revenue and reduced profitability in any or all of the Company’s principal businesses. For example: 

  

  A portion of the Company’s revenues will be derived from fees generated from its asset management business segment. Asset management fees often are primarily comprised of base management and performance (or incentive) fees. Management fees are primarily based on assets under management. Assets under management balances are impacted by net inflow/outflow of client assets and changes in market values. Poor investment performance by the Company’s portfolio managers could result in a loss of managed accounts and could result in reputational damage that might make it more difficult to attract new investors, and, thus further impact the Company’s business and financial condition. If the Company experiences losses of managed accounts, fee revenue will decline. In addition, in periods of declining market values, the values of assets under management may ultimately decline, which would negatively impact fee revenues.

 

7

 

 

  In the past decade, passively managed index funds have seen greater investor interest, and this trend has become more prevalent in recent years. A continued lessening of investor interest in active investing and continued increase in passive investing may lead to a continued decline in the revenue the Company generates from commissions on the execution of trading transactions and, in respect of its market-making activities, a reduction in the value of its trading positions and commissions and spreads.

 

  The Company expects its investment banking revenue, in the form of underwriting, placement and financial advisory fees, to be directly related to the volume and value of transactions as well as the Company’s role in these transactions and will typically only be earned upon the successful completion of a transaction. In an environment of uncertain or unfavorable market or economic conditions, the volume and size of capital-raising transactions and acquisitions and dispositions typically decreases, thereby reducing the demand for the Company’s investment banking services and increasing price competition among financial services companies seeking such engagements.  Accordingly, the Company’s business will be highly dependent on market conditions, the decisions and actions of its clients, and interested third parties. The number of engagements the Company has at any given time will be subject to change and may not necessarily result in future revenues.

   

The Company may make strategic acquisitions of businesses, engage in joint ventures or divest or exit existing businesses, which could result in unforeseen expenses or disruptive effects on its business.

 

From time to time, the Company may consider acquisitions of other businesses or joint ventures with other businesses. Any acquisition or joint venture that the Company determines to pursue will be accompanied by a number of risks. After the announcement or completion of an acquisition or joint venture, the Company’s stock price could decline if investors view the transaction as too costly or unlikely to improve the Company’s competitive position.

 

Costs or difficulties relating to such a transaction, including integration of products, employees, offices, technology systems, accounting systems and management controls, may be difficult to predict accurately and be greater than expected causing the Company’s estimates to differ from actual results. The Company may be unable to retain key personnel after the transaction, and the transaction may impair relationships with customers and business partners. In addition, the Company may be unable to achieve anticipated benefits and synergies from the transaction as fully as expected or within the expected time frame. Divestitures or elimination of existing businesses or products could have similar effects, including the loss of earnings of the divested business or operation. These difficulties could disrupt the Company’s ongoing business, increase its expenses, and adversely affect its operating results and financial condition. As the costs of doing business increase, the Company may not be able to continue to grow its revenues through “organic” growth (the growth attendant to hiring one employee at a time or through expanding into a new business line through a limited investment in technology and employment). In lieu of organic growth, it becomes increasingly necessary to grow through the acquisition of a business or businesses that fulfill the Company’s strategic decisions for growth. However, due to competition or the cost of such acquisitions, such expansion may not be available on a profitable basis and may threaten the Company’s ongoing ability to expand its business.

 

The ability to attract, develop and retain highly skilled and productive employees, particularly qualified financial advisors is critical to the success of the Company’s business.

 

The Company faces intense competition for qualified employees from other businesses in the financial services industry, and the performance of its business may suffer to the extent it is unable to attract and retain employees effectively, particularly given the relatively small size of the Company and its employee base compared to some of its competitors. The primary sources of revenue in each of the Company’s business lines are commissions and fees earned on advisory and underwriting transactions and customer accounts managed by its employees, who are regularly recruited by other firms and in certain cases are able to take their client relationships with them when they change firms. Experienced employees are regularly offered financial inducements by larger competitors to change employers, and thus competitors can de-stabilize the Company’s relationship with valued employees. Some specialized areas of the Company’s business are operated by a relatively small number of employees, the loss of any of whom could jeopardize the continuation of that business following the employee’s departure.

 

8

 

  

Turnover in the financial services industry is high. The cost of retaining skilled professionals in the financial services industry has escalated considerably. Financial industry employers are increasingly offering guaranteed contracts, upfront payments, and increased compensation. These can be important factors in a current employee’s decision to leave us as well as in a prospective employee’s decision to join us. As competition for skilled professionals in the industry remains intense, we may have to devote significant resources to attracting and retaining qualified personnel. To the extent we have compensation targets, we may not be able to retain our employees, which could result in increased recruiting expenses or result in our recruiting additional employees at compensation levels that are not within our target range. In particular, our financial results may be adversely affected by the costs we incur in connection with any upfront loans or other incentives we may offer to newly recruited financial advisors and other key personnel. If we were to lose the services of any of our investment bankers, sales and trading professionals, asset managers, or executive officers to a competitor or otherwise, we may not be able to retain valuable relationships and some of our clients could choose to use the services of a competitor instead of our services. If we are unable to retain our senior professionals or recruit additional professionals, our reputation, business, results of operations and financial condition could be adversely affected. Further, new business initiatives and efforts to expand existing businesses generally require that we incur compensation and benefits expense before generating additional revenues.

 

Moreover, companies in our industry whose employees accept positions with competitors frequently claim that those competitors have engaged in unfair hiring practices. We may be subject to claims in the future as we seek to hire qualified personnel, some of whom may work for our competitors. Some of these claims may result in material litigation.

  

We could incur substantial costs in defending against these claims, regardless of their merits. Such claims could also discourage potential employees who work for our competitors from joining us. Recent actions by some larger competitors to reject the “Recruiting Protocol”, an industry adopted set of practices permitting financial advisors to port their client relationships to a new firm under strict rules, is likely to increase the likelihood of litigation among competitors surrounding the employment of new advisors and their solicitation of their clients and may act as a new barrier to recruitment of financial advisors.

 

If we fail to manage our anticipated growth effectively, our business, financial condition and operating results could be harmed.

 

To manage our growth effectively, we must continue to implement our operational plans and strategies, improve, and expand our infrastructure of people and information systems and expand, train and manage our employee base. To support continued growth, we must effectively integrate, develop and motivate new employees. We face significant competition for personnel. Failure to manage our hiring needs effectively or successfully integrate our new hires may have a material adverse effect on our business, financial condition and operating results. Additionally, the growth of our business places significant demands on our operations, as well as our management and other employees. The growth of our business may require significant additional resources to meet these daily requirements, which may not scale in a cost-effective manner or may negatively affect the quality of our services and client experience. We are also required to manage relationships with a growing number of partners, institutions, clients and other third parties. Our information technology systems and our internal controls and procedures may not be adequate to support future growth of our operations and employee base. If we are unable to manage the growth of our operations effectively, our business, financial condition and operating results may be materially adversely affected.

 

The Company depends on its senior employees and the loss of their services could harm its business.

 

The Company’s success is dependent in large part upon the services of its senior executives and employees. Any loss of services of the chief executive officer and other senior executive officers may adversely affect the business and operations of the Company. If the Company’s senior executives or employees terminate their employment and the Company is unable to find suitable replacements in relatively short periods of time, its operations may be materially and adversely affected.

 

9

 

 

The precautions the Company takes to prevent and detect employee misconduct may not be effective and the Company could be exposed to unknown and unmanaged risks or losses.

 

The Company runs the risk that employee misconduct could occur. Misconduct by employees could include, employees binding the Company to transactions that exceed authorized limits or present unacceptable risks to the Company (rogue trading); employee theft and improper use of Company or client property; employees conspiring with other employees or third parties to defraud the Company; employees hiding unauthorized or unsuccessful activities from the Company, including outside business activities that are undisclosed and may result in liability to the Company; employees steering or soliciting their clients into investments which have not been sponsored by the Company and without the proper diligence; the improper use of confidential information; employee conduct outside of acceptable norms including harassment; or employees engaging in “hacking” or breaching our cybersecurity safeguards.

 

These types of misconduct could result in unknown and unmanaged risks or losses to the Company including regulatory sanctions and serious harm to its reputation. The precautions the Company takes to prevent and detect these activities may not be effective. If employee misconduct does occur, the Company’s business operations could be materially adversely affected.

 

There have been a number of highly-publicized cases involving fraud or other misconduct by employees in the financial services industry and there is a risk that our employees could engage in misconduct in the future that adversely affects our business. We are subject to a number of obligations and standards arising from our asset management business and our authority over the assets managed by our asset management business. In addition, our financial advisors may act in a fiduciary capacity, providing financial planning, investment advice and discretionary asset management. The violation of these obligations and standards by any of our employees could adversely affect our clients and us. It is not always possible to deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in all cases. If our employees engage in misconduct, our business could be materially adversely affected, including our cash position.

 

Employee misconduct, including harassment in the workplace, has come under increasing scrutiny in the national media. While the Company has adopted a Code of Conduct and instituted training for its employees, it is difficult to predict when an employee may deviate from acceptable practices and open the Company to liability either from actions taken by other employees or by authorities. The Company could also become liable for its actions in enforcing its rules of conduct on former employees who disagree with the Company’s actions.

 

Our failure to deal appropriately with conflicts of interest could damage our reputation and adversely affect our business.

 

Appropriately dealing with conflicts of interest is complex and difficult and our reputation could be damaged if we fail, or appear to fail, to deal appropriately with one or more potential or actual conflicts of interest. It is possible that potential or perceived conflicts could give rise to investor dissatisfaction or litigation or regulatory enforcement actions. In addition, regulatory scrutiny of, or litigation in connection with, conflicts of interest would have a material adverse effect on our reputation, which could materially and adversely affect our business in a number of ways, including an inability to raise additional funds, a reluctance of counterparties to do business with us and the costs of defending litigation.

 

Our results of operations may be materially affected by market fluctuations and by global and economic conditions and other factors, including changes in asset values.

 

Our results of operations may be materially affected by market fluctuations due to global financial markets, economic conditions, changes to global trade policies and tariffs and other factors, including the level and volatility of equity, fixed income and commodity prices, the level and term structure of interest rates, inflation and currency values, and the level of other market indices. The results of our Capital Markets business segment, particularly results relating to our involvement in primary and secondary markets for all types of financial products, are subject to substantial market fluctuations due to a variety of factors that we cannot control or predict with great certainty. These fluctuations impact results by causing variations in business flows and activity and in the fair value of securities and other financial products. Fluctuations also occur due to the level of global market activity, which, among other things, affects the size, number and timing of investment banking client assignments and transactions and the realization of returns from our principal investments.

 

10

 

  

During periods of unfavorable market or economic conditions, the level of individual investor participation in the global markets, as well as the level of client assets, may also decrease, which would negatively impact the results of our Private Client and Asset Management business segments. Substantial market fluctuations could also cause variations in the value of our investments in our funds, the flow of investment capital into or from Assets Under Management, and the way customers allocate capital among money market, equity, fixed income or other investment alternatives, which could negatively impact our Private Client and Asset Management business segments.

 

The Company may incur losses and be subject to reputational harm to the extent that, for any reason, it is unable to sell securities it purchased as an underwriter at anticipated price levels. As an underwriter, the Company is subject to heightened standards regarding liability for material misstatements or omissions in prospectuses and other offering documents relating to offerings it underwrites. Any such misstatement or omission could subject the Company to enforcement action by the SEC and claims of investors, either of which could have a material adverse impact on the Company’s results of operations, financial condition and reputation. As a market maker and dealer, the Company may own large positions in specific securities, and these undiversified holdings concentrate the risk of market fluctuations and may result in greater losses than would be the case if the Company’s holdings were more diversified.

 

The value of our financial instruments may be materially affected by market fluctuations. Market volatility, illiquid market conditions and disruptions in the credit markets may make it extremely difficult to value and monetize certain of our financial instruments, particularly during periods of market displacement. Subsequent valuations in future periods, in light of factors then prevailing, may result in significant changes in the values of these instruments and may adversely impact historical or prospective fees and performance-based fees (also known as incentive fees, which include carried interest) in respect of certain businesses. In addition, at the time of any sales and settlements of these financial instruments, the price we ultimately realize will depend on the demand and liquidity in the market at that time and may be materially lower than their current fair value. Any of these factors could cause a decline in the value of our financial instruments, which may have an adverse effect on our results of operations in future periods. In addition, financial markets are susceptible to severe events evidenced by rapid depreciation in asset values accompanied by a reduction in asset liquidity. Under these extreme conditions, hedging and other risk management strategies may not be as effective at mitigating trading losses as they would be under more normal market conditions. Moreover, under these conditions, market participants are particularly exposed to trading strategies employed by many market participants simultaneously and on a large scale. Our risk management and monitoring processes seek to quantify and mitigate risk to more extreme market moves. However, severe market events have historically been difficult to predict and we could realize significant losses if extreme market events were to occur.

 

Holding large and concentrated positions may expose us to losses. Concentration of risk may reduce revenues or result in losses in our market-making, investing, underwriting, including block trading, and lending businesses in the event of unfavorable market movements, or when market conditions are more favorable for our competitors. Changes in interest rates (especially if such changes are rapid), sustained low or high interest rates or uncertainty regarding the future direction of interest rates, may create a less favorable environment for certain of the Company’s businesses, particularly its fixed income business, resulting in reduced business volume and reduced revenue. If interest rates remain at low levels, the Company’s profitability will be negatively impacted.

 

The Company is exposed to the risk that third parties that owe it money, securities or other assets will not perform their obligations.

 

The Company is exposed to credit risk related to third parties such as trading counterparties, customers, clearing agents, exchanges, clearing houses, and other financial intermediaries as well as issuers whose securities we hold. These parties may default on their obligations owed to the Company due to bankruptcy, lack of liquidity, operational failure or other reasons. This default risk may arise, for example, from holding securities of third parties, executing securities trades that fail to settle at the required time due to non-delivery by the counterparty or systems failure by clearing agents, exchanges, clearing houses or other financial intermediaries, and extending credit to clients through bridge or margin loans or other arrangements. Significant failures by third parties to perform their obligations owed to the Company could adversely affect the Company’s revenue and its ability to borrow in the credit markets.

 

11

 

 

Liquidity is essential to our businesses and we rely on external sources to finance a significant portion of our operations.

 

Our liquidity could be negatively affected by our inability to raise funding in the long-term or short-term debt capital markets, our inability to access the secured lending markets, or unanticipated outflows of cash or collateral by customers or clients. Factors that we cannot control, such as disruption of the financial markets or negative views about the financial services industry generally, including concerns regarding fiscal matters in the U.S. and other geographic areas, could impair our ability to raise funding. In addition, our ability to raise funding could be impaired if investors or lenders develop a negative perception of our long-term or short-term financial prospects due to factors such as an incurrence of large trading losses, a downgrade by the rating agencies, a decline in the level of our business activity, if regulatory authorities take significant action against us or our industry, or we discover significant employee misconduct or illegal activity. If we are unable to raise funding using the methods described above, we would likely need to finance or liquidate unencumbered assets, such as our investment portfolios or trading assets, to meet maturing liabilities or other obligations. We may be unable to sell some of our assets or we may have to sell assets at a discount to market value, either of which could adversely affect our results of operations, cash flows and financial condition.

 

From time to time we may invest in securities that are illiquid or subject to restrictions.

 

From time to time we may invest in securities that are subject to restrictions which prohibit us from selling the securities for a period of time. Such agreements may limit our ability to generate liquidity quickly through the disposition of the underlying investment while the agreement is effective. 

 

We are subject to operational risks, including a failure, breach or other disruption of our operations or security systems or those of our third parties (or third parties thereof), as well as human error or malfeasance, which could adversely affect our businesses or reputation.

 

Our businesses are highly dependent on our ability to process and report, on a daily basis, a large number of transactions across numerous markets. We may introduce new products or services or change processes or reporting, including in connection with new regulatory requirements, resulting in new operational risk that we may not fully appreciate or identify. The trend toward direct access to automated, electronic markets and the move to more automated trading platforms has resulted in the use of increasingly complex technology that relies on the continued effectiveness of the programming code and integrity of the data to process the trades. We rely on the ability of our employees, consultants, and internal systems to operate our different businesses and process a high volume of transactions. Additionally, we are subject to complex and evolving laws and regulations governing cybersecurity, privacy and data protection, which may differ and potentially conflict, in various jurisdictions. As a participant in the global capital markets, we face the risk of incorrect valuation or risk management of our trading positions due to flaws in data, models, electronic trading systems or processes or due to fraud or cyber-attack.

 

We also face the risk of operational failure or disruption of any of the clearing agents, exchanges, clearing houses or other financial intermediaries we use to facilitate our lending and securities transactions. In the event of a breakdown or improper operation of our or a direct or indirect third party’s systems (or third parties thereof) or processes or improper or unauthorized action by third parties, including consultants and subcontractors or our employees, we could suffer financial loss, an impairment to our liquidity position, a disruption of our businesses, regulatory sanctions or damage to our reputation. In addition, the interconnectivity of multiple financial institutions with central agents, exchanges and clearing houses, and the increased importance of these entities, increases the risk that an operational failure at one institution or entity may cause an industry-wide operational failure that could materially impact our ability to conduct business. Furthermore, the concentration of Company and personal information held by a handful of third parties increases the risk that a breach at a key third party may cause an industry-wide data breach that could significantly increase the cost and risk of conducting business. There can be no assurance that our business contingency and security response plans fully mitigate all potential risks to us. Our ability to conduct business may be adversely affected by a disruption in the infrastructure that supports our businesses and the communities where we are located. This may include a disruption involving physical site access; cybersecurity incidents; terrorist activities; political unrest; disease pandemics; catastrophic events; climate-related incidents and natural disasters (such as earthquakes, tornadoes, hurricanes and wildfires); electrical outages; environmental hazards; computer servers; communications or other services we use; and our employees or third parties with whom we conduct business. Although we employ backup systems for our data, those backup systems may be unavailable following a disruption, the affected data may not have been backed up or may not be recoverable from the backup, or the backup data may be costly to recover, which could adversely affect our business.

 

12

 

  

Notwithstanding evolving technology and technology-based risk and control systems, our businesses ultimately rely on people, including our employees and those of third parties with which we conduct business. As a result of human error or engagement in violations of applicable policies, laws, rules or procedures, certain errors or violations are not always discovered immediately by our technological processes or by our controls and other procedures, which are intended to prevent and detect such errors or violations. These can include calculation errors, mistakes in addressing emails or other communications, errors in software or model development or implementation, or errors in judgment, as well as intentional efforts to disregard or circumvent applicable policies, laws, rules or procedures. Human errors and malfeasance, even if promptly discovered and remediated, can result in material losses and liabilities for us. Any theft of data, technology or intellectual property may negatively impact our operations and reputation, including disrupting the business activities of our subsidiaries, affiliates, joint ventures or clients conducting business in those jurisdictions.

  

The Company’s information systems may experience an interruption or breach in security.

 

The Company relies heavily on communications and information systems to conduct its business. Any failure, interruption or breach in security of these systems could result in failures or disruptions in the Company’s customer relationship management, regulatory or other reporting, general ledger, and other systems. While the Company has policies and procedures designed to prevent or limit the effect of the failure, interruption or security breach of its information systems, there can be no assurance that any such failures, interruptions or security breaches will not occur or, if they do occur, that they will be adequately addressed. Recent disclosures of such incursions by foreign and domestic unauthorized agents aimed at large financial institutions reflect higher risks for all such institutions. The occurrence of any failures, interruptions or security breaches of the Company’s information systems could damage the Company’s reputation, result in a loss of customer business, subject the Company to additional regulatory scrutiny, or expose the Company to civil litigation and possible financial liability, any of which could have a material adverse effect on the Company’s financial condition and results of operations.

 

Our businesses rely extensively on data processing and communications systems. In addition to better serving clients, the effective use of technology increases efficiency and enables us to reduce costs. Adapting or developing our technology systems to meet new regulatory requirements, client needs, and competitive demands is critical for our business. Introduction of new technology presents challenges on a regular basis. There are significant technical and financial costs and risks in the development of new or enhanced applications, including the risk that we might be unable to effectively use new technologies or adapt our applications to emerging industry standards. Our continued success depends, in part, upon our ability to: (i) successfully maintain and upgrade the capability of our technology systems; (ii) address the needs of our clients by using technology to provide products and services that satisfy their demands; and (iii) retain skilled information technology employees. Failure of our technology systems, which could result from events beyond our control, or an inability to effectively upgrade those systems or implement new technology-driven products or services, could result in financial losses, liability to clients, and violations of applicable privacy and other applicable laws and regulatory sanctions.

 

Cybersecurity and security breaches of our technology systems, or those of our clients or other third-party vendors we rely on, could subject us to significant liability and harm our reputation.

 

Our operational systems and infrastructure must continue to be safeguarded and monitored for potential failures, disruptions, cyber-attacks and breakdowns. Our operations rely on the secure processing, storage and transmission of confidential and other information in our computer systems and networks. Although cybersecurity incidents among financial services firms are on the rise, we have not experienced any material losses relating to cyber-attacks or other information security breaches. However, there can be no assurance that we will not suffer such losses in the future.

 

13

 

  

Despite our implementation of protective measures and endeavoring to modify them as circumstances warrant, our computer systems, software and networks may be vulnerable to human error, natural disasters, power loss, spam attacks, unauthorized access, distributed denial of service attacks, computer viruses and other malicious code and other events that could have an impact on the security and stability of our operations. Notwithstanding the precautions we take, if one or more of these events were to occur, this could jeopardize the information we confidentially maintain, including that of our clients and counterparties, which is processed, stored in and transmitted through our computer systems and networks, or otherwise cause interruptions or malfunctions in our operations or the operations of our clients and counterparties. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures or to make required notifications or disclosures. We may also be subject to litigation and financial losses that are neither insured nor covered under any of our current insurance policies.

 

A technological breakdown could also interfere with our ability to comply with financial reporting and other regulatory requirements, exposing us to potential disciplinary action by regulators. Our regulators have introduced programs to review our protections against such incidents which, if they determined that our systems do not reasonably protect our clients’ assets and their data, could result in enforcement activity and sanctions.

 

In providing services to clients, we may manage, utilize and store sensitive or confidential client or employee data, including personal data. As a result, we may be subject to numerous laws and regulations designed to protect this information, such as U.S. federal and state and international laws governing the protection of personally identifiable information. These laws and regulations are increasing in complexity and number. If any person, including any of our associates, negligently disregards or intentionally breaches our established controls with respect to client or employee data, or otherwise mismanages or misappropriates such data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution. In addition, unauthorized disclosure of sensitive or confidential client or employee data, whether through system failure, employee negligence, fraud or misappropriation, could damage our reputation and cause us to lose clients and related revenue.

  

Potential liability in the event of a security breach of client data could be significant. Depending on the circumstances giving rise to the breach, this liability may not be subject to a contractual limit or an exclusion of consequential or indirect damages. The federally mandated Consolidated Audit Trail (“CAT”) program which requires that client personally identifiable information be submitted to a database not controlled by us may expose us to liability for breaches of that database not under our control.

 

As a result of the foregoing, the Company has and is likely to incur significant costs in preparing its infrastructure and maintaining it to resist any such attacks. In addition to personnel dedicated to overseeing the infrastructure and systems to defend against cybersecurity incidents, senior management is regularly briefed on issues, preparedness and any incidents requiring response. At its regularly scheduled meetings, the Board of Directors is briefed and brought up to date on cybersecurity matters.

 

The Company continually encounters technological change.

 

The financial services industry is continually undergoing rapid technological change with frequent introductions of new technology-driven products and services, driven by the emergence of the Fintech industry. The effective use of technology increases efficiency and enables financial institutions to better serve customers and reduce costs. The Company’s future success depends, in part, upon its ability to address the needs of its customers by using technology to provide products and services that will satisfy customer demands, as well as to create additional efficiencies in the Company’s operations. Many of the Company’s competitors have substantially greater resources to invest in technological improvements. Failure to successfully keep pace with technological change affecting the financial services industry could have a material adverse impact on the Company’s business and, in turn, the Company’s financial condition and results of operations.

 

There is risk associated with the sufficiency of coverage under the Company’s insurance policies.

 

The Company’s operations and financial results are subject to risks and uncertainties related to the use of a combination of insurance, self-insured retention and self-insurance for a number of risks, including most significantly property and casualty, general liability, cyber-crime, workers’ compensation, and the portion of employee-related health care benefits plans funded by the Company, and certain errors and omissions liability, among others.

 

14

 

 

While the Company endeavors to purchase insurance coverage that is appropriate to its assessment of risk, it is unable to predict with certainty the frequency, nature or magnitude of claims for direct or consequential damages. The Company’s business may be negatively affected if in the future its insurance proves to be inadequate or unavailable. In addition, insurance claims may divert management resources away from operating the business.

 

Climate change concerns could disrupt our businesses, adversely affect client activity levels, adversely affect the creditworthiness of our counterparties and damage our reputation.

 

Climate change may cause extreme weather events that, among other things, could damage our facilities and equipment, injure our employees, disrupt operations at one or more of our primary locations, negatively affect our ability to service and interact with our clients, and adversely affect the value of our investments. Any of these events may increase our costs including our costs to insure against these events.

 

Climate change may also have a negative impact on the financial condition of our clients, which may decrease revenues from those clients and increase the credit exposures to those clients. Additionally, our reputation and client relationships may be damaged as a result of our involvement, or our clients’ involvement, in certain industries associated with causing or exacerbating, or alleged to cause or exacerbate, climate change. We also may be negatively impacted by any decisions we make to continue to conduct or change our activities in response to considerations relating to climate change. New regulations or guidance relating to climate change, as well as the perspectives of stockholders, employees and other stakeholders regarding climate change, may affect whether and on what terms and conditions we engage in certain activities or offer certain products.

 

The Company is subject to extensive securities regulation and the failure to comply with these regulations could subject it to monetary penalties or sanctions.

 

The securities industry and the Company’s businesses are subject to extensive regulation by the SEC, state securities regulators, other governmental regulatory authorities and industry self-regulatory organizations. The Company may be adversely affected by new or revised legislation or regulations or changes in the interpretation or enforcement of existing laws and rules by these governmental authorities and self-regulatory organizations.

 

Dominari Securities is a broker-dealer and investment adviser registered with the SEC and is primarily regulated by FINRA. Broker-dealers are subject to regulations which cover all aspects of the securities business, including, without limitation sales methods and supervision, underwriting, trading practices among broker-dealers, emerging standards concerning fees and charges imposed on clients for fee-based programs, use and safekeeping of customers’ funds and securities, anti-money laundering and the USA Patriot Act (the “Patriot Act”) compliance, capital structure of securities firms, trade and regulatory reporting, cybersecurity, pricing of services, compliance with Department of Labor rules and regulations for retirement accounts, compliance with lending practices (Regulation T), record keeping, and the conduct of directors, officers and employees.

 

Compliance with many of the regulations applicable to the Company involves a number of risks, particularly in areas where applicable regulations may be subject to varying interpretation. The requirements imposed by these regulations are designed to ensure the integrity of the financial markets and to protect customers and other third parties who deal with the Company. New regulations may result in enhanced standards of duty on broker-dealers in their dealings with their clients (fiduciary standards). Consequently, these regulations often serve to limit the Company’s activities, including through net capital, customer protection and market conduct requirements, including those relating to principal trading. Much of the regulation of broker-dealers has been delegated to self-regulatory organizations, principally FINRA. FINRA adopts rules, subject to approval by the SEC, which govern its members and conducts periodic examinations of member firms’ operations.

 

If the Company is found to have violated any applicable laws, rules or regulations, formal administrative or judicial proceedings may be initiated against it that may result in censure, fine, civil or criminal penalties, including treble damages in the case of insider trading violations, the issuance of cease-and-desist orders, the suspension or termination of our broker-dealer or investment advisory activities, the suspension or disqualification of our officers or employees; or other adverse consequences.

 

The imposition of any of the above or other penalties could have a material adverse effect on our operating results and financial condition.

 

15

 

 

Financial services firms have been subject to increased regulatory scrutiny increasing the risk of financial liability and reputational harm resulting from adverse regulatory actions.

 

Firms in the financial services industry have been operating in an onerous regulatory environment. The industry has experienced increased scrutiny from a variety of regulators, including the SEC, FINRA, and state regulators. Penalties and fines sought by regulatory authorities have increased substantially. We may be adversely affected by changes in the interpretation or enforcement of existing laws and rules by these governmental authorities and SROs. Each of the regulatory bodies with jurisdiction over us has regulatory powers dealing with many different aspects of financial services, including, but not limited to, the authority to fine us and to grant, cancel, restrict or otherwise impose conditions on the right to continue operating particular businesses. For example, the failure to comply with the obligations imposed by the Exchange Act on broker-dealers and the Advisers Act on investment advisers, including recordkeeping, registration, advertising and operating requirements, disclosure obligations and prohibitions on fraudulent activities, or by the Investment Company Act of 1940, as amended (the “1940 Act”), could result in investigations, sanctions and reputational damage. Increasingly, regulators have instituted a practice of “regulation by enforcement” where new interpretations of existing regulations are introduced by bringing enforcement actions against securities firms for activities that occurred in the past but were not then thought to be problematic. We also may be adversely affected as a result of new or revised legislation or regulations imposed by the SEC, other U.S. or foreign governmental regulatory authorities or SROs (e.g., FINRA) that supervise the financial markets. Substantial legal liability or significant regulatory action taken against us could have a material adverse effect on our business prospects including our cash position.

 

Numerous regulatory changes and enhanced regulatory and enforcement activity relating to the asset management business may increase our compliance and legal costs and otherwise adversely affect our business.

 

U.S. and foreign governments have taken regulatory actions impacting the investment management industry, and may continue to take further actions, including expanding current (or enacting new) standards, requirements and rules that may be applicable to us and our subsidiaries, particularly those subsidiaries that are SEC registered investment advisers. For example, the SEC and several states and municipalities in the United States have adopted “pay-to-play” rules, which could limit our ability to charge advisory fees. Such “pay-to-play” rules could affect the profitability of that portion of our business. Additionally, the use of “soft dollars,” where a portion of commissions paid to broker-dealers in connection with the execution of trades also pays for research and other services provided to advisors has been mostly prohibited in Europe and, is periodically reexamined in the U.S. and may be limited or modified in the future. Furthermore, new regulations regarding the management of hedge funds and the use of certain investment products may impact our investment management business and result in increased costs. For example, many regulators around the world adopted disclosure and reporting requirements relating to the hedge fund business.

 

On June 5, 2019, the SEC adopted Regulation Best Interest (“Reg BI”) as Rule 15l-1 under the Exchange Act. Reg BI imposes a new federal standard of conduct on registered broker-dealers and their associated persons when dealing with retail clients and requires that a broker-dealer and its representatives act in the best interest of such client and not place its own interests ahead of the customer’s interests. Reg BI requires enhanced documentation for recommendations of securities transactions to broker-dealer retail clients. The new rules and processes related thereto will likely limit revenue and most likely involve increased costs, including, but not limited to, compliance costs associated with new or enhanced technology as well as increased litigation costs.

 

It is not possible to determine the extent of the impact of any new laws, regulations or initiatives that may be imposed, or whether any existing proposals will become law. Conformance with any new laws or regulations could make compliance more difficult and expensive and affect the manner in which we conduct business.

 

16

 

 

If the Company violates the securities laws or is involved in litigation in connection with a violation, the Company’s reputation and results of operations may be adversely affected.

 

Many aspects of the Company’s business involve substantial risks of liability. An underwriter is exposed to substantial liability under federal and state securities laws, other federal and state laws, and court decisions, including decisions with respect to underwriters’ liability and limitations on indemnification of underwriters by issuers. For example, a firm that acts as an underwriter may be held liable for material misstatements or omissions of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel. The Company’s underwriting activities will usually involve offerings of the securities of smaller companies, which often involve a higher degree of risk and are more volatile than the securities of more established companies. In comparison with more established companies, smaller companies are also more likely to be the subject of securities class actions, to carry directors and officers liability insurance policies with lower limits or not at all, and to become insolvent. In addition, in market downturns, claims tend to increase. Each of these factors increases the likelihood that an underwriter may be required to contribute to an adverse judgment or settlement of a securities lawsuit.

 

The Company’s risk management policies and procedures may leave it exposed to unidentified risks or an unanticipated level of risk.

 

The policies and procedures the Company employs to identify, monitor and manage risks may not be fully effective. Some methods of risk management are based on the use of observed historical market behavior. As a result, these methods may not predict future risk exposures, which could be significantly greater than historical measures indicate. Other risk management methods depend on evaluation of information regarding markets, clients or other matters that are publicly available or otherwise accessible. This information may not be accurate, complete, up-to-date or properly evaluated. Management of operational, legal and regulatory risk requires, among other things, policies and procedures to properly record and verify a large number of transactions and events. The Company cannot give assurances that its policies and procedures will effectively and accurately record and verify this information.

 

The Company seeks to monitor and control its risk exposure through a variety of separate but complementary financial, credit, operational, compliance and legal reporting systems. The Company believes that it effectively evaluates and manages the market, credit and other risks to which it is exposed. Nonetheless, the effectiveness of the Company’s ability to manage risk exposure can never be completely or accurately predicted or fully assured, and there can be no guarantee that the Company’s risk management will be successful. For example, unexpectedly large or rapid movements or disruptions in one or more markets or other unforeseen developments can have a material adverse effect on the Company’s financial condition and results of operations. The consequences of these developments can include losses due to adverse changes in securities values, decreases in the liquidity of trading positions, higher volatility in earnings, and increases in general systemic risk. Certain of the Company’s risk management systems are subject to regulatory review and may be found to be insufficient by the Company’s regulators potentially leading to regulatory sanctions. There can be no guarantee that the operation of these systems will allow the Company to prevent or mitigate the various risks faced by its businesses. Various regulators periodically review companies’ risk control practices, and, if found inadequate, bring enforcement actions and sanctions against such firms.

  

Risks Associated with the Company’s Common Stock

 

Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards.

 

Our common stock is currently traded on The Nasdaq Capital Market (“Nasdaq”), under the symbol “DOMH.” If we fail to meet any of the continued listing standards of Nasdaq, our common stock could be delisted from Nasdaq. These continued listing standards include specifically enumerated criteria, such as:

 

  a $1.00 minimum closing bid price;

 

  stockholders’ equity of $2.5 million;

 

  500,000 shares of publicly held common stock with a market value of at least $1 million;

 

  300 public stockholders; and

 

  compliance with Nasdaq’s corporate governance requirements, as well as additional or more stringent criteria that may be applied in the exercise of Nasdaq’s discretionary authority.

 

17

 

 

If we fail to comply with Nasdaq’s continued listing standards, we may be delisted and our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, the delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Further, delisting of our common stock would likely result in our common stock becoming a “penny stock” under the Exchange Act.

 

Our share price may be volatile and there may not be an active trading market for our common stock.

 

There can be no assurance that the market price of our common stock will not decline below its present market price or that there will be an active trading market for our common stock. The market prices of upstart financial services companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for upstart financial services stocks could have a significant impact on the volatility of our common stock price. We have experienced significant volatility in the price of our common stock. From January 1, 2023 through December 31, 2023, the closing share price of our common stock (on a split-adjusted basis) ranged from a high of $4.45 to a low of $1.85. The reason for the volatility in our common stock is not well understood and may continue. Factors that may have contributed to such volatility include, but are not limited to:

 

developments regarding regulatory filings;

 

our funding requirements and the terms of our financing arrangements;

 

introduction of new technologies by us or our competitors;

 

government regulations and laws;

 

public sentiment relating to our industry;

 

the number of shares issued and outstanding;

 

the number of shares trading on an average trading day;

 

block sales of our shares by stockholders to whom we have sold stock in private placements, or the cessation of transfer restrictions with respect to those shares; and

 

market speculation regarding any of the foregoing.

   

Our shares of common stock are thinly traded and, as a result, stockholders may be unable to sell at or near ask prices, or at all, if they need to sell shares to raise money or otherwise desire to liquidate their shares.

 

Our common stock has been “thinly-traded” meaning that the number of persons interested in purchasing our common stock at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we become more seasoned and viable. Our trading volumes may have been further adversely affected by the 17-for-1 reverse stock split that was effective as of June 7, 2022. In addition, we believe that due to the limited number of shares of our common stock outstanding, an options market has not been established for our common stock, limiting the ability of market participants to hedge or otherwise undertake trading strategies available for larger companies with broader stockholder bases which prevents institutions and others from acquiring or trading in our securities. Consequently, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained.

 

18

 

 

Our stock price and trading volume could decline as a result of inaccurate or unfavorable research, or the cessation of research cover, about our business published by securities or industry analysts.

 

The trading market for our common stock may be affected by the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price could decline. In addition, the analysts’ projections may have little or no relationship to the results we actually achieve and could cause our stock price to decline if we fail to meet their projections. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, our stock price or trading volume could decline.

 

Because of the “anti-takeover” provisions in our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware General Corporation Law, a third party may be discouraged from making a takeover offer that could be beneficial to our stockholders.

 

The effect of certain provisions of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and the anti-takeover provisions of the Delaware General Corporation Law (the “DGCL”), could delay or prevent a third party from acquiring us or replacing members of our Board of Directors, or make more costly any attempt to acquire control of the Company, even if the acquisition or the Board designees would be beneficial to our stockholders. These factors could also reduce the price that certain investors might be willing to pay for shares of the common stock and result in the market price being lower than it would be without these provisions.

 

We incur increased costs as a result of being a public company.

 

As a public company, we incur significant levels of legal, accounting, regulatory and other expenses. Sarbanes-Oxley and related rules of the SEC, together with the listing requirements of Nasdaq, impose significant requirements relating to disclosure controls and procedures and internal control over financial reporting. We have incurred costs as a result of compliance with these public company requirements, and we may need to hire additional qualified personnel in order to continue to satisfy these public company requirements. We are required to expend considerable time and resources complying with public company regulations. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action.

 

Because of their significant stock ownership, some of our executive officers and directors will be able to exert control over us and our significant corporate decisions.

 

Our executive officers, directors and their affiliates own or control, in the aggregate, beneficially own approximately 32.93% of our outstanding common stock as of December 31, 2023. These stockholders may be able to exercise influence over matters requiring stockholder approval, such as the election of directors and the approval of significant corporate transactions, including transactions involving an actual or potential change of control of the company or other transactions that non-controlling stockholders may not deem to be in their best interests. This concentration of ownership may harm the market price of our common stock by, among other things: delaying, deferring, or preventing a change in control of our company; impeding a merger, consolidation, takeover, or other business combination involving our company; causing us to enter into transactions or agreements that are not in the best interests of all stockholders; or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.

 

Dividends on our common stock are not likely.

 

During the last five years, we have not paid cash dividends on our common stock, and we do not anticipate paying cash dividends on our common stock in the foreseeable future. Investors must look solely to the potential for appreciation in the market price of the shares of our common stock to obtain a return on their investment.

 

Item 1B. UNRESOLVED STAFF COMMENTS

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

19

 

 

Item 1C. CYBERSECURITY

 

We maintain a comprehensive process for identifying, assessing, and managing material risks from cybersecurity threats (as such term is defined in Item 106(a) of Regulation S-K) as part of our broader risk management system and processes. The cybersecurity risk management system involves risk assessments, implementation of security measures, and ongoing monitoring of systems and networks, including networks on which we rely. We actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We obtain input, as appropriate, for our cybersecurity risk management program on the security industry and threat trends from consultants, cybersecurity assessors, auditors and other third parties to gather certain insights designed to identify and assess material cybersecurity threat risks, their severity and potential mitigations. We depend on and engage various third parties, including suppliers, vendors, and service providers. Our risk management, legal, information technology, and compliance personnel identify and oversee risks from cybersecurity threats associated with our use of such entities. Any incident assessed as potentially being or potentially becoming material is immediately escalated for further assessment, and then reported to Mr. Blattner, our designated member of our Board of Directors.

 

Mr. Blattner has oversight responsibility for risks and incidents relating to cybersecurity threats, including compliance with disclosure requirements, cooperation with law enforcement, and related effects on financial and other risks, and report any findings and recommendations, as appropriate, to the full Board of Directors for consideration. Senior management regularly discusses cyber risks and trends and, should they arise, any material incidents with the designated member of the Board of Directors.

 

Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. Further, a cyber incident impacting our systems or a third-party’s systems could subject us to business, regulatory, litigation and reputational risk, which could have a negative effect on our business, results of operations and financial condition. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report.

 

Item 2. PROPERTIES

 

We lease offices located in New York, New York and we believe that the New York offices are sufficient to meet our current needs.

 

Item 3. LEGAL PROCEEDINGS

 

Many aspects of the Company’s business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company’s business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

20

 

 

PART II

 

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our common stock is traded on the Nasdaq Capital Market under the symbol “DOMH”. On March 26, 2024, the closing price of our common stock, as reported by the Nasdaq Capital Market, was $2.35.

 

Holders

 

As of March 26, 2024, we had approximately 136 holders of record of our common stock.

 

Dividend Policy

 

We have never declared or paid cash dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our Board of Directors may deem relevant.

 

Share Repurchases

 

We did not purchase any of our registered equity securities during the quarterly period covered by this Annual Report. 

   

Equity Compensation Plan Information

 

The following table provides information about our common stock that may be issued upon the exercise of options, warrants and rights under all of our existing equity compensation plans as of December 31, 2023. 

 

Plan Category  Number of
securities
to be
issued upon exercise of
outstanding
options,
warrants
and
rights (1)
   Weighted
average
exercise
price of
outstanding
options,
warrants and
rights
   Number of
securities
remaining available for
future
issuance
under
equity
compensation
plans
(excluding
securities
reflected in
column (1)) (2)
 
Equity compensation plans approved by security holder   556,477   $4.94    839,686 
Equity compensation plans not approved by security holder   -    -    - 
    556,477         839,686 

 

(1)Consists of options to acquire 24,454 shares of common stock under the 2014 Equity Incentive Plan and 395,714 shares of common stock under the 2022 Equity Incentive Plan, and restricted stock awards to acquire 136,309 shares of common stock under the 2022 Equity Incentive Plan.

 

(2)Consists of shares of common stock available for future issuance under our equity incentive plans.

 

21

 

 

Item 6. [RESERVED]

 

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s consolidated financial statements as of and for the years ended December 31, 2023 and 2022 and the related notes included in Part II, Item 8 of this Annual Report. This discussion contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. The Company’s actual results could differ materially from such forward-looking statements. The Company does not undertake to update, revise or correct any of the forward-looking information unless required to do so under the federal securities laws. Readers are cautioned that such forward-looking statements should be read in conjunction with the Company’s disclosures under the heading “Special Cautionary Notice Regarding Forward Looking Statements and Risk Factor Summary” included in this report. Additionally, the Company’s historical results are not necessarily indicative of the results that may be expected in any future period. Amounts are presented in U.S. dollars.

 

You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those identified below and those discussed in Part I, Item 1A “Risk Factors” of this Annual Report:

 

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. The MD&A is organized as follows:

 

Overview. Discussion of our business and overall analysis of financial and other highlights affecting the Company in order to provide context for the remainder of the MD&A.

 

Critical Accounting Estimate. Accounting estimates we believe are most important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.

 

Recently Issued Accounting Pronouncements. A discussion of recent accounting standards.

 

Results of Operations. An analysis of our financial results is presented to compare 2023 to 2022. We also provide a discussion of our Liquidity and Capital Resources position and usage.

 

Overview

 

Dominari is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management.  In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. 

 

Dominari Financial, a wholly-owned subsidiary of Dominari, executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually-registered broker dealer and investment advisor from Fieldpoint was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities and is a wholly-owned subsidiary of Dominari Financial.

 

22

 

 

The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. These biotechnology assets consist of patented technology from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, SARS-CoV-2 and acute lymphoblastic leukemia.  

 

Reverse Stock Split

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

 

Critical Accounting Estimates

 

Stock-Based Compensation

 

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

 

The Company estimates the fair value of stock option grants using the Black-Scholes (“Black-Scholes”) option pricing model. The determination of fair value within Black-Scholes involves a number of significant estimates, judgements and assumptions that may affect the value of employee stock options used in the model. These include the expected volatility of our stock and employee exercise behavior which are based on historical data as well as uncertain expectations of future developments over the term of the option. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The uncertainty of these judgments and assumption could result in significant change in our stock-based compensation expense amounts in the future.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

 

Expected Dividend - The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

 

The Company accounts for forfeitures as they occur. 

 

Fair Value Option - Short-Term Note and Convertible Note

 

The guidance in ASC 825, Financial Instruments, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

 

23

 

 

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.

 

Long-Term Investments

 

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

 

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment. Our investments are valued at $24 million as of December 31, 2023.  In valuing these investments there are judgements and assumptions that may affect the values derived for each security including the determination of a change in value and whether or not there are indicators of an impairment of value. These judgments could impact the estimation uncertainty and the impact of these estimates could have an effect on the financial condition and results of operations. Management’s estimates and assumptions include considerations of industry and market conditions and well as uncertain factors identified specific to each investment that could impact the carrying values.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the consolidated financial statements for a discussion of recent accounting standards.

 

Results of Operations

 

Fiscal Year Ended December 31, 2023 Compared to Fiscal Year Ended December 31, 2022

 

During the year ended December 31, 2023, we recognized approximately $2.0 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the years ended December 31, 2023 and 2022, we incurred a loss from operations of approximately $21.8 million and $14.3 million, respectively. The increase in loss in operations was primarily attributable to the following:

 

  i. An approximate $12.2 million increase in general and administrative expenses – driven by approximately $0.1 million and $1.9 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $9.5 million due to growing operations.

 

  ii. An approximate $2.7 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

 

During the years ended December 31, 2023 and 2022, other expenses was approximately $(1.1) million and $(7.8) million, respectively. The activity for the years ended December 31, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of note receivable, and short and long-term investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.6 million for the year ended December 31, 2023. The decrease of approximately $6.6 million in losses over the prior period is a direct result of a decrease in unrealized losses of approximately $6.0 million, an increase in dividend income of approximately $0.4 million and a decrease in realized loss of approximately $0.2 million. The decreases were driven by both market improvement and a decrease in sale activity resulting in fewer realized losses.

 

24

 

 

  ii. Note receivable – the changes over the years ended December 31, 2023 and 2022 are a function of observable market transactions which resulted in an increase in unrealized loss of approximately $3.2 million on the adjusted fair value of the note receivable during the year ended December 31, 2023.
     
  iii. Short-term and long-term investments – the changes over the years ended December 31, 2023 and 2022 are a function of observable market transactions which resulted in an increase in unrealized gain of approximately $3.3 million on the adjusted fair value of the investments during the year ended December 31, 2023.

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

seeking additional funds raised through the sale of additional securities in the future; and

 

seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our business plan to support our transition into the financial services industry. Our working capital amounted to approximately $26.5 million as of December 31, 2023. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations.

 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

25

 

 

Cash Flows from Operating Activities

 

For the years ended December 31, 2023 and 2022, net cash used in operations was approximately $22.2 million and $10.6 million, respectively. The cash used in operating activities for the year ending December 31, 2023, is primarily attributable to a net loss of approximately $22.9 million, approximately $1.0 million of unrealized gain on marketable securities, change in fair value of long-term investment of approximately $0.8 million and changes in operating assets and liabilities of $5.3 million, partially offset by $3.0 million stock-based compensation expense, approximately $3.2 million in unrealized losses on note receivable and approximately $1.2 million in realized losses on marketable securities. The cash used in operating activities for the year ending December 31, 2022, is primarily attributable to a net loss of approximately $22.1 million. The net loss was slightly offset by approximately $4.9 million in unrealized losses on marketable securities, approximately $2.6 million relating to the change in fair value of short-term investments, approximately $1.8 million in research and development expense related to acquired licenses, approximately $1.5 million related to stock-based compensation, and approximately $1.4 million of realized loss on marketable securities.

 

Cash Flows from Investing Activities

 

For the years ended December 31, 2023 and 2022, net cash used in investing activities was approximately $7.2 million and $14.6 million, respectively. The cash used in investing activities for the year ended December 31, 2023, primarily resulted from our purchase of marketable securities of approximately $34.1 million and the acquisition of FPS for approximately $1.1 million, partially offset by our sale of marketable securities of approximately $27.6 million and collection of principal on note receivable of approximately $1.1 million. The cash used in investing activities for the year ended December 31, 2022, primarily resulted from our purchase of marketable securities of approximately $26.8 million, purchase of investments of approximately $15.0 million, purchase of research and development licenses of approximately $1.8 million, and the purchase of promissory notes of approximately $1.6 million, partially offset by our sale of marketable securities of approximately $28.7 million since we invest excess cash into marketable securities until additional cash is needed.

 

Cash Flows from Financing Activities

 

For the year ended December 31, 2023, cash used in financing activities was approximately $0.9 million, which reflects the cost for the purchase of treasury stock of approximately $0.9 million. For the year ended December 31, 2022, cash used in financing activities was approximately $7.2 million, which reflects the cost for redemption of Series O and Series P Redeemable Convertible Preferred Stock of approximately $22.0 million and cost for purchase of treasury stock of approximately $3.1 million, partially offset by net proceeds of approximately $17.9 million from investors in exchange of issuance of issuance of Series O and Series P Redeemable Convertible Preferred Stock. For the year ended December 31, 2021, cash provided by financing activities was approximately $78.2 million, which is primarily attributable to the approximate $78.2 million from investors in exchange of issuance of common stock and warrants.

 

Contractual obligations

 

None.

 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

26

 

 

Item 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Consolidated financial statements and supplementary data required by this Item 8 follow.

 

Index to Consolidated Financial Statements

 

    Page
     
Report of Independent Registered Public Accounting Firms (PCAOB ID Number 688)   F-2
Consolidated Balance Sheets as of December 31, 2023 and 2022   F-3
Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022   F-4
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholder’s Equity for the Years Ended December 31, 2023 and 2022   F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022   F-6
Notes to the Consolidated Financial Statements   F-7

 

F-1

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors of

Dominari Holdings Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Dominari Holdings Inc. and Subsidiaries (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in redeemable convertible preferred stock and stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

 

Valuation of Long-term Investments

 

As of December 31, 2023, the Company had $24.15 million of investments in companies without readily determinable fair values. The Company typically measures these investments at cost less any impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment. We identified the valuation of these investments as a critical audit matter because of the significant judgement management uses to estimate the investment value. This is a challenging audit area due to the subjectivity in assessing whether observable price changes have occurred for investments that are identical or similar to the investment the Company holds, and in assessing whether an investment is impaired.

 

The following are the primary procedures we performed to address this critical audit matter. We obtained an understanding of management’s process for accounting for their investments that do not have readily determinable fair values. We considered the appropriateness of the Company’s application of accounting policy by obtaining and reviewing the Company’s analysis and confirming its compliance with accounting principles generally accepted in the United States. We tested the mathematical accuracy of the Company’s carrying value calculations. We evaluated the accounting conclusions reached by the Company as to whether any observable transactions had occurred that were identical or similar in nature through reading the Company’s available financial and other information regarding the investee and through public searches for corroborating or contradictory information. Further, we evaluated the appropriateness of the Company’s impairment conclusions considering this internal and external information. For certain investments, we utilized our internal valuation group specialists to assess the appropriateness of the valuation methodologies and recompute the valuations derived. We also evaluated the adequacy of the Company’s disclosures in the notes to the consolidated financial statements in relation to this matter.

 

/s/ Marcum llp

 

Marcum llp

 

We have served as the Company’s auditor since 2022.

 

New York, NY

April 1, 2024

F-2

 

 

DOMINARI HOLDINGS INC.

Consolidated Balance Sheets

($ in thousands except share and per share amounts)

 

   December 31,   December 31, 
   2023   2022 
         
ASSETS        
Current assets        
Cash and cash equivalents  $2,833   $33,174 
Marketable securities   13,547    7,130 
Deposits with clearing broker   7,687    - 
Prepaid expenses and other assets   898    564 
Prepaid acquisition cost   -    301 
Short-term investments at fair value   -    13 
Notes receivable, at fair value - current portion   3,177    7,474 
Investment in Fieldpoint Securities   -    2,000 
Total current assets   28,142    50,656 
           
Property and equipment, net   344    - 
Notes receivable, at fair value - non-current portion   1,129    1,100 
Investments   24,150    23,103 
Right-of-use assets   3,335    919 
Security deposit   458    458 
Total assets  $57,558   $76,236 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued expenses  $1,036   $447 
Accrued salaries and benefits   51    1,260 
Accrued commissions   77    - 
Lease liability - current   421    82 
Other current liability   22    - 
Total current liabilities   1,607    1,789 
           
Lease liability   3,028    680 
Total liabilities   4,635    2,469 
           
Stockholders’ equity          
Preferred stock, $0.0001 par value, 50,000,000 authorized   
 
    
 
 
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at December 31, 2023 and 2022; liquidation value of $0.0001 per share   -    - 
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at December 31, 2023 and 2022; liquidation value of $0.0001 per share   -    - 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 and 5,485,096 shares issued at December 31, 2023 and 2022, respectively; 5,934,917 and 5,017,079 shares outstanding at December 31, 2023 and 2022, respectively   -    - 
Additional paid-in capital   262,187    262,970 
Treasury stock, at cost, 60,148 and 468,017 shares at December 30, 2023 and December 31, 2022, respectively   (501)   (3,322)
Accumulated deficit   (208,763)   (185,881)
Total stockholders’ equity   52,923    73,767 
Total liabilities and stockholders’ equity  $57,558   $76,236 

 

See accompanying notes to consolidated financial statements.

 

F-3

 

 

DOMINARI HOLDINGS INC.

Consolidated Statements of Operations

($ in thousands except share and per share amounts)

 

   Years Ended December 31, 
   2023   2022 
Revenues  $2,039   $- 
           
Operating costs and expenses          
General and administrative  $23,838   $11,683 
Research and development   3    830 
Research and development - license acquired   (6)   1,833 
Total operating expenses   23,835    14,346 
Loss from operations   (21,796)   (14,346)
           
Other income (expenses)          
Other income   36    64 
Interest income   716    687 
Gain (loss) on marketable securities   630    (5,952)
Unrealized loss on note receivable   (3,248)   - 
Change in fair value of investments   780    (2,560)
Total other expenses   (1,086)   (7,761)
Net loss  $(22,882)  $(22,107)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock   -    (4,109)
Net Loss Attributable to Common Shareholders  $(22,882)  $(26,216)
           
Net loss per share, basic and diluted          
Basic and Diluted  $(4.38)  $(4.91)
           
Weighted average number of shares outstanding, basic and diluted          
Basic and Diluted   5,229,477    5,334,075 

 

See accompanying notes to consolidated financial statements. 

 

F-4

 

 

DOMINARI HOLDINGS INC.

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity

($ in thousands except share and per share amounts)

 

   Redeemable Convertible Preferred Stock                   Additional               Total 
   Series O   Series P   Preferred Stock   Common Stock   Paid-in   Treasury Stock   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at December 31, 2021       -   $     -        -   $     -    4,659   $     -    5,275,329   $     -   $265,633    -   $(264)  $(163,774)  $101,595 
Issuance of Series O redeemable convertible preferred stock for cash   11,000    11,000    -    -    -    -    -    -    -    -    -    -    - 
Issuance of Series P redeemable convertible preferred stock for cash   -    -    11,000    11,000    -    -    -    -    -    -    -    -    - 
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock   -    (1,504)   -    (1,505)   -    -    -    -    -    -    -    -    - 
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock   -    1,504    -    1,505    -    -    -    -    (4,109)   -    -    -    (4,109)
Redemption of Series O Redeemable Convertible Preferred Stock   (11,000)   (11,000)   -    -    -    -    -    -    -    -    -    -    - 
Redemption of  Series P Redeemable Convertible Preferred Stock   -    -    (11,000)   (11,000)   -    -    -    -    -    -    -    -    - 
Purchase of treasury stock   -    -    -    -    -    -    -    -    -    468,017    (3,058)   -    (3,058)
Stock-based compensation   -    -    -    -    -    -    238,244    -    1,472    -    -    -    1,472 
Cancellation of common stock related to investment in CBM   -    -    -    -    -    -    (22,812)   -    -    -    -    -    - 
Fractional shares adjusted for reverse split   -    -    -    -    -    -    (5,665)   -    (26)   -    -    -    (26)
Net loss   -    -    -    -    -    -    -    -    -    -    -    (22,107)   (22,107)
Balance at December 31, 2022   -   $-    -   $-    4,659   $-    5,485,096   $-   $262,970    468,017   $(3,322)  $(185,881)  $73,767 
Stock-based compensation   -    -    -    -    -    -    1,179,468    -    2,977    -    -    -    2,977 
Cancellation of common stock   -    -    -    -    -    -    (25,000)   -    -    -    -    -    - 
Purchase of treasury stock   -    -    -    -    -    -    -    -    -    236,630    (939)   -    (939)
Retirement of treasury stock   -    -    -    -    -    -    (644,499)   -    (3,760)   (644,499)   3,760    -    - 
Net loss   -    -    -    -    -    -    -    -    -    -    -    (22,882)   (22,882)
Balance at December 31, 2023   -   $-    -   $-    4,659   $-    5,995,065   $-   $262,187    60,148   $(501)  $(208,763)  $52,923 

 

See accompanying notes to consolidated financial statements. 

 

F-5

 

 

DOMINARI HOLDINGS INC.

Consolidated Statements of Cash Flows

($ in thousands)

 

   Years Ended December 31, 
   2023   2022 
Cash flows from operating activities        
Net loss  $(22,882)  $(22,107)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of right-of-use assets   359    (188)
Depreciation   83    
-
 
Change in fair value of short-term investment   13    2,621 
Change in fair value of long-term investment   (793)   (61)
Research and development-acquired license, expensed   
-
    1,833 
Stock-based compensation   2,977    1,472 
Realized loss on marketable securities   1,180    1,405 
Unrealized (gain) loss on marketable securities   (1,049)   4,867 
Unrealized loss on note receivable   3,248    
-
 
Realized gain on receiving shares in exchange of note receivable extension   (36)     
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   (406)   (215)
Prepaid acquisition cost   301    (301)
Clearing broker deposits   (4,137)   
-
 
Accounts payable and accrued expenses   376    66 
Accrued salaries and benefits   (1,209)   580 
Accrued commissions   52    
-
 
Lease liabilities   (88)   31 
Other current liabilities   (99)   
-
 
Notes receivable, at fair value – net interest accrued   (122)   (600)
Net cash used in operating activities   (22,232)   (10,597)
           
Cash flows from investing activities          
Purchase of membership interest in FPS   
-
    (2,000)
Purchase of marketable securities   (34,125)   (26,798)
Sale of marketable securities   27,574    28,658 
Proceeds from sale of digital currencies   
-
    93 
Purchase of fixed assets   (427)   
-
 
Acquisition of FPS, net of cash acquired and receivable owed from FPS   (1,112)   
-
 
Return of deposit (funding of deposit) into a managed account, net   
-
    3,898 
Collection of principal on note receivable   1,102    
-
 
Funds to employee forgivable loan   (107)   
-
 
Purchase of research and development licenses   
-
    (1,833)
Purchase of short-term and long-term investments   (75)   (15,016)
Purchase of short-term and long-term promissory notes   
-
    (1,600)
Net cash used in investing activities   (7,170)   (14,598)
           
Cash flows from financing activities          
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost   
-
    17,891 
Payment for fractional shares   
-
    (26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock   
-
    (22,000)
Purchase of treasury stock   (939)   (3,058)
Net cash used in financing activities   (939)   (7,193)
           
Net decrease in cash and cash equivalents and restricted cash   (30,341)   (32,388)
Cash and cash equivalents, beginning of period   33,174    65,562 
           
Cash and cash equivalents, end of period  $2,833   $33,174 
           
Cash paid for interest and taxes  $686   $
-
 
           
Non-cash investing and financing activities          
Receiving shares in exchange of note receivable extension  $179   $
-
 
Note receivable principal and interest receivable reduced due to receiving shares  $143      
Transfer from short-term investment to marketable securities  $
-
   $1,497 
Reclassify from convertible note receivable to notes receivable at fair value  $
-
   $2,147 
Transfer from long-term investment to marketable securities  $
-
   $1,439 
Promissory convertible note receivable conversion into common shares  $
-
   $899 
           
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:          
Net assets acquired, net of cash acquired and receivable owed from FPS  $3,112      
Less - Deposit previously transferred in October 2022 to FPS  $(2,000)     
Net cash paid  $1,112      

 

See accompanying notes to consolidated financial statements. 

 

F-6

 

 

DOMINARI HOLDINGS INC.

(Formerly AIkido Pharma, Inc.)

 

Notes to Consolidated Financial Statements

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

On September 9, 2022, Dominari entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”).   Pursuant to the terms of the FPS Purchase Agreement, Dominari purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari.  The FPS Purchase Agreement provides for Dominari’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari of 20% of the FPS Membership Interests.   Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari of the remaining 80% of the Membership Interests. 

 

Reverse Stock Split

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

 

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

 

F-7

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note 3. Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial information.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

  

Use of Estimates

 

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Segments

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company’s chief executive officer is the CODM. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

Concentration of Cash

 

The Company maintains cash balances at four financial institutions in checking accounts. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2023 and 2022, the Company had no cash equivalents.

 

Marketable Securities

 

Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices.

 

Property and Equipment

 

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.

 

F-8

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Research and Development

 

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

 

Accounting for Warrants

 

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).

 

Stock-based Compensation

 

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

 

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

 

The Company accounts for forfeitures as they occur. 

 

Fair Value Option - Short-term Note and Convertible Note

 

The guidance in ASC 825, Financial Instruments, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

 

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.

 

F-9

 

  

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $6.7 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of December 31, 2023.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 11 - Leases).

 

Revenue

 

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - Revenue).

 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

 

  Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

  Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

  Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.

 

Treasury Stock

 

Treasury stock is recorded at cost and is presented as a reduction of stockholders’ equity.

  

F-10

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company’s consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

 

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.

 

Long-term investments

 

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

 

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s consolidated financial statements from the implementation of ASU 2021-08.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

F-11

 

  

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these consolidated financial statements.

  

Note 4. FPS Acquisition

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.4 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. 

 

Consideration Transferred

 

The FPS Acquisition was accounted for as a business combination under ASC 805.

 

Under the terms of the FPS Purchase Agreement and subsequent amendments and side letters to the agreement 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price.

 

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the consolidated statement of operations.

 

F-12

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Fair Value of Net Assets Acquired

 

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition ($ in thousands):

 

   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 

 

Note 5. Investments in Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows ($ in thousands):

 

   Years Ended December 31, 
   2023   2022 
Realized loss  $(1,180)  $(1,405)
Unrealized gain (loss)   1,049    (4,867)
Dividend income   762    320 
Total  $630   $(5,952)

 

Note 6. Short-term investments

 

The following table presents the Company’s short-term investments as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   
     -
    13 
Total   
-
    13 

 

The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):

 

Beginning balance  $13 
Change in fair value of short-term investment   (13)
Ending balance  $
-
 

 

F-13

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Investment in Vicinity Motor Corp.

 

On October 25, 2021, the Company entered into a warrant agreement with Vicinity Motor Corp. (“Vicinity”) that entitles the Company to purchase up to 246,399 shares of Vicinity common stock at $5.10 per share. The warrant expires on October 25, 2024. The fair value was determined using a Black-Scholes simulation. The Company recorded the fair value of the Vicinity warrant of approximately $0 and $13,000 in the consolidated balance sheet as of December 31, 2023 and 2022, respectively, reflecting the benefit received as part of its purchase of Vicinity common stock through its brokerage account. Gains or losses associated with changes in the fair value of investments in Vicinity warrants are recognized as change in fair value of investment on the consolidated statements of operations. During the year ended December 31, 2023, the Company recorded approximately $13,000 of change in fair value of investment for this investment.

 

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

 

   December 31,
2023
   December 31,
2022
 
Option term (in years)         0.8    1.8 
Volatility   67.2%   76.90%
Risk-free interest rate   5.43%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $
-
   $0.96 

 

Note 7. Long-Term Investments

 

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of December 31, 2023 and 2022 ($ in thousands):

 

   Cost Basis   December 31,
2023
   December 31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    1,033    1,000 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    3,500    3,500 
Investment in Tesspay**   1,240    2,679    2,500 
Investment in SpaceX*   3,500    4,867    3,674 
Investment in Databricks*   1,200    842    1,200 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    300    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $24,150   $23,103 

 

The change in the value of the long-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

 

Beginning balance  $23,103 
Purchase of investments   75 
Receiving shares in exchange of note receivable extension   179 
Change in fair value of long-term investments   793 
Ending balance  $24,150 

 

F-14

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note 8. Notes Receivable

 

The following table presents the Company’s notes receivable as of December 31, 2023 and 2022 ($ in thousands):

 

December 31, 2023

 

   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  12/2/2024      8%  $1,006   $58   $1,064 
Raefan Industries LLC Investment  12/31/2024   8%  $1,363   $751   $2,114 
American Innovative Robotics Investment  04/01/2027   8%  $1,106   $22   $1,129 
                        
Notes receivable, at fair value - current portion                    $3,177 
                        
Notes receivable, at fair value - non-current portion                    $1,129 

 

 

December 31, 2022

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair Value 
Short-term convertible notes receivable                   
Convergent Investment  01/29/2023     8%  $2,000   $307   $2,307 
                        
Short-term notes receivable                       
Raefan Industries LLC Investment  6/30/2023   8%  $4,730   $437   $5,167 
Total                    $7,474 
                        
Long-term notes receivable                       
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $
-
   $1,100 

 

F-15

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Convergent Therapeutics, Inc. Investment

 

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

 

The principal balance of the Convergent Convertible Note was approximately $1.0 and $2.0 million as of December 31, 2023 and 2022, respectively. The Company recorded an interest income receivable of approximately $13,000 and $0.2 million on the Convergent Convertible Note as of December 31, 2023 and 2022, respectively.

 

The Company recorded principal repayment of $1.0 million and $0, interest receivable repayment of approximately $0.3 million and $0, and an unrealized gain on the note of approximately $6,000 and $0 on the Convergent Convertible Note for the years ended December 31, 2023 and 2022, respectively.

 

Raefan Industries LLC Investment

  

On December 6, 2021, the Company purchased an 8% promissory note (“Raefan Industries Promissory Note”) issued by Raefan Industries, LLC (“Raefan Industries”) in the principal amount of approximately $2.0 million pursuant to a Note Purchase Agreement with Raefan Industries.  On December 6, 2022, the Company, Raefan Industries and Mr. Jeffrey Cooper entered into a Consolidated, Amended and Restated Promissory Note agreement (the “Raefan Amended Note Agreement”).

 

On October 20, 2023, in consideration for extending the maturity date of the Raefan Amended Note (See Note 8 – Notes Receivable) to December 31, 2024, Raefan Industries agreed and had delivered to the Company 357,143 shares of TessPay at $0.5 per share of common stock. The Company reduced approximately $0.1 million of principal and interest receivable balance of Raefan Amended Note and recorded an income of approximately $35,000 for receiving TessPay shares.

 

The Company recorded an interest income receivable of approximately $0.4 million and $26,000 on the Amended Note as of December 31, 2023 and 2022 and an unrealized loss on the note of approximately $3.3 million and $0 for the years ended December 31, 2023 and 2022, respectively.

 

American Innovative Robotics, LLC Investment

 

The Company recorded interest income of approximately $89,000 and $67,000, and an unrealized gain on the note of approximately $6,000 and $0 on the Robotics Promissory Note for the year ended December 31, 2023 and 2022, respectively.

 

F-16

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Kaya Now Inc. Investment

 

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of December 31, 2023 and 2022.

 

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the year ended December 31, 2023.

   

Note 9. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

F-17

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 ($ in thousands):

 

   Fair value measured as of December 31, 2023     
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $13,547   $13,547   $
     -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Short-term investment  $-   $
-
   $
-
   $- 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 

 

   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
     -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

F-18

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Short-term investment at December 31, 2021  $419 
Change in fair value of investment   (406)
Short-term investment at December 31, 2022  $13 
Change in fair value of investment   (13)
Short-term investment at December 31, 2023  $
-
 

 

Notes receivable at fair value, current portion at December 31, 2021  $6,984 
Accrued interest receivable   600 
Reclassify from convertible note receivable to notes receivable at fair value   2,147 
Purchase of notes receivable   500 
Change in fair value of short-term investment   (1,858)
Conversion of note receivable to marketable securities   (899)
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (1,000)
Unrealized loss on note receivable   (3,254)
Principle reduced due to receiving shares   (143)
Accrued interest receivable   100 
Notes receivable at fair value, current portion at December 31, 2023  $3,177 

 

 

Notes receivable at fair value, non-current portion at December 31, 2021  $
-
 
Purchase of notes receivable   1,100 
Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Unrealized gain on note receivable   6 
Accrued interest receivable   23 
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 

 

F-19

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note Receivable at fair value

   

As of December 31, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors.

 

Note 10. Property and Equipment

 

Property and equipment, net, consists of the following as of December 31, 2023 and 2022:

 

   Estimated
Useful Lives
  December 31,
2023
   December 31,
2022
 
Leasehold improvements  Shorter of the remaining lease term or estimated useful life  $    50   $
    -
 
Machinery, equipment and computer software   1 to 15 years   169    
-
 
Furniture and fixtures   3 to 5 years   208    
-
 
Total     $427   $
-
 
Less: Accumulated depreciation and amortization      (83)   
-
 
Total property and equipment, net     $344   $
-
 

 

Depreciation expense was $83,000 and $0 during the years ended December 31, 2023 and 2022, respectively.

 

Note 11. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date”). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on February 1, 2023. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month.

  

F-20

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

The tables below represent the Company’s lease assets and liabilities as of December 31, 2023 and 2022:

 

 

   December 31,
2023
   December 31,
2022
 
Assets:        
Operating lease right-of-use-assets  $3,335   $   919 
           
Liabilities:          
Current          
Operating   421    82 
Long-term          
Operating   3,028    680 
   $3,449   $762 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   December 31,
2023
   December 31,
2022
 
Weighted-average remaining lease term – operating leases (in years)   6.5    7.1 
Weighted-average discount rate – operating leases   10.0%   10.0%

 

During the years ended December 31, 2023 and 2022, the Company recorded approximately $0.8 million and 0.1 million of lease expense to current period operations.

 

   Year Ended   Year Ended 
   December 31,
2023
   December 31,
2022
 
Operating leases        
Operating lease cost  $668   $    73 
Operating lease expense   668    73 
Short-term lease rent expense   105    67 
Net rent expense  $773   $140 

 

Supplemental cash flow information related to leases were as follows:

 

   Year Ended
December 31,
2023
  

Year Ended
December 31,
2022

 
Operating cash flows - operating leases  $396   $  231 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,780   $960 

 

As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
   $ 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,728 
Less present value discount   (1,279)
Operating lease liabilities  $3,449 

 

F-21

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note 12. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2023, and 2022 are as follows:

 

   As of December 31, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,168    54,722 
Total   1,001,307    499,552 

 

Note 13. Redeemable Convertible Preferred Stock

 

Series O and Series P Redeemable Convertible Preferred Stock

 

On February 24, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Offerings”), (i) 11,000 shares of the Company’s Series O Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series O Preferred Stock”), and (ii) 11,000 shares of the Company’s Series P Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series P Preferred Stock” and together with the Series O Preferred Stock, the “Preferred Stock”), in each case, at an offering price of $952.38 per share, representing a 5% original issue discount to the stated value of $1,000 per share of Preferred Stock, for gross proceeds of each Offering of $10,476,180, or approximately $21.0 million in the aggregate for the Offerings, before the deduction of the placement agent’s fee and offering expenses. The shares of Series O Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The shares of Series P Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The Series O Preferred Stock and the Series P Preferred Stock are being offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-238172) (the “Registration Statement”) filed under the Securities Act of 1933, as amended (the “Securities Act”). The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The closing of the Offerings occurred on March 2, 2022. In connection with this transaction, the Company received net proceeds of $21.0 million, which was deposited in an escrow account.

 

In connection with the Offerings, the Company has entered into an engagement agreement (the “Engagement Agreement Agreement”) with H.C Wainwright & Company, LLC, as placement agent (“HCW”), pursuant to which the Company agreed to pay HCW an aggregate cash fee equal to 8% of the aggregate gross proceeds raised in the offerings and issue HCW common stock purchase warrants to purchase up to 103,528 shares of common stock in the aggregate at an exercise price of $21.25. The warrants were recorded as a component of stockholders’ equity in accordance with ASC 815.

 

F-22

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Redemption Rights

 

After (i) the earlier of (1) the receipt of stockholder approval and (2) the date that is 90 days following the Original Issue Date (the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock) and (ii) before the date that is 120 days after the Original Issue Date (the “Redemption Period”), each Holder shall have the right to cause the Company to redeem all or part of such Holder’s shares of Preferred Stock at a price per share equal to 105% of the Stated Value.

 

As a result, the Preferred Stock were recorded separately from stockholders’ equity because they are redeemable upon the occurrence of redemption events that are considered not solely within the Company’s control.

 

During the second quarter of 2022, the Company redeemed for cash at a price equal to 105% of the $1,000 stated value per share all of its 11,000 outstanding shares of Series O Preferred Stock and its 11,000 Series P Preferred Stock. The total redemption amount was $23.1 million. As a result, all shares of the Series O Preferred Stock and Series P Preferred Stock have been retired and are no longer outstanding.

 

During the year ended December 31, 2023 and 2022, the Company recognized approximately $0 and $4.1 million in deemed dividends related to the Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable preferred stock and stockholders’ equity, respectively.

 

Note 14. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

 

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by an executive.

 

Treasury Stock

 

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the year ended December 31, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. During the year ended December 31, 2022, the Company repurchased 468,017 shares at a cost of approximately $3.1 million or $6.53 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

 

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

 

Preferred Stock

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of December 31, 2023 and 2022, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

F-23

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of December 31, 2023 and 2022, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

 

Warrants

 

A summary of warrant activity for years ended December 31, 2023 and 2022 is presented below:

 

   Warrants   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   341,268   $31.68    
   -
    3.87 
Issued   103,528    21.25    
-
    4.15 
Outstanding as of December 31, 2022   444,796   $29.25    
-
    3.20 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 

 

Confirmation of Mutual Understanding - In March 2022, pursuant to a Confirmation of Mutual Understanding (the “Confirmation”), all parties to the Confirmation acknowledged and confirmed a scrivener’s error set forth in warrants to purchase shares of the Company’s common stock (the “Warrants”) dated March 10, 2020, April 15, 2020 and March 2, 2021. Pursuant to the Confirmation, all parties, which were involved in the original execution of the warrants, agreed that clause (v) of the definition of Fundamental Transaction in Section 3(d) of the Warrants, is as follows:

 

the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the Company’s outstanding equity securities, including with respect to the election of directors (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)”. 

 

F-24

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Restricted Stock Awards

 

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

December 19, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,287,129 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.6 million. Pursuant to the Grant Agreement, the Company withheld 657,079 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

December 19, 2023, pursuant to the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Joshua Shipley was granted 33,003 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $67,000. Pursuant to the Grant Agreement, the Company withheld 13,300 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $27,000 and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

During the year ended December 31, 2023, the Company also issued an aggregate of 136,309 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.

 

During the year ended December 31, 2022, the Company issued an aggregate of 238,244 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.

 

A summary of restricted stock awards activity for the years ended December 31, 2023 and 2022, is presented below: 

 

   Number of
Restricted
Stock Awards
   Weighted
Average
Grant Day
Fair Value
 
Nonvested at December 31, 2021   
-
   $
-
 
Granted   238,244    6.13 
Vested   (230,176)   6.14 
Nonvested at December 31, 2022   8,068   $5.90 
Granted   1,315,777   $2.27 
Vested   (1,187,536)   2.30 
Nonvested at December 31, 2023   136,309   $2.26 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $2.7 million and $1.4 million for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

As of December 31, 2023, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards.

 

F-25

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for year ended December 31, 2023 and 2022 is presented below:

 

   Number of
Shares
   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   28,203   $548.35   $
      -
    8.2 
Employee options granted   170,587    5.95    
-
    0.3 
Employee options forfeited   (167,381)   41.90    
-
    - 
Employee options expired   (216)   73.70    
-
    - 
Outstanding as of December 31, 2022   31,193   $302.97   $
-
    7.9 
Employee options granted   395,714    3.42    
-
    9.4 
Employee options forfeited   (5,882)   5.95    
-
    - 
Employee options expired   (857)  $9,719.07    
-
    - 
Outstanding as of December 31, 2023   420,168   $5.80   $
-
    9.3 
Options vested and exercisable   84,929   $15.16   $
-
    8.8 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $0.2 million and $13,000 for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.5 million.

 

Note 15. Revenue

 

The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):

 

   Years Ended
December 31,
 
   2023   2022 
Underwriting  $594   $
   -
 
Commissions   1,096    
-
 
Advisory fees   209    
-
 
Other   140    
-
 
Total  $2,039   $
-
 

 

Note 16. Commitments and Contingencies

 

Legal Proceedings

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than as described above and ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

F-26

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note 17. Income Taxes

 

The income tax provision consists of the following ($ in thousands):

 

    For the years ended
December 31,
 
    2023     2022  
Federal            
Current   $ -     $ -  
Deferred     (3,820 )     (3,618 )
Increase in valuation allowance     3,820       3,618  
State and local                
Current    
 
     
 
 
Deferred     (3,012 )     (4,825 )
Increase in valuation allowance     3,012       4,825  
Income Tax Provision (Benefit)   $ -     $ -  

 

The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2023 and 2022:

 

    For the years ended
December 31,
 
    2023     2022  
U.S. Statutory Federal Rate     21.00 %     21.00 %
State Taxes, Net of Federal Tax Benefit     15.36 %     13.58 %
Other Permanent Differences     (0.54 )%     (0.11 )%
State rate change in effect     (4.18 )%     2.95 %
AMT credit benefit     - %     - %
Decrease due to true up of State NOL     (0.11 )%     0.69 %
Decrease due to change in Federal NOL and other true ups     (1.67 )%     0.04 %
Change in Valuation Allowance     (29.85 )%     (38.15 )%
Income Tax Benefit     0.00 %     0.00 %

 

As of December 31, 2023 and 2022, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):

 

    As of December 31,  
    2023     2022  
Deferred tax assets:            
Net-operating loss carryforward   $ 33,124     $ 26,241  
Stock based compensation     9,754       8,358  
Patents & Licenses     8,061       9,898  
Transaction Costs     209       23  
Research & Development     1,937       2,207  
Operating lease liability     1,202       272  
Investment portfolio and other     2,879       2,445  
Total Deferred Tax assets     57,166       49,443  
Valuation allowance     (55,946 )     (49,115 )
Deferred Tax Asset, Net of Allowance   $ 1,220     $ 328  
Deferred tax liability:                
Depreciation     (57 )     -  
Right of use asset     (1,163 )     (328 )

 

F-27

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December 31, 2023 and 2022. As of December 31, 2023, the change in valuation allowance is approximately $6.8 million.

  

As of December 31, 2023, the Company has approximately $40.7 million federal net operating loss carryovers (“NOLs”), which expire from 2033 through 2037, and $68.5 million of federal NOLs which will never expire. The Company has approximately $152.3 million of state and city NOLs, which expire from 2035 through 2043. As of December 31, 2023, the Company also had federal research and development tax credit carryforwards of $0.2 million which may be available to offset future income tax liabilities and begin to expire in 2042.

 

Utilization of the U.S. NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. If the Company experiences an ownership change, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. The Company determined an ownership change occurred on September 10, 2013, and any NOLs generated prior to this date are therefore limited by Section 382. Any carryforwards that will expire prior to utilization due to this limitation were removed from deferred tax assets, with a corresponding reduction of the valuation allowance. The Company has not yet determined if any additional ownership changes occurred after September 10, 2013. Any past or future ownership changes may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.

 

As of December 31, 2023 and 2022, no liability for unrecognized tax benefit was required to be reported. The Company’s policy is to record interest and penalties related to income taxes outside of its income tax provision and classify as interest and penalties in general and administrative expense in the statement of operations. As of December 31, 2023 or 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s statement of operations. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files U.S. federal and state income tax returns (New York, New York City, Virginia, and Texas). As of December 31, 2023, the statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for all years since 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. There are no audits pending in any of the above-mentioned jurisdictions during 2023 and 2022. The Company believes that its income tax positions would be sustained upon an audit and does not anticipate any adjustments that would result in material changes to its consolidated financial position.

 

In December, 2023, the FASB issued 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09) which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Public business entities must apply the ASU’s guidance to annual periods beginning after December 15, 2024. The Company may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted. The Company has chosen not to early adopt this standard.

 

Note 18. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of December 31, 2023, Dominari Securities had net capital of approximately $4.9 million, which was approximately $4.7 million in excess of required minimum net capital of $0.2 million.

 

Note 19. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $75,000 and $1.0 million during the years ending December 31, 2023, and 2022, respectively. These fees were included in general and administrative expenses in the consolidated statements of operations.

  

F-28

 

 

DOMINARI HOLDINGS INC.
(Formerly AIkido Pharma, Inc.)

Notes to Consolidated Financial Statements

 

Note 20. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Year Ended December 31, 2023 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue   2,039    
-
    2,039 
Operating Costs               
General and administrative   15,750    8,088    23,839 
Research and development   
-
    (3)   (3)
Loss from operations   (13,711)   (8,085)   (21,797)
                
Other (expenses) income               
Other income   
-
    36    36 
Interest income   229    487    716 
Gain on marketable securities   
-
    630    630 
Unrealized loss on note receivable   
-
    (3,248)   (3,248)
Change in fair value of investments   
-
    780    780 
Total other (expenses) income   229    (1,315)   (1,086)
Net loss   (13,482)   (9,400)   (22,882)

  

   Year Ended December 31, 2022 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue 
-
  
-
  
-
 
Operating Costs            
General and administrative   157    11,526    11,683 
Research and development   -    2,663    2,663 
Loss from operations   (157)   (14,189)   (14,346)
                
Other (expenses) income               
Other income   
-
    64    64 
Interest income   -    687    687 
Gain on marketable securities   
-
    (5,952)   (5,952)
Unrealized loss on note receivable   
-
    -    - 
Change in fair value of investments   -    (2,560)   (2,560)
Total other (expenses) income   -    (7,761)   (7,761)
Net loss   (157)   (21,950)   (22,107)

  

Note 21. Subsequent Events

 

Litigation

 

In March 2024 the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities LLC. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. At this time the Company has no reasonable basis to assess or record any potential income statement impact related to this petition. See Note 16 Commitment and Contingencies for further information.

 

F-29

 

 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

New independent registered public accounting firm

 

On July 5, 2022, the Company engaged Marcum LLP (“Marcum”), as the Company’s new independent registered public accounting firm. The decision to engage Marcum was approved by the Company’s Audit Committee.

 

During the fiscal year ending December 31, 2021, and through July 5, 2022, the Company had not consulted Marcum regarding (i) application of accounting principles to any specified transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on the Company’s consolidated financial statements, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv)) or a reportable event (as defined in Item 304(a)(1)(v)). During the fiscal year ending December 31, 2020, Marcum acted as the Company’s independent registered public accounting firm.

 

Item 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

 

The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. With respect to the annual period ended December 31, 2023, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our management has concluded that as of December 31, 2023, our disclosure controls and procedures were not effective due to the material weakness in our internal controls.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Material Weaknesses in Internal Controls

The Company’s management has concluded that our control around the accounting for certain notes receivable accounted for at fair value was not effectively designed or maintained, and therefore initially were not accounted for correctly. As a result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with accounting principles generally accepted in the United States of America. Management understands that the accounting standards applicable to our financial statements are complex and will seek to enhance controls over its experienced third-party professionals with whom management can consult with respect to accounting issues and remediate this material weakness.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal controls over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, including our Chief Executive Officer and Chief Financial Officer assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 and concluded that our internal controls over financial reporting were not effective, due to the material weakness in our internal control over financial reporting as described above. In making this assessment, our management used the 2013 framework established in “Internal Control-Integrated Framework” promulgated by the Committee of Sponsoring Organizations of the Treadway Commission, commonly referred to as the “COSO” criteria.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to the preparation and presentation of the consolidated financial statements.

 

This Annual Report does not contain an attestation report of our independent registered public accounting firm regarding internal control over financial reporting since the rules for smaller reporting companies provide for this exemption.

 

Changes in Internal Control over Financial Reporting

 

Other than the material weakness described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the year ended December 31, 2023 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. OTHER INFORMATION

 

None.

 

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

None.

 

27

 

 

PART III

 

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Directors and Executive Officers

 

The following table sets forth the name, age and position of each current director and executive officer of the Company.

 

            Director
Name   Age   Position   Since
Anthony Hayes(4)(6)   56   Chief Executive Officer and Chairman of the Board   2013
Tim S. Ledwick (1)(5)   66   Director   2015
Gregory James Blattner(3)(4)(7)   46   Director   2018
Robert Dudley(1)(2)(3)(6)   68   Director   2020
Kyle Wool(4)(7)   46   President and Director   2021
Soo Yu(6)   53   Director   2022
Kyle Haug(1)(2)(4)(5)   41   Director   2023
George Way   57   Chief Financial Officer   -
Christopher Devall   42   Chief Operating Officer   -

 

(1) Member of our Audit Committee.

(2) Member of our Compensation Committee.

(3) Member of our Nominating Committee.

(4) Member of our Investment Committee.

(5) Class I Director whose directorship will be voted on by stockholders at the 2024 Annual Stockholder Meeting.

(6) Class II Director whose directorship will be voted on by stockholders at the 2025 Annual Stockholder Meeting.

(7) Class III Director whose directorship will be voted on by stockholders at the 2026 Annual Stockholder Meeting.

 

The biographies of our current directors and significant employees are as follows:

 

Anthony Hayes

 

Mr. Anthony Hayes, a director and Chief Executive Officer since 2013, has served as the Chief Executive Officer of North South since March 2013 and since June 2013, as a consultant to our Company. Mr. Hayes was the fund manager of JaNSOME IP Management LLC and JaNSOME Patent Fund LP from August 2012 to August 2013, both of which he co-founded. Mr. Hayes was the founder and Managing Member of Atwater Partners of Texas LLC from March 2010 to August 2012 and a partner at Nelson Mullins Riley & Scarborough LLP from May 1999 to March 2010. Mr. Hayes received his Juris Doctorate from Tulane University School of Law and his B.A. in economics from Mary Washington College. The Board of Directors believes Mr. Hayes is qualified to serve as a director of the Company based on his intimate knowledge of the Company through his service as Chief Executive Officer.

 

Tim S. Ledwick

 

Mr. Tim S. Ledwick, who joined as a director in 2015, was most recently the Chief Financial Officer of SYFT, a private equity-backed company that provides software solutions and services to hospitals focused on reducing costs through superior inventory management practices which was successfully sold to GHX in 2022. In addition, since 2012 he has served on the board and Chair of the Audit Committee of Telkonet, Inc. (TKOI) a smart energy management technology company. From 2007 to 2011, Mr. Ledwick provided CFO consulting services to a $150 million services firm and, in addition, from 2007-2008 also acted as special advisor to The Dellacorte Group, a middle market financial advisory firm focused on transactions between $100 million and $1 billion. From 2002 through 2006, Mr. Ledwick was a member of the Board of Directors and Executive Vice President-CFO of Dictaphone Corporation playing a lead role in developing a business plan which revitalized the company, resulting in the successful sale of the firm and delivering seven times return to stockholders. From 2001-2002, Mr. Ledwick was brought on as CFO to lead the restructuring efforts of Lernout & Hauspie Speech Products, a Belgium-based Nasdaq listed speech technology company, whose market cap had at one point reached a high of $9 billion. From 1999 through 2001, he was CFO of Cross Media Marketing Corp, an $80 million public company headquartered in New York City, playing a lead role in the firm’s acquisition activity, tax analysis and capital raising. Mr. Ledwick is a member of the Connecticut Society of Certified Public Accountants and received his BBA in Accounting from The George Washington University and his MS in Finance from Fairfield University. The Board of Directors believes that Mr. Ledwick’s executive experience and financial expertise qualifies him to serve as a director of the Company.

 

28

 

 

Robert Dudley

 

Mr. Robert Dudley, who joined as a member of our Board of Directors in 2020, currently serves as the National and Metropolitan New York City Regional Sales Manager for Select Sector Standard & Poor’s Depositary Receipts (“SPDRs”). Prior to joining Select Sector SPDRs in 2008, Mr. Dudley held several managerial positions at Merrill Lynch from 1981 through 2007. Mr. Dudley began his career in the Merrill Lynch White Weld Capital Markets in Corporate Bond Syndicate, later moving to Sales Manager for Taxable Fixed Income and Equity Marketing. Later, Mr. Dudley managed Merrill Lynch Consults for the New York City District and ended his career as a Financial Advisor and Sales Manager at the Merrill Lynch Rockefeller Center Branch Office. The Board of Directors believes that Mr. Dudley’s executive experience and financial expertise qualifies him to serve as a director of the Company.

 

Kyle Wool

 

Mr. Kyle Wool, who joined as a member of our Board of Directors in 2021, currently serves as the President of Dominari Holdings, CEO of Dominari Financial, and the CEO of Dominari Securities. He boasts over 20 years in various aspects of global finance previously as a Managing Director of Oppenheimer & Co., Head of Wealth Management for their Asian branch, Executive Director at Morgan Stanley, and President of Revere Securities LLC. His extensive knowledge allows him to provide strategic guidance while advising those on the team managing all facets related to financial services categories with senior level insights within an organizing whose growth strategies, he actively contributes towards cultivating. Mr. Wool is also active in various philanthropic endeavors both domestically and abroad. He currently serves as a board member of LifeLine NY, a board member of the CIRSD (Center for International Relations and Sustainable Development), a board member of Project Rousseau and also a board member of Lang Lang International Music Foundation. Mr. Wool holds Series 7, 63, & 24 Securities licenses. The Board of Directors believes that Mr. Wool’s extensive experience in banking and wealth management qualifies him to serve as a director of the Company.

 

Soo Yu

 

Ms. Soo Yu, who joined as a member of our Board of Directors in 2022, is the managing Director of International Private Client Services for Dominari Securities where she leads the top performing Wool Group. With more than a decade of experience working in financial services, she focuses on international business development and the cultivation of overseas client banking relationships. A naturalized U.S. citizen originally from South Korea, Ms. Yu brings significant expertise in Asian markets and expansive global reach through her connectivity with international contacts. Before joining Dominari, Ms. Yu was Managing Director of Revere Securities. Ms. Yu earned her B.A. in Fine Arts from the Fashion Institute of Technology and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7, 66, 24 Securities licenses, New York Life, Accident and Health Insurance Agent/Broker, New York Property and Casualty Insurance Agent/Broker and Real Estate License. Previously, she maintained her Series 79 Securities license. Ms. Yu actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly as well as sustainability. She is currently a board member of The Korean Community Services of Metropolitan New York, Inc. The Board of Directors believes that Ms. Yu’s wealth management experience qualifies her to serve as a director of the Company.

 

Gregory James Blattner

 

Mr. Gregory James Blattner, who joined as a member of our Board of Directors in 2018, has nearly ten years of experience in the technology industry specializing in financial services. Since January 2022, he has served as the Vice President of AHEAD’s Managed Services business. AHEAD is technology services integrator that helps its clients architect, deploy and manage all multiplatform hybrid technology solutions. Prior to AHEAD, Mr. Blattner spent 7 years at Agio, a progressive managed information technology and cybersecurity services provider, where he was responsible for sales and account management of enterprise accounts. Prior to Agio, from May 2013 to December 2013, Mr. Blattner was a business development manager for the Eikon platform at Thomson Reuters. From 2010 to 2013, Mr. Blattner was a sales manager at American Express for its foreign exchange business. From 2005 to 2009, Mr. Blattner held various positions at JPMorgan, first in the operational risk management arm of the investment bank and later in Foreign Exchange product sales for its treasury services business. From 2000 to 2004, Mr. Blattner was an associate at Morgan Stanley’s corporate treasury funding desk. He earned a bachelor’s degree from Iona College. The Board of Directors believes Mr. Blattner’s extensive experience in technology and operations solutions qualifies him to serve as a director of the Company.

 

Kyle Haug

 

Mr. Kyle Haug, a member of the Board of Directors since 2023, currently serves as the Chief Operating Officer, Chief Technology Officer and Chief Marketing Officer for Haug Partners LLP. Haug Partners is an intellectual property law firm with offices in New York, Washington D.C. and West Palm Beach. The firm specializes in protecting innovator portfolios in the life science, automobile and technology sectors. Mr. Haug graduated with a B.S. in Administration of Justice from Penn State University where he was a collegiate swimmer. Mr. Haug served on the Junior Council for the American Museum of Natural History for over a decade and is a current committee member at the Metropolitan Club, Plandome Country Club and Haug Family Foundation. The Board of Directors believes Mr. Haug’s extensive experience and skill in aiding the growth of company operations qualifies him to serve as a director of the Company.

 

29

 

 

George Way

 

Mr. George Way has served as the Chief Financial Officer of the Company since April 3, 2023. Mr. Way has had a distinguished career as a senior executive with expertise in financial leadership, operations management, and acquisition due diligence. He has been a trusted business advisor to members of senior management with experience in solving complex business challenges, improving productivity, and reducing expenses. Prior to joining Dominari, Mr. Way served as the first Chief Financial Officer of Steward Partners, a wealth advisory firm responsible for financial reporting and analysis, tax strategy and reporting. Mr. Way also served as Chief Operating Officer of Ridgeworth Capital Management, a multi-boutique asset management firm with a broad range of responsibility encompassing operations, technology and infrastructure while leading the effort to consolidate of all central service platforms. He was also a Vice President of Equities Controlling & Head of Americas Equities Management Reporting Business at Deutsche Bank Securities Inc. Mr. Way started his career at Deloitte LLP and was an audit manager in their asset management practice. Mr. Way holds series 7 & 24 securities licenses. He received his Bachelor of Business Administration from Pace University and is a Certified Public Accountant in the State of New York. Mr. Way has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Way and any other person pursuant to which he was appointed as an officer of the Company. The Board of Directors believes that Mr. Way’s prior financial background qualifies him to serve as the Chief Financial Officer of the Company.

 

Christopher Devall

 

Mr. Christopher Devall has served as the Chief Operating Officer of the Company since January 1, 2023. Prior to that he was the Company’s Vice President of Operations from July 1, 2022 to January 1, 2023 and was a member of its advisory board from April 2022 to June 2022. Mr. Devall served as senior operations department head in the Department of Defense from February 2019 to June 2022, and as a senior operations department manager from April 2016 to January 2019. Mr. Devall is a retired military veteran and received his Masters of Business Administration from the University of Virginia Darden School of Business and holds a B.S. in Strategic Studies and Defense Analysis from Norwich University. Mr. Devall has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Devall and any other person pursuant to which he was appointed as an officer of the Company. The Board of Directors believes that Mr. Devall’s prior operations background qualifies him to serve as the Chief Operating Officer of the Company.

 

Family Relationships

 

There are no arrangements between our directors, executive officers and any other person pursuant to which our directors were nominated or elected for their positions. Mr. Wool and Ms. Yu have been married since December 2010.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act, requires our directors and executive officers, and anyone who beneficially owns ten percent (10%) or more of our common stock, to file with the SEC initial reports of beneficial ownership and reports of changes in beneficial ownership of common stock. Anyone required to file such reports also needs to provide us with copies of all Section 16(a) forms they file.

 

30

 

 

Based solely upon a review of (i) copies of the Section 16(a) filings received during or with respect to 2023 and (ii) certain written representations of our officers and directors, we believe that all filings required to be made pursuant to Section 16(a) of the Exchange Act during and with respect to 2023 were filed in a timely manner.

 

Audit Committee

 

The Audit Committee has been established in accordance with Section 3(a)(58)(A) of the Exchange Act and is currently comprised of Mr. Tim Ledwick (Chairman), Mr. Robert Dudley and Mr. Kyle Haug, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements for audit committee members. The Board of Directors has also determined that Mr. Ledwick is an “audit committee financial expert,” as defined by the applicable rules of the SEC and Nasdaq.

 

The Audit Committee is responsible for, among other things:

 

  reviewing the independence, qualifications, services, fees and performance of our independent registered public accounting firm;

 

  appointing, replacing and discharging our independent registered public accounting firm;

 

  pre-approving the professional services provided by our independent registered public accounting firm;

 

  reviewing the scope of the annual audit and reports and recommendations submitted by our independent registered public accounting firm; and

 

  reviewing our financial reporting and accounting policies, including any significant changes, with our management and our independent registered public accounting firm.

 

Nominating Committee

 

The Nominating Committee currently consists of Mr. Gregory James Blattner (Chairman) and Mr. Robert Dudley, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements.

 

The Nominating Committee reviews, evaluates and proposes candidates for election to our Board of Directors, and considers any nominees properly recommended by stockholders. The Nominating Committee promotes the proper constitution of our Board of Directors in order to meet its fiduciary obligations to our stockholders, and oversees the establishment of, and compliance with, appropriate governance standards.

 

Compensation Committee

 

The Compensation Committee currently consists of Mr. Robert Dudley (Chairman) and Mr. Kyle Haug, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements. In addition, each member of the Compensation Committee has been determined to be a non-employee director under Rule 16b-3 as promulgated under the Exchange Act. The Compensation Committee reviews and recommends to the Board of Directors the compensation for our executive officers and our non-employee directors for their services as members of the Board of Directors.

 

Compensation Committee Interlocks and Insider Participation

 

None of the members of our Compensation Committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past year has served, other than Mr. Wool who previously served on our Compensation Committee until his appointment as President, as a member of the Compensation Committee of any entity that has one or more of its executive officers serving on our Board of Directors or Compensation Committee.

 

Compensation Recovery

 

Under the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), in the event of material noncompliance with the financial reporting requirements that results in a financial restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our current and former executive officers. We have adopted a clawback policy to address this, which is attached as an exhibit filed with this Annual Report.

 

Investment Committee

 

The Investment Committee currently consists of Mr. Kyle Wool (Chairman), Mr. Anthony Hayes and Mr. Kyle Haug. The Investment Committee recommends and oversees the Company’s investment transactions, management, policies, and guidelines, including reviews of investment manager selection, establishment of investment benchmarks, review of investment performance and oversight of investment risk management exposure policies and guidelines.

 

31

 

 

Code of Ethics and Code of Conduct

 

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on our website, www.dominari.com. The information on or accessed through our website is deemed not to be incorporated in this Annual Report or to be part of this Annual Report.

 

Item 11. EXECUTIVE COMPENSATION

 

Named Executive Officers

 

Our named executive officers (“NEOs”), which consist of (i) all individuals serving as our principal executive officers during fiscal year 2023, (ii) two other of our most highly compensated executive officers who were serving as executive officers at December 31, 2023, and (iii) up to two other of our most highly compensated executive officers for whom disclosure would have been provided pursuant to clause (ii) but for the fact that the individual was not serving as an executive officer at December 31, 2023, are:

 

Anthony Hayes, our Chief Executive Officer, Director, Principal Accounting Officer, and Principal Financial Officer;

 

Soo Yu, our Special Projects Manager; and

 

Kyle Wool, our President.

 

The following Summary of Compensation table sets forth the compensation paid by our Company during the two fiscal years ended December 31, 2023 and 2022, to our NEOs.

 

Summary of Compensation Table

 

Name and Principal Position  Year  Salary
($)
   Bonus
($)
   Stock
Awards
($)(1)
   Non-Equity
Incentive Plan
Compensation
($)(2)
   All Other
Compensation
($)(3)
   Total
($)
 
Anthony Hayes,  2023   500,000    500,000    -    -    -    1,000,000 
Chief Executive Officer, Director,  2022   500,000    500,000    484,888    -    208,462    1,693,350 
Principal Accounting Officer and                                 
Principal Financial Officer                                 
Soo Yu,  2023   106,875    -    5,266,666    2,916,124    16,250    8,305,915 
Special Projects Manager  2022   -    -    -    -    -    - 
Kyle Wool  2023   500,000    -    -    -    100,360    600,360 
President  2022   -    -    -    -    -    - 

 

(1)The amount reported in this column represents the aggregate grant date fair value of stock granted to Ms. Yu during 2023, as calculated in accordance with FASB ASC Topic 718. The stock was earned pursuant to the attainment of certain assets under management goals, as set forth in Ms. Yu’s employment agreement (described below). The stock was fully vested on the grant date.

(2) The amount reported in this column represents the cash payment earned by Ms. Yu pursuant to her employment agreement for attaining certain assets under management goals, as more fully discussed below. The amount also includes performance compensation based on sales production paid at a rate of 60%.

(3)For Ms. Yu, the amounts reported in this column consist of director fees. For Mr. Wool, the amounts reported in this column consists of payments for reimbursement to support health and wellness and client development used exclusively for business.

 

32

 

 

Narrative Disclosure to Summary of Compensation Table

 

Employment Agreements

 

Anthony Hayes

 

On June 28, 2021, we entered into an employment agreement with Anthony Hayes (the “Hayes Agreement”), pursuant to which Mr. Hayes serves as our Chief Executive Officer. Under an amendment effective April 1, 2023, the term of the Hayes Agreement is for five years from the effective date of the amendment with automatic one-year extensions unless either the Company or Mr. Hayes gives six months’ non-renewal notice.

 

Pursuant to an amendment effective December 6, 2023, the Hayes Agreement provides that Mr. Hayes shall receive an annual base salary of $500,000 and an annual bonus. The annual bonus is paid in a combination of cash and shares of our common stock upon the Company’s achievement of certain annual revenue targets, as stated in the table below.

 

Annual Revenue   Annual Bonus
$3,500,000 or more  

$150,000, plus

154,559 shares

Between $7.5mm and $15mm  

$250,000, plus

154,599 shares

$15mm or more  

$500,000, plus

154,559 shares

 

Our Board of Directors may adopt different or additional performance criteria for future years after consultation with Mr. Hayes, provided that such criteria must be reasonably attainable. The bonus, to the extent earned, will be paid following the completion of our annual audit and public announcement of such results (and in all cases by July 31 of the year following the performance year), provided that Mr. Hayes is actively employed on April 15th of the year following the performance year.

 

The Hayes Agreement also provides that Mr. Hayes will be entitled to participate in pension, profit sharing, group insurance, hospitalization, group health and benefit plans, perquisites, and all other benefits and plans the Company provides to its senior officers. If at any time during the term, the Company does not provide its senior executives with health insurance, Mr. Hayes will be entitled to secure such insurance for himself and his immediate family and the Company will reimburse him for the cost of such insurance.

 

The Hayes Agreement provides that upon Mr. Hayes’ termination due to (A) his death, (B) disability, (C) by the Company without cause (as defined in the Hayes Agreement), or (D) due to the Company not renewing the Hayes Agreement term, he or his estate will be entitled to the following: (i) twelve months’ base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, and (iii) the pro-rata portion of any earned annual bonus.

 

If Mr. Hayes’ employment is terminated (A) by Mr. Hayes for good reason (as defined in the Hayes Agreement) or (B) within 30 days of a change in control (as defined in the Hayes Agreement), then Mr. Hayes will be entitled to receive the following: (i) twelve months’ base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, (iii) the pro-rata portion of any earned annual bonus, and (iv) full vesting of all outstanding and then unvested equity awards.

 

Soo Yu

 

On April 3, 2023, we entered into an employment agreement with Soo Yu (the “Yu Agreement”), pursuant to which Ms. Yu serves as both the Special Projects Manager and a registered representative of the Company performing broker services. The Yu Agreement has a one-year term, which the Company may extend at its discretion. If the Company does not extend the term, Ms. Yu’s continued service with us will be limited to broker services, which will be provided on an at-will basis.

 

The Yu Agreement provides that Ms. Yu shall receive a base salary of $150,000 per annum, which must be paid through the end of the term or any extension of the term unless Ms. Yu is terminated for cause (as defined in the Yu Agreement) or terminates voluntarily without Good Reason (as defined in the Yu Agreement). Additionally, the Yu Agreement provides that Ms. Yu will be entitled to receive a performance bonus based on the gross revenue she generates over a trailing twelve-month period in accordance with the formula below.

 

Trailing 12 month Gross Revenue ($)  Grid 
1 to 999,999   50%
1,000,000 to 1,999,999   55%
2,000,000 and up   60%

 

33

 

 

Any compensation earned by Ms. Yu pursuant to the table will be paid to Ms. Yu on a monthly basis on or about the 15th day following the end of each calendar month in which the underlying Gross Revenue was generated by Ms. Yu, with compensation earned being limited by the proceeds actually paid to the Company (rather than accrued). We agreed to commence Ms. Yu’s performance at the $2,000,000 level based on her most recent 12-month production with her prior employer. This level may only be adjusted after April 3, 2024. 

 

In addition to the gross revenue bonus, the Yu Agreement also provides for production payments (“Production Payments”) of up to $8,000,000, to be paid in equal payments of $2,666,666, upon Ms. Yu’s attainment of the following production goals:

 

Completing all required registrations and providing binding commitments and opening accounts for clients with assets under management or account value of at least $50,000,000;

 

Providing binding commitments and opening accounts for clients with assets under management or account value of at least $150,000,000 in the aggregate; and

 

Providing binding commitments and opening accounts for clients with assets under management or account value of at least $560,000,000 in the aggregate.

 

The account values are inclusive of prior account values. Each of the Production Payments will be paid as soon as administratively feasible after the date on which the conditions for a given payment are met but no later than 30 days, provided that the Company is in full compliance with its net capital and other regulatory requirements at that time. Production Payments will be made fifty percent (50%) in cash and fifty percent (50%) in shares of the Company. The Production Payments are subject to pro rata clawback if Ms. Yu is terminated for cause or resigns without good reason during the seven (7) years following the payment date of any Production Payment.

 

Pursuant to the Yu Agreement, Ms. Yu is subject to a perpetual confidentiality covenant, and for the duration of Ms. Yu’s employment and for the twelve months immediately following her termination of employment with the Company, a covenant not to solicit the Company’s clients and service providers.

 

Kyle Wool

 

On October 12, 2022, our subsidiary Dominari Financial entered into an employment agreement with Kyle Wool (the “Wool Agreement”), pursuant to which Mr. Wool serves as the Chief Executive Officer of Dominari Financial. The term of the Wool Agreement is five years with automatic one-year extensions unless either Dominari Financial or Mr. Wool gives six months’ non-renewal notice.

 

The Wool Agreement provides that Mr. Wool shall receive an annual base salary of $500,000 and an annual bonus. The annual bonus is paid in a combination of cash and shares of our common stock upon Dominari Financial’s achievement of certain annual revenue targets, as stated in the table below.

 

Annual Revenue   Annual Bonus
$3,500,000 or more  

$150,000, plus

154,559 shares

Between $7.5mm and $15mm  

$250,000, plus

154,599 shares

$15mm or more  

$500,000, plus

154,559 shares

 

Our Board of Directors may adopt different or additional performance criteria for future years after consultation with Mr. Wool, provided that such criteria must be reasonably attainable. The bonus, to the extent earned, will be paid following the completion of our annual audit and public announcement of such results (and in all cases by July 31 of the year following the performance year), provided that Mr. Wool is actively employed on April 15th of the year following the performance year.

 

The Wool Agreement also provides that Mr. Wool will be entitled to participate in pension, profit sharing, group insurance, hospitalization, group health and benefit plans, perquisites, and all other benefits and plans Financial provides to its senior officers. If at any time during the term, Dominari Financial does not provide its senior executives with health insurance, Mr. Wool will be entitled to secure such insurance for himself and his immediate family and Dominari Financial will reimburse him for the cost of such insurance.

 

Pursuant to the Wool Agreement, Mr. Wool is entitled to receive the following: (i) the support of an administrative assistant, (ii) reimbursement for his personal cell phone expenses, (iii) a monthly expense account of up to $20,000 for his business use, (iv) up to $100,000 in reimbursement for health care and social club memberships, and (v) subject to Dominari Financial’s consent, reimbursement for all other reasonable out-of-pocket expenses actually incurred or paid by Mr. Wool in the course of his employment.

 

The Wool Agreement provides that upon Mr. Wool’s termination due to (A) his death, (B) his disability, (C) within 40 days of the consummation of change in control transaction (as defined in the Wool Agreement), or (D) due to Dominari Financial not renewing the Wool Agreement term, he or his estate will be entitled to the following: (i) twelve months’ base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, and (iii) the pro-rata portion of any earned annual bonus.

 

If Mr. Wool’s employment is terminated (A) by Mr. Wool for good reason (as defined in the Wool Agreement) or (B) by Dominari Financial without cause (as defined in the Wool Agreement), then Mr. Wool will be entitled to receive the following: (i) twelve months’ base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, (iii) the pro-rata portion of any earned annual bonus, and (iv) full vesting of all outstanding and then unvested equity awards.

 

34

 

 

Retirement Benefits

 

Our NEOs are eligible to participate in our 401(k) plan, which is a defined contribution plan offered to all of our full-time employees. There are no other retirement benefit arrangements covering our NEOs.

 

Termination and Change in Control Benefits

  

The material terms of the contracts with each of our NEOs are summarized above, including the payments to NEOs at, following, or in connection with the resignation, change in control, or other termination of an NEO.

 

Outstanding Equity Awards at December 31, 2023

 

   Option Awards 
Name  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable(1)
   Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
   Option
Exercise
Price ($)
   Option
Expiration
Date
 
Anthony Hayes   2,941    -   $10.88    12/23/2030 
Soo Yu   -    -    -    - 
Kyle Wool   -    -    -    - 

 

(1)These options are fully vested.

 

Pay versus Performance

 

Pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information regarding “compensation actually paid”, as defined in Item 402(v). In accordance with SEC rules, the “compensation actually paid” amounts shown in the table below for each applicable year reflect certain adjustments to the values reported in the Summary of Compensation Table as described in the footnotes to the following table.

 

In accordance with the transitional relief under the SEC rules for smaller reporting companies, only three years of information is required as this is the Company’s first year of disclosure under Item 402(v) of Regulation S-K.

 

Year  Summary
Compensation
Table
Total for
PEO(1)
   Compensation
Actually Paid
to PEO(2)
   Average
Summary
Compensation
Table Total for
Non-PEO
NEOs(3)
   Average
Compensation
Actually Paid
to Non-PEO
NEOs(4)
   Value of
Initial Fixed
$100
Investment
Based On
TSR(5)
   Net Income
(Loss)(6)
 
(a)  (b)   (c)   (d)   (e)   (f)   (g) 
2023  $1,000,000   $1,000,000   $4,453,138   $4,453,138   $(25.14)  $(22,882)
2022  $1,693,350   $1,693,350   $406,499   $406,499   $(66.73)  $(22,107)
2021  $960,000   $962,663   $108,333   $108,333   $(32.18)  $(7,171)

 

(1)For each year shown, the PEO was the Chief Executive Officer, Anthony Hayes. The values reflected in this column reflect the “Total Compensation” paid to Mr. Hayes, the Company’s Principal Executive Officer, as set forth in the Summary of Compensation Table.

 

35

 

 

(2)The dollar amounts reported in this column represent the amount of “compensation actually paid” to Mr. Hayes, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Hayes during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to determine the “compensation actually paid” amounts reported above for Mr. Hayes:

 

Reconciliation of Summary of Compensation Table Total to Compensation Actually Paid for CEO  2023   2022   2021 
Summary of Compensation Table Total  $1,000,000   $1,693,350   $960,000 
Less: Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year       $(484,888)     
Plus: Fair Value of Awards Granted during Applicable Fiscal Year that Remain Unvested as of Applicable Fiscal Year End, Determined as of Applicable Fiscal Year End               
Plus: Fair Value of Awards Granted During the Applicable Fiscal Year that Vested During the Applicable Fiscal Year, Determined as of the Vesting Date       $484,888      
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that were Outstanding and Unvested as of the Applicable Fiscal Year End, Determined Based on the Change in ASC 718 Fair Value from Prior Fiscal year End to the Applicable Fiscal Year End            $2,663 
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that Vested During the Applicable Fiscal year, Determined based on the Change in ASC 718 Fair Value from the Prior Fiscal Year End to the Vesting Date               
Less: ASC 718 Fair Value of Awards Granted During a Prior Fiscal Year that were Forfeited During the Applicable Fiscal Year, determined as of the Prior Fiscal Year End               
Plus: Dividends or Other Earnings Paid During the Applicable Fiscal year Prior to the Vesting Date               
Plus: Incremental Fair Value of Options/SARs Modified During the Applicable Fiscal Year               
Compensation Actually Paid  $1,000,000   $1,693,350   $962,663 

 

(3)For 2021 and 2022, the non-PEO NEOs were Darrell Dotson, Carlos Aldavero and Christopher Devall. For 2023, the non-PEO NEOs were Soo Yu and Kyle Wool. The values reflected in this column reflect the average “Total Compensation” paid to each of the non-PEO NEOs in the applicable year, as set forth in the Summary of Compensation Table for the applicable year.

 

36

 

 

(4)The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the non-PEO NEOs, as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not necessarily reflect the actual average amount of compensation earned by or paid to such persons during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the non-PEO NEOs as a group for each year to determine the compensation actually paid:

 

Reconciliation of Average Summary of Compensation Table Totals for non-PEO NEOs to Average Compensation Actually Paid to non-PEO NEOs  2023   2022   2021 
Average Summary of Compensation Table Total  $4,453,138   $406,499   $108,333 
Less: Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year  $(5,266,666)  $(193,851)     
Plus: Fair Value of Awards Granted during Applicable Fiscal Year that Remain Unvested as of Applicable Fiscal Year End, Determined as of Applicable Fiscal Year End               
Plus: Fair Value of Awards Granted During the Applicable Fiscal Year that Vested During the Applicable Fiscal Year, Determined as of the Vesting Date  $5,266,666   $193,851      
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that were Outstanding and Unvested as of the Applicable Fiscal Year End, Determined Based on the Change in ASC 718 Fair Value from Prior Fiscal year End to the Applicable Fiscal Year End               
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that Vested During the Applicable Fiscal year, Determined based on the Change in ASC 718 Fair Value from the Prior Fiscal Year End to the Vesting Date               
Less: ASC 718 Fair Value of Awards Granted During a Prior Fiscal Year that were Forfeited During the Applicable Fiscal Year, determined as of the Prior Fiscal Year End               
Plus: Dividends or Other Earnings Paid During the Applicable Fiscal year Prior to the Vesting Date               
Plus: Incremental Fair Value of Options/SARs Modified During the Applicable Fiscal Year               
Average Compensation Actually Paid  $4,453,138   $406,499   $108,333 

 

(5)Cumulative Total Share Return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period.

(6)The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable year.

 

37

 

 

Analysis of the Information Presented in the Pay versus Performance Table

 

The Company’s executive compensation program reflects a variable pay-for-performance philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table.

 

Compensation Actually Paid and Cumulative TSR

 

The following graph illustrates the amount of “compensation actually paid” (“CAP”) to Mr. Hayes and the average amount of CAP to the Company’s Named Executive Officers as a group (excluding Mr. Hayes) relative to the Company’s cumulative TSR over the three years presented in the table.

 

 

 

38

 

 

Compensation Actually Paid and Net Loss

 

As demonstrated by the following table, the amount of CAP to Mr. Hayes and the average amount of CAP to the Company’s Named Executive officers as a group (excluding Mr. Hayes) is not aligned with the Company’s net loss over the three years presented in the table. The Company has not used net loss as a performance measure in the overall executive compensation program.

 

 

Director Compensation

 

Our non-employee directors received the following annual compensation for service as a member of the Board of Directors for the fiscal year ended December 31, 2023:

 

Annual Retainer  $65,000   To be paid in cash in four equal quarterly installments.
Additional Retainer  $5,000   To be paid to the Chairman of the Board upon election annually.

 

The following table summarizes the compensation paid to non-employee directors during the year ended December 31, 2023.

 

   Fees earned or paid in cash ($)   Stock Awards ($)(1)(2)   Option Awards ($)   Non-Equity Incentive Plan Compensation ($)   Non-Qualified Deferred Compensation Earnings
($)
   All Other Compensation
($)
   Total
($)
 
Robert J. Vander Zanden (3)   65,000          -          -          -          -          -    65,000 
Tim Ledwick (4)   65,000    -    -    -    -    -    65,000 
Gregory Blattner (5)   65,000    -    -    -    -    -    65,000 
Robert Dudley (6)   65,000    -    -    -    -    -    65,000 
Kyle Haug (7)   10,833    -    -    -    -    -    10,833 

  

(1)All stock awards were granted in accordance with ASC Topic 718 – Compensation – Stock Compensation.
(2)As of December 31, 2023, the aggregate number of stock and option awards held by each director was as follows:
Robert J. Vander Zander holds 2,941 option awards;
Tim Ledwick holds 2,941 option awards;
Gregory Blattner holds 2,941 option awards; and
Robert Dudley holds 2,941 option awards.
(3)Mr. Vander Zanden was paid $65,000 in cash compensation for his service as a director in 2023.
(4)Mr. Ledwick was paid $65,000 in cash compensation for his service as a director in 2023.
(5)Mr. Blattner was paid $65,000 in cash compensation for his service as a director in 2023.
(6)Mr. Dudley was paid $65,000 in cash compensation for his service as a director in 2023.
(7)Mr. Haug was paid $10,833 in cash compensation for his service as a director in 2023.

 

39

 

 

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table provides information about our common stock that may be issued upon the exercise of options, warrants and rights under all of our existing equity compensation plans as of December 31, 2023.

 

Plan Category  Number of
securities
to be
issued upon
exercise of
outstanding options,
warrants
and rights
(1)
   Weighted
average
exercise
price of
outstanding
options,
warrants and
rights
   Number of
securities
remaining available for
future
issuance under
equity compensation
plans
(excluding
securities
reflected in column (1)) (2)
 
Equity compensation plans approved by security holder   556,477   $4.94    839,686 
Equity compensation plans not approved by security holder   -    -    - 
    556,477         839,686 

 

(1)Consists of options to acquire 24,454 shares of common stock under the 2014 Equity Incentive Plan and 395,714 shares of common stock under the 2022 Equity Incentive Plan, and restricted stock awards to acquire 136,309 shares of common stock under the 2022 Equity Incentive Plan.

(2)Consists of shares of common stock available for future issuance under our equity incentive plans.

 

40

 

 

Beneficial Ownership of our Capital Stock by Certain Beneficial Owners and Management

 

The following tables set forth certain information concerning the number of shares of our common stock, Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and Series D-1 Convertible Preferred Stock (the “Series D-1 Preferred Stock”) owned beneficially as of March 26, 2024 by (i) our officers and directors as a group and (ii) each person (including any group) known to us to own more than 5% of our common stock, Series D Preferred Stock and Series D-1 Preferred Stock. As of March 26, 2024 there were 5,934,917 shares of common stock outstanding, 3,825 shares of Series D Preferred Stock outstanding and 834 shares of Series D-1 Preferred Stock outstanding. Unless otherwise indicated, it is our understanding and belief that the stockholders listed possess sole voting and investment power with respect to the shares shown.

 

   Common Stock
Beneficially Owned
   Series D
Preferred Stock
   Series D-1
Preferred Stock
 
Name of Beneficial Owner(1)  Shares   Percentage   Shares   Percentage   Shares   Percentage 
Anthony Hayes   317,310(2)   5.35%                
Tim S. Ledwick   12,826(3)   *                 
Robert Dudley   12,411(4)   *                 
Gregory James Blattner   12,411(5)   *                 
Kyle Wool   246,431(6)   4.15%                
Soo Yu   1,243,466(7)   20.95%                
Kyle Haug       *                 
George Way   32,103(8)   *                 
Christopher Devall   77,651(9)   1.31%                
All Directors and Officers as a Group (9 persons)   1,954,609    32.93%                    
                               
Stockholders                              
Daniel W. Armstrong
611 Loch Chalet Ct Arlington, TX 76012-3470
   10(10)   *    1,350    35.29%        
R. Douglas Armstrong 570 Ocean Dr. Apt 201 Juno Beach, FL 33408-1953   4(11)   *    450    11.76%        
Francis Howard 376 Victoria Place London, SW1 V1AA United Kingdom   7(12)   *    900    23.53%        
Charles Strogen 6 Winona Ln Sea Ranch Lakes, FL 33308-2913   9(13)   *    1,125    29.42%        
Chai Lifeline Inc. 151 West 30th Street, Fl 3 New York, NY 10001-4027   7(14)   *            834    100%

  

*Less than 1% of the outstanding shares of the Company’s common stock.

 

(1)Under Rule 13d-3 of the Exchange Act a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

(2)Includes 314,369 shares of common stock and 2,941 options for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(3)Includes 9,885 shares of common stock and 2,941 options for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(4)Includes 9,470 shares of common stock and 2,941 options for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(5)Includes 9,470 shares of common stock and 2,941 options for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(6)Includes 246,431 shares of common stock.

(7)Includes 1,243,466 shares of common stock.

 

41

 

 

(8)Includes 32,103 restricted stock awards for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(9)Includes 30,033 shares of common stock and 47,618 options for purchase of shares of common stock, which are exercisable within 60 days of March 26, 2024.

(10)Represents 10 shares of common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 26, 2024.

(11)Represents 4 shares of common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 26, 2024.

(12)Represents 7 shares of common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 26, 2024.

(13)Represents 9 shares of common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 26, 2024.

(14)Represents 7 shares of common stock issuable upon conversion of the Series D-1 Preferred Stock, which are convertible within 60 days of March 26, 2024.

 

Effective October 11, 2023, the Company and Continental Stock Transfer & Trust Co. entered into a certain rights agreement (the “Rights Agreement”). The Rights Agreement provides each stockholder of record a dividend distribution of one “right” for each outstanding share of common stock. Rights become exercisable at the earlier of ten days following: (1) a public announcement that an acquirer has purchased or has the right to acquire 4.99% or more of our common stock, in connection with, (x) the Company consolidating, or merging into any other person, (y) any person consolidates or merges with or into the Company or (z) the Company sells or otherwise transfers to any person or persons, in one or more transactions, assets or earning power aggregating 50% or more of the assets or earning power of the Company or (2) the commencement of a tender offer which would result in an offer or beneficially owning 10% or more of our outstanding common stock. All rights held by an acquirer or offer or expire on the announced acquisition date, and all rights expire at the earliest of: (i) the close of business on October 11, 2024, subject to extension; (ii) the time at which the Rights are redeemed; (iii) the time at which the rights are exchanged; (iv) the closing of any merger or other acquisition transaction involving the Company pursuant to a specified agreement; (vi) the close of business on the date the Board of Directors determines that the Rights Agreement is no longer necessary or desirable for the preservation of tax benefits; and (vii) the close of business on the first day of a taxable year of the Company to which the Board of Directors determines that no tax benefits are available to be carried forward. Each right entitles a stockholder to acquire, at a price of $5.00 per one one-thousandth of a share of our Series Q Preferred Stock, subject to adjustments, which carries voting and dividend rights similar to one share of our common stock. The purchase price of the preferred stock fractional amount is subject to adjustment for certain events as described in the Rights Agreement. At the discretion of a majority of the Board of Directors and within a specified time period, we may redeem all of the rights at a price of $0.0001 per right. The Board of Directors may also amend any provisions of the Rights Agreement prior to exercise.

 

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

 

The current Board of Directors consists of: Mr. Anthony Hayes, Mr. Tim S. Ledwick, Mr. Robert Dudley, Mr. Kyle Wool, Mr. Gregory James Blattner, Ms. Soo Yu and Mr. Kyle Haug. The Board of Directors has determined that Mr. Ledwick, Mr. Blattner, and Mr. Haug are independent directors within the meaning of the applicable Nasdaq rules. Our Audit, Compensation, and Nominating Committees consist solely of independent directors.

 

There have been no transactions, since January 1, 2022, to which we have been a party, in which the amount involved exceeds or will exceed $120,000 and in which any of our directors, executive officers, holders of more than 5% of our capital stock, or immediate family member thereof, had or will have a direct or indirect material interest.

 

We have not adopted written policies and procedures specifically for related person transactions. Our Board of Directors is responsible for the approval of all related party transactions.

 

42

 

 

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees

 

The following table sets forth the fees for professional services rendered by Marcum for audit and other services provided for the fiscal years ended December 31, 2023 and December 31, 2022.

 

   2023   2022 
Audit Fees  $419,360   $60,517 
Audit Related Fees   -    - 
Tax Fees   -    - 
All Other Fees   -    - 
Total  $419,360   $60,517 

   

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

 

Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee has established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. No non-audit services were performed by our principal accountants during the fiscal years ended December 31, 2023 and 2022. Our Audit Committee pre-approves these services by category and service. Our Audit Committee has pre-approved all of the services provided by our principal accountants.

 

43

 

 

PART IV

  

Item 15. EXHIBIT AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES

 

Consolidated Financial Statements

 

The following consolidated financial statements are included in Item 8 herein:

 

2. Consolidated Financial Statement Schedules

 

None.

 

EXHIBITS

 

Exhibit No.   Description
     
3.1   Amended and Restated Certificate of Incorporation of Spherix Incorporated, dated April 24, 2014 (incorporated by reference to Form 8-K filed April 25, 2014)
     
3.2   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Spherix Incorporated, dated March 2, 2016 (incorporated by reference to Form 8-K filed March 18, 2016)
     
3.3   Amended and Restated Bylaws of Spherix Incorporated (incorporated by reference to Form 8-K filed October 15, 2013)
     
3.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Spherix Incorporated, effective March 4, 2016 (incorporated by reference to Form 10-K filed March 29, 2016)
     
3.5   Second Amended and Restated Bylaws of AIkido Pharma Inc. (incorporated by reference from the Company’s Proxy Statement on Form DEF 14A filed October 5, 2020)
     
3.6   Amendment No. 1 to the Second Amended and Restated Bylaws of AIkido Pharma Inc. (incorporated by reference to Form 8-K filed on November 9, 2021)
     
3.7   Certificate of Amendment to Amended and Restated Articles of Incorporation of Aikido Inc., effective on June 7, 2022 (incorporated by reference to Form 8-K filed on June 10, 2022)
     
3.8   Certificate of Amendment to Amended and Restated Articles of Incorporation of Aikido Inc., effective on December 22, 2022 (incorporated by reference to Form 8-K filed on December 22, 2022)
     
3.9   Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Form 8-K filed on April 4, 2013)
     
3.10   Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (incorporated by reference to Form 8-K filed on November 29, 2013)
     
3.11   Certificate of Designation of Preferences, Rights and Limitations of Series Q Preferred Stock (incorporated by reference to Form 8-K filed on October 17, 2023)
     
4.1   Specimen Certificate for common stock, par value $0.0001 per share, of Spherix Incorporated (incorporated by reference to Form S-3/A filed April 17, 2014)
     
4.2   Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Form 10-K filed on March 31, 2023)
     
4.3   Rights Agreement, dated as of October 11, 2023, by and between Dominari Holdings Inc., as the Company, and Continental Stock Transfer & Trust Company, as Rights Agent (incorporated by reference to Form 8-K filed on October 17, 2023)  

 

44

 

 

10.1   Spherix Incorporated 2014 Equity Incentive Plan (incorporated by reference from the Company’s Proxy Statement on Form DEF 14A filed December 20, 2013)
     
10.2   Amendment to Spherix Incorporated 2014 Equity Incentive Plan (incorporated by reference from the Company’s Proxy Statement on Form DEF 14A filed on March 28, 2014)
     
10.3   Form of Indemnification Agreement (incorporated by reference to the Form 8-K filed on September 10, 2013)
     
10.4   Employment Agreement, effective as of April 1, 2016, by and between Spherix Incorporated and Anthony Hayes (incorporated by reference to Form 8-K filed May 26, 2016)
     
10.5   Amendment to Employment Agreement, by and between Spherix Incorporated and Anthony Hayes (incorporated by reference to the Form 8-K filed on October 25, 2017)
     
10.6   Technology Monetization Agreement, dated as of March 11, 2016, and amended as of April 22, 2016, April 27, 2016 and May 22, 2016, by and between Spherix Incorporated and Equitable IP Corporation (incorporated by reference to Form 8-K filed August 2, 2016)
     
10.7   At The Market Offering Agreement, dated as of August 9, 2019, by and between Spherix Incorporated and H.C. Wainwright & Co., LLC (incorporated by reference to Form 8-K filed August 9, 2019)
     
10.8   Amendment to Aikido Pharma Inc. 2014 Equity Incentive Plan (incorporated by reference from the Company’s Proxy Statement on Form DEF 14A filed October 5, 2020)
     
10.9   Form of Securities Purchase Agreement Between AIKido Pharma Inc. and the Investors thereto, dated February 24, 2022 (incorporated by reference to Form 8-K filed on March 2, 2022)
     
10.10   Confirmation of Mutual Understanding Between Aikido Pharma Inc. and each of the Warrant Holders, dated as of March 24, 2022 (incorporated by reference from the Company’s Annual Report on Form 10-K filed on March 28, 2022)
     
10.11   Aikido Pharma Inc. 2022 Equity Incentive Plan (incorporated by reference from the Company’s Proxy Statement on Form DEF 14A filed October 21, 2022)
     
10.12   Employment Agreement, Made and Entered into as of July 1, 2022, By and Between Aikido Pharma Inc. and Christopher Devall (incorporated by reference to Form 8-K Filed on January 6, 2023)
     
10.13   Employment Agreement, Made and Entered into as of July 22, 2022, By and Between Aikido Pharma Inc. and Carlos Aldavero (incorporated by reference to Form 10-K filed on March 31, 2023)
     
10.14   Amendment to Employment Agreement, Dated as of January 1, 2023, By and Between Dominari Holdings Inc. and Christopher Devall (incorporated by reference to Form 8-K filed on January 6, 2023)
     
10.15   Amended and Restated Membership Interest Purchase Agreement, Dated as of March 27, 2023, by and among Fieldpoint Private Securities, LLC, Fieldpoint Private Bank & Trust, and Dominari Financial Inc. (incorporated by reference to Form 8-K filed on March 28, 2023)
     
10.16   Employment Agreement, Made and Entered into as of March 29, 2023, By and Between Dominari Holdings Inc. and George M. Way (incorporated by reference to Form 8-K filed on April 3, 2023)
     
10.17   Employment Agreement, Made and Entered into as of April 3, 2023, By and Between Dominari Securities LLC and Soo Yu (incorporated by reference to Form 10-Q filed on May 11, 2023)

 

45

 

 

10.18   Amendment to Employment Agreement, Made and Entered into as of April 19, 2023, By and Between Dominari Securities LLC and Soo Yu (incorporated by reference to Form 10-Q filed on May 11, 2023)
     
21.1*   List of Subsidiaries
     
23.1*   Consent of Marcum LLP
     
31.1*   Certification of Principal Executive Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
97.1*   Clawback Policy
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*

**

Filed herewith.

Furnished herewith.

 

Item 16. FORM 10-K SUMMARY

 

Not applicable.

 

46

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Dominari Holdings Inc.
     
  By: /s/ Anthony Hayes
    Anthony Hayes
Date: April 1, 2024   Chief Executive Officer and Chairman

 

  By: /s/ George Way
    George Way
Date: April 1, 2024   Chief Financial Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Anthony Hayes   Chief Executive Officer and Chairman   April 1, 2024
Anthony Hayes        
         
/s/ George Way   Chief Financial Officer   April 1, 2024
George Way        
         
/s/ Kyle Wool    President and Director   April 1, 2024
Kyle Wool        
         
/s/ Tim S. Ledwick   Director   April 1, 2024
Tim S. Ledwick        
         
/s/ Robert Dudley   Director   April 1, 2024
Robert Dudley        
         
/s/ Gregory James Blattner   Director   April 1, 2024
Gregory James Blattner        
         
/s/ Soo Yu   Director   April 1, 2024
Soo Yu        
         
/s/ Kyle Haug   Director   April 1, 2024
Kyle Haug        

 

 

47

 

 

 

3.95 4.91 5229477 5334075 false FY 0000012239 0000012239 2023-01-01 2023-12-31 0000012239 2023-06-30 0000012239 2024-03-26 0000012239 2023-12-31 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-12-31 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2023-12-31 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-12-31 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-12-31 0000012239 srt:MinimumMember 2023-12-31 0000012239 srt:MaximumMember 2023-12-31 0000012239 domh:FPSMembershipInterestsMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-12-31 0000012239 domh:FPSMembershipInterestsMember 2023-12-31 0000012239 domh:FPSPurchaseAgreementMember 2023-12-31 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:VicinityMotorCorpMember 2021-10-25 2021-10-25 0000012239 domh:VicinityMotorCorpMember us-gaap:CommonStockMember 2021-10-25 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000012239 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0000012239 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000012239 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0000012239 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000012239 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0000012239 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000012239 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0000012239 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0000012239 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2023-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-12-31 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInUnusualMachinesMember 2023-12-31 0000012239 domh:InvestmentInUnusualMachinesMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-12-31 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-12-31 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-12-31 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-12-31 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-12-31 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-12-31 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-12-31 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-12-31 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-12-31 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-12-31 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2022-01-01 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2021-12-06 2021-12-06 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2021-12-06 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-10-20 2023-10-20 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-10-20 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowIncInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowIncInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-12-31 0000012239 domh:ConvergentInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:ConvergentInvestmentMember 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2022-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000012239 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000012239 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000012239 domh:SeriesORedeemableConvertiblePreferredStockMember 2022-02-24 0000012239 domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-02-24 0000012239 domh:SeriesOPreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:SeriesOPreferredStockMember 2022-02-24 0000012239 us-gaap:PreferredStockMember 2022-02-24 0000012239 us-gaap:PreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:SeriesPPreferredStockMember 2022-02-24 0000012239 domh:SeriesPPreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:RedemptionRightsMember 2023-06-30 0000012239 2023-01-01 2023-06-30 0000012239 domh:SeriesOPreferredStockMember 2023-06-30 0000012239 domh:SeriesPPreferredStockMember 2023-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 2022-01-21 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 2023-03-06 2023-03-06 0000012239 domh:SeriesDConvertiblePreferredStockMember 2023-12-31 0000012239 domh:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2022-12-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 domh:BusinessCombinationMember 2023-12-31 0000012239 domh:SooYuMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember us-gaap:RestrictedStockUnitsRSUMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember us-gaap:CommonStockMember 2023-12-19 2023-12-19 0000012239 domh:SooYuMember 2023-12-19 2023-12-19 0000012239 domh:JoshuaShipleyMember us-gaap:CommonStockMember 2023-12-19 2023-12-19 0000012239 domh:JoshuaShipleyMember 2023-12-19 2023-12-19 0000012239 srt:DirectorMember us-gaap:CommonStockMember 2023-12-31 0000012239 srt:DirectorMember us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-12-31 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2021-12-31 2021-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2023-12-31 0000012239 us-gaap:WarrantMember 2023-12-31 2023-12-31 0000012239 2021-12-31 2021-12-31 0000012239 us-gaap:OperatingIncomeLossMember 2023-01-01 2023-12-31 0000012239 domh:DominariSecuritiesMember 2023-12-31 0000012239 domh:DominariFinancialMember 2023-01-01 2023-12-31 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-12-31 0000012239 domh:ConsolidatedMember 2023-01-01 2023-12-31 0000012239 domh:DominariFinancialMember 2022-01-01 2022-12-31 0000012239 domh:LegacyAIkidoPharmaMember 2022-01-01 2022-12-31 0000012239 domh:ConsolidatedMember 2022-01-01 2022-12-31 0000012239 2023-10-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
EX-21.1 2 ea020251101ex21-1_dominari.htm LIST OF SUBSIDIARIES

EXHIBIT 21.1

 

List of Subsidiaries

 

AIkido Labs LLC

 

Dominari Financial Inc.

 

Dominari Securities LLC

EX-23.1 3 ea020251101ex23-1_dominari.htm CONSENT OF MARCUM LLP

EXHIBIT 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in the Registration Statement of Dominari Holdings Inc. and Subsidiaries on Form S-8 (File No. 333-271179, File No. 333-267318, File No. 333-210627, File No. 333-197429, and File No. 333-185524) and Form S-3 ( File No. 333-238172), of our report dated April 1, 2024, with respect to our audits of the consolidated financial statements of Dominari Holdings Inc. and Subsidiaries as of December 31, 2023 and 2022, and for each of the two years ended December 31, 2023, which report is included in this Annual Report on Form 10-K of Dominari Holdings, Inc. for the year ended December 31, 2023.

 

/s/ Marcum llp

 

Marcum llp

New York, NY

April 1, 2024

 

EX-31.1 4 ea020251101ex31-1_dominari.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Dominari Holdings Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 1, 2024

 

/s/ Anthony Hayes  
Anthony Hayes,
Chief Executive Officer and Chairman
 

 

EX-31.2 5 ea020251101ex31-2_dominari.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO EXCHANGE ACT

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, George Way, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Dominari Holdings Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 1, 2024

 

/s/ George Way  
George Way,
Chief Financial Officer
 

 

EX-32.1 6 ea020251101ex32-1_dominari.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002
CERTIFICATION

 

In connection with the Annual Report of Dominari Holdings Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Anthony Hayes  
Anthony Hayes  
Chief Executive Officer and Chairman  

 

April 1, 2024

 

EX-32.2 7 ea020251101ex32-2_dominari.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

CERTIFICATION

 

In connection with the Annual Report of Dominari Holdings Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ George Way  
George Way  
Chief Financial Officer  

 

April 1, 2024

 

EX-97.1 8 ea020251101ex97-1_dominari.htm CLAWBACK POLICY

EXHIBIT 97.1

 

DOMINARI HOLDINGS INC.

 

EXECUTIVE COMPENSATION CLAWBACK POLICY

 

Effective as of December 1, 2023

 

The Board of Directors (the “Board”) of Dominari Holdings Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in any agreement between the Company, or any subsidiary of the Company, and any person covered by this Policy. If any such other policy or agreement provides that a greater amount of compensation shall be subject to clawback, such other policy or agreement shall apply to the amount in excess of the amount subject to clawback under this Policy.

 

This Policy shall be interpreted to comply with United States Securities and Exchange Commission (“SEC”) Rule 10D-1 and Listing Rule 5608 (the “Listing Rule”) of The Nasdaq Stock Market, LLC (“Nasdaq”), as may be amended or supplemented and interpreted from time to time by Nasdaq. To the extent this Policy is in any manner deemed inconsistent with the Listing Rule, this Policy shall be treated as having been amended to be compliant with the Listing Rule.

 

1. Definitions. Unless the context otherwise the following definitions apply for purposes of this Policy:

 

(a) Executive Officer. An executive officer is the Company’s chief executive officer and/or president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of the Listing Rule would include at a minimum executive officers identified in the Listing Rule.

 

(b) Financial Reporting Measures. Financial reporting measures are measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also financial reporting measures. A financial reporting measure need not be presented within the financial statements or included in a filing with the SEC and may be such financial measures as may be determined by the Board or the Compensation Committee thereof (the “Compensation Committee”).

 

(c) Incentive-Based Compensation. Incentive-based compensation is any compensation that is granted, earned or vested based wholly or in part upon the attainment of a financial reporting measure(collectively, “Incentive-Based Compensation”).

 

 

 

 

(d) Received. Incentive-Based Compensation is deemed “received” in the Company’s fiscal period during which the financial reporting measure specified in the Incentive- Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.

 

2. Application of this Policy. This recovery of Incentive-Based Compensation from an executive officer as provided for in this Policy shall apply only in the event that the Company is required to prepare an accounting restatement due to the material noncompliance of Company with any financial reporting requirement under the United States securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

 

3. Recovery Period.

 

(a) The Incentive-Based Compensation subject to recovery is the Incentive- Based Compensation received during the three (3) completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described in Section

2 above, provided that the person served as an Executive Officer at any time during the performance period applicable to the Incentive-Based Compensation in question. The date that the Company is required to prepare an accounting restatement shall be determined pursuant to the Listing Rule.

 

(b) Notwithstanding the foregoing, this Policy shall only apply if the Incentive- Based Compensation is received (i) while the Company has a class of securities listed on Nasdaq and (ii) on or after October 2, 2023.

 

(c) The provisions of the Listing Rule shall apply with respect to Incentive- Based Compensation received during a transition period arising due to a change in the Company’s fiscal year.

 

4. Erroneously Awarded Compensation. The amount of Incentive-Based Compensation subject to recovery from the applicable executive officers under this Policy (“Erroneously Awarded Compensation”) shall be equal to the amount of Incentive-Based Compensation received that exceeds the amount of Incentive Based-Compensation that otherwise would have been received had it been determined based on the restated amounts and shall be computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement: (a) the amount shall be based on a reasonable estimate by the Company’s Chief Financial Officer (or principal accounting officer, if the office of Chief Financial Officer is not then filled) of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, which estimate shall be subject to the review and approval of the Compensation Committee; and (b) the Company must maintain reasonable documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq if requested. Notwithstanding the foregoing, if the proposed Incentive-Based Compensation recovery would affect compensation paid to the Company’s Chief Financial Officer, the determination shall be made by the Compensation Committee.

 

2

 

 

5. Timing of Recovery. The Company shall recover any Erroneously Awarded Compensation reasonably promptly except to the extent that the conditions of paragraphs (a), (b), or (c) below apply. The Compensation Committee shall determine the repayment schedule for each amount of Erroneously Awarded Compensation in a manner that complies with this “reasonably promptly” requirement. Such determination shall be consistent with any applicable legal guidance by the SEC, Nasdaq, judicial opinion, or otherwise. The determination of “reasonably promptly” may vary from case to case and the Compensation Committee is authorized to adopt additional rules or policies to further describe what repayment schedules satisfy this requirement.

 

(a) Erroneously Awarded Compensation need not be recovered if the direct expense paid to a third party to assist in enforcing (or making determinations in connection with the enforcement of) this Policy would exceed the amount to be recovered and the Compensation Committee has made a determination that recovery would be impracticable. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall (i) make a reasonable attempt to recover such Erroneously Awarded Compensation, (ii) document such reasonable attempt or attempts to recover, and (iii) provide appropriate documentation to the Compensation Committee or Nasdaq, if requested.

 

(b) Erroneously Awarded Compensation need not be recovered if recovery would violate home country law where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on a violation of home country law, the Company shall obtain an opinion of home country counsel, in form and substance that would be reasonably acceptable to Nasdaq, that recovery would result in such a violation and shall provide such opinion to Nasdaq, if requested.

 

(c) Erroneously Awarded Compensation need not be recovered if recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder (as such provision may be amended, modified or supplemented).

 

6. Compensation Committee Decisions. Decisions of the Compensation Committee with respect to this Policy shall be final, conclusive, and binding on all executive officers subject to this Policy.

 

7. No Indemnification. Notwithstanding anything to the contrary in any other policy of the Company or any agreement between the Company and an executive officer, no executive officer shall be indemnified by the Company against the loss arising from the recovery of any Erroneously Awarded Compensation.

 

3

 

 

8. Agreement to Policy by Executive Officers. The Company shall take reasonable steps to inform executive officers of this Policy and obtain their express agreement to this Policy, which steps may constitute the inclusion of this Policy as an attachment to any award that is accepted by an executive officer. This Policy shall be deemed to apply to each employment or grant agreement between the Company or any of its subsidiaries and any executive officer subject to this Policy.

 

 

# # #

 

 

4

 

GRAPHIC 9 img_001.jpg GRAPHIC begin 644 img_001.jpg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end GRAPHIC 10 img_002.jpg GRAPHIC begin 644 img_002.jpg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end EX-101.SCH 11 domh-20231231.xsd XBRL SCHEMA FILE 995301 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Consolidated Statements of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 995306 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - FPS Acquisition link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Investments in Marketable Securities link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Short-Term Investments link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Notes Receivable link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Redeemable Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995321 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 995322 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995323 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 995324 - Disclosure - Regulatory link:presentationLink link:definitionLink link:calculationLink 995325 - Disclosure - Related Party Transaction link:presentationLink link:definitionLink link:calculationLink 995326 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 995327 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - FPS Acquisition (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Investments in Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Short-Term Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Long-Term Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Notes Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Organization and Description of Business and Recent Developments (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - FPS Acquisition (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Short-Term Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about the Company’s Operating Leases link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations link:presentationLink link:definitionLink link:calculationLink 996035 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases link:presentationLink link:definitionLink link:calculationLink 996036 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments link:presentationLink link:definitionLink link:calculationLink 996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share link:presentationLink link:definitionLink link:calculationLink 996038 - Disclosure - Redeemable Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996039 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996040 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity link:presentationLink link:definitionLink link:calculationLink 996041 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity link:presentationLink link:definitionLink link:calculationLink 996042 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity link:presentationLink link:definitionLink link:calculationLink 996043 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type link:presentationLink link:definitionLink link:calculationLink 996044 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 996045 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision link:presentationLink link:definitionLink link:calculationLink 996046 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rates link:presentationLink link:definitionLink link:calculationLink 996047 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 996048 - Disclosure - Regulatory (Details) link:presentationLink link:definitionLink link:calculationLink 996049 - Disclosure - Related Party Transaction (Details) link:presentationLink link:definitionLink link:calculationLink 996050 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 996051 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 12 domh-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 domh-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 14 domh-20231231_lab.xml XBRL LABEL FILE EX-101.PRE 15 domh-20231231_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 26, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Financial Statement Error Correction [Flag] false    
Entity Interactive Data Current Yes    
ICFR Auditor Attestation Flag false    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Information [Line Items]      
Entity Registrant Name DOMINARI HOLDINGS INC.    
Entity Central Index Key 0000012239    
Entity File Number 001-41845    
Entity Tax Identification Number 52-0849320    
Entity Incorporation, State or Country Code DE    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Public Float     $ 12,149,343
Entity Contact Personnel [Line Items]      
Entity Address, Address Line One 725 5th Avenue    
Entity Address, Address Line Two 22nd Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10022    
Entity Phone Fax Numbers [Line Items]      
City Area Code (212)    
Local Phone Number 393-4540    
Entity Listings [Line Items]      
Title of 12(b) Security Common Stock ($0.0001 par value per share)    
Trading Symbol DOMH    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   5,934,917  

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Audit Information
12 Months Ended
Dec. 31, 2023
Auditor [Table]  
Auditor Name Marcum llp
Auditor Firm ID 688
Auditor Location New York, NY
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 2,833 $ 33,174
Marketable securities 13,547 7,130
Deposits with clearing broker 7,687
Prepaid expenses and other assets 898 564
Prepaid acquisition cost 301
Short-term investments at fair value 13
Notes receivable, at fair value - current portion 3,177 7,474
Investment in Fieldpoint Securities 2,000
Total current assets 28,142 50,656
Property and equipment, net 344
Notes receivable, at fair value - non-current portion 1,129 1,100
Investments 24,150 23,103
Right-of-use assets 3,335 919
Security deposit 458 458
Total assets 57,558 76,236
Current liabilities    
Accounts payable and accrued expenses 1,036 447
Accrued salaries and benefits 51 1,260
Accrued commissions 77
Lease liability - current 421 82
Other current liability 22
Total current liabilities 1,607 1,789
Lease liability 3,028 680
Total liabilities 4,635 2,469
Stockholders’ equity    
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 and 5,485,096 shares issued at December 31, 2023 and 2022, respectively; 5,934,917 and 5,017,079 shares outstanding at December 31, 2023 and 2022, respectively
Additional paid-in capital 262,187 262,970
Treasury stock, at cost, 60,148 and 468,017 shares at December 30, 2023 and December 31, 2022, respectively (501) (3,322)
Accumulated deficit (208,763) (185,881)
Total stockholders’ equity 52,923 73,767
Total liabilities and stockholders’ equity 57,558 76,236
Series D Preferred Stock    
Stockholders’ equity    
Preferred stock value
Series D-1 Preferred Stock    
Stockholders’ equity    
Preferred stock value
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 5,995,065 5,485,096
Common stock, shares outstanding 5,934,917 5,017,079
Treasury stock, at cost 60,148 468,017
Series D Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 3,825 3,825
Preferred stock, shares outstanding 3,825 3,825
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
Series D-1 Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 834 834
Preferred stock, shares outstanding 834 834
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenues $ 2,039
Operating costs and expenses    
General and administrative 23,838 11,683
Research and development 3 830
Research and development - license acquired (6) 1,833
Total operating expenses 23,835 14,346
Loss from operations (21,796) (14,346)
Other income (expenses)    
Other income 36 64
Interest income 716 687
Gain (loss) on marketable securities 630 (5,952)
Unrealized loss on note receivable (3,248)
Change in fair value of investments 780 (2,560)
Total other expenses (1,086) (7,761)
Net loss (22,882) (22,107)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock (4,109)
Net Loss Attributable to Common Shareholders $ (22,882) $ (26,216)
Net loss per share, basic and diluted    
Net loss per share, basic (in Dollars per share) $ (4.38) $ (4.91)
Weighted average number of shares outstanding, basic and diluted    
Weighted average number of shares outstanding, basic (in Shares) 5,229,477 5,334,075
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations (Parentheticals) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net loss per share, diluted $ (3.95) $ (4.91)
Weighted average number of shares outstanding, diluted 5,229,477 5,334,075
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Redeemable Convertible Preferred Stock
Series O
Redeemable Convertible Preferred Stock
Series P
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Total
Balance at Dec. 31, 2021 $ 265,633 $ (264) $ (163,774) $ 101,595
Balance (in Shares) at Dec. 31, 2021 4,659 5,275,329      
Issuance of Series O redeemable convertible preferred stock for cash $ 11,000
Issuance of Series O redeemable convertible preferred stock for cash (in Shares) 11,000              
Issuance of Series P redeemable convertible preferred stock for cash $ 11,000
Issuance of Series P redeemable convertible preferred stock for cash (in Shares)   11,000            
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock (1,504) $ (1,505)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock 1,504 1,505 (4,109) (4,109)
Redemption of Series O Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares) (11,000)              
Redemption of Series P Redeemable Convertible Preferred Stock $ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)   (11,000)          
Purchase of treasury stock $ (3,058) (3,058)
Purchase of treasury stock (in Shares)           468,017    
Stock-based compensation 1,472 1,472
Stock-based compensation (in Shares)       238,244        
Cancellation of common stock related to investment in CBM
Cancellation of common stock related to investment in CBM (in Shares)       (22,812)        
Fractional shares adjusted for reverse split (26) (26)
Fractional shares adjusted for reverse split (in Shares)       (5,665)        
Net loss (22,107) (22,107)
Balance at Dec. 31, 2022 262,970 $ (3,322) (185,881) 73,767
Balance (in Shares) at Dec. 31, 2022 4,659 5,485,096   468,017    
Purchase of treasury stock $ (939) (939)
Purchase of treasury stock (in Shares)           236,630    
Stock-based compensation 2,977 2,977
Stock-based compensation (in Shares)       1,179,468        
Cancellation of common stock
Cancellation of common stock (in Shares)       (25,000)        
Retirement of treasury stock (3,760) $ 3,760
Retirement of treasury stock (in Shares)       (644,499)   (644,499)    
Fractional shares adjusted for reverse split               (26,000)
Net loss (22,882) (22,882)
Balance at Dec. 31, 2023 $ 262,187 $ (501) $ (208,763) $ 52,923
Balance (in Shares) at Dec. 31, 2023 4,659 5,995,065   60,148    
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (22,882) $ (22,107)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of right-of-use assets 359 (188)
Depreciation 83
Change in fair value of short-term investment 13 2,621
Change in fair value of long-term investment (793) (61)
Research and development-acquired license, expensed 1,833
Stock-based compensation 2,977 1,472
Realized loss on marketable securities 1,180 1,405
Unrealized (gain) loss on marketable securities (1,049) 4,867
Unrealized loss on note receivable 3,248
Realized gain on receiving shares in exchange of note receivable extension (36)  
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (406) (215)
Prepaid acquisition cost 301 (301)
Clearing broker deposits (4,137)
Accounts payable and accrued expenses 376 66
Accrued salaries and benefits (1,209) 580
Accrued commissions 52
Lease liabilities (88) 31
Other current liabilities (99)
Notes receivable, at fair value – net interest accrued (122) (600)
Net cash used in operating activities (22,232) (10,597)
Cash flows from investing activities    
Purchase of membership interest in FPS (2,000)
Purchase of marketable securities (34,125) (26,798)
Sale of marketable securities 27,574 28,658
Proceeds from sale of digital currencies 93
Purchase of fixed assets (427)
Acquisition of FPS, net of cash acquired and receivable owed from FPS (1,112)
Return of deposit (funding of deposit) into a managed account, net 3,898
Collection of principal on note receivable 1,102
Funds to employee forgivable loan (107)
Purchase of research and development licenses (1,833)
Purchase of short-term and long-term investments (75) (15,016)
Purchase of short-term and long-term promissory notes (1,600)
Net cash used in investing activities (7,170) (14,598)
Cash flows from financing activities    
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost 17,891
Payment for fractional shares (26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock (22,000)
Purchase of treasury stock (939) (3,058)
Net cash used in financing activities (939) (7,193)
Net decrease in cash and cash equivalents and restricted cash (30,341) (32,388)
Cash and cash equivalents, beginning of period 33,174 65,562
Cash and cash equivalents, end of period 2,833 33,174
Cash paid for interest and taxes 686
Non-cash investing and financing activities    
Receiving shares in exchange of note receivable extension 179
Note receivable principal and interest receivable reduced due to receiving shares 143  
Transfer from short-term investment to marketable securities 1,497
Reclassify from convertible note receivable to notes receivable at fair value 2,147
Transfer from long-term investment to marketable securities 1,439
Promissory convertible note receivable conversion into common shares $ 899
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:    
Net assets acquired, net of cash acquired and receivable owed from FPS 3,112  
Less - Deposit previously transferred in October 2022 to FPS (2,000)  
Net cash paid $ 1,112  
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Organization and Description of Business and Recent Developments
12 Months Ended
Dec. 31, 2023
Organization and Description of Business and Recent Developments [Abstract]  
Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

On September 9, 2022, Dominari entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”).   Pursuant to the terms of the FPS Purchase Agreement, Dominari purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari.  The FPS Purchase Agreement provides for Dominari’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari of 20% of the FPS Membership Interests.   Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari of the remaining 80% of the Membership Interests. 

 

Reverse Stock Split

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Liquidity and Capital Resources
12 Months Ended
Dec. 31, 2023
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial information.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

  

Use of Estimates

 

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Segments

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company’s chief executive officer is the CODM. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

Concentration of Cash

 

The Company maintains cash balances at four financial institutions in checking accounts. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2023 and 2022, the Company had no cash equivalents.

 

Marketable Securities

 

Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices.

 

Property and Equipment

 

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.

 

Research and Development

 

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

 

Accounting for Warrants

 

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).

 

Stock-based Compensation

 

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

 

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

 

The Company accounts for forfeitures as they occur. 

 

Fair Value Option - Short-term Note and Convertible Note

 

The guidance in ASC 825, Financial Instruments, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

 

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $6.7 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of December 31, 2023.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 11 - Leases).

 

Revenue

 

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - Revenue).

 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

 

  Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

  Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

  Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.

 

Treasury Stock

 

Treasury stock is recorded at cost and is presented as a reduction of stockholders’ equity.

  

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company’s consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

 

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.

 

Long-term investments

 

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

 

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s consolidated financial statements from the implementation of ASU 2021-08.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these consolidated financial statements.

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.24.1
FPS Acquisition
12 Months Ended
Dec. 31, 2023
FPS Acquisition [Abstract]  
FPS Acquisition

Note 4. FPS Acquisition

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.4 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. 

 

Consideration Transferred

 

The FPS Acquisition was accounted for as a business combination under ASC 805.

 

Under the terms of the FPS Purchase Agreement and subsequent amendments and side letters to the agreement 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price.

 

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the consolidated statement of operations.

 

Fair Value of Net Assets Acquired

 

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition ($ in thousands):

 

   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Investments in Marketable Securities
12 Months Ended
Dec. 31, 2023
Investments in Marketable Securities [Abstract]  
Investments in Marketable Securities

Note 5. Investments in Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows ($ in thousands):

 

   Years Ended December 31, 
   2023   2022 
Realized loss  $(1,180)  $(1,405)
Unrealized gain (loss)   1,049    (4,867)
Dividend income   762    320 
Total  $630   $(5,952)
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments
12 Months Ended
Dec. 31, 2023
Short-Term Investments [Abstract]  
Short-term investments

Note 6. Short-term investments

 

The following table presents the Company’s short-term investments as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   
     -
    13 
Total   
-
    13 

 

The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):

 

Beginning balance  $13 
Change in fair value of short-term investment   (13)
Ending balance  $
-
 

 

Investment in Vicinity Motor Corp.

 

On October 25, 2021, the Company entered into a warrant agreement with Vicinity Motor Corp. (“Vicinity”) that entitles the Company to purchase up to 246,399 shares of Vicinity common stock at $5.10 per share. The warrant expires on October 25, 2024. The fair value was determined using a Black-Scholes simulation. The Company recorded the fair value of the Vicinity warrant of approximately $0 and $13,000 in the consolidated balance sheet as of December 31, 2023 and 2022, respectively, reflecting the benefit received as part of its purchase of Vicinity common stock through its brokerage account. Gains or losses associated with changes in the fair value of investments in Vicinity warrants are recognized as change in fair value of investment on the consolidated statements of operations. During the year ended December 31, 2023, the Company recorded approximately $13,000 of change in fair value of investment for this investment.

 

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

 

   December 31,
2023
   December 31,
2022
 
Option term (in years)         0.8    1.8 
Volatility   67.2%   76.90%
Risk-free interest rate   5.43%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $
-
   $0.96 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Long-Term Investments
12 Months Ended
Dec. 31, 2023
Long-Term Investments [Abstract]  
Long-Term Investments

Note 7. Long-Term Investments

 

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of December 31, 2023 and 2022 ($ in thousands):

 

   Cost Basis   December 31,
2023
   December 31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    1,033    1,000 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    3,500    3,500 
Investment in Tesspay**   1,240    2,679    2,500 
Investment in SpaceX*   3,500    4,867    3,674 
Investment in Databricks*   1,200    842    1,200 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    300    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $24,150   $23,103 

 

The change in the value of the long-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

 

Beginning balance  $23,103 
Purchase of investments   75 
Receiving shares in exchange of note receivable extension   179 
Change in fair value of long-term investments   793 
Ending balance  $24,150 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Notes Receivable
12 Months Ended
Dec. 31, 2023
Notes Receivable [Abstract]  
Notes Receivable

Note 8. Notes Receivable

 

The following table presents the Company’s notes receivable as of December 31, 2023 and 2022 ($ in thousands):

 

December 31, 2023

 

   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  12/2/2024      8%  $1,006   $58   $1,064 
Raefan Industries LLC Investment  12/31/2024   8%  $1,363   $751   $2,114 
American Innovative Robotics Investment  04/01/2027   8%  $1,106   $22   $1,129 
                        
Notes receivable, at fair value - current portion                    $3,177 
                        
Notes receivable, at fair value - non-current portion                    $1,129 

 

 

December 31, 2022

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair Value 
Short-term convertible notes receivable                   
Convergent Investment  01/29/2023     8%  $2,000   $307   $2,307 
                        
Short-term notes receivable                       
Raefan Industries LLC Investment  6/30/2023   8%  $4,730   $437   $5,167 
Total                    $7,474 
                        
Long-term notes receivable                       
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $
-
   $1,100 

 

Convergent Therapeutics, Inc. Investment

 

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

 

The principal balance of the Convergent Convertible Note was approximately $1.0 and $2.0 million as of December 31, 2023 and 2022, respectively. The Company recorded an interest income receivable of approximately $13,000 and $0.2 million on the Convergent Convertible Note as of December 31, 2023 and 2022, respectively.

 

The Company recorded principal repayment of $1.0 million and $0, interest receivable repayment of approximately $0.3 million and $0, and an unrealized gain on the note of approximately $6,000 and $0 on the Convergent Convertible Note for the years ended December 31, 2023 and 2022, respectively.

 

Raefan Industries LLC Investment

  

On December 6, 2021, the Company purchased an 8% promissory note (“Raefan Industries Promissory Note”) issued by Raefan Industries, LLC (“Raefan Industries”) in the principal amount of approximately $2.0 million pursuant to a Note Purchase Agreement with Raefan Industries.  On December 6, 2022, the Company, Raefan Industries and Mr. Jeffrey Cooper entered into a Consolidated, Amended and Restated Promissory Note agreement (the “Raefan Amended Note Agreement”).

 

On October 20, 2023, in consideration for extending the maturity date of the Raefan Amended Note (See Note 8 – Notes Receivable) to December 31, 2024, Raefan Industries agreed and had delivered to the Company 357,143 shares of TessPay at $0.5 per share of common stock. The Company reduced approximately $0.1 million of principal and interest receivable balance of Raefan Amended Note and recorded an income of approximately $35,000 for receiving TessPay shares.

 

The Company recorded an interest income receivable of approximately $0.4 million and $26,000 on the Amended Note as of December 31, 2023 and 2022 and an unrealized loss on the note of approximately $3.3 million and $0 for the years ended December 31, 2023 and 2022, respectively.

 

American Innovative Robotics, LLC Investment

 

The Company recorded interest income of approximately $89,000 and $67,000, and an unrealized gain on the note of approximately $6,000 and $0 on the Robotics Promissory Note for the year ended December 31, 2023 and 2022, respectively.

 

Kaya Now Inc. Investment

 

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of December 31, 2023 and 2022.

 

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the year ended December 31, 2023.

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value of Financial Assets and Liabilities
12 Months Ended
Dec. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]  
Fair Value of Financial Assets and Liabilities

Note 9. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 ($ in thousands):

 

   Fair value measured as of December 31, 2023     
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $13,547   $13,547   $
     -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Short-term investment  $-   $
-
   $
-
   $- 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 

 

   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
     -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Short-term investment at December 31, 2021  $419 
Change in fair value of investment   (406)
Short-term investment at December 31, 2022  $13 
Change in fair value of investment   (13)
Short-term investment at December 31, 2023  $
-
 

 

Notes receivable at fair value, current portion at December 31, 2021  $6,984 
Accrued interest receivable   600 
Reclassify from convertible note receivable to notes receivable at fair value   2,147 
Purchase of notes receivable   500 
Change in fair value of short-term investment   (1,858)
Conversion of note receivable to marketable securities   (899)
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (1,000)
Unrealized loss on note receivable   (3,254)
Principle reduced due to receiving shares   (143)
Accrued interest receivable   100 
Notes receivable at fair value, current portion at December 31, 2023  $3,177 

 

 

Notes receivable at fair value, non-current portion at December 31, 2021  $
-
 
Purchase of notes receivable   1,100 
Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Unrealized gain on note receivable   6 
Accrued interest receivable   23 
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 

 

Note Receivable at fair value

   

As of December 31, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors.

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment
12 Months Ended
Dec. 31, 2023
Property and Equipment [Abstract]  
Property and Equipment

Note 10. Property and Equipment

 

Property and equipment, net, consists of the following as of December 31, 2023 and 2022:

 

   Estimated
Useful Lives
  December 31,
2023
   December 31,
2022
 
Leasehold improvements  Shorter of the remaining lease term or estimated useful life  $    50   $
    -
 
Machinery, equipment and computer software   1 to 15 years   169    
-
 
Furniture and fixtures   3 to 5 years   208    
-
 
Total     $427   $
-
 
Less: Accumulated depreciation and amortization      (83)   
-
 
Total property and equipment, net     $344   $
-
 

 

Depreciation expense was $83,000 and $0 during the years ended December 31, 2023 and 2022, respectively.

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Leases
12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Leases

Note 11. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date”). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on February 1, 2023. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month.

  

The tables below represent the Company’s lease assets and liabilities as of December 31, 2023 and 2022:

 

 

   December 31,
2023
   December 31,
2022
 
Assets:        
Operating lease right-of-use-assets  $3,335   $   919 
           
Liabilities:          
Current          
Operating   421    82 
Long-term          
Operating   3,028    680 
   $3,449   $762 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   December 31,
2023
   December 31,
2022
 
Weighted-average remaining lease term – operating leases (in years)   6.5    7.1 
Weighted-average discount rate – operating leases   10.0%   10.0%

 

During the years ended December 31, 2023 and 2022, the Company recorded approximately $0.8 million and 0.1 million of lease expense to current period operations.

 

   Year Ended   Year Ended 
   December 31,
2023
   December 31,
2022
 
Operating leases        
Operating lease cost  $668   $    73 
Operating lease expense   668    73 
Short-term lease rent expense   105    67 
Net rent expense  $773   $140 

 

Supplemental cash flow information related to leases were as follows:

 

   Year Ended
December 31,
2023
  

Year Ended
December 31,
2022

 
Operating cash flows - operating leases  $396   $  231 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,780   $960 

 

As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
   $ 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,728 
Less present value discount   (1,279)
Operating lease liabilities  $3,449 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2023
Net Loss per Share [Abstract]  
Net Loss per Share

Note 12. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2023, and 2022 are as follows:

 

   As of December 31, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,168    54,722 
Total   1,001,307    499,552 
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Redeemable Convertible Preferred Stock
12 Months Ended
Dec. 31, 2023
Redeemable Convertible Preferred Stock [Abstract]  
Redeemable Convertible Preferred Stock

Note 13. Redeemable Convertible Preferred Stock

 

Series O and Series P Redeemable Convertible Preferred Stock

 

On February 24, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Offerings”), (i) 11,000 shares of the Company’s Series O Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series O Preferred Stock”), and (ii) 11,000 shares of the Company’s Series P Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series P Preferred Stock” and together with the Series O Preferred Stock, the “Preferred Stock”), in each case, at an offering price of $952.38 per share, representing a 5% original issue discount to the stated value of $1,000 per share of Preferred Stock, for gross proceeds of each Offering of $10,476,180, or approximately $21.0 million in the aggregate for the Offerings, before the deduction of the placement agent’s fee and offering expenses. The shares of Series O Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The shares of Series P Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The Series O Preferred Stock and the Series P Preferred Stock are being offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-238172) (the “Registration Statement”) filed under the Securities Act of 1933, as amended (the “Securities Act”). The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The closing of the Offerings occurred on March 2, 2022. In connection with this transaction, the Company received net proceeds of $21.0 million, which was deposited in an escrow account.

 

In connection with the Offerings, the Company has entered into an engagement agreement (the “Engagement Agreement Agreement”) with H.C Wainwright & Company, LLC, as placement agent (“HCW”), pursuant to which the Company agreed to pay HCW an aggregate cash fee equal to 8% of the aggregate gross proceeds raised in the offerings and issue HCW common stock purchase warrants to purchase up to 103,528 shares of common stock in the aggregate at an exercise price of $21.25. The warrants were recorded as a component of stockholders’ equity in accordance with ASC 815.

 

Redemption Rights

 

After (i) the earlier of (1) the receipt of stockholder approval and (2) the date that is 90 days following the Original Issue Date (the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock) and (ii) before the date that is 120 days after the Original Issue Date (the “Redemption Period”), each Holder shall have the right to cause the Company to redeem all or part of such Holder’s shares of Preferred Stock at a price per share equal to 105% of the Stated Value.

 

As a result, the Preferred Stock were recorded separately from stockholders’ equity because they are redeemable upon the occurrence of redemption events that are considered not solely within the Company’s control.

 

During the second quarter of 2022, the Company redeemed for cash at a price equal to 105% of the $1,000 stated value per share all of its 11,000 outstanding shares of Series O Preferred Stock and its 11,000 Series P Preferred Stock. The total redemption amount was $23.1 million. As a result, all shares of the Series O Preferred Stock and Series P Preferred Stock have been retired and are no longer outstanding.

 

During the year ended December 31, 2023 and 2022, the Company recognized approximately $0 and $4.1 million in deemed dividends related to the Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable preferred stock and stockholders’ equity, respectively.

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock
12 Months Ended
Dec. 31, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Stockholders’ Equity and Convertible Preferred Stock

Note 14. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

 

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by an executive.

 

Treasury Stock

 

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the year ended December 31, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. During the year ended December 31, 2022, the Company repurchased 468,017 shares at a cost of approximately $3.1 million or $6.53 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

 

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

 

Preferred Stock

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of December 31, 2023 and 2022, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of December 31, 2023 and 2022, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

 

Warrants

 

A summary of warrant activity for years ended December 31, 2023 and 2022 is presented below:

 

   Warrants   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   341,268   $31.68    
   -
    3.87 
Issued   103,528    21.25    
-
    4.15 
Outstanding as of December 31, 2022   444,796   $29.25    
-
    3.20 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 

 

Confirmation of Mutual Understanding - In March 2022, pursuant to a Confirmation of Mutual Understanding (the “Confirmation”), all parties to the Confirmation acknowledged and confirmed a scrivener’s error set forth in warrants to purchase shares of the Company’s common stock (the “Warrants”) dated March 10, 2020, April 15, 2020 and March 2, 2021. Pursuant to the Confirmation, all parties, which were involved in the original execution of the warrants, agreed that clause (v) of the definition of Fundamental Transaction in Section 3(d) of the Warrants, is as follows:

 

the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the Company’s outstanding equity securities, including with respect to the election of directors (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)”. 

Restricted Stock Awards

 

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

December 19, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,287,129 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.6 million. Pursuant to the Grant Agreement, the Company withheld 657,079 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

December 19, 2023, pursuant to the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Joshua Shipley was granted 33,003 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $67,000. Pursuant to the Grant Agreement, the Company withheld 13,300 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $27,000 and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

 

During the year ended December 31, 2023, the Company also issued an aggregate of 136,309 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.

 

During the year ended December 31, 2022, the Company issued an aggregate of 238,244 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.

 

A summary of restricted stock awards activity for the years ended December 31, 2023 and 2022, is presented below: 

 

   Number of
Restricted
Stock Awards
   Weighted
Average
Grant Day
Fair Value
 
Nonvested at December 31, 2021   
-
   $
-
 
Granted   238,244    6.13 
Vested   (230,176)   6.14 
Nonvested at December 31, 2022   8,068   $5.90 
Granted   1,315,777   $2.27 
Vested   (1,187,536)   2.30 
Nonvested at December 31, 2023   136,309   $2.26 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $2.7 million and $1.4 million for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

As of December 31, 2023, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for year ended December 31, 2023 and 2022 is presented below:

 

   Number of
Shares
   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   28,203   $548.35   $
      -
    8.2 
Employee options granted   170,587    5.95    
-
    0.3 
Employee options forfeited   (167,381)   41.90    
-
    - 
Employee options expired   (216)   73.70    
-
    - 
Outstanding as of December 31, 2022   31,193   $302.97   $
-
    7.9 
Employee options granted   395,714    3.42    
-
    9.4 
Employee options forfeited   (5,882)   5.95    
-
    - 
Employee options expired   (857)  $9,719.07    
-
    - 
Outstanding as of December 31, 2023   420,168   $5.80   $
-
    9.3 
Options vested and exercisable   84,929   $15.16   $
-
    8.8 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $0.2 million and $13,000 for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.5 million.

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue
12 Months Ended
Dec. 31, 2023
Revenue [Abstract]  
Revenue

Note 15. Revenue

 

The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):

 

   Years Ended
December 31,
 
   2023   2022 
Underwriting  $594   $
   -
 
Commissions   1,096    
-
 
Advisory fees   209    
-
 
Other   140    
-
 
Total  $2,039   $
-
 
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 16. Commitments and Contingencies

 

Legal Proceedings

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than as described above and ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
12 Months Ended
Dec. 31, 2023
Income Taxes [Abstract]  
Income Taxes

Note 17. Income Taxes

 

The income tax provision consists of the following ($ in thousands):

 

    For the years ended
December 31,
 
    2023     2022  
Federal            
Current   $ -     $ -  
Deferred     (3,820 )     (3,618 )
Increase in valuation allowance     3,820       3,618  
State and local                
Current    
 
     
 
 
Deferred     (3,012 )     (4,825 )
Increase in valuation allowance     3,012       4,825  
Income Tax Provision (Benefit)   $ -     $ -  

 

The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2023 and 2022:

 

    For the years ended
December 31,
 
    2023     2022  
U.S. Statutory Federal Rate     21.00 %     21.00 %
State Taxes, Net of Federal Tax Benefit     15.36 %     13.58 %
Other Permanent Differences     (0.54 )%     (0.11 )%
State rate change in effect     (4.18 )%     2.95 %
AMT credit benefit     - %     - %
Decrease due to true up of State NOL     (0.11 )%     0.69 %
Decrease due to change in Federal NOL and other true ups     (1.67 )%     0.04 %
Change in Valuation Allowance     (29.85 )%     (38.15 )%
Income Tax Benefit     0.00 %     0.00 %

 

As of December 31, 2023 and 2022, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):

 

    As of December 31,  
    2023     2022  
Deferred tax assets:            
Net-operating loss carryforward   $ 33,124     $ 26,241  
Stock based compensation     9,754       8,358  
Patents & Licenses     8,061       9,898  
Transaction Costs     209       23  
Research & Development     1,937       2,207  
Operating lease liability     1,202       272  
Investment portfolio and other     2,879       2,445  
Total Deferred Tax assets     57,166       49,443  
Valuation allowance     (55,946 )     (49,115 )
Deferred Tax Asset, Net of Allowance   $ 1,220     $ 328  
Deferred tax liability:                
Depreciation     (57 )     -  
Right of use asset     (1,163 )     (328 )

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December 31, 2023 and 2022. As of December 31, 2023, the change in valuation allowance is approximately $6.8 million.

  

As of December 31, 2023, the Company has approximately $40.7 million federal net operating loss carryovers (“NOLs”), which expire from 2033 through 2037, and $68.5 million of federal NOLs which will never expire. The Company has approximately $152.3 million of state and city NOLs, which expire from 2035 through 2043. As of December 31, 2023, the Company also had federal research and development tax credit carryforwards of $0.2 million which may be available to offset future income tax liabilities and begin to expire in 2042.

 

Utilization of the U.S. NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. If the Company experiences an ownership change, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. The Company determined an ownership change occurred on September 10, 2013, and any NOLs generated prior to this date are therefore limited by Section 382. Any carryforwards that will expire prior to utilization due to this limitation were removed from deferred tax assets, with a corresponding reduction of the valuation allowance. The Company has not yet determined if any additional ownership changes occurred after September 10, 2013. Any past or future ownership changes may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.

 

As of December 31, 2023 and 2022, no liability for unrecognized tax benefit was required to be reported. The Company’s policy is to record interest and penalties related to income taxes outside of its income tax provision and classify as interest and penalties in general and administrative expense in the statement of operations. As of December 31, 2023 or 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s statement of operations. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files U.S. federal and state income tax returns (New York, New York City, Virginia, and Texas). As of December 31, 2023, the statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for all years since 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. There are no audits pending in any of the above-mentioned jurisdictions during 2023 and 2022. The Company believes that its income tax positions would be sustained upon an audit and does not anticipate any adjustments that would result in material changes to its consolidated financial position.

 

In December, 2023, the FASB issued 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09) which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Public business entities must apply the ASU’s guidance to annual periods beginning after December 15, 2024. The Company may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted. The Company has chosen not to early adopt this standard.

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Regulatory
12 Months Ended
Dec. 31, 2023
Regulatory [Abstract]  
Regulatory

Note 18. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of December 31, 2023, Dominari Securities had net capital of approximately $4.9 million, which was approximately $4.7 million in excess of required minimum net capital of $0.2 million.

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Transaction
12 Months Ended
Dec. 31, 2023
Related Party Transaction [Abstract]  
Related Party Transaction

Note 19. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $75,000 and $1.0 million during the years ending December 31, 2023, and 2022, respectively. These fees were included in general and administrative expenses in the consolidated statements of operations.

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting

Note 20. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Year Ended December 31, 2023 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue   2,039    
-
    2,039 
Operating Costs               
General and administrative   15,750    8,088    23,839 
Research and development   
-
    (3)   (3)
Loss from operations   (13,711)   (8,085)   (21,797)
                
Other (expenses) income               
Other income   
-
    36    36 
Interest income   229    487    716 
Gain on marketable securities   
-
    630    630 
Unrealized loss on note receivable   
-
    (3,248)   (3,248)
Change in fair value of investments   
-
    780    780 
Total other (expenses) income   229    (1,315)   (1,086)
Net loss   (13,482)   (9,400)   (22,882)

  

   Year Ended December 31, 2022 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue 
-
  
-
  
-
 
Operating Costs            
General and administrative   157    11,526    11,683 
Research and development   -    2,663    2,663 
Loss from operations   (157)   (14,189)   (14,346)
                
Other (expenses) income               
Other income   
-
    64    64 
Interest income   -    687    687 
Gain on marketable securities   
-
    (5,952)   (5,952)
Unrealized loss on note receivable   
-
    -    - 
Change in fair value of investments   -    (2,560)   (2,560)
Total other (expenses) income   -    (7,761)   (7,761)
Net loss   (157)   (21,950)   (22,107)
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Events
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 21. Subsequent Events

 

Litigation

 

In March 2024 the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities LLC. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. At this time the Company has no reasonable basis to assess or record any potential income statement impact related to this petition. See Note 16 Commitment and Contingencies for further information.

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure    
Net Income (Loss) $ (22,882) $ (22,107)
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Accounting Policies, by Policy (Policies)
12 Months Ended
Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial information.

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Segments

Segments

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company’s chief executive officer is the CODM. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

Concentration of Cash

Concentration of Cash

The Company maintains cash balances at four financial institutions in checking accounts. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2023 and 2022, the Company had no cash equivalents.

Marketable Securities

Marketable Securities

Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.

 

Research and Development

Research and Development

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

Accounting for Warrants

Accounting for Warrants

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).

Stock-based Compensation

Stock-based Compensation

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company accounts for forfeitures as they occur. 

Fair Value Option - Short-term Note and Convertible Note

Fair Value Option - Short-term Note and Convertible Note

The guidance in ASC 825, Financial Instruments, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.

 

Deposits with clearing broker

Deposits with clearing broker

Deposits with Dominari Securities’ clearing broker consisted of approximately $6.7 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of December 31, 2023.

Leases

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 11 - Leases).

Revenue

Revenue

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - Revenue).

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

  Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.
  Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
  Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.
Treasury Stock

Treasury Stock

Treasury stock is recorded at cost and is presented as a reduction of stockholders’ equity.

  

Income Taxes

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company’s consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.

Long-term investments

Long-term investments

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

Recently adopted accounting standards

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s consolidated financial statements from the implementation of ASU 2021-08.

Effect of new accounting pronouncements not yet adopted

Effect of new accounting pronouncements not yet adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these consolidated financial statements.

XML 49 R33.htm IDEA: XBRL DOCUMENT v3.24.1
FPS Acquisition (Tables)
12 Months Ended
Dec. 31, 2023
FPS Acquisition [Abstract]  
Schedule of Fair Values of the Assets Acquired and Liabilities The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition ($ in thousands):
   March 27, 
   2023 
   (Unaudited) 
ASSETS    
Cash and cash equivalents  $92 
Deposits with Clearing Broker-Dealer   3,550 
Other receivables   53 
Prepaid and other current assets   89 
Total assets acquired   3,784 
      
Liabilities     
Accrued expenses  $273 
Accrued commissions   25 
Wealth management liabilities   62 
Total liabilities assumed   360 
      
Total net assets of FPS Acquisition   3,424 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Investments in Marketable Securities (Tables)
12 Months Ended
Dec. 31, 2023
Investments in Marketable Securities [Abstract]  
Schedule of Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows ($ in thousands):
   Years Ended December 31, 
   2023   2022 
Realized loss  $(1,180)  $(1,405)
Unrealized gain (loss)   1,049    (4,867)
Dividend income   762    320 
Total  $630   $(5,952)
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments (Tables)
12 Months Ended
Dec. 31, 2023
Short-Term Investments [Abstract]  
Schedule of Short-Term Investments The following table presents the Company’s short-term investments as of December 31, 2023 and 2022 ($ in thousands):
   December 31,
2023
   December 31,
2022
 
Investment in Vicinity Motor Corp.   
     -
    13 
Total   
-
    13 
Schedule of Change in the Fair Value of the Short-Term Investments The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):
Beginning balance  $13 
Change in fair value of short-term investment   (13)
Ending balance  $
-
 

 

Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:
   December 31,
2023
   December 31,
2022
 
Option term (in years)         0.8    1.8 
Volatility   67.2%   76.90%
Risk-free interest rate   5.43%   4.47%
Expected dividends   0.00%   0.00%
Stock price  $
-
   $0.96 
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Long-Term Investments (Tables)
12 Months Ended
Dec. 31, 2023
Long-Term Investments [Abstract]  
Schedule of Long-Term Investments The following table presents the Company’s long-term investments as of December 31, 2023 and 2022 ($ in thousands):
   Cost Basis   December 31,
2023
   December 31,
2022
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    1,033    1,000 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    3,500    3,500 
Investment in Tesspay**   1,240    2,679    2,500 
Investment in SpaceX*   3,500    4,867    3,674 
Investment in Databricks*   1,200    842    1,200 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    300    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $24,150   $23,103 
*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
**Investments made in these companies are through both an SPV and direct investments.
Schedule of Companies are Through Both an SPV and Direct Investments
Beginning balance  $23,103 
Purchase of investments   75 
Receiving shares in exchange of note receivable extension   179 
Change in fair value of long-term investments   793 
Ending balance  $24,150 
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Notes Receivable (Tables)
12 Months Ended
Dec. 31, 2023
Notes Receivable [Abstract]  
Schedule of Notes Receivable The following table presents the Company’s notes receivable as of December 31, 2023 and 2022 ($ in thousands):
   Maturity Date  Stated Interest Rate   Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                   
Convergent convertible note - current  12/2/2024      8%  $1,006   $58   $1,064 
Raefan Industries LLC Investment  12/31/2024   8%  $1,363   $751   $2,114 
American Innovative Robotics Investment  04/01/2027   8%  $1,106   $22   $1,129 
                        
Notes receivable, at fair value - current portion                    $3,177 
                        
Notes receivable, at fair value - non-current portion                    $1,129 
   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair Value 
Short-term convertible notes receivable                   
Convergent Investment  01/29/2023     8%  $2,000   $307   $2,307 
                        
Short-term notes receivable                       
Raefan Industries LLC Investment  6/30/2023   8%  $4,730   $437   $5,167 
Total                    $7,474 
                        
Long-term notes receivable                       
American Innovative Robotics Investment  04/01/2027   8%  $1,100   $
-
   $1,100 

 

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value of Financial Assets and Liabilities (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]  
Schedule of Fair Value Assets and Liabilities are Measured at Fair Value The following table presents the Company’s assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 ($ in thousands):
   Fair value measured as of December 31, 2023     
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $13,547   $13,547   $
     -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Short-term investment  $-   $
-
   $
-
   $- 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 
   Fair value measured as of December 31, 2022 
   Total at
December 31,
   Quoted
prices in
active
markets
   Significant other
observable inputs
   Significant
unobservable
inputs
 
   2022   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $7,130   $7,130   $
     -
   $
-
 
Total marketable securities  $7,130   $7,130   $
-
   $
-
 
Short-term investment  $13   $
-
   $
-
   $13 
Notes receivable at fair value, current portion  $7,474   $
-
   $
-
   $7,474 
Notes receivable at fair value, non-current portion  $1,100   $
-
   $
-
   $1,100 

 

Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):
Short-term investment at December 31, 2021  $419 
Change in fair value of investment   (406)
Short-term investment at December 31, 2022  $13 
Change in fair value of investment   (13)
Short-term investment at December 31, 2023  $
-
 
Notes receivable at fair value, current portion at December 31, 2021  $6,984 
Accrued interest receivable   600 
Reclassify from convertible note receivable to notes receivable at fair value   2,147 
Purchase of notes receivable   500 
Change in fair value of short-term investment   (1,858)
Conversion of note receivable to marketable securities   (899)
Notes receivable at fair value, current portion at December 31, 2022  $7,474 
Collection of principal outstanding   (1,000)
Unrealized loss on note receivable   (3,254)
Principle reduced due to receiving shares   (143)
Accrued interest receivable   100 
Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Notes receivable at fair value, non-current portion at December 31, 2021  $
-
 
Purchase of notes receivable   1,100 
Notes receivable at fair value, non-current portion at December 31, 2022  $1,100 
Unrealized gain on note receivable   6 
Accrued interest receivable   23 
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 

 

XML 55 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2023
Property and Equipment [Abstract]  
Schedule of Property and Equipment, Net Property and equipment, net, consists of the following as of December 31, 2023 and 2022:
   Estimated
Useful Lives
  December 31,
2023
   December 31,
2022
 
Leasehold improvements  Shorter of the remaining lease term or estimated useful life  $    50   $
    -
 
Machinery, equipment and computer software   1 to 15 years   169    
-
 
Furniture and fixtures   3 to 5 years   208    
-
 
Total     $427   $
-
 
Less: Accumulated depreciation and amortization      (83)   
-
 
Total property and equipment, net     $344   $
-
 
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Tables)
12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Lease Assets and Liabilities The tables below represent the Company’s lease assets and liabilities as of December 31, 2023 and 2022:
   December 31,
2023
   December 31,
2022
 
Assets:        
Operating lease right-of-use-assets  $3,335   $   919 
           
Liabilities:          
Current          
Operating   421    82 
Long-term          
Operating   3,028    680 
   $3,449   $762 
Schedule of Summarize Quantitative Information about the Company’s Operating Leases The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:
   December 31,
2023
   December 31,
2022
 
Weighted-average remaining lease term – operating leases (in years)   6.5    7.1 
Weighted-average discount rate – operating leases   10.0%   10.0%
Schedule of Lease Expense to Current Period Operations During the years ended December 31, 2023 and 2022, the Company recorded approximately $0.8 million and 0.1 million of lease expense to current period operations.
   Year Ended   Year Ended 
   December 31,
2023
   December 31,
2022
 
Operating leases        
Operating lease cost  $668   $    73 
Operating lease expense   668    73 
Short-term lease rent expense   105    67 
Net rent expense  $773   $140 
Schedule of Supplemental Cash Flow Information Related To Leases Supplemental cash flow information related to leases were as follows:
   Year Ended
December 31,
2023
  

Year Ended
December 31,
2022

 
Operating cash flows - operating leases  $396   $  231 
Right-of-use assets obtained in exchange for operating lease liabilities  $2,780   $960 
Schedule of Future Minimum Payments As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:
   Operating 
   Leases 
   $ 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,728 
Less present value discount   (1,279)
Operating lease liabilities  $3,449 
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2023
Net Loss per Share [Abstract]  
Schedule of Computation of Diluted Loss Per Share Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2023, and 2022 are as follows:
   As of December 31, 
   2023   2022 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,168    54,722 
Total   1,001,307    499,552 
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock (Tables)
12 Months Ended
Dec. 31, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Schedule of Warrant Activity A summary of warrant activity for years ended December 31, 2023 and 2022 is presented below:
   Warrants   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   341,268   $31.68    
   -
    3.87 
Issued   103,528    21.25    
-
    4.15 
Outstanding as of December 31, 2022   444,796   $29.25    
-
    3.20 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 
Schedule of Restricted Stock Awards Activity A summary of restricted stock awards activity for the years ended December 31, 2023 and 2022, is presented below:
   Number of
Restricted
Stock Awards
   Weighted
Average
Grant Day
Fair Value
 
Nonvested at December 31, 2021   
-
   $
-
 
Granted   238,244    6.13 
Vested   (230,176)   6.14 
Nonvested at December 31, 2022   8,068   $5.90 
Granted   1,315,777   $2.27 
Vested   (1,187,536)   2.30 
Nonvested at December 31, 2023   136,309   $2.26 
Schedule of Stock Option Activity A summary of option activity under the Company’s stock option plan for year ended December 31, 2023 and 2022 is presented below:
   Number of
Shares
   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2021   28,203   $548.35   $
      -
    8.2 
Employee options granted   170,587    5.95    
-
    0.3 
Employee options forfeited   (167,381)   41.90    
-
    - 
Employee options expired   (216)   73.70    
-
    - 
Outstanding as of December 31, 2022   31,193   $302.97   $
-
    7.9 
Employee options granted   395,714    3.42    
-
    9.4 
Employee options forfeited   (5,882)   5.95    
-
    - 
Employee options expired   (857)  $9,719.07    
-
    - 
Outstanding as of December 31, 2023   420,168   $5.80   $
-
    9.3 
Options vested and exercisable   84,929   $15.16   $
-
    8.8 
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2023
Revenue [Abstract]  
Schedule of Total Revenues Disaggregated by Revenue Type The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):
   Years Ended
December 31,
 
   2023   2022 
Underwriting  $594   $
   -
 
Commissions   1,096    
-
 
Advisory fees   209    
-
 
Other   140    
-
 
Total  $2,039   $
-
 
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Taxes [Abstract]  
Schedule of Income Tax Provision The income tax provision consists of the following ($ in thousands):
    For the years ended
December 31,
 
    2023     2022  
Federal            
Current   $ -     $ -  
Deferred     (3,820 )     (3,618 )
Increase in valuation allowance     3,820       3,618  
State and local                
Current    
 
     
 
 
Deferred     (3,012 )     (4,825 )
Increase in valuation allowance     3,012       4,825  
Income Tax Provision (Benefit)   $ -     $ -  
Schedule of Effective Income Tax Rates The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2023 and 2022:
    For the years ended
December 31,
 
    2023     2022  
U.S. Statutory Federal Rate     21.00 %     21.00 %
State Taxes, Net of Federal Tax Benefit     15.36 %     13.58 %
Other Permanent Differences     (0.54 )%     (0.11 )%
State rate change in effect     (4.18 )%     2.95 %
AMT credit benefit     - %     - %
Decrease due to true up of State NOL     (0.11 )%     0.69 %
Decrease due to change in Federal NOL and other true ups     (1.67 )%     0.04 %
Change in Valuation Allowance     (29.85 )%     (38.15 )%
Income Tax Benefit     0.00 %     0.00 %
Schedule of Deferred Tax Assets and Liabilities As of December 31, 2023 and 2022, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):
    As of December 31,  
    2023     2022  
Deferred tax assets:            
Net-operating loss carryforward   $ 33,124     $ 26,241  
Stock based compensation     9,754       8,358  
Patents & Licenses     8,061       9,898  
Transaction Costs     209       23  
Research & Development     1,937       2,207  
Operating lease liability     1,202       272  
Investment portfolio and other     2,879       2,445  
Total Deferred Tax assets     57,166       49,443  
Valuation allowance     (55,946 )     (49,115 )
Deferred Tax Asset, Net of Allowance   $ 1,220     $ 328  
Deferred tax liability:                
Depreciation     (57 )     -  
Right of use asset     (1,163 )     (328 )

 

XML 61 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.
   Year Ended December 31, 2023 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue   2,039    
-
    2,039 
Operating Costs               
General and administrative   15,750    8,088    23,839 
Research and development   
-
    (3)   (3)
Loss from operations   (13,711)   (8,085)   (21,797)
                
Other (expenses) income               
Other income   
-
    36    36 
Interest income   229    487    716 
Gain on marketable securities   
-
    630    630 
Unrealized loss on note receivable   
-
    (3,248)   (3,248)
Change in fair value of investments   
-
    780    780 
Total other (expenses) income   229    (1,315)   (1,086)
Net loss   (13,482)   (9,400)   (22,882)
   Year Ended December 31, 2022 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue 
-
  
-
  
-
 
Operating Costs            
General and administrative   157    11,526    11,683 
Research and development   -    2,663    2,663 
Loss from operations   (157)   (14,189)   (14,346)
                
Other (expenses) income               
Other income   
-
    64    64 
Interest income   -    687    687 
Gain on marketable securities   
-
    (5,952)   (5,952)
Unrealized loss on note receivable   
-
    -    - 
Change in fair value of investments   -    (2,560)   (2,560)
Total other (expenses) income   -    (7,761)   (7,761)
Net loss   (157)   (21,950)   (22,107)
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Organization and Description of Business and Recent Developments (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]        
Seller paid $ 2,000      
Additional seller paid   $ 1,400    
Description of reverse stock split   On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”).    
Reverse stock split   $ 26,000 $ 26  
FPS Purchase Agreement [Member]        
Organization and Description of Business and Recent Developments [Line Items]        
Membership interests rate       100.00%
FPS Purchase Agreement [Member]        
Organization and Description of Business and Recent Developments [Line Items]        
Membership interests rate 20.00% 80.00%    
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details)
$ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
Summary of Significant Accounting Policies (Details) [Line Items]  
Grant and expire year 10 years
Money market funds (in Dollars) $ 6.7
Tax benefit percentage 50.00%
Minimum [Member]  
Summary of Significant Accounting Policies (Details) [Line Items]  
Property and equipment estimated useful lives 3 years
Maximum [Member]  
Summary of Significant Accounting Policies (Details) [Line Items]  
Property and equipment estimated useful lives 5 years
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.24.1
FPS Acquisition (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 04, 2022
Dec. 31, 2023
Sep. 09, 2022
FPS Acquisition (Details) [Line Items]      
Cash   $ 3,400  
FPS Membership Interests [Member]      
FPS Acquisition (Details) [Line Items]      
Membership interests rate   80.00% 100.00%
FPS Purchase Agreement [Member]      
FPS Acquisition (Details) [Line Items]      
Membership interests rate 20.00%    
FPS Purchase Agreement [Member]      
FPS Acquisition (Details) [Line Items]      
Consideration amount $ 2,000    
Additional consideration   $ 1,400  
Percentage of acquired membership interest   100.00%  
Purchase price   $ 1  
Transaction costs   $ 300  
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.1
FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities - Business Combination [Member]
$ in Thousands
Mar. 27, 2023
USD ($)
ASSETS  
Cash and cash equivalents $ 92
Deposits with Clearing Broker-Dealer 3,550
Other receivables 53
Prepaid and other current assets 89
Total assets acquired 3,784
Liabilities  
Accrued expenses 273
Accrued commissions 25
Wealth management liabilities 62
Total liabilities assumed 360
Total net assets of FPS Acquisition $ 3,424
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Investments in Marketable Securities (Details) - Schedule of Marketable Securities - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Marketable Securities [Abstract]    
Realized loss $ (1,180) $ (1,405)
Unrealized gain (loss) 1,049 (4,867)
Dividend income 762 320
Total $ 630 $ (5,952)
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Oct. 25, 2021
Dec. 31, 2023
Dec. 31, 2022
Short-Term Investments [Line Items]      
Fair value of the vicinity warrant   $ 13
Change in fair value of investment   $ 13 $ 2,621
Vicinity Motor Corp. [Member]      
Short-Term Investments [Line Items]      
Purchase of shares (in Shares) 246,399    
Common Stock [Member] | Vicinity Motor Corp. [Member]      
Short-Term Investments [Line Items]      
Common stock, per share value (in Dollars per share) $ 5.1    
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments (Details) - Schedule of Short-Term Investments - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Short-Term Investments [Line Items]    
Total short-term investments $ 13
Investment in Vicinity Motor Corp. [Member]    
Schedule of Short-Term Investments [Line Items]    
Total short-term investments $ 13
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Schedule of Change in the Fair Value of the Short-Term Investments [Abstract]  
Short-term investment, Balance beginning $ 13
Change in fair value of short-term investment (13)
Short-term investment, balance ending
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs
Dec. 31, 2023
Dec. 31, 2022
Option Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement inputs 0.8 1.8
Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement inputs 67.2 76.9
Risk-Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement inputs 5.43 4.47
Expected Dividends [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement inputs 0 0
Stock Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement inputs 0.96
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Long-Term Investments (Details) - Schedule of Long-Term Investments - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis $ 20,922  
Long-term investments, Total 24,150 $ 23,103
Investment In Kerna Health Inc [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 2,140  
Long-term investments, Total 4,940 4,940
Investment in Kaya Now [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,500  
Long-term investments, Total
Investment in Tevva Motors [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,972  
Long-term investments, Total 2,794 2,794
Investment in ASP Isotopes [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,300  
Long-term investments, Total
Investment in Unusual Machines [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,075  
Long-term investments, Total 1,033 1,000
Investment in Qxpress [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,000  
Long-term investments, Total [1] 1,000 1,000
Investment in Masterclass [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 170  
Long-term investments, Total [1] 170 170
Investment in Kraken [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 597  
Long-term investments, Total [1] 597 597
Investment in Epic Games [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500  
Long-term investments, Total [1] 3,500 3,500
Investment in Tesspay [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 1,240  
Long-term investments, Total [2] 2,679 2,500
Investment in SpaceX [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500  
Long-term investments, Total [1] 4,867 3,674
Investment in Databricks [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,200  
Long-term investments, Total [1] 842 1,200
Investment in Discord [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 476  
Long-term investments, Total [1] 476 476
Investment in Thrasio [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 300  
Long-term investments, Total [1] 300 300
Investment in Automation Anywhere [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 476  
Long-term investments, Total [1] 476 476
Investment in Anduril [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476  
Long-term investments, Total $ 476 $ 476
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
[2] Investments made in these companies are through both an SPV and direct investments.
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Schedule of Companies are Through Both an SPV and Direct Investments [Abstract]  
Beginning balance $ 23,103
Purchase of investments 75
Receiving shares in exchange of note receivable extension 179
Change in fair value of long-term investments 793
Ending balance $ 24,150
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Notes Receivable (Details) - USD ($)
12 Months Ended
Oct. 20, 2023
Dec. 06, 2021
Dec. 31, 2023
Dec. 31, 2022
Notes Receivable [Line Items]        
Accrued interest     $ 250,000  
Interest income receivable       $ 200,000
Repayment of interest receivable     300,000 0
Unrealized gain     1,049,000 (4,867,000)
Impairment charges       0
Convergent convertible note [Member]        
Notes Receivable [Line Items]        
Principal amount     1,000,000 2,000,000
Unrealized gain     $ 6,000,000,000 0
Convergent Therapeutics, Inc. Investment [Member]        
Notes Receivable [Line Items]        
Promissory note percentage     8.00%  
Principal amount     $ 1,800,000  
Promissory note maturity date     Jan. 29, 2023  
Interest income receivable     $ 13,000  
Repayment of principal amount     1,000,000 0
Raefan Industries LLC Investment [Member]        
Notes Receivable [Line Items]        
Principal amount $ 100,000 $ 2,000,000    
Debt instrument purchase price percentage   8.00%    
Shares of common stock (in Shares) 357,143      
Common stock per share value (in Dollars per share) $ 0.5      
Interest income receivable $ 35,000   400,000 26,000
Unrealized loss     3,300,000 0
American Innovative Robotics, LLC Investment [Member]        
Notes Receivable [Line Items]        
Unrealized gain     6,000 0
Interest income     89,000 67,000
Kaya Now Inc. Investment [Member]        
Notes Receivable [Line Items]        
Interest income     10,000  
Impairment charges     $ 0 $ 500,000
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Notes Receivable (Details) - Schedule of Notes Receivable - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Notes receivable, at fair value    
Interest Receivable   $ 200
Fair Value   $ 7,474
Convergent convertible note - current [Member]    
Notes receivable, at fair value    
Maturity Date Dec. 02, 2024  
Stated Interest Rate 8.00%  
Principal Amount $ 1,006  
Interest Receivable 58  
Fair Value $ 1,064  
Raefan Industries LLC Investment [Member]    
Notes receivable, at fair value    
Maturity Date Dec. 31, 2024 Jun. 30, 2023
Stated Interest Rate 8.00% 8.00%
Principal Amount $ 1,363 $ 4,730
Interest Receivable 751 437
Fair Value $ 2,114 $ 5,167
American Innovative Robotics Investment [Member]    
Notes receivable, at fair value    
Maturity Date Apr. 01, 2027 Apr. 01, 2027
Stated Interest Rate 8.00% 8.00%
Principal Amount $ 1,106 $ 1,100
Interest Receivable 22
Fair Value 1,129 $ 1,100
Notes Receivable, at Fair Value - Current Portion [Member]    
Notes receivable, at fair value    
Fair Value 3,177  
Notes Receivable, at Fair Value - Non-Current Portion [Member]    
Notes receivable, at fair value    
Fair Value $ 1,129  
Convergent Investment [Member]    
Notes receivable, at fair value    
Maturity Date   Jan. 29, 2023
Stated Interest Rate   8.00%
Principal Amount   $ 2,000
Interest Receivable   307
Fair Value   $ 2,307
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Marketable securities:      
Equities $ 13,547 $ 7,130  
Total marketable securities 13,547 7,130  
Short-term investment 13  
Notes receivable at fair value, current portion 3,177 7,474  
Notes receivable at fair value, non-current portion 1,129 1,100  
Quoted prices in active markets (Level 1) [Member]      
Marketable securities:      
Equities 13,547 7,130  
Total marketable securities 13,547 7,130  
Short-term investment  
Notes receivable at fair value, current portion  
Notes receivable at fair value, non-current portion  
Significant other observable inputs (Level 2) [Member]      
Marketable securities:      
Equities  
Total marketable securities  
Short-term investment  
Notes receivable at fair value, current portion  
Notes receivable at fair value, non-current portion  
Significant unobservable inputs (Level 3) [Member]      
Marketable securities:      
Equities  
Total marketable securities  
Short-term investment   13  
Notes receivable at fair value, current portion 3,177 7,474 $ 6,984
Notes receivable at fair value, non-current portion $ 1,129 $ 1,100
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis - Level 3 [Member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]    
Short-term investment, Balance beginning $ 13 $ 419
Change in fair value of investment (13) (406)
Short-term investment, balance ending 13
Notes receivable at fair value, current portion, Balance beginning 7,474 6,984
Notes receivable at fair value, non-current portion, Balance beginning 1,100
Collection of principal outstanding (1,000)  
Unrealized loss on note receivable (3,254)  
Principle reduced due to receiving shares (143)  
Accrued interest receivable 100 600
Reclassify from convertible note receivable to notes receivable at fair value   2,147
Purchase of notes receivable   500
Change in fair value of short-term investment   (1,858)
Conversion of note receivable to marketable securities   (899)
Notes receivable at fair value, current portion, Balance ending 3,177 7,474
Purchase of notes receivable   1,100
Notes receivable at fair value, non-current portion, Balance ending 1,129 $ 1,100
Unrealized gain on note receivable 6  
Accrued interest receivable $ 23  
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property and Equipment [Abstract]    
Depreciation expense $ 83
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment (Details) - Schedule of Property and Equipment, Net - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 427
Less: Accumulated depreciation and amortization (83)
Total property and equipment, net $ 344
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 3 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 5 years  
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives Shorter of the remaining lease term or estimated useful life  
Property and equipment, gross $ 50
Machinery, equipment and computer software [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 169
Machinery, equipment and computer software [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 1 year  
Machinery, equipment and computer software [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 15 years  
Furniture and fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 208
Furniture and fixtures [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 3 years  
Furniture and fixtures [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Lives 5 years  
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - USD ($)
12 Months Ended
Jan. 11, 2023
Sep. 23, 2022
Dec. 31, 2023
Dec. 31, 2022
Jul. 11, 2022
Leases [Abstract]          
Lease term   7 years     7 years
Rent expenses $ 12,874        
Increase rent amount   $ 51,868 $ 13,502    
Rent payment   $ 49,368      
Lease expenses     $ 773,000 $ 140,000  
Future minimum payments lease term     5 years    
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets:    
Operating lease right-of-use-assets $ 3,335 $ 919
Liabilities:    
Operating 421 82
Long-term    
Operating 3,028 680
Total $ 3,449 $ 762
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - Schedule of Summarize Quantitative Information about the Company’s Operating Leases
Dec. 31, 2023
Dec. 31, 2022
Schedule of Smmarize Quantitative Information about the Company’s Operating Leases [Abstract]    
Weighted-average remaining lease term – operating leases (in years) 6 years 6 months 7 years 1 month 6 days
Weighted-average discount rate – operating leases 10.00% 10.00%
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - Schedule of Lease Expense to Current Period Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating leases    
Operating lease cost $ 668 $ 73
Operating lease expense 668 73
Short-term lease rent expense 105 67
Net rent expense $ 773 $ 140
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]    
Operating cash flows - operating leases $ 396 $ 231
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,780 $ 960
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Details) - Schedule of Future Minimum Payments - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Future Minimum Payments [Abstract]    
Year Ended December 31, 2024 $ 747  
Year Ended December 31, 2025 685  
Year Ended December 31, 2026 685  
Year Ended December 31, 2027 685  
Year Ended December 31, 2028 766  
Thereafter 1,160  
Total 4,728  
Less present value discount (1,279)  
Operating lease liabilities $ 3,449 $ 762
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 1,001,307 499,552
Convertible preferred stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 34 34
Warrants to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 444,796 444,796
Restricted stock awards [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 136,309
Options to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 420,168 54,722
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.24.1
Redeemable Convertible Preferred Stock (Details) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Feb. 24, 2022
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Redeemable Convertible Preferred Stock [Line Items]        
Net proceeds received     $ 21,000,000  
Aggregate cash fee, percentage     8.00%  
Common stock purchase warrants (in Shares)     103,528  
Exercise price (in Dollars per share)     $ 21.25  
Stated value, percentage     105.00%  
Redeemed cash   $ 1,000    
Redemption amount   $ 23,100,000    
Deemed dividends     $ 0 $ 4,100,000
Preferred Stock [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Stated value $ 1,000      
Gross proceeds $ 10,476,180      
Series O Redeemable Convertible Preferred Stock [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Convertible preferred stock, shares issued (in Shares) 11,000      
Convertible preferred stock, par value (in Dollars per share) $ 0.001      
Series P Redeemable Convertible Preferred Stock [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Convertible preferred stock, par value (in Dollars per share) $ 0.001      
Preferred stock, shares outstanding (in Shares) 11,000      
Series O Preferred Stock [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Preferred stock, shares outstanding (in Shares)   11,000    
Offering price, per share (in Dollars per share) $ 952.38      
Original issue, percentage 5.00%      
Stated value $ 1,000      
Gross proceeds $ 21,000,000      
Conversion price, per share (in Dollars per share) $ 1      
Shares issued (in Shares) 11,000,000      
Series P Preferred Stock [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Preferred stock, shares outstanding (in Shares)   11,000    
Stated value $ 1,000      
Conversion price, per share (in Dollars per share) $ 1      
Shares issued (in Shares) 11,000,000      
Redemption Rights [Member]        
Redeemable Convertible Preferred Stock [Line Items]        
Original issue, percentage   105.00%    
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)
12 Months Ended
Dec. 19, 2023
Jun. 27, 2023
Mar. 06, 2023
Dec. 31, 2023
Dec. 31, 2022
Mar. 20, 2023
Jan. 21, 2022
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Shares cancelled     644,499     25,000  
Treasury stock shares     644,499 60,148 468,017    
Buyback program amount (in Dollars)             $ 3,000,000
Retired shares of treasury stock     644,499        
Original cost (in Dollars)     $ 3,800,000        
Preferred stock, par value (in Dollars per share)       $ 0.0001 $ 0.0001    
Preferred stock, share authorized       50,000,000 50,000,000    
Granted shares       395,714 170,587    
Restricted stock (in Dollars)       $ 2,700,000 $ 1,400,000    
Unrecognized compensation expense (in Dollars)       200,000      
Estimated future stock-based compensation expense (in Dollars)       $ 500,000      
Treasury Stock, Common [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Price per share (in Dollars per share)       $ 3.97      
Over-Allotment Option [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Share based compensation expense (in Dollars)       $ 200,000 $ 13,000    
Treasury Stock, Common [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Company repurchased shares       236,630 468,017    
Cost of repurchase (in Dollars)       $ 900,000 $ 3,100,000    
Price per share (in Dollars per share)         $ 6.53    
Series D Convertible Preferred Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Preferred stock, share issued       1,379,685      
Preferred stock, par value (in Dollars per share)       $ 0.0001      
Convertible preferred stock       convertible into 10 over 1,373 of a share of Common Stock.      
Series D Preferred Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Preferred stock, share issued       3,825 3,825    
Preferred stock, share authorized       5,000,000 5,000,000    
Preferred stock, share outstanding       3,825 3,825    
Series D-1 Convertible Preferred Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Preferred stock, par value (in Dollars per share)         $ 0.0001    
Convertible preferred stock       convertible into 10 over 1,373 of a share of Common Stock.      
Series D-1 Preferred Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Preferred stock, share issued       834 834    
Preferred stock, share authorized       5,000,000 5,000,000    
Preferred stock, share outstanding       834 834    
Soo Yu [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Total fair value (in Dollars) $ 2,600,000            
Restricted stock issued withheld shares 657,079 503,876          
Restricted stock issued withheld value (in Dollars) $ 1,300,000 $ 1,300,000          
Soo Yu [Member] | Common Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Granted shares 1,287,129            
Joshua Shipley [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Total fair value (in Dollars) $ 67,000            
Restricted stock issued withheld shares 13,300            
Restricted stock issued withheld value (in Dollars) $ 27,000            
Joshua Shipley [Member] | Common Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Granted shares 33,003            
Board of Directors [Member] | Common Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Common stock share issued       136,309 238,244    
Restricted Stock Awards [Member] | Soo Yu [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Total fair value (in Dollars)   $ 2,700,000          
Restricted Stock Awards [Member] | Soo Yu [Member] | Common Stock [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Granted shares   1,033,591          
Business Combination [Member]              
Stockholders’ Equity and Convertible Preferred Stock [Line Items]              
Voting power       50.00%      
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2021
Dec. 31, 2022
Class of Warrant or Right [Line Items]      
Number of shares, ending balance (in Shares) 444,796 341,268 444,796
Weighted Average per share, ending balance $ 29.25 $ 31.68 $ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life 2 years 2 months 12 days 3 years 10 months 13 days 3 years 2 months 12 days
Issued, Warrants (in Shares)     103,528
Issued, Weighted Average Exercise Price     $ 21.25
Issued, Total Intrinsic Value (in Dollars)    
Issued, Weighted Average Remaining Contractual Life     4 years 1 month 24 days
XML 89 R73.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]    
Number of shares, beginning balance (in Shares) 8,068
Weighted Average per share, beginning balance $ 5.9
Number of Restricted Stock Awards, Granted 1,315,777 238,244
Weighted Average Grant Day Fair Value, Granted $ 2.27 $ 6.13
Number of Restricted Stock Awards, Vested (1,187,536) (230,176)
Weighted Average Grant Day Fair Value, Vested $ 2.3 $ 6.14
Number of shares, ending balance (in Shares) 136,309 8,068
Weighted Average per share, ending balance $ 2.26 $ 5.9
XML 90 R74.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]      
Employee options granted, Number of Shares   395,714 170,587
Employee options granted, Weighted Average Exercise Price   $ 3.42 $ 5.95
Employee options granted, Intrinsic Value  
Employee options granted, Weighted Average Remaining Contractual Life   9 years 4 months 24 days 3 months 18 days
Employee options forfeited, Number of Shares   (5,882) (167,381)
Employee options forfeited, Weighted Average Exercise Price   $ 5.95 $ 41.9
Employee options forfeited, Intrinsic Value  
Employee options expired, Number of Shares   (857) (216)
Employee options expired, Weighted Average Exercise Price   $ 9,719.07 $ 73.7
Employee options expired, Intrinsic Value  
Outstanding ending balance, Number of Shares 28,203 420,168 31,193
Outstanding ending balance, Weighted Average Exercise Price $ 548.35 $ 5.8 $ 302.97
Outstanding ending balance, Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life 8 years 2 months 12 days 9 years 3 months 18 days 7 years 10 months 24 days
Number of Shares, Options vested and exercisable   84,929  
Weighted Average Exercise Price, Options vested and exercisable   $ 15.16  
Total Intrinsic Value, Options vested and exercisable    
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable   8 years 9 months 18 days  
XML 91 R75.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Total Revenues Disaggregated by Revenue Type [Abstract]    
Underwriting $ 594
Commissions 1,096
Advisory fees 209
Other 140
Total $ 2,039
XML 92 R76.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details)
$ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
Income Taxes (Details) [Line Items]  
Change in valuation allowance $ 6.8
Federal net operating loss carryovers 40.7
State and city net operating loss 152.3
Tax credit carryforwards $ 0.2
Percentage of stock corporation 50.00%
Net Operating Loss [Member]  
Income Taxes (Details) [Line Items]  
Federal net operating loss carryovers $ 68.5
XML 93 R77.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details) - Schedule of Income Tax Provision - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal    
Current
Deferred (3,820) (3,618)
Increase in valuation allowance 3,820 3,618
State and local    
Current
Deferred (3,012) (4,825)
Increase in valuation allowance 3,012 4,825
Income Tax Provision (Benefit)
XML 94 R78.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details) - Schedule of Effective Income Tax Rates
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Effective Income Tax Rates [Abstract]    
U.S. Statutory Federal Rate 21.00% 21.00%
State Taxes, Net of Federal Tax Benefit 15.36% 13.58%
Other Permanent Differences (0.54%) (0.11%)
State rate change in effect (4.18%) 2.95%
AMT credit benefit
Decrease due to true up of State NOL (0.11%) 0.69%
Decrease due to change in Federal NOL and other true ups (1.67%) 0.04%
Change in Valuation Allowance (29.85%) (38.15%)
Income Tax Benefit 0.00% 0.00%
XML 95 R79.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Deferred Tax Assets And Liabilities Abstract    
Net-operating loss carryforward $ 33,124 $ 26,241
Stock based compensation 9,754 8,358
Patents & Licenses 8,061 9,898
Transaction Costs 209 23
Sec. 174 research & development 1,937 2,207
Net lease liability 1,202 272
Investment portfolio and other 2,879 2,445
Total Deferred Tax assets 57,166 49,443
Valuation allowance (55,946) (49,115)
Deferred Tax Asset, Net of Allowance 1,220 328
Depreciation (57)
Right of use asset $ (1,163) $ (328)
XML 96 R80.htm IDEA: XBRL DOCUMENT v3.24.1
Regulatory (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Regulatory [Line Items]  
Net capital amount $ 0.2
Excess amount 4.7
Dominari Securities [Member]  
Regulatory [Line Items]  
Net capital amount $ 4.9
XML 97 R81.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Transaction (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Abstract]    
Incurred fees $ 75,000 $ 1,000,000
XML 98 R82.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting (Details)
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Reportable segments 2
XML 99 R83.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dominari Financial [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 2,039
General and administrative 15,750 157
Research and development  
Loss from operations (13,711) (157)
Other (expenses) income    
Other income
Interest income 229  
Gain on marketable securities
Unrealized loss on note receivable
Change in fair value of investments  
Total other (expenses) income 229  
Net loss (13,482) (157)
Legacy AIkido Pharma [Member]    
Segment Reporting Information [Line Items]    
Revenue
General and administrative 8,088 11,526
Research and development (3) 2,663
Loss from operations (8,085) (14,189)
Other (expenses) income    
Other income 36 64
Interest income 487 687
Gain on marketable securities 630 (5,952)
Unrealized loss on note receivable (3,248)  
Change in fair value of investments 780 (2,560)
Total other (expenses) income (1,315) (7,761)
Net loss (9,400) (21,950)
Consolidated [Member]    
Segment Reporting Information [Line Items]    
Revenue 2,039
General and administrative 23,839 11,683
Research and development (3) 2,663
Loss from operations (21,797) (14,346)
Other (expenses) income    
Other income 36 64
Interest income 716 687
Gain on marketable securities 630 (5,952)
Unrealized loss on note receivable (3,248)  
Change in fair value of investments 780 (2,560)
Total other (expenses) income (1,086) (7,761)
Net loss $ (22,882) $ (22,107)
EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GZT?V(^Z4O9LM&J:]>EX;(N5J+G]2Z^%NXA[_B][=8T_/Z6.Y"S47;B#KB0QC;=+[KC<\>X$>[' MNZ6VT5>R:H2YY(WXQ^AV+=72'\9=Q3BXC*X=]I^[1CPU_Z<9]6(A"W&IB[86 MJMFUHQ&5!U1V)==VQ!2OQ=GH0F^$\=?C3G!=[JZM<5!!2YE3Z3:8Z[+#HT,Y M;TO9L&NUV]EM#; B@!718EVX95W)TIV]9'_SBJM"L.[.V@ P!H#QT0#9FQD/ M(!, F?Q&R+F'\#M8IA?L\[K7 U, F1X1\FL40&8 ,CL:Y,6*AX,F!Y#Y\2"Y M70604P YI87\;)9X36LQY6]?<;/T-GLNEDFXWKAIV7A2Z58T,,:%B MB!US-9L[)M>B5AX89H(4,R%VS+7:"-OLAHA4[#]N'H1+*"H7QT71]OR,1#,A M-LU\I4WS]DZ8F@7$(1TRS(18,3=:+2$<,LN$6"V?7)YJW; MA-SP[M3/7$@F M$V*;7'%IV!=>M<(/W2NI7/8@78 YM];G#R$FTLF$V"Z.)AI:M2&/NUZVU[^W;0(2:L2XBE<2LV M0K6]5D-RB,C+D+J63PY[:JS&5;7"Q9/>V(B0(R)B1URK0M>"W?$??2:DAHA8 M#;=BV;K5VFQ#(B2%B%@*MWZE2]QGW(?<.\.5Y<5A18YT$!'K8"Z6_A?.IVN7 MD;A>%H(A$T3$)IBW]U9\:SW;Q\U!_A$A*43$4ICQ+=MT2NAV]U,$E](6E;9M M+_#&R \QL1^NE94NZ/H>5[J;RLZ-ZWI+<9C(Q4@.,?4LU5-%X_!FKL+UP>U/ M=K_=+6S#A"E&8ZL^K<; MV20AMLFK@.PMFQ?AHYH$V20AM@E.&./P 2*R2TK]'.25A/&I44-,9)B4VC ( MLS=X4F28E-@P&+-WTY%PTJ,\%]EC)B$F4D]ZC 9VP"^TA)A)02BT@6'7U!CD24$HL((P9#O(,"2@C%M!K MQ>%+ 65(0!FQ@"!F_U4;)*",6$#[&G9@:&?(.!FQ<0ZY=KF:*-NJZYTA)C). M1FTQ<3!F+P(A[63$VL&8:8B)M),1:V=H'BA M#C&1=C)B[.Y),3RV>8[E=+AICP MO6-B^4#,?KA$\LF)Y8,Q>^$2R2/I5#NVX[T[#;G\>%A_'PVE85;MQ//^HZV&]*\=V>.C.Y70YLNGZ M8SM>EOVV/K?K]W9;:EDNO>[O9U3/3_@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ M+01Z*^JM!'HKZJT$>BOJK01ZZ^1E"8'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z* M>BN!WHIZ*X'>AGH;@=Z&>AN!WH9Z&X'>AGH;@=XV>=E-H+>AWD:@MZ'>1J"W MH=Y&H+>AWD:@MZ'>1J!W1KTS@=X9]F?4.Q/HG5'O3*!W1KTS@=YY\K&2 M0.^,>F<"O3/JG0GTSJAW)M [H]Z90&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>] MG4!O1[V=0&^?_&Q"H+>CWDZ@MZ/>3J"WH]Y.H'>@WD&@=Z#>0:!WH-Y!H'>@ MWD&@=Z#>0:!WH-Y!H'>@WD&@=TQ^%B30.U#O(- [4.\@T+M!O1L"O1O4NR'0 MNT&]&P*]&]2[^4Z]A_'S4(9;S]<:K_^=5(^7<\OM\M?EU\[)K7+%N;ZO&)[_ M E!+ P04 " I/H%8(' .V20" "I+P $P %M#;VYT96YT7U1Y<&5S M72YX;6S-VDUNVS 0!>"K&-H&%LU_M8BS:;MML^@%6&D<"Y9$@F12Y_:EY"1 MB]1(X )]&PLVR7DC#O"M?/W],5!:'<=A2MMJGW/XR%AJ]S2Z5/M 4UG9^3BZ M7+[&.Q9<>W!WQ,1F8UCKITQ37N>Y1G5S_9EV[G[(JR_'\G/J_;2M(@VI6GTZ M;9RSMI4+8>A;E\LZ>YBZ/U+63PEU.;GL2?L^I*NRH6*O)LPK?P]X.O?M@6+L M.UK=NIB_NK'L8L>!I?PX4*K/EWBE1[_;]2UUOKT?RY$ZA4BN2WNB/ [UJ>C5 M^>1<;IA.G_SB_*7,N<"R\S;ZD,K$(KT_[GDD\^EU*(4HYO[\*[XDEM(7OQ_- MT^ZH>V-VN=Z?/AZ6>22V/"Z_X]]G_%+_G7T(D#XD2!\*I \-THL/[P__./X MY5F/KI^>\]GR#_V;7U!+ 0(4 Q0 ( "D^@5@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ *3Z! M6$?=DB+O *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ *3Z!6)E9&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6#9!J+PN @ G04 !@ ("! M$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*3Z!6)UL1!U@!0 3!4 !@ ("!FAT 'AL+W=O&PO=V]R:W-H965T!0 "XW 9 " M@5!& !X;"]W;W)K&UL4$L! A0#% @ *3Z! M6))+NE(9!P UQ$ !D ("!_UH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6#2N&HRO! #PL M !D ("!TVD 'AL+W=O&PO=V]R:W-H965T!U !X;"]W;W)K&UL4$L! A0#% @ *3Z!6'X]P9CY @ F@8 !D M ("!>7T 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ *3Z!6.)Z7EH " TQ4 !D ("!BHH 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6(S1 M%"\+! ^0@ !D ("!.:( 'AL+W=O&PO=V]R:W-H965T , +D' 9 " @7RS !X;"]W;W)K&UL4$L! A0#% @ *3Z!6&,.GB(< P N08 !D M ("!*[< 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ *3Z!6%A)U:%( @ I 4 !D ("! MLL, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *3Z!6/F56CD> P R@8 !D ("!R-X 'AL+W=O&PO=V]R:W-H965TVP0 ,T/ 9 " @7;Q !X;"]W;W)K&UL4$L! A0#% @ *3Z!6#'RW;[O @ @@8 !D M ("!B/8 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *3Z!6& &PO=V]R:W-H965T&UL4$L! A0#% @ M*3Z!6%B'!B@V! S0D !D ("!P X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6,/O_$?J P M*18 !D ("!RQH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6(.B]].' P EP\ !D M ("!=24! 'AL+W=O&PO=V]R:W-H M965T,K 0!X;"]W;W)K&UL4$L! M A0#% @ *3Z!6&G&-4<( M !*1@ &0 @(%C,@$ >&PO=V]R:W-H965T$Z 0!X;"]W;W)K&UL4$L! A0#% @ *3Z! M6%_THH&P!@ ,S0 !D ("!]CT! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6&%J_9WJ! TA0 M !D ("!\D\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6'.IIH]< P [! !D M ("!^%P! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ *3Z!6!KKEY:Q @ H@< !D ("!*V8! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6&"# M_V*0 P 2A$ !D ("!16\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6&:5$2WB P ;P\ !D M ("!'8@! 'AL+W=O&PO M=V]R:W-H965TJ/ 0!X;"]W;W)K&UL4$L! A0#% @ *3Z!6$H)@2/5 @ \@@ !D ("! M0)4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *3Z!6/3%B/F4 P $PP !D ("!K9X! 'AL+W=ONOLC T" ")! &0 M@(&$JP$ >&PO=V]R:W-H965T&UL4$L! A0#% @ *3Z!6"U[9>Q2 P SA4 T M ( !G[0! 'AL+W-T>6QE&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ *3Z!6#1..WUZ @ #$ !H M ( !(K\! 'AL+U]R96QS+W=O XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 220 441 1 true 83 0 false 4 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995300 - Document - Audit Information Sheet http://xbrl.sec.gov/dei/role/document/AuditInformation Audit Information Cover 2 false false R3.htm 995301 - Statement - Consolidated Balance Sheets Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 3 false false R4.htm 995302 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 4 false false R5.htm 995303 - Statement - Consolidated Statements of Operations Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations Statements 5 false false R6.htm 995304 - Statement - Consolidated Statements of Operations (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations (Parentheticals) Statements 6 false false R7.htm 995305 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity Sheet http://www.aikidopharma.com/role/ShareholdersEquityType2or3 Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity Statements 7 false false R8.htm 995306 - Statement - Consolidated Statements of Cash Flows Sheet http://www.aikidopharma.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 8 false false R9.htm 995307 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments Organization and Description of Business and Recent Developments Notes 9 false false R10.htm 995308 - Disclosure - Liquidity and Capital Resources Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResources Liquidity and Capital Resources Notes 10 false false R11.htm 995309 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995310 - Disclosure - FPS Acquisition Sheet http://www.aikidopharma.com/role/FPSAcquisition FPS Acquisition Notes 12 false false R13.htm 995311 - Disclosure - Investments in Marketable Securities Sheet http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities Investments in Marketable Securities Notes 13 false false R14.htm 995312 - Disclosure - Short-Term Investments Sheet http://www.aikidopharma.com/role/ShortTermInvestments Short-Term Investments Notes 14 false false R15.htm 995313 - Disclosure - Long-Term Investments Sheet http://www.aikidopharma.com/role/LongTermInvestments Long-Term Investments Notes 15 false false R16.htm 995314 - Disclosure - Notes Receivable Notes http://www.aikidopharma.com/role/NotesReceivable Notes Receivable Notes 16 false false R17.htm 995315 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 17 false false R18.htm 995316 - Disclosure - Property and Equipment Sheet http://www.aikidopharma.com/role/PropertyandEquipment Property and Equipment Notes 18 false false R19.htm 995317 - Disclosure - Leases Sheet http://www.aikidopharma.com/role/Leases Leases Notes 19 false false R20.htm 995318 - Disclosure - Net Loss Per Share Sheet http://www.aikidopharma.com/role/NetLossPerShare Net Loss Per Share Notes 20 false false R21.htm 995319 - Disclosure - Redeemable Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStock Redeemable Convertible Preferred Stock Notes 21 false false R22.htm 995320 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock Stockholders??? Equity and Convertible Preferred Stock Notes 22 false false R23.htm 995321 - Disclosure - Revenue Sheet http://www.aikidopharma.com/role/Revenue Revenue Notes 23 false false R24.htm 995322 - Disclosure - Commitments and Contingencies Sheet http://www.aikidopharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 995323 - Disclosure - Income Taxes Sheet http://www.aikidopharma.com/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 995324 - Disclosure - Regulatory Sheet http://www.aikidopharma.com/role/Regulatory Regulatory Notes 26 false false R27.htm 995325 - Disclosure - Related Party Transaction Sheet http://www.aikidopharma.com/role/RelatedPartyTransaction Related Party Transaction Notes 27 false false R28.htm 995326 - Disclosure - Segment Reporting Sheet http://www.aikidopharma.com/role/SegmentReporting Segment Reporting Notes 28 false false R29.htm 995327 - Disclosure - Subsequent Events Sheet http://www.aikidopharma.com/role/SubsequentEvents Subsequent Events Notes 29 false false R30.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 30 false false R31.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 31 false false R32.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.aikidopharma.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 32 false false R33.htm 996001 - Disclosure - FPS Acquisition (Tables) Sheet http://www.aikidopharma.com/role/FPSAcquisitionTables FPS Acquisition (Tables) Tables http://www.aikidopharma.com/role/FPSAcquisition 33 false false R34.htm 996002 - Disclosure - Investments in Marketable Securities (Tables) Sheet http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables Investments in Marketable Securities (Tables) Tables http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities 34 false false R35.htm 996003 - Disclosure - Short-Term Investments (Tables) Sheet http://www.aikidopharma.com/role/ShortTermInvestmentsTables Short-Term Investments (Tables) Tables http://www.aikidopharma.com/role/ShortTermInvestments 35 false false R36.htm 996004 - Disclosure - Long-Term Investments (Tables) Sheet http://www.aikidopharma.com/role/LongTermInvestmentsTables Long-Term Investments (Tables) Tables http://www.aikidopharma.com/role/LongTermInvestments 36 false false R37.htm 996005 - Disclosure - Notes Receivable (Tables) Notes http://www.aikidopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables http://www.aikidopharma.com/role/NotesReceivable 37 false false R38.htm 996006 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities 38 false false R39.htm 996007 - Disclosure - Property and Equipment (Tables) Sheet http://www.aikidopharma.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.aikidopharma.com/role/PropertyandEquipment 39 false false R40.htm 996008 - Disclosure - Leases (Tables) Sheet http://www.aikidopharma.com/role/LeasesTables Leases (Tables) Tables http://www.aikidopharma.com/role/Leases 40 false false R41.htm 996009 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aikidopharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.aikidopharma.com/role/NetLossPerShare 41 false false R42.htm 996010 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Tables) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables Stockholders??? Equity and Convertible Preferred Stock (Tables) Tables http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock 42 false false R43.htm 996011 - Disclosure - Revenue (Tables) Sheet http://www.aikidopharma.com/role/RevenueTables Revenue (Tables) Tables http://www.aikidopharma.com/role/Revenue 43 false false R44.htm 996012 - Disclosure - Income Taxes (Tables) Sheet http://www.aikidopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.aikidopharma.com/role/IncomeTaxes 44 false false R45.htm 996013 - Disclosure - Segment Reporting (Tables) Sheet http://www.aikidopharma.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.aikidopharma.com/role/SegmentReporting 45 false false R46.htm 996014 - Disclosure - Organization and Description of Business and Recent Developments (Details) Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails Organization and Description of Business and Recent Developments (Details) Details http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments 46 false false R47.htm 996015 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 47 false false R48.htm 996016 - Disclosure - FPS Acquisition (Details) Sheet http://www.aikidopharma.com/role/FPSAcquisitionDetails FPS Acquisition (Details) Details http://www.aikidopharma.com/role/FPSAcquisitionTables 48 false false R49.htm 996017 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities Details http://www.aikidopharma.com/role/FPSAcquisitionTables 49 false false R50.htm 996018 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities Sheet http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable Investments in Marketable Securities (Details) - Schedule of Marketable Securities Details http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables 50 false false R51.htm 996019 - Disclosure - Short-Term Investments (Details) Sheet http://www.aikidopharma.com/role/ShortTermInvestmentsDetails Short-Term Investments (Details) Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 51 false false R52.htm 996020 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments Sheet http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable Short-Term Investments (Details) - Schedule of Short-Term Investments Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 52 false false R53.htm 996021 - Disclosure - Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments Sheet http://www.aikidopharma.com/role/ScheduleofChangeintheFairValueoftheShortTermInvestmentsTable Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 53 false false R54.htm 996022 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs Sheet http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs Details http://www.aikidopharma.com/role/ShortTermInvestmentsTables 54 false false R55.htm 996023 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments Sheet http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable Long-Term Investments (Details) - Schedule of Long-Term Investments Details http://www.aikidopharma.com/role/LongTermInvestmentsTables 55 false false R56.htm 996024 - Disclosure - Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments Sheet http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments Details http://www.aikidopharma.com/role/LongTermInvestmentsTables 56 false false R57.htm 996025 - Disclosure - Notes Receivable (Details) Notes http://www.aikidopharma.com/role/NotesReceivableDetails Notes Receivable (Details) Details http://www.aikidopharma.com/role/NotesReceivableTables 57 false false R58.htm 996026 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable Notes http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable Notes Receivable (Details) - Schedule of Notes Receivable Details http://www.aikidopharma.com/role/NotesReceivableTables 58 false false R59.htm 996027 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value Sheet http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value Details http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables 59 false false R60.htm 996028 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis Sheet http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis Details http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables 60 false false R61.htm 996029 - Disclosure - Property and Equipment (Details) Sheet http://www.aikidopharma.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://www.aikidopharma.com/role/PropertyandEquipmentTables 61 false false R62.htm 996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment, Net Sheet http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable Property and Equipment (Details) - Schedule of Property and Equipment, Net Details http://www.aikidopharma.com/role/PropertyandEquipmentTables 62 false false R63.htm 996031 - Disclosure - Leases (Details) Sheet http://www.aikidopharma.com/role/LeasesDetails Leases (Details) Details http://www.aikidopharma.com/role/LeasesTables 63 false false R64.htm 996032 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable Leases (Details) - Schedule of Lease Assets and Liabilities Details http://www.aikidopharma.com/role/LeasesTables 64 false false R65.htm 996033 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about the Company???s Operating Leases Sheet http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable Leases (Details) - Schedule of Summarize Quantitative Information about the Company???s Operating Leases Details http://www.aikidopharma.com/role/LeasesTables 65 false false R66.htm 996034 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations Sheet http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable Leases (Details) - Schedule of Lease Expense to Current Period Operations Details http://www.aikidopharma.com/role/LeasesTables 66 false false R67.htm 996035 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases Sheet http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases Details http://www.aikidopharma.com/role/LeasesTables 67 false false R68.htm 996036 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Sheet http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable Leases (Details) - Schedule of Future Minimum Payments Details http://www.aikidopharma.com/role/LeasesTables 68 false false R69.htm 996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share Sheet http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share Details http://www.aikidopharma.com/role/NetLossPerShareTables 69 false false R70.htm 996038 - Disclosure - Redeemable Convertible Preferred Stock (Details) Sheet http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails Redeemable Convertible Preferred Stock (Details) Details http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStock 70 false false R71.htm 996039 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails Stockholders??? Equity and Convertible Preferred Stock (Details) Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 71 false false R72.htm 996040 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Sheet http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 72 false false R73.htm 996041 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Sheet http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 73 false false R74.htm 996042 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity Sheet http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 74 false false R75.htm 996043 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type Sheet http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type Details http://www.aikidopharma.com/role/RevenueTables 75 false false R76.htm 996044 - Disclosure - Income Taxes (Details) Sheet http://www.aikidopharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.aikidopharma.com/role/IncomeTaxesTables 76 false false R77.htm 996045 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision Sheet http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable Income Taxes (Details) - Schedule of Income Tax Provision Details http://www.aikidopharma.com/role/IncomeTaxesTables 77 false false R78.htm 996046 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rates Sheet http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable Income Taxes (Details) - Schedule of Effective Income Tax Rates Details http://www.aikidopharma.com/role/IncomeTaxesTables 78 false false R79.htm 996047 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities Sheet http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities Details http://www.aikidopharma.com/role/IncomeTaxesTables 79 false false R80.htm 996048 - Disclosure - Regulatory (Details) Sheet http://www.aikidopharma.com/role/RegulatoryDetails Regulatory (Details) Details http://www.aikidopharma.com/role/Regulatory 80 false false R81.htm 996049 - Disclosure - Related Party Transaction (Details) Sheet http://www.aikidopharma.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://www.aikidopharma.com/role/RelatedPartyTransaction 81 false false R82.htm 996050 - Disclosure - Segment Reporting (Details) Sheet http://www.aikidopharma.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.aikidopharma.com/role/SegmentReportingTables 82 false false R83.htm 996051 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss Sheet http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss Details http://www.aikidopharma.com/role/SegmentReportingTables 83 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - ea0202511-10k_domin.htm 10111, 10112, 10113, 10114 domh-20231231.xsd domh-20231231_cal.xml domh-20231231_def.xml domh-20231231_lab.xml domh-20231231_pre.xml ea0202511-10k_domin.htm img_001.jpg img_002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0202511-10k_domin.htm": { "nsprefix": "domh", "nsuri": "http://www.aikidopharma.com/20231231", "dts": { "schema": { "local": [ "domh-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd", "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] }, "calculationLink": { "local": [ "domh-20231231_cal.xml" ] }, "definitionLink": { "local": [ "domh-20231231_def.xml" ] }, "labelLink": { "local": [ "domh-20231231_lab.xml" ] }, "presentationLink": { "local": [ "domh-20231231_pre.xml" ] }, "inline": { "local": [ "ea0202511-10k_domin.htm" ] } }, "keyStandard": 370, "keyCustom": 71, "axisStandard": 19, "axisCustom": 0, "memberStandard": 29, "memberCustom": 45, "hidden": { "total": 253, "http://fasb.org/us-gaap/2023": 202, "http://www.aikidopharma.com/20231231": 48, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 220, "entityCount": 1, "segmentCount": 83, "elementCount": 881, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 929, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation", "longName": "995300 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R5": { "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R6": { "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "995304 - Statement - Consolidated Statements of Operations (Parentheticals)", "shortName": "Consolidated Statements of Operations (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": null, "uniqueAnchor": null }, "R7": { "role": "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "longName": "995305 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity", "shortName": "Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c14", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c14", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "longName": "995306 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "domh:AmortizationOfRightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R9": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments", "longName": "995307 - Disclosure - Organization and Description of Business and Recent Developments", "shortName": "Organization and Description of Business and Recent Developments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResources", "longName": "995308 - Disclosure - Liquidity and Capital Resources", "shortName": "Liquidity and Capital Resources", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "995309 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.aikidopharma.com/role/FPSAcquisition", "longName": "995310 - Disclosure - FPS Acquisition", "shortName": "FPS Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities", "longName": "995311 - Disclosure - Investments in Marketable Securities", "shortName": "Investments in Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.aikidopharma.com/role/ShortTermInvestments", "longName": "995312 - Disclosure - Short-Term Investments", "shortName": "Short-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.aikidopharma.com/role/LongTermInvestments", "longName": "995313 - Disclosure - Long-Term Investments", "shortName": "Long-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.aikidopharma.com/role/NotesReceivable", "longName": "995314 - Disclosure - Notes Receivable", "shortName": "Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities", "longName": "995315 - Disclosure - Fair Value of Financial Assets and Liabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.aikidopharma.com/role/PropertyandEquipment", "longName": "995316 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aikidopharma.com/role/Leases", "longName": "995317 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aikidopharma.com/role/NetLossPerShare", "longName": "995318 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStock", "longName": "995319 - Disclosure - Redeemable Convertible Preferred Stock", "shortName": "Redeemable Convertible Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock", "longName": "995320 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.aikidopharma.com/role/Revenue", "longName": "995321 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.aikidopharma.com/role/CommitmentsandContingencies", "longName": "995322 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.aikidopharma.com/role/IncomeTaxes", "longName": "995323 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.aikidopharma.com/role/Regulatory", "longName": "995324 - Disclosure - Regulatory", "shortName": "Regulatory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransaction", "longName": "995325 - Disclosure - Related Party Transaction", "shortName": "Related Party Transaction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aikidopharma.com/role/SegmentReporting", "longName": "995326 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aikidopharma.com/role/SubsequentEvents", "longName": "995327 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c219", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c219", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.aikidopharma.com/role/FPSAcquisitionTables", "longName": "996001 - Disclosure - FPS Acquisition (Tables)", "shortName": "FPS Acquisition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables", "longName": "996002 - Disclosure - Investments in Marketable Securities (Tables)", "shortName": "Investments in Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.aikidopharma.com/role/ShortTermInvestmentsTables", "longName": "996003 - Disclosure - Short-Term Investments (Tables)", "shortName": "Short-Term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.aikidopharma.com/role/LongTermInvestmentsTables", "longName": "996004 - Disclosure - Long-Term Investments (Tables)", "shortName": "Long-Term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.aikidopharma.com/role/NotesReceivableTables", "longName": "996005 - Disclosure - Notes Receivable (Tables)", "shortName": "Notes Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "longName": "996006 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.aikidopharma.com/role/PropertyandEquipmentTables", "longName": "996007 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.aikidopharma.com/role/LeasesTables", "longName": "996008 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.aikidopharma.com/role/NetLossPerShareTables", "longName": "996009 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables", "longName": "996010 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.aikidopharma.com/role/RevenueTables", "longName": "996011 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.aikidopharma.com/role/IncomeTaxesTables", "longName": "996012 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.aikidopharma.com/role/SegmentReportingTables", "longName": "996013 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "longName": "996014 - Disclosure - Organization and Description of Business and Recent Developments (Details)", "shortName": "Organization and Description of Business and Recent Developments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c47", "name": "domh:InvestmentsCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c47", "name": "domh:InvestmentsCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "longName": "996016 - Disclosure - FPS Acquisition (Details)", "shortName": "FPS Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CashAcquiredFromAcquisition", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CashAcquiredFromAcquisition", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable", "longName": "996017 - Disclosure - FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities", "shortName": "FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c58", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c58", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable", "longName": "996018 - Disclosure - Investments in Marketable Securities (Details) - Schedule of Marketable Securities", "shortName": "Investments in Marketable Securities (Details) - Schedule of Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails", "longName": "996019 - Disclosure - Short-Term Investments (Details)", "shortName": "Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:OtherShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c59", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R52": { "role": "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable", "longName": "996020 - Disclosure - Short-Term Investments (Details) - Schedule of Short-Term Investments", "shortName": "Short-Term Investments (Details) - Schedule of Short-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:OtherShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c62", "name": "us-gaap:OtherShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R53": { "role": "http://www.aikidopharma.com/role/ScheduleofChangeintheFairValueoftheShortTermInvestmentsTable", "longName": "996021 - Disclosure - Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments", "shortName": "Short-Term Investments (Details) - Schedule of Change in the Fair Value of the Short-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable", "longName": "996022 - Disclosure - Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs", "shortName": "Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c63", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c63", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "longName": "996023 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investments", "shortName": "Long-Term Investments (Details) - Schedule of Long-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable", "longName": "996024 - Disclosure - Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments", "shortName": "Long-Term Investments (Details) - Schedule of Companies are Through Both an SPV and Direct Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PaymentsToAcquireInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R57": { "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "longName": "996025 - Disclosure - Notes Receivable (Details)", "shortName": "Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:DepositLiabilitiesAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:DepositLiabilitiesAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "longName": "996026 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable", "shortName": "Notes Receivable (Details) - Schedule of Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:InterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:NotesReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R59": { "role": "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "longName": "996027 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable", "longName": "996028 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c143", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c144", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R61": { "role": "http://www.aikidopharma.com/role/PropertyandEquipmentDetails", "longName": "996029 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "longName": "996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment, Net", "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.aikidopharma.com/role/LeasesDetails", "longName": "996031 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c160", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c160", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable", "longName": "996032 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities", "shortName": "Leases (Details) - Schedule of Lease Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable", "longName": "996033 - Disclosure - Leases (Details) - Schedule of Summarize Quantitative Information about the Company\u2019s Operating Leases", "shortName": "Leases (Details) - Schedule of Summarize Quantitative Information about the Company\u2019s Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "longName": "996034 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations", "shortName": "Leases (Details) - Schedule of Lease Expense to Current Period Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "longName": "996035 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases", "shortName": "Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "longName": "996036 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments", "shortName": "Leases (Details) - Schedule of Future Minimum Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "longName": "996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share", "shortName": "Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "longName": "996038 - Disclosure - Redeemable Convertible Preferred Stock (Details)", "shortName": "Redeemable Convertible Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:RestrictedCashAndInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:RestrictedCashAndInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "longName": "996039 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c182", "name": "domh:SharesCancelled", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c182", "name": "domh:SharesCancelled", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "longName": "996040 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c208", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c208", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "longName": "996041 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R74": { "role": "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "longName": "996042 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "unique": true } }, "R75": { "role": "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable", "longName": "996043 - Disclosure - Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type", "shortName": "Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:UnderwritingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:UnderwritingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.aikidopharma.com/role/IncomeTaxesDetails", "longName": "996044 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable", "longName": "996045 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision", "shortName": "Income Taxes (Details) - Schedule of Income Tax Provision", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable", "longName": "996046 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rates", "shortName": "Income Taxes (Details) - Schedule of Effective Income Tax Rates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable", "longName": "996047 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities", "shortName": "Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.aikidopharma.com/role/RegulatoryDetails", "longName": "996048 - Disclosure - Regulatory (Details)", "shortName": "Regulatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CapitalUnitsNetAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CapitalUnitsNetAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "longName": "996049 - Disclosure - Related Party Transaction (Details)", "shortName": "Related Party Transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.aikidopharma.com/role/SegmentReportingDetails", "longName": "996050 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable", "longName": "996051 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss", "shortName": "Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c213", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c213", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202511-10k_domin.htm", "first": true, "unique": true } } }, "tag": { "domh_AccountingForWarrantstextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AccountingForWarrantstextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Warrants", "documentation": "Accounting for Warrants [text block]", "label": "Accounting For Warrantstext Block" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Notes Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries and benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "domh_AccruedInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AccruedInterestReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable", "documentation": "Accrued interest receivable.", "label": "Accrued Interest Receivable" } } }, "auth_ref": [] }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRentCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent payment", "label": "Accrued Rent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements." } } }, "auth_ref": [ "r98", "r99", "r141" ] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r732" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r54", "r179", "r566" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Values of the Assets Acquired and Liabilities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_AcquisitionOfFPSNetOfCashAcquiredAndReceivableOwedFromFPS": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AcquisitionOfFPSNetOfCashAcquiredAndReceivableOwedFromFPS", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of FPS, net of cash acquired and receivable owed from FPS", "documentation": "Acquisition of FPS, net of cash acquired and receivable owed from FPS.", "label": "Acquisition Of FPSNet Of Cash Acquired And Receivable Owed From FPS" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r827" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r103", "r757", "r974" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r425", "r426", "r427", "r598", "r914", "r915", "r916", "r951", "r975" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r871" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r871" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r869" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r833" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Fractional shares adjusted for reverse split", "terseLabel": "Reverse stock split", "label": "Adjustments to Additional Paid in Capital, Stock Split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": [ "r12", "r128" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series O redeemable convertible preferred stock for cash", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r12", "r55", "r128" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "domh_AggregateCashFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AggregateCashFeePercentage", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cash fee, percentage", "documentation": "Aggregate cash fee percentage.", "label": "Aggregate Cash Fee Percentage" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r789", "r801", "r817", "r845" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r792", "r804", "r820", "r848" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r833" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r840" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r796", "r805", "r821", "r840", "r849", "r853", "r861" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r859" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r423", "r432" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated future stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "domh_AmericanInnovativeRoboticsInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AmericanInnovativeRoboticsInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics Investment [Member]", "label": "American Innovative Robotics Investment Member" } } }, "auth_ref": [] }, "domh_AmericanInnovativeRoboticsLLCInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AmericanInnovativeRoboticsLLCInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics, LLC Investment [Member]", "label": "American Innovative Robotics LLCInvestment Member" } } }, "auth_ref": [] }, "domh_AmortizationOfRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AmortizationOfRightofuseAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization Of Rightofuse Assets" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r797" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total diluted loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r231" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r44" ] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "FPS Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r139", "r180", "r203", "r243", "r257", "r262", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r459", "r461", "r482", "r560", "r641", "r757", "r768", "r937", "r938", "r962" ] }, "domh_AssetsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "AssetsAbstract0", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets Abstract0" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r174", "r187", "r203", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r459", "r461", "r482", "r757", "r937", "r938", "r962" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r797" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r781", "r784", "r797" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r781", "r784", "r797" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r781", "r784", "r797" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r856" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r857" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r852" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r855" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r854" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r853" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r853" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r119" ] }, "us-gaap_BrokerageCommissionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BrokerageCommissionsRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions", "label": "Brokerage Commissions Revenue", "documentation": "Amount of commission revenue from buying and selling securities on behalf of customers." } } }, "auth_ref": [ "r87", "r147" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r457", "r752", "r753" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r74", "r76", "r457", "r752", "r753" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voting power", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r75" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration amount", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r10" ] }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredOther1", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional consideration", "label": "Business Combination, Consideration Transferred, Other", "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash." } } }, "auth_ref": [ "r11" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisition" ], "lang": { "en-us": { "role": { "terseLabel": "FPS Acquisition", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r135", "r458" ] }, "domh_BusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "BusinessCombinationMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination [Member]", "label": "Business Combination Member" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits with Clearing Broker-Dealer", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Wealth management liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total net assets of FPS Acquisition", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r77", "r78" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of acquired membership interest", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r784", "r797" ] }, "domh_CancellationOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "CancellationOfCommonStock", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of common stock", "documentation": "Cancellation of common stock.", "label": "Cancellation Of Common Stock" } } }, "auth_ref": [] }, "domh_CancellationOfCommonStockRelatedToInvestmentInCBMinShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "CancellationOfCommonStockRelatedToInvestmentInCBMinShares", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of common stock related to investment in CBM", "documentation": "Cancellation of common stock related to investment in CBM.", "label": "Cancellation Of Common Stock Related To Investment In CBMin Shares" } } }, "auth_ref": [] }, "domh_CancellationOfCommonStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "CancellationOfCommonStockShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of common stock (in Shares)", "documentation": "Cancellation of common stock shares.", "label": "Cancellation Of Common Stock Shares" } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsNetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsNetAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net capital amount", "label": "Capital Units, Net Amount", "documentation": "Net amount applicable to investors of capital units or shares." } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r176", "r729" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r116", "r199" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r116" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfLongtermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ChangeInFairValueOfLongtermInvestment", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of long-term investment", "documentation": "Change in fair value of long-term investment.", "label": "Change In Fair Value Of Longterm Investment" } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ChangeInFairValueOfLongtermInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of long-term investments", "documentation": "Change in fair value of long-term investments.", "label": "Change In Fair Value Of Longterm Investments" } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfShorttermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ChangeInFairValueOfShorttermInvestment", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of short-term investment", "verboseLabel": "Change in fair value of investment", "documentation": "Change in fair value of short-term investment.", "label": "Change In Fair Value Of Shortterm Investment" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r831" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r167", "r182", "r183", "r184", "r203", "r224", "r225", "r228", "r230", "r237", "r238", "r307", "r329", "r331", "r332", "r333", "r336", "r337", "r357", "r358", "r362", "r365", "r372", "r482", "r588", "r589", "r590", "r591", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r629", "r650", "r674", "r717", "r718", "r719", "r720", "r721", "r880", "r909", "r919" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r182", "r183", "r184", "r237", "r357", "r358", "r360", "r362", "r365", "r370", "r372", "r588", "r589", "r590", "r591", "r748", "r880", "r909" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock purchase warrants (in Shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r68" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r832" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r832" ] }, "domh_CollectionOfPrincipalOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "CollectionOfPrincipalOutstanding", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal outstanding", "documentation": "Amount of collection of principal outstanding.", "label": "Collection Of Principal Outstanding" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r123", "r323", "r324", "r725", "r936" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r914", "r915", "r951", "r971", "r975" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r102" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r102", "r629" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r102" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r102", "r629", "r647", "r975", "r976" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 and 5,485,096 shares issued at December 31, 2023 and 2022, respectively; 5,934,917 and 5,017,079 shares outstanding at December 31, 2023 and 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r102", "r562", "r757" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r837" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r836" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r838" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r835" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Cash", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r93", "r157" ] }, "domh_ConsolidatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConsolidatedMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated [Member]", "label": "Consolidated Member" } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r784" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContainedFileInformationFileDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContainedFileInformationFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "domh_ConvergentConvertibleNoteCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConvergentConvertibleNoteCurrentMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convergent convertible note - current [Member]", "label": "Convergent Convertible Note Current Member" } } }, "auth_ref": [] }, "domh_ConvergentConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConvergentConvertibleNoteMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convergent Convertible Note [Member]", "verboseLabel": "Convergent convertible note [Member]", "label": "Convergent Convertible Note Member" } } }, "auth_ref": [] }, "domh_ConvergentInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConvergentInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convergent Investment [Member]", "label": "Convergent Investment Member" } } }, "auth_ref": [] }, "domh_ConvergentTherapeuticsIncInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConvergentTherapeuticsIncInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convergent Therapeutics, Inc. Investment [Member]", "label": "Convergent Therapeutics Inc Investment Member" } } }, "auth_ref": [] }, "domh_ConversionOfNoteReceivableToMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ConversionOfNoteReceivableToMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of note receivable to marketable securities", "documentation": "The amount of conversion of note receivable to marketable securities.", "label": "Conversion Of Note Receivable To Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in Shares)", "label": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock [Member]", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r943" ] }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock", "label": "Preferred Stock, Convertible, Terms", "documentation": "Description of conversion terms for preferred stock." } } }, "auth_ref": [ "r20", "r61", "r64", "r101", "r126", "r127" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r884" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r884", "r912", "r949" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption amount", "label": "Debt Instrument, Debt Default, Amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r201" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r97", "r98", "r140", "r142", "r205", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r489", "r743", "r744", "r745", "r746", "r747", "r910" ] }, "us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleLiquidationPreferenceValue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated value", "label": "Debt Instrument, Convertible, Liquidation Preference, Value", "documentation": "Amount of excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share." } } }, "auth_ref": [ "r343" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note percentage", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r84", "r85", "r338", "r489", "r744", "r745" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Membership interests rate", "verboseLabel": "Original issue, percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r26", "r84", "r355", "r489" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stated Interest Rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r26", "r339" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r165", "r743", "r953" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r27", "r205", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r489", "r743", "r744", "r745", "r746", "r747", "r910" ] }, "domh_DebtInstrumentPurchasePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DebtInstrumentPurchasePricePercentage", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument purchase price percentage", "documentation": "Debt instrument purchase price percentage.", "label": "Debt Instrument Purchase Price Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated value, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r18" ] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of principal amount", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r591" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r27", "r61", "r64", "r83", "r84", "r85", "r92", "r126", "r127", "r205", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r489", "r743", "r744", "r745", "r746", "r747", "r910" ] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss", "label": "Debt Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r572", "r902", "r903" ] }, "domh_DeemedDividendsRelatedToSeriesOAndSeriesPRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DeemedDividendsRelatedToSeriesOAndSeriesPRedeemableConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock", "documentation": "The amount of deemed dividends related to series O and series P redeemable convertible preferred stock.", "label": "Deemed Dividends Related To Series OAnd Series PRedeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r912", "r948", "r949" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r912", "r948", "r949" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total Deferred Tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r444" ] }, "us-gaap_DeferredTaxAssetsHedgingTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsHedgingTransactions", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Costs", "label": "Deferred Tax Assets, Hedging Transactions", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions." } } }, "auth_ref": [ "r73", "r947" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Sec. 174 research & development", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r73", "r947" ] }, "us-gaap_DeferredTaxAssetsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInvestments", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment portfolio and other", "label": "Deferred Tax Assets, Investments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net lease liability", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r946" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset, Net of Allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r946" ] }, "domh_DeferredTaxAssetsNetOperatingLossCarryForwardsFederal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DeferredTaxAssetsNetOperatingLossCarryForwardsFederal", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal net operating loss carryovers", "documentation": "Represents deferred tax assets net operating loss carry forwards federal.", "label": "Deferred Tax Assets Net Operating Loss Carry Forwards Federal" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net-operating loss carryforward", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r73", "r947" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and city net operating loss", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r73", "r947" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other." } } }, "auth_ref": [ "r72", "r73", "r947" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r73", "r947" ] }, "domh_DeferredTaxAssetsTaxPatentsAndLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DeferredTaxAssetsTaxPatentsAndLicenses", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Patents & Licenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and licenses.", "label": "Deferred Tax Assets Tax Patents And Licenses" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r445" ] }, "us-gaap_DeferredTaxLiabilitiesRegulatoryAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesRegulatoryAssetsAndLiabilities", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Right of use asset", "label": "Deferred Tax Liabilities, Regulatory Assets and Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets and liabilities." } } }, "auth_ref": [ "r73", "r947" ] }, "domh_DeferredTaxLiabilityDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DeferredTaxLiabilityDepreciation", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation", "documentation": "Represents deferred tax liability depreciation.", "label": "Deferred Tax Liability Depreciation" } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r809", "r810", "r824" ] }, "us-gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Deposit Liabilities, Accrued Interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": [ "r88" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits with clearing broker", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r900" ] }, "domh_DepositsWithClearingBrokerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DepositsWithClearingBrokerPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits with clearing broker", "documentation": "Deposits with clearing broker.", "label": "Deposits With Clearing Broker Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r53" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r617", "r620", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r662", "r663", "r664", "r665", "r668", "r669", "r670", "r671", "r702", "r703", "r704", "r705", "r759", "r761" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r617", "r620", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r662", "r663", "r664", "r665", "r668", "r669", "r670", "r671", "r702", "r703", "r704", "r705", "r733", "r759", "r761" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurement inputs", "label": "Derivative Liability, Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r478" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors [Member]", "label": "Director [Member]" } } }, "auth_ref": [ "r923", "r973" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenues Disaggregated by Revenue Type", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r942" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Regulatory [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r809", "r810", "r824" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r5", "r128" ] }, "us-gaap_DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockCash", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemed cash", "label": "Dividends, Preferred Stock, Cash", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r5", "r128" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r784" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r781", "r784", "r797" ] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentCopyrightInformation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentCreationDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentEffectiveDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r781", "r784", "r797", "r841" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r781", "r784", "r797", "r841" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r782" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r770" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r784" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r784" ] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentSubtitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentSynopsis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r825" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentVersion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r773" ] }, "domh_DominariFinancialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DominariFinancialMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Financial [Member]", "label": "Dominari Financial Member" } } }, "auth_ref": [] }, "domh_DominariSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "DominariSecuritiesMember", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Securities [Member]", "label": "Dominari Securities Member" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r195", "r211", "r212", "r213", "r214", "r215", "r221", "r224", "r228", "r229", "r230", "r234", "r472", "r473", "r547", "r570", "r735" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic and diluted", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r195", "r211", "r212", "r213", "r214", "r215", "r224", "r228", "r229", "r230", "r234", "r472", "r473", "r547", "r570", "r735" ] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Diluted Loss Per Share [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r225", "r228" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r220", "r231", "r232", "r233" ] }, "domh_EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of new accounting pronouncements to be adopted in future periods", "documentation": "Effect of new accounting pronouncements to be adopted in future periods.", "label": "Effect Of New Accounting Pronouncements To Be Adopted In Future Periods Policy Text Block" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r875" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Income Tax Benefit", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r439" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Statutory Federal Rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r204", "r439", "r453" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Valuation Allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r945", "r950" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "State rate change in effect", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r453", "r945" ] }, "domh_EffectiveIncomeTaxRateReconciliationDecreaseDueToChangeInFederalNOLAndOtherTrueUps": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationDecreaseDueToChangeInFederalNOLAndOtherTrueUps", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease due to change in Federal NOL and other true ups", "documentation": "Percentage of decrease due to change in federal NOL and other true ups.", "label": "Effective Income Tax Rate Reconciliation Decrease Due To Change In Federal NOLAnd Other True Ups" } } }, "auth_ref": [] }, "domh_EffectiveIncomeTaxRateReconciliationDecreaseDueToTrueUpOfStateNOL": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationDecreaseDueToTrueUpOfStateNOL", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease due to true up of State NOL", "documentation": "Percentage of decrease due to true up of State NOL.", "label": "Effective Income Tax Rate Reconciliation Decrease Due To True Up Of State NOL" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other Permanent Differences", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r945", "r950" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "State Taxes, Net of Federal Tax Benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r945", "r950" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of stock corporation", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to investment tax credit." } } }, "auth_ref": [ "r945", "r950" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "calculation": { "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofEffectiveIncomeTaxRatesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "AMT credit benefit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits." } } }, "auth_ref": [ "r945", "r950" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r875" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r876" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r875" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r876" ] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r874" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r876" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r878" ] }, "domh_EmployeeOptionsGrantedWeightedAverageRemainingContractualLifeinYears": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "EmployeeOptionsGrantedWeightedAverageRemainingContractualLifeinYears", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Weighted Average Remaining Contractual Life", "documentation": "Employee options granted, weighted average remaining contractual.", "label": "Employee Options Granted Weighted Average Remaining Contractual Lifein Years" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r424" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase common stock [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r772" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r776" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r772" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityContactPersonnelLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r772" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r877" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r772" ] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityHomeCountryISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r867" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r866" ] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityLegalForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingForeign", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingParValuePerShare", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingPrimary", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingSecurityTradingCurrency", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityNumberOfEmployees", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r797" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r772" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r772" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r772" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r772" ] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r868" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r172", "r191", "r192", "r193", "r206", "r207", "r208", "r210", "r216", "r218", "r236", "r308", "r309", "r374", "r425", "r426", "r427", "r449", "r450", "r463", "r464", "r465", "r466", "r467", "r468", "r471", "r483", "r484", "r485", "r486", "r487", "r488", "r504", "r576", "r577", "r578", "r598", "r674" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r304", "r305", "r306" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Membership interests rate", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r304" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized loss", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r904", "r905", "r907" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Equities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r181", "r481", "r730" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r834" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r789", "r801", "r817", "r845" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r786", "r798", "r814", "r842" ] }, "us-gaap_ExcessCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExcessCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess amount", "label": "Banking Regulation, Total Risk-Based Capital, Excess, Actual", "documentation": "Amount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": [ "r553" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r840" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r873" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r873" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "domh_FPSAcquisitionDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FPSAcquisitionDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) [Line Items]" } } }, "auth_ref": [] }, "domh_FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FPSAcquisitionDetailsScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired and Liabilities [Table]" } } }, "auth_ref": [] }, "domh_FPSAcquisitionDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FPSAcquisitionDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "FPS Acquisition (Details) [Table]" } } }, "auth_ref": [] }, "domh_FPSMembershipInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FPSMembershipInterestsMember", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FPS Membership Interests [Member]", "label": "FPSMembership Interests Member" } } }, "auth_ref": [] }, "domh_FPSPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FPSPurchaseAgreementMember", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FPS Purchase Agreement [Member]", "label": "FPSPurchase Agreement Member" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of investments", "negatedTerseLabel": "Change in fair value of investments", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r8" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r13" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r13" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r346", "r385", "r386", "r387", "r388", "r389", "r390", "r476", "r516", "r517", "r518", "r744", "r745", "r749", "r750", "r751" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Assets and Liabilities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r474" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r346", "r385", "r390", "r476", "r516", "r749", "r750", "r751" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r346", "r385", "r390", "r476", "r517", "r744", "r745", "r749", "r750", "r751" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "verboseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r346", "r385", "r386", "r387", "r388", "r389", "r390", "r476", "r518", "r744", "r745", "r749", "r750", "r751" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Option - Short-term Note and Convertible Note", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r346", "r385", "r386", "r387", "r388", "r389", "r390", "r516", "r517", "r518", "r744", "r745", "r749", "r750", "r751" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r14", "r17" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r14", "r17" ] }, "domh_FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value [Line Items]" } } }, "auth_ref": [] }, "domh_FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities are Measured at Fair Value [Table]" } } }, "auth_ref": [] }, "domh_FederalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FederalAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Federal Abstract" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r354", "r370", "r469", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r569", "r742", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r928", "r929", "r930", "r931" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r793", "r805", "r821", "r849" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r793", "r805", "r821", "r849" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r793", "r805", "r821", "r849" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r793", "r805", "r821", "r849" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r793", "r805", "r821", "r849" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r783", "r808" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "domh_FractionalSharesAdjustedForReverseSplits": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "FractionalSharesAdjustedForReverseSplits", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Fractional shares adjusted for reverse split (in Shares)", "documentation": "Number of fractional shares adjusted for reverse split.", "label": "Fractional Shares Adjusted For Reverse Splits" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on note receivable", "label": "Gain (Loss) on Sale of Accounts Receivable", "documentation": "Amount of gain (loss) on sale of accounts receivable." } } }, "auth_ref": [ "r526" ] }, "us-gaap_GainLossOnSaleOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfNotesReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on note receivable", "negatedLabel": "Unrealized loss on note receivable", "label": "Gain (Loss) on Sale of Financing Receivable", "documentation": "Amount of gain (loss) on sale of financing receivable." } } }, "auth_ref": [ "r526" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized gain on receiving shares in exchange of note receivable extension", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r8", "r56", "r57" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r110", "r653" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r781", "r784", "r797" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r321", "r322", "r659" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r322", "r659" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r204", "r435", "r440", "r441", "r447", "r451", "r454", "r455", "r456", "r594" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Provision (Benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r154", "r164", "r217", "r218", "r247", "r438", "r452", "r574" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r190", "r436", "r437", "r441", "r442", "r446", "r448", "r587" ] }, "domh_IncomeTaxesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncomeTaxesDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "auth_ref": [] }, "domh_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncomeTaxesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash paid", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r36", "r38" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "domh_IncreaseDecreaseInAccruedCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncreaseDecreaseInAccruedCommissions", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "documentation": "Increase decrease in accrued commissions.", "label": "Increase Decrease In Accrued Commissions" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedSalaries", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries and benefits", "label": "Increase (Decrease) in Accrued Salaries", "documentation": "The increase (decrease) during the period in accrued salaries." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Clearing broker deposits", "label": "Increase (Decrease) in Deposit Assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInNotesReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInNotesReceivables", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Notes receivable, at fair value \u2013 net interest accrued", "label": "Increase (Decrease) in Notes Receivables", "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r883", "r906" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r906" ] }, "domh_IncreaseDecreaseInPrepaidAcquisitionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncreaseDecreaseInPrepaidAcquisitionCost", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid acquisition cost", "documentation": "Increase Decrease In Prepaid Acquisition Cost.", "label": "Increase Decrease In Prepaid Acquisition Cost" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidRent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase rent amount", "label": "Increase (Decrease) in Prepaid Rent", "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods." } } }, "auth_ref": [ "r7" ] }, "domh_IncreaseDecreaseInValuationAllowanceFederal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncreaseDecreaseInValuationAllowanceFederal", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "documentation": "The amount of Increase in valuation allowance.", "label": "Increase Decrease In Valuation Allowance Federal" } } }, "auth_ref": [] }, "domh_IncreaseInValuationAllowanceStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IncreaseInValuationAllowanceStateAndLocal", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "documentation": "The amount of Increase in valuation allowance.", "label": "Increase In Valuation Allowance State And Local" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r796", "r805", "r821", "r840", "r849", "r853", "r861" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r859" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r785", "r865" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r785", "r865" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r785", "r865" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "domh_InterestIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InterestIncomeReceivable", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Income Receivable" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeShortTermInvestmentIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeShortTermInvestmentIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofChangeintheFairValueoftheShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of short-term investment", "label": "Interest Income, Short-Term Investment, Increase (Decrease)", "documentation": "Amount of increase (decrease) in interest income on short-term investment." } } }, "auth_ref": [ "r168" ] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaid", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest and taxes", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": [ "r908" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable", "verboseLabel": "Interest income receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r899", "r977" ] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r810", "r811", "r812", "r813" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r826" ] }, "us-gaap_InvestmentCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFeePaidIndirectly", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional seller paid", "label": "Investment Company, Fee Paid Indirectly", "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction." } } }, "auth_ref": [ "r592", "r653", "r654", "r655", "r656", "r659" ] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r826" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r826" ] }, "domh_InvestmentInASPIsotopesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInASPIsotopesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in ASP Isotopes [Member]", "label": "Investment In ASPIsotopes Member" } } }, "auth_ref": [] }, "domh_InvestmentInAndurilMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInAndurilMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Anduril [Member]", "label": "Investment In Anduril Member" } } }, "auth_ref": [] }, "domh_InvestmentInAutomationAnywhereMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInAutomationAnywhereMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Automation Anywhere [Member]", "label": "Investment In Automation Anywhere Member" } } }, "auth_ref": [] }, "domh_InvestmentInDatabricksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInDatabricksMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Databricks [Member]", "label": "Investment In Databricks Member" } } }, "auth_ref": [] }, "domh_InvestmentInDiscordMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInDiscordMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Discord [Member]", "label": "Investment In Discord Member" } } }, "auth_ref": [] }, "domh_InvestmentInEpicGamesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInEpicGamesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Epic Games [Member]", "label": "Investment In Epic Games Member" } } }, "auth_ref": [] }, "domh_InvestmentInFieldPointSecuritie": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInFieldPointSecuritie", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Fieldpoint Securities", "documentation": "Investment in Field Point Securities.", "label": "Investment In Field Point Securitie" } } }, "auth_ref": [] }, "domh_InvestmentInKayaNowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInKayaNowMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kaya Now [Member]", "label": "Investment In Kaya Now Member" } } }, "auth_ref": [] }, "domh_InvestmentInKernaHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInKernaHealthIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment In Kerna Health Inc [Member]", "label": "Investment In Kerna Health Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInKrakenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInKrakenMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kraken [Member]", "label": "Investment In Kraken Member" } } }, "auth_ref": [] }, "domh_InvestmentInMasterclassMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInMasterclassMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Masterclass [Member]", "label": "Investment In Masterclass Member" } } }, "auth_ref": [] }, "domh_InvestmentInQxpressMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInQxpressMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Qxpress [Member]", "label": "Investment In Qxpress Member" } } }, "auth_ref": [] }, "domh_InvestmentInSpaceXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInSpaceXMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in SpaceX [Member]", "label": "Investment In Space XMember" } } }, "auth_ref": [] }, "domh_InvestmentInTesspayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInTesspayMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tesspay [Member]", "label": "Investment In Tesspay Member" } } }, "auth_ref": [] }, "domh_InvestmentInTevvaMotorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInTevvaMotorsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tevva Motors [Member]", "label": "Investment In Tevva Motors Member" } } }, "auth_ref": [] }, "domh_InvestmentInThrasioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInThrasioMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Thrasio [Member]", "label": "Investment In Thrasio Member" } } }, "auth_ref": [] }, "domh_InvestmentInUnusualMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInUnusualMachinesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Unusual Machines [Member]", "label": "Investment In Unusual Machines Member" } } }, "auth_ref": [] }, "domh_InvestmentInVicinityMotorCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentInVicinityMotorCorpMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Vicinity Motor Corp. [Member]", "label": "Investment In Vicinity Motor Corp Member" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeDividend", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Investment Income, Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": [ "r111" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r112", "r246" ] }, "us-gaap_InvestmentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentMaturityDate", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note maturity date", "label": "Investment Maturity Date", "documentation": "Maturity date of investment, in YYYY-MM-DD format." } } }, "auth_ref": [ "r682", "r683", "r691", "r692", "r693", "r694", "r708", "r709", "r761", "r926", "r927" ] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, Cost Basis", "label": "Investment Owned, Cost", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r583", "r615", "r616", "r686", "r690", "r698", "r714", "r761", "r768", "r972" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of investment", "label": "Investment Owned, Fair Value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r583", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r618", "r621", "r622", "r632", "r633", "r681", "r684", "r685", "r687", "r696", "r697", "r699", "r700", "r701", "r706", "r707", "r713", "r715", "r716", "r761", "r768", "r972" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r571", "r583", "r584", "r585", "r586", "r688", "r689" ] }, "us-gaap_InvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Companies are Through Both an SPV and Direct Investments", "label": "Investment [Table Text Block]", "documentation": "Tabular disclosure of investment." } } }, "auth_ref": [ "r885", "r886", "r924" ] }, "domh_InvestmentsCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "InvestmentsCompanyFeePaidIndirectly", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seller paid", "documentation": "InvestmentsCompanyFeePaidIndirectly.", "label": "Investments Company Fee Paid Indirectly" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/InvestmentsinMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r138", "r149", "r150", "r169", "r272", "r273", "r479", "r480" ] }, "domh_IssuanceOfSeriesORedeemableConvertiblePreferredStockForCashinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IssuanceOfSeriesORedeemableConvertiblePreferredStockForCashinShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series O redeemable convertible preferred stock for cash (in Shares)", "documentation": "Issuance of Series O redeemable convertible preferred stock for cash.", "label": "Issuance Of Series ORedeemable Convertible Preferred Stock For Cashin Shares" } } }, "auth_ref": [] }, "domh_IssuanceOfSeriesPRedeemablesConvertiblePreferredStockForCash": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IssuanceOfSeriesPRedeemablesConvertiblePreferredStockForCash", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series P redeemable convertible preferred stock for cash (in Shares)", "documentation": "Issuance of Series P redeemable convertible preferred stock for cash.", "label": "Issuance Of Series PRedeemables Convertible Preferred Stock For Cash" } } }, "auth_ref": [] }, "domh_IssuedWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "IssuedWeightedAverageRemainingContractualLife", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, Weighted Average Remaining Contractual Life", "documentation": "Issued, Weighted Average Remaining Contractual Life.", "label": "Issued Weighted Average Remaining Contractual Life" } } }, "auth_ref": [] }, "domh_JoshuaShipleyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "JoshuaShipleyMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joshua Shipley [Member]", "label": "Joshua Shipley Member" } } }, "auth_ref": [] }, "domh_KayaNowIncInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "KayaNowIncInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kaya Now Inc. Investment [Member]", "label": "Kaya Now Inc Investment Member" } } }, "auth_ref": [] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expenses", "label": "Operating Leases, Rent Expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails", "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net rent expense", "verboseLabel": "Lease expenses", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r495", "r756" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense to Current Period Operations", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r959" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r122" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofFutureMinimumPaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofFutureMinimumPaymentsLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Payments [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofFutureMinimumPaymentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofFutureMinimumPaymentsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Future Minimum Payments [Table]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of lease expense to current period operations [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Lease Expense to Current Period Operations [Table]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Smmarize Quantitative Information about the Company\u2019s Operating Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable" ], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Summarize Quantitative Information about the Company\u2019s Operating Leases [Table]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LeasesDetailsScheduleofSupplementalCashFlowInformationRelatedToLeasesTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases [Table]" } } }, "auth_ref": [] }, "domh_LegacyAIkidoPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LegacyAIkidoPharmaMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy AIkido Pharma [Member]", "label": "Legacy AIkido Pharma Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r769" ] }, "domh_LessDepositPreviouslyTransferredInOctober2022ToFPS": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LessDepositPreviouslyTransferredInOctober2022ToFPS", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_IncomeTaxesPaid", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Less - Deposit previously transferred in October 2022 to FPS", "documentation": "Amount of increase in lease obligation from new lease.", "label": "Less Deposit Previously Transferred In October2022 To FPS" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r494" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r960" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum payments lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r957" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r958" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r490" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r23", "r203", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r460", "r461", "r462", "r482", "r628", "r736", "r768", "r937", "r962", "r963" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r107", "r143", "r564", "r757", "r911", "r932", "r955" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r25", "r175", "r203", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r460", "r461", "r462", "r482", "r757", "r937", "r962", "r963" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of short-term investment", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiquidationBasisOfAccountingTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResources" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Capital Resources", "label": "Liquidation Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the liquidation basis of accounting." } } }, "auth_ref": [ "r96" ] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r922" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "domh_LongTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "LongTermAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term", "label": "Long Term Abstract" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Investments", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r124" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Investments", "verboseLabel": "Long-term investments, Total", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r177" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and computer software [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r89", "r896" ] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Investments in Marketable Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r896" ] }, "us-gaap_MarketableSecuritiesGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesGainLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r91" ] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized loss on marketable securities", "label": "Marketable Security, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/InvestmentsinMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on marketable securities", "verboseLabel": "Total", "netLabel": "Gain on marketable securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r109" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r391", "r544", "r575", "r619", "r620", "r682", "r691", "r694", "r695", "r708", "r726", "r727", "r739", "r748", "r754", "r758", "r939", "r964", "r965", "r966", "r967", "r968", "r969" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r832" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r832" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Dividends [Member]", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r952" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Option Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r952" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r952" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-Free Interest Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r952" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price [Member]", "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r952" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationRegardingLevel3FairValueMeasurementsInputsTable" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r477" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r391", "r544", "r575", "r619", "r620", "r682", "r691", "r694", "r695", "r708", "r726", "r727", "r739", "r748", "r754", "r758", "r939", "r964", "r965", "r966", "r967", "r968", "r969" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Membership interests rate", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r852" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds (in Dollars)", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r860" ] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NameChangeEventDateAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NameChangeEventLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NameChangeEventTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r833" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r198" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r198" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r116", "r117", "r118" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r108", "r118", "r146", "r173", "r188", "r189", "r193", "r203", "r209", "r211", "r212", "r213", "r214", "r217", "r218", "r226", "r243", "r256", "r261", "r264", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r473", "r482", "r568", "r649", "r672", "r673", "r737", "r767", "r937" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss Attributable to Common Shareholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r197", "r211", "r212", "r213", "r214", "r221", "r222", "r227", "r230", "r243", "r256", "r261", "r264", "r737" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of new accounting pronouncements not yet adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r810", "r811", "r812", "r813" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r872" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r872" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r832" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r793", "r805", "r821", "r840", "r849" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r830" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r829" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r840" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r860" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r860" ] }, "us-gaap_NoninterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestIncomeOther", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Noninterest Income, Other", "documentation": "Represents the total of noninterest income derived from certain activities and assets including (for example): (1) venture capital investments; (2) bank owned life insurance; (3) foreign currency transactions; and (4) mortgage servicing rights." } } }, "auth_ref": [ "r148" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r113" ] }, "domh_NoteReceivablePrincipalAndInterestReceivableReducedDueToReceivingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "NoteReceivablePrincipalAndInterestReceivableReducedDueToReceivingShares", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Note receivable principal and interest receivable reduced due to receiving shares", "documentation": "Note receivable principal and interest receivable reduced due to receiving shares.", "label": "Note Receivable Principal And Interest Receivable Reduced Due To Receiving Shares" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at fair value, current portion, Balance beginning", "periodEndLabel": "Notes receivable at fair value, current portion, Balance ending", "terseLabel": "Notes receivable, at fair value - current portion", "verboseLabel": "Notes receivable at fair value, current portion", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r270", "r271", "r546" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at fair value, non-current portion, Balance beginning", "periodEndLabel": "Notes receivable at fair value, non-current portion, Balance ending", "terseLabel": "Notes receivable, at fair value - non-current portion", "verboseLabel": "Notes receivable at fair value, non-current portion", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "domh_NotesReceivableAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "NotesReceivableAtFairValueAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable, at fair value", "label": "Notes Receivable At Fair Value Abstract" } } }, "auth_ref": [] }, "domh_NotesReceivableAtFairvalueCurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "NotesReceivableAtFairvalueCurrentPortionMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, at Fair Value - Current Portion [Member]", "label": "Notes Receivable At Fairvalue Current Portion Member" } } }, "auth_ref": [] }, "domh_NotesReceivableAtFairvalueNoncurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "NotesReceivableAtFairvalueNoncurrentPortionMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, at Fair Value - Non-Current Portion [Member]", "label": "Notes Receivable At Fairvalue Noncurrent Portion Member" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Notes Receivable, Fair Value Disclosure", "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date." } } }, "auth_ref": [ "r954" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableGross", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r163", "r170", "r171", "r185", "r312", "r315", "r740", "r741", "r894", "r933" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r921" ] }, "domh_OfferingPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "OfferingPricePerShare", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price, per share (in Dollars per share)", "documentation": "Offering price per share.", "label": "Offering Price Per Share" } } }, "auth_ref": [] }, "domh_OnMarch272023TheCompanyAcquiredAllAssetsAndLiabilitiesOfFpsAsDisclosedInNote4Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "OnMarch272023TheCompanyAcquiredAllAssetsAndLiabilitiesOfFpsAsDisclosedInNote4Abstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:", "label": "On March272023 The Company Acquired All Assets And Liabilities Of Fps As Disclosed In Note4 Abstract" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs and expenses", "verboseLabel": "Operating Costs", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r243", "r256", "r261", "r264", "r737" ] }, "us-gaap_OperatingIncomeLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLossMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Operating Loss [Member]", "label": "Operating Income (Loss) [Member]", "documentation": "Primary financial statement caption encompassing operating income (loss)." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r496", "r756" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r956" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Assets and Liabilities", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r235", "r503" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r492" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability - current", "verboseLabel": "Operating", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r492" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "verboseLabel": "Operating", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r492" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows - operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r493", "r498" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "verboseLabel": "Operating lease right-of-use-assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r491" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate \u2013 operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r501", "r756" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term \u2013 operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r500", "r756" ] }, "domh_OperatingLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "OperatingLeasesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Leases Abstract" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business and Recent Developments", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r95", "r137", "r581", "r582" ] }, "domh_OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Line Items]" } } }, "auth_ref": [] }, "domh_OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments (Details) [Table]" } } }, "auth_ref": [] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r907", "r934" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r573", "r651", "r710", "r711", "r712" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "verboseLabel": "Other (expenses) income", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Other Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liability", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r24", "r757" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r196" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expenses) income", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_OtherOwnershipInterestsCapitalAccountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOwnershipInterestsCapitalAccountAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r832" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r784" ] }, "us-gaap_OtherShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherShortTermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofFairValueAssetsandLiabilitiesareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments at fair value", "verboseLabel": "Total short-term investments", "netLabel": "Short-term investment", "label": "Fair value of the vicinity warrant", "documentation": "Amount of short-term investments classified as other." } } }, "auth_ref": [ "r90", "r559", "r900" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r791", "r803", "r819", "r847" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r794", "r806", "r822", "r850" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r794", "r806", "r822", "r850" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over-Allotment Option [Member]", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ParentEntityLegalName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r828" ] }, "us-gaap_PaymentsForMergerRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForMergerRelatedCosts", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory fees", "label": "Payments for Merger Related Costs", "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers." } } }, "auth_ref": [ "r6" ] }, "domh_PaymentsForPurchaseOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PaymentsForPurchaseOfTreasuryStock", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury stock", "documentation": "Represents the amount of purchase of treasury stock.", "label": "Payments For Purchase Of Treasury Stock" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment for fractional shares", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of research and development licenses", "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r115" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r925" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of notes receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of membership interest in FPS", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r115" ] }, "us-gaap_PaymentsToAcquireOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherReceivables", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable", "label": "Payments to Acquire Other Receivables", "documentation": "Amount of cash outflow from the purchase of receivables classified as other." } } }, "auth_ref": [ "r115" ] }, "domh_PaymentsToAcquireTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PaymentsToAcquireTangibleAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of fixed assets", "documentation": "Represents the amount of purchase of fixed assets.", "label": "Payments To Acquire Tangible Assets" } } }, "auth_ref": [] }, "domh_PaymentsToEmployeeForgivableLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PaymentsToEmployeeForgivableLoan", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Funds to employee forgivable loan", "documentation": "Represents the amount of funds to employee forgivable loan.", "label": "Payments To Employee Forgivable Loan" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r831" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r831" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r830" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r840" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r833" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r829" ] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PhoneFaxNumberDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r770" ] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r770" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r777" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r778" ] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r770" ] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r770" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price, per share (in Dollars per share)", "label": "Preferred Stock, Convertible, Conversion Price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r359" ] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock", "label": "Preferred Stock Dividends and Other Adjustments", "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders." } } }, "auth_ref": [ "r42", "r879", "r920" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference (in Dollars per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r61", "r62", "r101", "r909", "r940" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "verboseLabel": "Preferred Stock [Member]", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r759", "r760", "r763", "r764", "r765", "r766", "r971", "r975" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r101", "r357" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, share authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r629" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, share issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r101", "r357" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock, share outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r101", "r629", "r647", "r975", "r976" ] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Stock", "label": "Preferred Stock [Text Block]", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": [ "r125" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock value", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r101", "r561", "r757" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r901" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid acquisition cost", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r186", "r319", "r320", "r731" ] }, "domh_PrincipleReducedDueToReceiving": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PrincipleReducedDueToReceiving", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Principle reduced due to receiving shares", "documentation": "Represents principle reduced due to receiving shares.", "label": "Principle Reduced Due To Receiving" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal on note receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series O and Series P Redeemable Convertible Preferred Stock", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of digital currencies", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ProgramRightsObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProgramRightsObligations", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback program amount (in Dollars)", "label": "Program Rights Obligations", "documentation": "Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements." } } }, "auth_ref": [] }, "domh_PromissoryConvertibleNoteReceivableConversionIntoCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PromissoryConvertibleNoteReceivableConversionIntoCommonShares", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory convertible note receivable conversion into common shares", "documentation": "Promissory convertible note receivable conversion into common shares.", "label": "Promissory Convertible Note Receivable Conversion Into Common Shares" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r121", "r158", "r161", "r162" ] }, "domh_PropertyPlantAndEquipmentEstimatedUsefulLive": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PropertyPlantAndEquipmentEstimatedUsefulLive", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Lives", "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Live" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r122", "r178", "r567" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r549", "r567", "r757" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r158", "r161", "r565" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r122" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Lives", "verboseLabel": "Property and equipment estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "domh_PurchaseOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PurchaseOfNotesReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of notes receivable", "documentation": "Amount of cash outflow from the purchase of receivables classified as other.", "label": "Purchase Of Notes Receivable" } } }, "auth_ref": [] }, "domh_PurchaseOfShorttermAndLongtermPromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "PurchaseOfShorttermAndLongtermPromissoryNotes", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of short-term and long-term promissory notes", "documentation": "Purchase of short-term and long-term promissory notes.", "label": "Purchase Of Shortterm And Longterm Promissory Notes" } } }, "auth_ref": [] }, "domh_Purchaseofshort-termandlong-terminvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "Purchaseofshort-termandlong-terminvestments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of short-term and long-term investments", "documentation": "Purchase of short-term and long-term investments.", "label": "Purchaseofshort-termandlong-terminvestments" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r828" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r828" ] }, "domh_RaefanIndustriesLLCInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RaefanIndustriesLLCInvestmentMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Raefan Industries LLC Investment [Member]", "verboseLabel": "Raefan Industries LLC Investment", "label": "Raefan Industries LLCInvestment Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r384", "r391", "r419", "r420", "r421", "r519", "r544", "r575", "r619", "r620", "r682", "r691", "r694", "r695", "r708", "r726", "r727", "r739", "r748", "r754", "r758", "r761", "r935", "r939", "r965", "r966", "r967", "r968", "r969" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r384", "r391", "r419", "r420", "r421", "r519", "r544", "r575", "r619", "r620", "r682", "r691", "r694", "r695", "r708", "r726", "r727", "r739", "r748", "r754", "r758", "r761", "r935", "r939", "r965", "r966", "r967", "r968", "r969" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Notes Receivable [Abstract]" } } }, "auth_ref": [] }, "domh_ReceivingSharesInExchangeOfNoteReceivableExtension": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ReceivingSharesInExchangeOfNoteReceivableExtension", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Receiving shares in exchange of note receivable extension", "documentation": "Receiving shares in exchange of note receivable extension.", "label": "Receiving Shares In Exchange Of Note Receivable Extension" } } }, "auth_ref": [] }, "domh_ReceivingSharesInExchangeOfNoteReceivableExtensions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ReceivingSharesInExchangeOfNoteReceivableExtensions", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCompaniesareThroughBothanSPVandDirectInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Receiving shares in exchange of note receivable extension", "documentation": "Receiving shares in exchange of note receivable extension.", "label": "Receiving Shares In Exchange Of Note Receivable Extensions" } } }, "auth_ref": [] }, "domh_RecentlyAdoptedAccountingStandardsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RecentlyAdoptedAccountingStandardsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recently adopted accounting standards", "documentation": "Recently adopted accounting standards [Policy Text Block].", "label": "Recently Adopted Accounting Standards Policy Text Block" } } }, "auth_ref": [] }, "domh_ReclassifyFromConvertibleNoteReceivableToNotesReceivableAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ReclassifyFromConvertibleNoteReceivableToNotesReceivableAtFairValue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassify from convertible note receivable to notes receivable at fair value", "documentation": "Reclassify from convertible note receivable to notes receivable at fair value.", "label": "Reclassify From Convertible Note Receivable To Notes Receivable At Fair Value" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r786", "r798", "r814", "r842" ] }, "domh_RedeemableConvertiblePreferredStockDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RedeemableConvertiblePreferredStockDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock [Line Items]" } } }, "auth_ref": [] }, "domh_RedeemableConvertiblePreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RedeemableConvertiblePreferredStockDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Stock", "label": "Redeemable Convertible Preferred Stock [Member]", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "domh_RedemptionOfSeriesPRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RedemptionOfSeriesPRedeemableConvertiblePreferredStock", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series P Redeemable Convertible Preferred Stock", "documentation": "The redemption (or callable) amount of redeemable preferred stock, excluding currently redeemable preferred stock. Includes amounts representing dividends not declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Redemption Of Series PRedeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "domh_RedemptionOfSeriesPRedeemablesConvertiblePreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RedemptionOfSeriesPRedeemablesConvertiblePreferredStock", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)", "documentation": "The redemption (or callable) amount of redeemable preferred stock, excluding currently redeemable preferred stock. Includes amounts representing dividends not declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Redemption Of Series PRedeemables Convertible Preferred Stock" } } }, "auth_ref": [] }, "domh_RedemptionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RedemptionRightsMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption Rights [Member]", "label": "Redemption Rights Member" } } }, "auth_ref": [] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r770" ] }, "us-gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Regulatory" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory", "label": "Regulatory Capital Requirements under Banking Regulations [Text Block]", "documentation": "The entire disclosure for regulatory capital requirement for depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company, foreign financial institution and credit union." } } }, "auth_ref": [ "r550", "r551", "r552", "r554", "r555", "r556", "r557", "r558" ] }, "domh_RegulatoryDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RegulatoryDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory [Line Items]" } } }, "auth_ref": [] }, "domh_RegulatoryDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RegulatoryDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred fees", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r86", "r508" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transaction [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransaction" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r505", "r506", "r507", "r509", "r510", "r595", "r596", "r597", "r657", "r658", "r659", "r678", "r680" ] }, "domh_RepaymentOfInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "RepaymentOfInterestReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of interest receivable", "documentation": "Amount of interest receivable repayment.", "label": "Repayment Of Interest Receivable" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r94", "r434", "r970" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r433" ] }, "domh_ResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expenses" } } }, "auth_ref": [] }, "domh_ResearchAndDevelopmentLicenseAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ResearchAndDevelopmentLicenseAcquired", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development - license acquired", "documentation": "Amount of other research and development expense.", "label": "Research And Development License Acquired" } } }, "auth_ref": [] }, "domh_ResearchAndDevelopmentacquiredLicenseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ResearchAndDevelopmentacquiredLicenseExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development-acquired license, expensed", "documentation": "Represents the amount of research and development-acquired license expense.", "label": "Research And Developmentacquired License Expense" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r787", "r799", "r815", "r843" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r788", "r800", "r816", "r844" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r795", "r807", "r823", "r851" ] }, "us-gaap_RestrictedCashAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndInvestments", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds received", "label": "Restricted Cash and Investments", "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet." } } }, "auth_ref": [ "r723", "r724" ] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock (in Dollars)", "label": "Restricted Stock or Unit Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards\t[Member]", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r44" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock issued withheld shares", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock issued withheld value (in Dollars)", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r104", "r128", "r563", "r579", "r580", "r593", "r630", "r757" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r172", "r206", "r207", "r208", "r210", "r216", "r218", "r308", "r309", "r425", "r426", "r427", "r449", "r450", "r463", "r465", "r466", "r468", "r471", "r576", "r578", "r598", "r975" ] }, "domh_ReturnOfDepositfundingOfDepositIntoAManagedAccountNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ReturnOfDepositfundingOfDepositIntoAManagedAccountNet", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Return of deposit (funding of deposit) into a managed account, net", "documentation": "Return of deposit (funding of deposit) into a managed account, net.\r \n.", "label": "Return Of Depositfunding Of Deposit Into AManaged Account Net" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r166", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r652", "r728", "r734" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable", "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Revenues", "verboseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r194", "r203", "r244", "r245", "r255", "r259", "r260", "r266", "r268", "r269", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r482", "r548", "r937" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "lang": { "en-us": { "role": { "label": "Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r499", "r756" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r860" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r860" ] }, "us-gaap_SaleLeasebackTransactionGrossProceedsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleLeasebackTransactionGrossProceedsInvestingActivities", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Sale Leaseback Transaction, Gross Proceeds, Investing Activities", "documentation": "Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in investing activities." } } }, "auth_ref": [ "r151", "r152", "r153" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable", "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "auth_ref": [ "r219", "r392", "r881", "r917" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Notes Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notes Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfCapitalizationLongtermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCapitalizationLongtermDebtLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information Related To Leases", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "domh_ScheduleOfChangeInTheFairValueOfTheShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfChangeInTheFairValueOfTheShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Change in the Fair Value of the Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "domh_ScheduleOfChangeInTheFairValueOfTheShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfChangeInTheFairValueOfTheShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in the Fair Value of the Short-Term Investments", "documentation": "Tabular disclosure of the change in the fair value of the short-term investments.", "label": "Schedule Of Change In The Fair Value Of The Short Term Investments Table Text Block" } } }, "auth_ref": [] }, "domh_ScheduleOfCompaniesAreThroughBothAnSPVAndDirectInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfCompaniesAreThroughBothAnSPVAndDirectInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Companies are Through Both an SPV and Direct Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Tax Provision", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r134" ] }, "domh_ScheduleOfComputationOfDilutedLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfComputationOfDilutedLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Computation Of Diluted Loss Per Share Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r27", "r61", "r64", "r83", "r84", "r85", "r92", "r126", "r127", "r744", "r746", "r913" ] }, "domh_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r133" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share." } } }, "auth_ref": [ "r43", "r45", "r224", "r225", "r228" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Diluted Loss Per Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": [ "r43", "r45", "r918" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rates", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r132" ] }, "domh_ScheduleOfEffectiveIncomeTaxRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfEffectiveIncomeTaxRatesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rates [Abstract]" } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r304", "r305", "r306" ] }, "domh_ScheduleOfFairValueAssetsAndLiabilitiesAreMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesAreMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of fair value assets and liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Assets and Liabilities are Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r475", "r476" ] }, "domh_ScheduleOfFairValuesOfTheAssetsAcquiredAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfFairValuesOfTheAssetsAcquiredAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Values Of The Assets Acquired And Liabilities Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets That Are Measured At Fair Value On ARecurring Basis Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfFutureMinimumPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfFutureMinimumPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Payments Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfIncomeTaxProvisionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfIncomeTaxProvisionAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Provision [Abstract]" } } }, "auth_ref": [] }, "domh_ScheduleOfLeaseAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfLeaseAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Lease Assets And Liabilities Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfLeaseExpenseToCurrentPeriodOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfLeaseExpenseToCurrentPeriodOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Lease Expense To Current Period Operations Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfLongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfLongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investments Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfNotesReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfNotesReceivableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Notes Receivable Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfOperatingLeaseCostWeightedAverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfOperatingLeaseCostWeightedAverageTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarize Quantitative Information about the Company\u2019s Operating Leases", "documentation": "Schedule of Operating Lease Cost Weighted Average [Table Text Block].", "label": "Schedule Of Operating Lease Cost Weighted Average Table Text Block" } } }, "auth_ref": [] }, "domh_ScheduleOfPropertyAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfPropertyAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Net Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Values of the Assets Acquired and Liabilities", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r136" ] }, "domh_ScheduleOfRestrictedStockAwardsActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfRestrictedStockAwardsActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Awards Activity Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenuesAndNetLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenuesAndNetLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule of segment profitability that are most relied upon by the CODM are gross revenues and net loss [Astract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r49", "r50", "r51", "r52" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r49", "r50", "r51", "r52" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r15", "r16", "r70" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Investments", "label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r21" ] }, "domh_ScheduleOfShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Short Term Investments Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfShortTermInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfShortTermInvestmentsLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofShortTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Investments [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r126", "r127", "r128", "r182", "r183", "r184", "r237", "r357", "r358", "r360", "r362", "r365", "r370", "r372", "r588", "r589", "r590", "r591", "r748", "r880", "r909" ] }, "domh_ScheduleOfStockOptionActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfStockOptionActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option Activity Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r68" ] }, "domh_ScheduleOfSummarizeQuantitativeInformationAboutTheCompanySOperatingLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfSummarizeQuantitativeInformationAboutTheCompanySOperatingLeasesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Summarize Quantitative Information About The Company SOperating Leases Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfTotalRevenuesDisaggregatedByRevenueTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfTotalRevenuesDisaggregatedByRevenueTypeAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Total Revenues Disaggregated by Revenue Type [Abstract]" } } }, "auth_ref": [] }, "domh_ScheduleOfWarrantActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ScheduleOfWarrantActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r771" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r775" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r895" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r774" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r779" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r239", "r240", "r241", "r242", "r243", "r248", "r258", "r262", "r263", "r264", "r265", "r266", "r267", "r269" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r249", "r250", "r251", "r252", "r253", "r254", "r268", "r738" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r110" ] }, "domh_SeriesD1ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesD1ConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Convertible Preferred Stock [Member]", "documentation": "Series D1 Convertible Preferred Stock Member.", "label": "Series D1 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesD1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesD1PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Preferred Stock", "verboseLabel": "Series D-1 Preferred Stock [Member]", "label": "Series D1 Preferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesDConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesDConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D Convertible Preferred Stock [Member]", "label": "Series DConvertible Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D Preferred Stock", "verboseLabel": "Series D Preferred Stock [Member]", "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r897", "r898", "r941" ] }, "domh_SeriesOPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesOPreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series O Preferred Stock [Member]", "label": "Series OPreferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesORedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesORedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Series O", "verboseLabel": "Series O Redeemable Convertible Preferred Stock [Member]", "label": "Series ORedeemable Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFairValuesoftheAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination [Member]", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r76" ] }, "domh_SeriesPPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesPPreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series P Preferred Stock [Member]", "label": "Series PPreferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesPRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SeriesPRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Series P", "verboseLabel": "Series P Redeemable Convertible Preferred Stock [Member]", "label": "Series PRedeemable Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock Awards, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r406", "r407" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, ending balance (in Shares)", "periodStartLabel": "Number of shares, beginning balance (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r406", "r407" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average per share, ending balance", "documentation": "Share based compensation payment arrangement weighted average exercise price per share.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceIssued": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceIssued", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, Weighted Average Exercise Price", "documentation": "Issued weighted average exercise price for warrants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Abstract]" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, Warrants (in Shares)", "documentation": "Share based compensation arrangement by share based payment award non option equity instrument issued.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee options expired, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee options forfeited, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r404" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfietedInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfietedInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options forfeited, Intrinsic Value", "documentation": "Employee options forfeited, Intrinsic Value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfieted In Period Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Number of Shares", "verboseLabel": "Granted shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r402" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Intrinsic Value", "documentation": "Employee options granted, Total Intrinsic Value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r412" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, Total Intrinsic Value (in Dollars)", "documentation": "Share based compensation arrangement by share based payment award options issued in period total intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Issued In Period Total Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r398", "r399" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r398", "r399" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total Intrinsic Value, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of shares (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r944" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options forfeited, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r393", "r397", "r416", "r417", "r418", "r419", "r422", "r428", "r429", "r430", "r431" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, per share value (in Dollars per share)", "verboseLabel": "Convertible preferred stock, par value (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant and expire year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r755" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average per share, beginning balance", "periodEndLabel": "Weighted Average per share, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r131" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in years), Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r415" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "domh_SharesCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SharesCancelled", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares cancelled", "documentation": "Number of shares cancelled.", "label": "Shares Cancelled" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock share issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r12" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock per share value (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r124" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofChangeintheFairValueoftheShortTermInvestmentsTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Short-term investment, Balance beginning", "periodEndLabel": "Short-term investment, balance ending", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r144", "r145", "r900" ] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "domh_ShortTermInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "ShortTermInvestmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease rent expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r497", "r756" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r119", "r200" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r780" ] }, "domh_SooYuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SooYuMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Soo Yu [Member]", "label": "Soo Yu Member" } } }, "auth_ref": [] }, "domh_StateAndLocalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "StateAndLocalAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxProvisionTable" ], "lang": { "en-us": { "role": { "terseLabel": "State and local", "label": "State And Local Abstract" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r167", "r182", "r183", "r184", "r203", "r224", "r225", "r228", "r230", "r237", "r238", "r307", "r329", "r331", "r332", "r333", "r336", "r337", "r357", "r358", "r362", "r365", "r372", "r482", "r588", "r589", "r590", "r591", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r629", "r650", "r674", "r717", "r718", "r719", "r720", "r721", "r880", "r909", "r919" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r29", "r172", "r191", "r192", "r193", "r206", "r207", "r208", "r210", "r216", "r218", "r236", "r308", "r309", "r374", "r425", "r426", "r427", "r449", "r450", "r463", "r464", "r465", "r466", "r467", "r468", "r471", "r483", "r484", "r485", "r486", "r487", "r488", "r504", "r576", "r577", "r578", "r598", "r674" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206", "r207", "r208", "r236", "r545", "r583", "r609", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r652", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r762" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseExpensetoCurrentPeriodOperationsTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable", "http://www.aikidopharma.com/role/ScheduleofSummarizeQuantitativeInformationabouttheCompanysOperatingLeasesTable", "http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedToLeasesTable" ], "auth_ref": [ "r219", "r392", "r881", "r882", "r917" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r206", "r207", "r208", "r236", "r545", "r583", "r609", "r621", "r623", "r624", "r625", "r626", "r627", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r652", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r762" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r790", "r802", "r818", "r846" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_IncomeTaxesPaid", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets acquired, net of cash acquired and receivable owed from FPS", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r12", "r61", "r101", "r102", "r128" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r101", "r102", "r128", "r588", "r674", "r718" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series O Redeemable Convertible Preferred Stock", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r12", "r29", "r128" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series P redeemable convertible preferred stock for cash", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r71", "r101", "r102", "r128" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of common stock related to investment in CBM (in Shares)", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company repurchased shares", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of repurchase (in Dollars)", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Retirement of treasury stock (in Shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r12", "r101", "r102", "r128" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of treasury stock (in Shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r12", "r101", "r102", "r128", "r591", "r674", "r720" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r102", "r105", "r106", "r120", "r631", "r647", "r675", "r676", "r757", "r768", "r911", "r932", "r955", "r975" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity and Convertible Preferred Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r125", "r202", "r356", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r374", "r470", "r677", "r679", "r722" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of reverse stock split", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r129" ] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards Activity [Abstract]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofStockOptionActivityTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofStockOptionActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Option Activity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponBytheCodmAreGrossRevenuesandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r511", "r512" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "domh_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "auth_ref": [] }, "domh_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalDeferredPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalDeferredPurchasePrice", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/FPSAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Supplemental Deferred Purchase Price", "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r839" ] }, "domh_TaxBenifitPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "TaxBenifitPercentage", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit percentage", "documentation": "Tax Benifit Percentage.", "label": "Tax Benifit Percentage" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock, shares issued (in Shares)", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r100" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/RedeemableConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in Shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r100" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r923", "r961" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r831" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r838" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r859" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r861" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "domh_TransferFromLongtermInvestmentToMarketableSecurites": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "TransferFromLongtermInvestmentToMarketableSecurites", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from long-term investment to marketable securities", "documentation": "Transfer from long-term investment to marketable securities.", "label": "Transfer From Longterm Investment To Marketable Securites" } } }, "auth_ref": [] }, "domh_TransferFromShorttermInvestmentToMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "TransferFromShorttermInvestmentToMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from short-term investment to marketable securities", "documentation": "Transfer from short-term investment to marketable securities.", "label": "Transfer From Shortterm Investment To Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r354", "r370", "r469", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r569", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r928", "r929", "r930", "r931" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r862" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r863" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r861" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r861" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r864" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r862" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Stock, Common [Member]", "netLabel": "Treasury Stock [Member]", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost", "verboseLabel": "Treasury stock shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original cost (in Dollars)", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r12", "r65", "r102" ] }, "us-gaap_TreasuryStockRetiredParValueMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredParValueMethodAmount", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Retirement of treasury stock", "label": "Treasury Stock, Retired, Par Value Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method." } } }, "auth_ref": [ "r12", "r65", "r102" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retired shares of treasury stock", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r12", "r102", "r128" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r130" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost, 60,148 and 468,017 shares at December 30, 2023 and December 31, 2022, respectively", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r28", "r66", "r67" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r12", "r66", "r128" ] }, "us-gaap_UnderwritingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnderwritingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenuesDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting", "label": "Underwriting Income (Loss)", "documentation": "The difference between the price paid by the public and the contract price less the related expenses. A broker-dealer may underwrite a security offering by contracting to buy the issue either at a fixed price or a price based on selling the offering on a best-effort basis." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r858" ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (gain) loss on marketable securities", "terseLabel": "Unrealized gain (loss)", "verboseLabel": "Unrealized gain", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r8" ] }, "domh_UnrealizedGainOnNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "UnrealizedGainOnNoteReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on note receivable", "documentation": "Amount of gain on sale of Unrealized financing receivable.", "label": "Unrealized Gain On Note Receivable" } } }, "auth_ref": [] }, "domh_UnrealizedLossOnNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "UnrealizedLossOnNoteReceivable", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on note receivable", "documentation": "Amount of (loss) on sale of unrealized financing receivable.", "label": "Unrealized Loss On Note Receivable" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r46", "r47", "r48", "r155", "r156", "r159", "r160" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r443" ] }, "domh_VicinityMotorCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20231231", "localname": "VicinityMotorCorpMember", "presentation": [ "http://www.aikidopharma.com/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vicinity Motor Corp. [Member]", "label": "Vicinity Motor Corp Member" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r759", "r760", "r763", "r764", "r765", "r766" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r223", "r230" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic and diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r221", "r230" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r870" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "20", "Section": "05", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481996/940-20-05-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-30/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505-30/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1D" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1F" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481019/946-20-45-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation", "URI": "www.leiroc.org", "URIDate": "2013-08-21" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r879": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r880": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r882": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" } } } ZIP 108 0001213900-24-028218-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-028218-xbrl.zip M4$L#!!0 ( "P^@5@\;4=JBQT #5I 0 1 9&]M:"TR,#(S,3(S,2YX MJ?[ M;&_'@8&+/13,7N]\'.T.1B<7%SO_?.,X/[SZG]U=YRT,8 1BZ#F3I7."%^'( M1WM]3OL\P00F!=_$,K?]WGI[M'148=_S8LF1,5 _B7#GU$F,K(41+?S MZ>IRQ+NN*$LQ>G%1O@SYH)-^S(MZ>#%OUB->',D[A'[H,-RL1F]WK[^[JL/* M($TWHH#$('#ASAOG!\=AN@"" ,<@ILK+%.H'IE3\YS!$P12_R7ZB/[(N?9F+ MX09.'=[)+QF0USL$+4*?"8?_-H_@]/4.XW@W9^IW'TR>48QY$1"Y$?:A7H*= M,,(AC&)$1512 $Y J+W.*/O:?S9EOLA!'\ZNS0-@D=KUQ8%:ZV M)B8/3K\Z7[1-%" )5UOBR07^5^>)MNDFOE14:URQPF/*A\/^\?'F0C]%<-(G M."#81QZ;\H^!SX;S: XAG6F0E[+^>_2[LM *0 YAU?UOCHX.^GM=NOR,J);Q MQ8'^NTS*R6@YG!AYU:E2$*@G!'K7P1O^[ZH"9]6S(MJJZSI2K>AHZU9D4:F< MBZ.S)@]A2&U14+\/042[80YC1*$1([E5Z]2+L6I_D\FUE:Q5TJR6>R.R5A5A7R?"X@-Q\-2Y#IE126NV8W)3R9D.RYIJ!G+=WT2N M[2!M*.H1_1O.L>_1O=G9GPF*EXQ #T?]-=%JBKVI$^2!N2!/YB"80>*@P+F! M'J2;B(D/684[9F6P?P^IZ0*CB-?$[JT#@NQ?&;C_^]_#7O?%_SLIR':8FP[S M$T#FYSZ^5P[HHH!L %5%_KR!R"E=AQ%NYV2ML*ZC&0C0%]XP5?I32-P(A>PO M/#U." H@(?3W&^C23CF%=]#'(>_D-8EN3L5@QGY!)7V*B.MCDD20_E%NC8_4 M4GM,]GF+_%O:IE-N5#YYMTI1*,4EHM.<1RQ5 MA7M8%6Y!DDLO(^H45-O1K%UVD\4"1$L\':%9@*;45@GB@>OB)(A1,!O2N=)% M%1$:5C$2YE%5F!EQ-BA+Y)T5?2=O0#HF6\'F@CT?C@8N'1B$XUX38.53[>:T MNU>5$J7@E$A(1-$*(A?$!;492@6QLR8'$$WB5!<'5SUI4W&5;=; ME5B)+C-J5Y2=%>EVIM1O4' 4CV&T*'5E96LB*6!@I'9[PB3(*.TR4F6YM1.> MW@3!P4PG'MGW^JFO+U@;E(R1:%K)Y))YCV-(F%6-[MB,LR:5ZC>3\;)?E0DG MXJRHM.+06@8 1;\ /X%X>H[HYLM%P!\0 F.VX;I$8()\<5TRKF0BP /!GJ#4 M'4Z>&7Y% T[: K?K2VVTXM6)=YB&PM@&B_F>0L'-+2U@(K;G5;'EE+B "EKM M.J5?IR @U4UQ^E.= [,K^#72BNUXT*X^,+[$A QAQ'W'ZZM/Y9O)*!#\#Y2( MPZ@XE(S#Z;2^?KU(5B[UDD>]<*AS+_J:F$S*FXA.\#:8^?9;<=;LC$IACS3< MP9Q[1I)M6+5NANP)G@IU2";U%K92WWP0W\$@@96!FOY6[Z/O"1Z*K&YK/=2$ MRA8+E&XZTY'"?*(P$)RTNG(&TA%<$B5Z^#IN:R6K&FL71LC)?%3\;V \]P?&PJM^ZP+6][[. ^Q#0O2+/ MG0>N$)10E3%Q=_<$AT)&S>'DG!*]5DXZ0P[.V Q_ T,8A1[N,E_]?Z MJJ(III?1\[T]80,CB7S_@YU%2@DZ/^8_2A,,6]')P^%CMN4GFJ!X5J#6** 2 M$S8RE>"X\V-*3)$!VLK(/%(N$9MIG9I('Y6CL.4Q"9GKA-L*5A#K -(NP26RGO3&+Q$MIIBM7(4-G/R8'R[X#4(RLO6N/*' M.L]DSK*8P!\K=TM#4G5NNK%#/@'WO U?DQ:[SU4F_G MQ*1,,9K5-/"AB8GTYLREL>.9+)55ZB;E,BIM,+@2.-A%KY%./1G4,O M\9E_+'>5$3R-YS!U8/$.I9:]Q%NV/C@W)V-DW@K^&J6TV3#.P'"/7.&?X]=4 M4$2Y:R['9' ^IE4745V4T4*%7JC+FTS5@F/(++RH4 KC\[NMY+512.DRK2EG M8)2+5QHH(I'M^MMPP"KCPXH!JRYO,& E1PEJY%@9H@T.<;?BEHD[O8,+L3O4 M2D$P^E=3/=B D(F"" ZKA@J2PF)S/UO3U\-P[!=S!6JU1]2>#PG=^"#&^!V\ M"-AEW1S-#9R!B-WV?H[9$W$3+#"^'4&I9&:I3 MPNH48!V.UNF75;",V$DAMU:ED=ZIDF(4FJ0L7NL$$L^#*!)H%(IA?)%%*V;9 MXH07(0BHT*)E68Z4B!S M6(0TP^8P<'3/Z5!XJ:^1 VS5:--T+=DF1%&D?O\AGH414[9T.X]62N)@ER7/ M*<:RM*C).B]X ]5BJPQ2D]MO6K'J_(6R?#HZX65&D ?BHJ21W[ IN3I/L7AP MIVG.7JUK45633?LY;@?$I1KMW&&H9.M)FW19C^6Z@ -PPUQY$37)CP%!>A_U M(ZD:&0^"RW);:E>MR.!K5,UA,4VG8,/A?+3;D8;YIS(K0U?.P-007)VJ'-2_ MBJN3O^_UKU^O?CGX][\^N6'R\#DX./*^O+B;?5X&'T^3^[]C/=^.S_OC=YU[AZ.3S[OW7FCZ+?C=\.' MV3_SWLZM/B\_#X^3O5W_BT?#M3Z?XP^CX[>S"ZTV/ M3C[!S_V3+Q^>/]S 9''LW[^=+Z-[=+B<]^;NY0W^X%V]N]^/Q@.$7YQ=32\' MG\>_7([? 7SQ_/#XP]5X//H5G1V]__!V=O;3U=GM,1Q/W(/;^[>3]Y?P'3Z\ M7,:?.K?]PSAZWAG=H>[?:2N?T.C]W_^(O4XP_7-X=4\7%_.]GW[[]"FY^>#N_=LY&=WD#Z-M;;J5:?1[&.OF4FT5DXFR+[B* MZ\9!94*4%_\'RU)M_<5&F=NRR6W]BY$@!9=NGKW=[I@:>L%8ORF/J:A\8?I* M!KNHON MK0JPZ@1CGQM<,]D./7EDCJ<=H2]0X1@'$YS$\1RF_J0ER=[)88[R MXGB%*HBW#=)&@U_TI^IUIT"F]K%S<#R8D\'+\M")4\#4W.'8ZIIR:CE["&% M!RT^H7L"V@U#&"'LK9Y?JIUFS C4V\!]T<-J,N-DS3LQ=C( 3HJ@YFFP5B7D MTT\8IJ_C C]_'F@M+,6KXCF#-08Q6RIL=1)4F>FY$P6@O(2:!/N(P:JL131>!7T$4\<,U=$?& MG@C5S/G2H@:NAOVMGC=6K 49."='U]H!QBIP TD<(3?.1N_@'D0>,5$(@XJU MN5G[8F[H]I5C!30KF$+5*4NK*)+-(^N[:WY2TD0]E,7KE4),Y=R^4J1?4WSM MM-%<&\:8OTC*;QX@5%A@-HO@C.VU)\O\4@-*6ZX\N2BJXS(52&G:+25KJ%TSZ93Z*9!GTQP-W0FTWKLM%6, MY"SX[8SD7+1;ECAONMVZF8K[-+-S:-X+OCLCT>=MW M*B ^T2%WSE6_UOO@]B4^N)Q*>[G"8U[ND$M(6]3$I2)YGTWQC$]CB(/C M)4]\\1;TR]L($Y)O^NC*D]V4J75E;+V=NL7U0/2+J?6EZMG(2J[!=1A>9\!" MIA2QDT)V&&;G>)DEWG@+7H #7VV+V>*<1^5:ZTROFJ?835C?#P+OC"4Z+4NI M"*EN:4OH5^KLS9.,0/F? Y8-RZF53 M_TT*( ;:4>[@ _Z7%QM+)*_ 1'&P:M58"B2*-Q #K54204%C70:FK!/H/IOA MNPY!K@F(:G'VC[6&&S4*76^7)),F#=,J&?-IW2K7C=KW(&K:/JV2MI_5?53[ M.3.;\-YVNM ^3-,%.8#7.[G5=%VZRNYZ.JY>93=8\XX,)B2.Z.9JQV%CZO4. M@X%>L@AC,+N(X8(M4#L.R$J]WHDC]O9O6BKDJ:MC7L]+HLPN")#O,ZLP+TOA M$[J8)^PK-<:2,&\$4?(E$_5Q\%=*H>H4V:T_-G*OQ;D^TZE8E=PN8B.G.ICE M=47%9N70O8TLJB":R;%RM+RB^JN#OX/5P5\;.^$Q;)3,*V4OK1^*SK>R(M'K M8+!^*-K*SGH\-_5S87[R<+!^]M'&_JB#6L]LZ7R9_6M?/5BSJ:/N_-2 '5$: M%^>G1I7S4S9VS;98,M28[*S.6'54R,8N:@;"T=#KA6G9$PD:FC3$;C8-*PK"-#*L@FJT8V@18&]DU VRRD9 D=]K( ML ZF"9OJ#,7CKA AJ2R>A?CWM(:) M4+QK(0O=9BST+&2AUXR%OH4L])NQL&\A"_O-6#BPD(6#9BP\MY"%Y\U8>&$A M"R^:L7!H(0N'S5@XLI"%HX9+FXW+O@7G4M7)U[C;AP,;%N=MKPH&-:W.W MK^;@.K@"D3OOO6#9#2O'?1'I]WW9INAZ>AZ2 [QZIQ9-GH5DKG3J *L]X M9F78XP&L FIBTO0LP"\#I52K+/G"'C6J M+T?JYQ]H 7$*F4WMH\)DTVDE(. MY]"CE7Q[F*@"TF5.Q""&;(N#79LXD,-2:9,8G[.&$34TC5!*E?*MIT69#EIT MS0(M-KJC>AIW5#$[G&!BDY8I<#6P!WLV^M5Z&K_:ZC3"17".H.\-,0KB$4NU M9HZ:=6X6.( QB)8R?J; )U*&TF.53?#KU;;"T(2!H3E&43,&V=P*_ Y MCE@Z*0IX-B&IJ#G_;<.^V5@#ML"%9O6HDA^NR),Z^A;V3B/XNL%S2JE [Q3= M(0\&'BD2BC,A4)T4&E2V9_$8VRJ;*HN+U5V$:-S5MQ)%ZKM(2 M5&NR!2-P4^2ZP7?"I.3[69KW"5Y0Z=L^DM28-;.OLI(URT\=0K6O1%6QF&/* MMLW)\95\S?T^9%S+DWKDGS->*#W@IT4'WA\)H;3H(L62'","1R'=--F@"\90 M=6-[L&"7 WW)^O &S>8QGB;Y^3B+A5\#7#?*YR"806K %\<\TP/A\=HY:8M9 M-V1 .Z6+))C_[WON @E^W0(OV\R ;!>3;6JR4WX6=T,C-C3;<6J 0)/8?K_ MBX :!R% 'M_5$7Y/$W-.V&P"&O.@&Q4BD8'K4A@>6UL082=#;)X2C>"K=@7% M\ULXV\N/Z0ACAN+3KP2/E7T==*7BEW3C>GH^'+V',;4CZ%ZT=!/**AIX?4_7 MU@@O:$&;>V-SIC1KY@V,DXB=\80AIK2G2>"A8%;\?1'$>' % C"CY%T7)_P" M 9M[:3.&Z@?/V2+T\1)":H3-TAZ^Q""PN2=JL6O48IC0Q8?.-'A*F &RR]9? M$'@^78KYO]'JVAFKNZ !&TH5R&B4;#$> TN-DB$=8G0&QM&2IQA\#YUAQHAN M.L+*UW*AF@U]F7;(*E,TJZ-;L(SAY<;K*F]Q6MYM^SAY@: M9QR_M7;%!LQHYHSU*L,(!2X*@4]UC$ZZD-*/5U]OH)>XT#M-X!A74%C<7]OB M4#75C-EMW5,8L75;LO$;XRL0W=+NH.2+T)3-_;49/_I8F^L#:O!.EXQF)3UR MU?ECK,[7M7EJV@9[FA%:EH>XJY:(P^X%;1-VE%N&U?JG[/;T YL&F169N26? M?,YZ]'+W*,;4J9^0D,RFIAOR.X03XB]SB43L#,:U&^,)C-B%NV/\Q'NK1TY4 M&S"C&6;9OH+.]]3$R"Z6(3%\B(_]DFGDQ='+XL>O[&&N0:A.Z>)=1'Y%\?S$ MAX!?GQ?A6Q@-L8_A/@_79CM+X]AUM9%D-Z6E5Z;9F/G;)4?DYMR Y+ M/FWZE^RN6OXDA%7]M1U&C&X)6\_R93[=7R&+_E 5IJL3F$&;>Z&WJ\G!4 M\O5E;WNLWB!97?&,IW'UBF?ITU]?.8?0BU_.:_4IV50MAT_3ID7VYU,SJ#L@+V^Z_/Q"K'I^X7M1S@;, M/%%/V:]K#=G0!*(4JMSDY8KO1;$VX>II>\Y^1=N4'YW%H6A*^E;(]Z);&O!- M54A*RGY-J8&M?0N$^66/*566D\WF-(YPP"*K,U[N>+DJDI'FKVXPXX^]_4R9 MYD\XDVNZOD;C.0C2URK(>\P]FM"K!!3.'JAP$6%I2"XL!T/"[(V6S<[5;WX/ MUK?M $TL;E-DM.$4@@"1'8>NGNG_)D?%GHZW)^C/[4AZO>\W5OAOV/=;[0?E MVQZ;HLLPI.0O@M0BXV_(7 1LJB;(??(\ND=ZBIZ>=_UM&(+@;N "T%6%7043 M\$Y) -W=3RM]F'?'5];C9HC55S6RS.DY]CT8D53#0> ISZ4+:Z_V12KK3*BG M9U8S_SYAVQ;9:%^'3>7T^;C6)<^-_;?IL)+%)]-<28O_/?JJ9>ZI%OFW//$S M7^C^,NN[EFVU^N;'Z,I4C!=.%'R&(")6K/A;8>0)-@@9GG,<31&,5Q;87T8Q MZSC773 FG!%G5=+V?1_?,_ZR*TAMC@(V84,U*^8T9'77[C"U6)/,>5#U@OQ1 MR!OHXL!%/@)I F;6VRR4/J8 /X;LJ51:[OWU966+S9+*OTFR]F-8J,UL;T"\ M2#I,U8^2IS)(M^Z\6?(==E@]3^II7KA%ESVT2IMCSV,'^1TEVTB?>J([/PWQ M-[P2^!2&$711)L@GX_VQ\VPM]*97[&21/)N/H]8 UPCZ.IJ!(+N3"K#:Q(T0 M7[+Q]#@AU$XG+!4S/7E3HIV'&*S;^VV'(?65S(\D;]&V;GNLZ"\H*K+6L]R* M,9@&:(IBFE"S:*!LB%LYA]"5Z1@R0BPIA TNNB?]]A:6%)5&FM(#3]9IL :E M\@R-K(I%ZEB#3S< )><9;15<+5:=&1>F#HCKZ?=U[$,/7+=?F<2KH&N>7LUC MJ3;-,&8P-0'(K$_2+>!61?IDCR\H$.LN.J^Y ]S6 =L4NOXJ6XBM&HNTF#3AJ1(=H/W%G*D MMI.85@*D]Z&G7C-[]QHJB#6WWU;J6#0CZ, U\#VRRU"+PPB84'E'T?(<1SSL M_Q7B'MOV11KQH[\I;9;X(,;1TE955B#4K7B5"A:IL0:;\HW1!45 =\D708#O M^$F;&SS!,7+)RIB_@HL)C,H+ 6T-(&G ^.F8:X"T.;.7ER??#[\RL,J5/7T[4\A$DZG;KVLE<'5!,)0QIL6E>>1J.#I(8IZ=*!\'RGLZ7 MEBR\1A@-U? 4Q&!"S>-;"[50P*9SDY>J(>+BR!*[5@W,2 7/0N2^I;]:*)TJ M-'7^YJK..[ $[_&]? G"/QX3NTG"UF2X3,24@1NH25[6R4N MT_7H"A!J;?![^.WC2 1GRM:'AY":4!:RM [,:""-0N#"3_:QLH;+5#!CRGP( MEO9QLP[,2#!C>'<'KJ@9&%FH:"(X8Q'-(T 0MI"E-6!&(OH8)"2A.UW@SID/ MT#Z>Y #-#+E?D(L"%"^YE$]P%-K'G@JB4G@_8S)/P&C.;CZT9):00=*-I7@X!]$"V,&-$I=..-*GA.[8<;/\3B[V'K,MH8N& M:&N>*Y-3>H\#][MB7058&Q\&<,HB7%["PJ70QC"<"43- P >7/ \??Z$N"4+ MG0*5,ID&,KY/N\ID*3NX,H6I/0*0T;"9/S53.I:^#^$9R4[#YK6]O,FAZRX!VE5_1YN<$J;X/(CB>4SBS^3&.YX-@-/R%'=#EQP9M[Y]- M>5#.6 5I60];E.YH"E1IGI]BEY]O8=??LYO&EZ4;>>T1M1%*)LQ7'U,THXL7ZI&MA5+;I-T M.AV(!"74%*" I&SEUQ^ %UD4"5X!D4SST*E#T[O+[P,6B\4">/?ST]QL+2&U M$,'O]PY>[N^U(-:(CO#T_=[]J-T=]?K]O9]_:K7^]>[?[7;K"F)(@0WUUF35 MZI'Y8J2AUI@";!F$SEO_M>?_:[5;,]M>O.UT'A\?7VKL'4M#%%K$H1JT^(-6 MN\T$!B)[%'*!;ULC![>N 6T=';3V]]\>OGK[ZJ!U/^ZU#O")RX&+?[SLY[$HMY%\ MN.AB=]3@?FD)3-XGNG8/4+IB 9WKB24;GTUGYQGW#;:[-/QU@&J!=>S'"-7A M*,E_HV,Y\[DKK8W8:![\O4')/(4]F^1&CE =4A8E[[4>(9K.;/ZCYRES<\7B MW =H\WXP@II#7=>KIGDE::H[+XDH^6P<2F#C'"Z(A1CC"KMYO(ZUP;7$7X"+ MC_S1%O)%_=:0P@5 ^L73 F(6E&#]EL6*5"47632NA]BZDI,)-I^J5U&JRC.U M"VZ:T4\$N/C@OY;43UQ^1S-"[3&D\SY>0LMVPU[)#(CUU+Y/)$#DD_%&3D^X M(2R.97UN0 "V[J &6=# ABDV#533*]+UA1I6+V)0?%A MUDLP#=G,U>Z<S21]L$535Q*?$C;A)$@JF!?&=_0["V8W^_H;*FG2,;7,)) M1!&&!@1/U09%<1J>'6:]"(A%0S 3*!2(+O@:(,)3-XM\QZ7=&O=^/EEV,)JH MJZX,I" DF!@4X<(?TU?^5%TR^MO2ZS$!B$,\@H,HWB_D7I[71]2$]S$*2HQ7 M74TC#NOT0[#BCI>Y8O:$.E!7_AUY-%<>78C1"(5Z>< 4!8(%6>1J+N8+DZP@ M/(,8&DC9(D2RLJK[?6:J$A$3AX4E^!D!DQE%YG-D\2(:I?0(=%4["N;B1H26 MU&@P//H&]JW44).BK!D])PTQN6ED-TNG?"P2:6G(N",$2915+AG8J(MHJIVG MQGQB:*Z48Q27ZXZ4Y0[2]=6I"^1P1S'I UDIGI%-M(<9,9E0B^>2[)7LF514 M0;DE4P,R)'17K(K"CC@-U<898HJVEN*BR @[=*$R&Q:]$*P,^(CX2KUG-M"C MD$CNGEU=1]Q28 X!TONX!Q;(!J;L*%N@I7)WF8T%(4BBX+H($W?0!@BS21:@ MF#EHB\7USISC ?5S-MO2I*>@,BAL@E_*@ILPRBY"U)BRL=.A*V6.*D9!0SI* M'#31J+I=9CWB.;[I8EUY<)&JKN)"OZQP" +SI(B\61\5]Y:XCO%=9ZLV^J== M%$QO[XXIN4;D%T5)+U**R"_<6;T];2;/[.ISA)%E<\E+Z$N6;'B:MDK#/2%K MFXTX%:^TWIHWXK @^P9>H'T.E] D[CJ_&G*2=54;9V3B)@4L45B>N[XJ7L\ M:6XMJK_#*U.5539)%0]@B=CG 41F*+XVRO/8 V(I<[(;&HI/'+RM3=)[K"^V M\M@S@8YP#PUP2,E*U/@;8KI#U+.4B9]O""9A4]3X>[&>DJL;GC 5*QJ^Y$K# MA%1Z(@L9 1XR%\@WBURY]#ZV(65/)*,N5%-M.)"+ S%4DA-U<3NV[C&;;YOH M&]2O ,(*AJF,2BL?(7)1EA5)\6:L0G,A7^XMYBOUMX9;R_EYUHRPY6B-@P\Q(W^8?7HL_1$ND0Z]9ZJ^[:$K>XCG\M=_M\@-85%1XY5!X*(='5 MCP@E^D$8)$D'E;AL]V8 3V$?K^<1MX9[T( =VFB7J4MD%-50EY0++2DE+R*- M?!^D''IB)#6RF^1!2D:=><+2&/#7Q/PELMC\?JXE0X' BE,4Q6G*!YO;%.2'Q7J\A@V>0^__?9QEFZ+TA9%" M1C2Q0Y;%7>9Q*[$V^'OK -T1S2%]#0U4<@#J\W=:=CXE5/6\)3+;K"J3H&J7 M3XJ/?-E0"N:X^VHZE6 /DO+.)=+;0#(+@!N0*FOO78QJGA3TM_KM!6!&_"JLL[@;FMM_.)),QU^DX5KU9C->L9POB 4T%5_OF"3'Q6I=XF&-3E0 MDLE/T':.HK5EA=I.M(KB%JL[."I-6X/[?RJ0 7.O9*RJUZ\TQ;V^YH_?KW][ M_>;PZIJ?''P[_OA^O+/-XJ7W;-W^U._8( M_OKM^.CAZ4 ;V/M?+B\/1Q\ZRZ>SWN?]I3ZB7\X^#)^F]XM?)SKY]OK;XM7) MZ]Z;B7DSO?XT_SP\)_CYJ/?MXYNG.^C, MS\S'J]F*/J*3U>QPI@WNR$?]^L/C*SKN(G)\<6T,NI_'OPW&'P#IOSDY^W@] M'H]^1Q>G-Q^OIA>_7%\\G,'Q1'O]\'@UN1G #^1DL+(_=1Z.3FSZIC-:HH,7 M3,LG-+IY\;>M=[#Q==A[;0#CZY?!R>G)X/C@[/+XQ?DI_'+WYD8?C*VSWM7R M_L]6;W07W/O3T/:>M1D #0A\(Z>,.1H@^2=%G_M+UK&'=RL/13,9T>3HHRCN ?W')2,-P2S6-\+= M#6*Y6[5[9+M<.?-\7R"LP>NIV0$+>#J)\"2GE_J'".ZR3\:H;'!DF W2@,93 M&<-E5.76\*R>PXC"[\N'1O$,*ASV),S7Q!)_*W8 M_J9$54F_='UUG4MG93$=T&AI5XD8/:)O%P-F)IWU+%5.\2+Z MQ@!/$:^;R%Y0G":CCM.F%#JR81,M\2K0H;S*Y><)]:UQ.1PQJV\-]Q),O[J, M14O/KOCV$>K<6[,7LU5\%Y;>R+Y4%M%H:5B1E*-?,L@B7,R3F>YDVW"PN[P6 M_+N/;=*]!AA,H>[7+45N%!*67!:1W-!!K@R6T4JOXAG$9X\0'&E_R5#PFA"_ M7">GNQ0(:6ZG2\0UE+C\N,64>[6+;]$)5&_L M-7&O(?/V-K"/X<6#A*[&B&9! #YLP/ ]]H7/!^W@$;7A@&U&3/SW9L?-71 M9C5<;1UZD;G H89'3M46P-@)@_ TBQ\ 9G.O4J\X] Y[&8,G:/'+7N27-H6D ME]A('HSB4#^0;&1(=,4M44!'Y.J'-1)2;J1RA^D!M"P_)\T"W"4BCF6NQA1@ MRXM^F3_4;#*!E %X."99%W$*B*UZ0$H@H3!2XF.M=WMFV$B;0=TQ(3'6IW98 MQ+!G_N)@L,H$\.:^\[%;2%%P0G/F6 @SQ'ID/F'NC'_,'=3(%//]/GV=N5!D M(+!>GMQ8Y]J\&(6U]SE[J*+B28&!A=VQ3%O\@6MCJ*HQ<#'&5COA4==L-YVY M:KYEEB)*M=7;VNN]N8,2G-W:_J/E2F\-,E-LRDQ7MT=@)R97'7K^8:*IW,-;]')S4-XY&+UC5S=>2RJK*R3;]C\1?A4LAJ# MF6[[]Q.5I=QZO^,F4?,YQL8O@EW;_M5IC6K-V[;_:,UJFD3-)QH;OW 'XT:U M8<_B'RU7)OTR=[?)-#BR(:!6;3/85/!]M,,-K%6UO^VC%N*;VP\@\_F,Q,M. MJU@4&E)^-Y6] EX>V2V'9Z"46@ *9 Y-P":68<'R:Q;%JLH59,;+O:+R[Y-) M459UEBX+G5M%E8G8R;WDGM6A,9)YE2:614G MM/*2+X\.H:NLR%.Z!PY[_EZP6%[R,G:EQT4G' XMV7 _<-V-_8&RJGUD"HFQ M]UH*8)/K'@7:;@C6=LG3AK[*Z\S+<[6)7D+ZH)(B'\=V*+Q&&,V=^7H?Y+.' M*M2(>/T3A (P B7GTO-KF=46[QY95=PP8L:/T%S":X+MF>P(L+ 9E1Y9D;=9 M;/:LXL#+S#YGM>(S!'3\2"IB/=!><2BX"[K70*<4C2NDF9%;E2-[UE]MAF5G M3'M82[ILL8@%E\21G5'/K;[R@&A7='M@BZL(E).-EE7V;%?]/X=L%VS159!J MR>X:-J05,QZVX1]!^Q;LB1=+5C$W&A,;F/ZZKW6.+#"=4CCEJ:K)RG\\9IJ> M9TM%VF@@7W*S6XLM,3#>,_3H(R^PQ5-EEZ,+E%0AK]>3 M*'E@O6<*-^ZA4U23DJ"IQAPD B28"Y0Y;.&2T&M(IY#>03=7K?*TA7A=U4;X M25RD8"2UT/F&8(39J $MV^MZ*FIV>''*'I12.2VT]*-)(?BPJT]7@>O+, :"Z:\]F=?0D8R,$2=?G<^BBOM1_A:SV=.D4"+Y-*@L-G%3H'O0&L-\8_]R!>U#:$K5 MBW+J6X:8!:GYRRRFL-&:*<*A-\Z1X9Y;92-@5M P4DVJ?%:LOH6DTR*(IU2U MDYY[.$D?7V# SS:I;E@1&/(/:!,B"L317;Z#/;+8$!Q;<^[ ,1E3!]XO^,EI M[+V;VT&X-0C.^2BOI9GC@RR(Q:G1'3 >-$$_L&$&!9O]/$.S'7*K0&TC@TEE M'(A2J*H'AV"3#'O)JWCCY\9X3)@F>>0'*U8X8F2QKMKTRN[&D$Q,12^*4-N, MV,,>LPG92K8L%;&@TCH9]:TA GC"91*B;-&[#E<]8=Z)MXS_ U!+ P04 M" L/H%8%'26*MM; "FZ 4 %0 &1O;6@M,C R,S$R,S%?9&5F+GAM;.U] M[7/C-M+G]_LKYN:^W-53LY.9;#;)UNY=R6^S?N*Q'5F3;)ZKJRV8A"3N4*1" M4AXK?_T!?)%("2!>V$V0'GW8C<>6T(U?-QJ-1J/[;__G>16^>J))&L31WU^_ M^],WKU_1R(O](%K\_?6GAS>3A_/KZ]?_YW^_>O7?_O;?W[QY]8%&-"$9]5\] M;E^=QZOU@Q>\FB4D2N=QLGKU/[/5_WKUYM4RR]9_??OVRYO[/__US^]>?9J= MOWK_S?L_%U_Y;W\+@^CS(TGI*\9WE/[]=8W2\V,2_BE.%F_??_/-MV^K#[XN M/OG79_Z+QN>_?)M_^MV//_[X-O_K[J-I(/H@&_;=VW]^O'GPEG1%W@11FI'( MXP32X*]I_LN;V"-9CJ22KU?23_!_O:D^]H;_ZLV[]V^^??>GY]3?L<@^XV<[ M,O4!OGM;_/$UQ^O5J[\E<4BG=/XJG^)?L^V:_OUU&JS6(><\_]TRH?._O_;C MU9)1>__MN_<%K?_!?_.OY%_G<93&8>!S(9V1D,_Y84EI]OH5'_K3]+HQ6Q)\ M#OQXO23)BG!9O^4?>BL=XVVA")A\_NN>)#3*EC0+/!*F$&P?#HDTBVNV$E?T M(6,_KQ@Y6\X/ARFX16<7"'?%J)"3>6!LT&4<^LP>7OZ^";+MC WR/DZ^-6&^ M992<67#%)/(O:.HEP9K_*YZ?;=(@ MHFG*?C^E'I/D!7VB8;SFLC72$7LBD"IS$S )^TS&C-0Y60<9":?55F#TX9EG&0S MFJQJ-,T,G>#[4#;D)HX6'7@3?1U0Y+=Q1E-N6H(G+AT3S@Z_"@78%0F27TBX MH?'\*F 6T0M(.$E3FG$K>!.0QR T5D;M,:$F<9_$:YKD5I!OG6M3MT?X?3"5 MI,PA-]/"XAMPV_XMS6[B-+VG2>YE&.G=P5>A4)E2G[*C#U-EYE.PDV06L!_O MV7=HDE#_(8N]SR9LZ@P'Q7H^6L-3X[LOQ"P,1X93D"ES=**-D6)47X$]%JQ6 M06%VBXES;X!&IMY%VS"0[!9GC!EY-MVK]U^#%.%B$Y(L3K9F4MQ]"VYEA_QX MP Y<[ C#0SS$,W6Z9$/ ^3!TP=5C2M?,%V'*8;1(#[\+)\.'S6-*?]^PT2^? MC-VJP^_"L77LF9]M\Y^,5*UE%#A6F^[ZC&\(9JZ+Z/M0*T/II)OSJSLDH!,K M\M_-&6\9!4X;!.Z\.:?R0:#TXL"W-V=1/ #@JM)TZ"W6F]G(<%,2N?SF[+>, M JC%^7' 0G'KWX/T>P[.!!;Z*AP =OAET.C\@;MF(6WQ"*!,>DOJ;T)N!2N#F,;S;$D+6YB[)$R=!#;1:"+V M5. \[QT/4F_%;DKRX<#._3M:4N?%CG7YR?P'/R8(. M_&1_WA!VX,A(%CS1ZXBG&N3W/NS02Q*>JW##[W>^W?'WD6V8FR2_+TROH_6F M$P! M.%!D?FS=M.4C@9YXMAK5;Q:DXBM;.XU+)-XLUB>Q1E3M8?[7_AM'C-? M7@:DP%:D$.RDR+FWFY)P)'@%V^FTR)%G:):J[I-L]TF(KF>89A MZI*)68@C,N7;5,(LP1E)@TZ;>4>B"#HK.A8PW&=N3"UNW3>_6/$LOWYQV1T=+EP:",I98+Y_7-&)2 MB,_96F!ZQ,ZA0>R7+,119Q'KC8]S?GC8K-G7^.H@896ATW _\LCZ+ :0L#DA M%).[R9B9^QA$P6JSNB?;KOM^RW@8[/,%L,E(D8!T$80;!MI1;,3>@U$/C:.& MOY(DR7-ZV+KGJ6SVLQ".!&\JI\R/2P(O*V,VDR_,2T\!V-<8%\53SJG=Y8EM M +.0CH;"^RS.\]CR2%5Z$:1DL4C8L8EA^+BM EAL_ [S,:* ,L==T(LY-D]! M6ETVV4U'-AC"!GHYGU.OV,Q+FE,&6Q>#VSHBP@PNRM@L(P3LWVF-C+&)E!%* M)OTY<[5R>ML9.P9,V$86IQG;BP/J?UK'T=DV][G\%?O+AX3M!=4:8)R60?DN M5@*<#3BPK/-^+VA& K,\],ZT("V.5J:MQ23-!@9+5VS$P]9Q:N(GB:?+K.3U:_5XE3][_:[ .6"4 M^4'HC4_G9!-FKU^59.J\[\8(HNPM^\K;\C-OC[]>2AZ9UWA%@LB:U>+;>^<1 M@]DE&R+Q-H_TS8ZP&;^B ;"5(0?FS8JN'FEBB&[CJSLW$8-+$H9FO/$O[#AB M>AI$N4][PV@WN*+/&8U\ZE=\\2]W>7Q=&!A&,XR]!J&0OV./DXI.2!YI^/?7 MF_3-@I#UOW9O<1F#])K]F!X#E5;SG9/T,9]T^>VWW$*]I6&65K_);58.7 N! MO6+9LUL>B'%8;40Y&F*<)$UNF=0K)DH%T-.0\COS)%[IR"*+Y1#$"7.*_O[Z M&_;97'?_ZL51QK3KLK@'8/I?[$G[OX=Q2OV_O\Z237V2EH(X#TF:WA6QR,ES M@*8^1W1V%A5<0$)KVBJPAC8*A74,T['<#N5B)9@ZH8MRYP*5B(! 8T'#RN)X M&VX5A$P;ZS(1(:0A#"!I_.N;?N2!+(S*?T.0!D>HE,<[8*-%$Q[]:AX6/Y8. M"*S9:J%46]K XFEZ5"+1R*U#PVJUX01LM_*S5TGPG5HRDL-;ZP"8YJDKY!K3 M5ZX%FZ507(64J1"3QS1+V)D:>!&(:>P8[ET2>OZ5!!D M2,ACRI/LG"3)-H@6>888](:A1=.EE6I5SL;FH0>?TF39B$Z4VEZR#"RP-DJC M$%,K5"CF[8*NXS1@JE!G$5@L8AKNS)NV."3@E()XW^8#6PF#;6MK$OAE AY; MKW?9DB:8HM&AB'=^A)25%G:EY+Z%/KTTB?;5EI %?*["\P M?G=^W-KKQ'5T%=#0OX_9)'>NB=:!4S7&@ V8'@8E[M_#GG#&[GFJ[5IL%AF=_-/Y1L_:&>Y ME=889*- JY)22]S3]BXFWPZW93 "_/ZE.?HXCBY'F%3HP\=D"IY0/+ Q;!75 M]"N Y:$3JYU@_[P$]X:EA=#0KUG:,%)'(JU4OG@'D=Z3+7<+F*/ ?L,&](]9 M@5X7!I3=NL9JS6VL(A-$U6<:2Z%R@I>K=1AO*3VC$8,,[8393LSI)F,LN5;8 MU+>=G<3U0$+&)B\(G/)T$E1I26@Y],VL1"6#3./6IKL377&\Q9&4@MB(UI4* M-JR;FCSHC;Z/R:B,:<^2(J6^N(%Q!=%=0,?B4*ABNP^(%_J4K$RTH)J:WJA6 MC1H]]>5:Q_6#MW <'I;,Q-! 0WTS9AN:.7ILB71\;2$T].-K&T;J3=XR&:.6 M'(J1&"BBX-!-5JOA03K&,3Q8;RR8&QY':'(X&M[E8C"1P3$N.N=(NX.D[^!/YU5/;9@SY"2JBXW;K-A")%"B?*-DOR$I=;M-4A(# F<8CPP=DPIOSM M>43]2Y)$S'-+)YZW66WRE_07#",/_-)%@^!HMA,=\#12_6#<+W2W:U0K2(0/ M^N%C$OGHF??),5\R;LD7[9^?O3?]_Y&#.1* MB;H^].EX8;KX826L-.GGQ-+))EO&O(V&CRJW(V).\R!LQ'4,ES+F""6CZS3= M]"*?DM#0[ZO:,.KCOJJ@>+?)THQ$?M[<&UTT=6ICE$\#+9STE";9F^#W#8^ M,'"*/]#(P]V;Q!1'9^@DP"FCDATO'WMR)W0HCD!D6L#IA"6[B S9@VBCY#9Z M;"@AJ>O0\B 91C8HGH.,RAA<<"E"Z@>P0"+!F12&69AY$!01Z8O9YG&;\MKBLJ)0B:8N:WFB$HP$=5ESL XT8[9 _^?-7 M#"!.C[>+*SD EIF*FKO3O;;VUN6F! _GK>24II1-C5?,K/4WPY%8.RV':6!6 M E,@!Y[EFM]6B(G>!%Y>"9"W2TL.SRF26QN]D5R>#XVD8H(.6E'+'<<5IUC; MU&[\T#4M1-S>EHT<>@4 MF*%"=>^I5 CFEZRBC"?L-^.%80L:E]3*6B!PLG PF M4<7R3U%"2;20[72Q1C%LU_%W$"VC<(*?CU+4SEU(+8!K5R:U$1#.T4U%S[+%M3 ?(H%S]'S2F#IX"GT9^NFOD ML%NKT*(Q(.PTL& L-1-$-7(& !;5Y(D$(=\39W'M.K9\[W9&TL##7'8:U,D@1C'9:#CT1@_"% B\=AQ%.3GW(QZ%#KZ6;2N&@ M/8_[E?)*TM2?/#%G9T%O-WPF=_.C'!6DU61,?C1WON; ZD1X,46,L1K-:#L] M(]BN!!NAZZ[IX207"9[76\=31YIK=&B8+X)PDX%GH,JHC,;P26'""M!+%EU) M%SLSU92Z2Q^_^_8E!U4CMZ)G:Y8SV:AF,F/#O8^3;U_;=\,XE09!3>9!3>9!3>9!1E >I&"MVS_-XM8XC'K#%-%Q"6E@2PC!=8K!P)'1 "\6 MB6E@!=3,[%>;8C;.)&*<=,[?,#(!-V-2J0S#E'42C)Y%LRZKE/J4KOI#/ MXXB=;[* _=BQU([!H&Y/\JTFXZ "CPE2T"Y!C8U[#($9##H>@9D@U4\E'I1J M8BU2&JJ0VM'1>?W0\84VBB".QW<9WM(6@@ 6Y9TG8/%[%%&TTW)X+ZTM%05: M2%6\!:^_4>0CIS,.P]6"DT9"'$AA?!2Y2(B,PH[) $+)D+-TP@ $9."G#;*F MI06". ^+O\:.!79-HO#<8^S[R&'=.&KB+[U.;/.([3RR7=;I+)8X'&4N/DI] M*7/Z3CNQZ C/ E+P!,/\",Q'Y^T@F!W6CEY!L"R2)'X 06>X:Q(. M2K07RSFY0I,R;BH$%C\FO'"&'\*//#G_F:T1U#]RA!,T%*90EVK MQ;!2E;)9K5,%>,'TA9&L M'NA,:=X];1:7II_WA=(.+FLM2%""0RT8C0 M5AW/-L4KV.$W?W?S3PS>/O?3 M8]H#ML:68"HK?P(*M'#,'$E41GRHZ]<62XV2H38EQGRZ6FW8'V1*O'L%QQ M5OQU>M[&HT=W5,+ @$UI%U@K 0.W:FYUI\2\?$C@"Z)8LS%T27?/3N MG;:2=NJGP@G<#&[@PM?M)F47#ZZ733T_^VAT'6T_^L OH3O 5MEH^45)AX7K MYT']N^2:F 4#PS!,+3(_6!3& *.\UOY:;)6]1JMM&:Q$ M&K[%E'IQY 4A;5">Q6Y7)PJ+0_#?-5XWQ) MH@6]CG8=+GCE4Z8Y&4U6^U"-7E!+;RBW>VHO:T\75'6T&D*>-W&T@!&G8*27 MO Q- 6M1>#+FW"2,A&G;,8I[ @CS3LS&-"A9].+6,W01:ICT$]Z3$L*S N5 ML I?K.('HFYLTX->;)?/7KCA[V7SYR$S9EUF=+6.$Y)LKU=K9F0P&M8 ,O:" M#0.&&%'*.AQW^+N+]IL1M/*HJ+F[^.A+(91X:[SQLI'SJ<%BOW+6;"/D+'PM3T7O8AS0!WY5LO6U^!385G-=$+6ORW MQGQY&8O794.7\""2333CFR9X(A4J.6;A/J',%V GC.*]2WF>V+73$X0S$<2K MQ83;)FB&*Z%=[GJ@H]0^E3*3OY]),;I^K4T#2G:,%O11%>**T(C\F/?$\GA*_813\FX \!F'N M&Z +5XN)%V1Z]4#':FXNY(=39]X\27J2=X.>\P9@T-)MH@D<%I5L"B59GDP< MI/S=OF;)+YV!QF9J#2!":GG>PO<-_W>UTJ'+5.K3'9M,+9!%B2H*Z/-]^WR3 M)'F^9'_;IHSN"Y*L#%EE)!%&L@>1+7R1'A%\05[/,9A859_T,P*!!6I V&70 MJ)MD3=!5QP4!Y5O<-3C,86YCX"7D,+<"C-)F@IV0JJ*IZ0TR MUUE#\QN=6M2HHN0_']$572%C2U1(TZ4U1I*I&%OP3.0=_23V*/73*S8W?BTX MB?R/).-TMW?S/N1L3-^A:P4D8//?87/7?SJ_L'-HO" MD:OJS>6%'ZJ#U=T7ZG.E81_4DI;]Z./=-;O"JHX:6B0R,],=\82*_#)HOLG; MA>S^?1UE\>0CB-72\!V(X_9T>T"*%+A^+HY/X_#D'J%WN$FJ^E2 M?5&[92N\ZAS$#EOFY6H=QEM*KQ@6!<&;F$2&>Z9DD)$;6S5(ZF@@R)F3IT\P M74E3\=L&[..GBOR8S:X]YJ"UX@M]*XMBQ?.4ORE[PU\BD<@/XVB1_QS(8DBR M]6DPWIAE: Z>3EEX>_G5W@0RI:G>E+')\2O<.-GF!MY(@GHC.HW7 HI0$S]U M>7C<0+VS /V(]U4;E-5%Y 'E?!5$)/(<7LBT,? 2+F1: 0:-0XC\['V#+LU. M#Z#'&1WJ US;&FM"=J[1PELG8;N3(UWV JZ8X9G'6'^\B-BI'&X4K6H89 MK=2T<<+*T-9GWYD;]0*V5A.4T1K^<@[X_WAO]B<2V316WAXVRN\LW]Y;.75V69,E_S^W$? M&XI\ <,70>3L]*KDES38P'M;IQ@ZU,FIY!^:XHCRS;U*[3P(VES4)V<0JH[/_ZY3Z M&X_WK*!Y*9'Z!+2D#D7+W7X,K@=@\.-4#YXE)$KG-,GS"X_+;LYB==*N1!?L M1G8;UP.7OB6\"!$?ID\A2=-@OBV28W:AXZ:"SN*#7)E)MBOFJ6OX.]-QZ<]A M; 3=@8>OF%K7S.,:K0+%M%CVNN.^('-O!2MX7*F(7>YN]Z5*5_R!.Q\\#[+L M0*:_W7>C\(*DWA%J',_^+OK(DZS>?\\%-UM27M:51-M=6G,8%KGJ/"%D_ZKZ M;GZU3B?5I/E1EL_CS^(3H$0O<"B/XJH>$WFDG.1:+\IWP ?\QM N=G7\A2#I M3?U.YS1GO*1O:)J6B>OW"7T*XDT:;JLM)\G?7WM9S%!@,WT_BW7??E@,.Y1V MN>^.%I\-1K"BJCVPCU=T1IYIBA(!;8[N1"(=M?*@5$03+=T]CQV6;YPJDO!1_ M^7JI<%YX:\IRM\+*M(/AR79A=:*^=^=F3 G.0OC\%G#VG!I;4/6K+WAX*6J9 M\3[-Q4W 7 P_R+;,)I0U5:8TC3>)1[E%L-)]7J3A[DO$SA++8%W%$-.J8DOQ MA UKU1O1MK\W+&#+A7]&TH"Y8N78[%R&M6CU:+J,3%E)OK[@-&$=XK[[L%FM M2+*-YP_!(@KF@4?85'?,WS/3X0762^IX(*RVBG)"EOF(XN!V&.=.U!^RO+1VJ_/Q;&P=+_V5D;!W!RN5F)_I'YB/P,?'=.TVB MCM5?(=&Z\NNB.,2-H5:N*HB$EVEVAE4T%-*J:"75J6G&#AI>7/PQRRL#5;1X M EBVK5%D'BI-,J97[.3.$PF+F!C^JD:%%.UQ33<73!KB*QQ,!=#I%-]LT^=/JRB8ZL1 MM>K/2(HLHF![QN!E:=)\ZGRKW;5&JI' ]Y'L>'#K +5(N:G[5O .\2RRR]>* M]Q'KPB\CC9MEZX6S(["'!&L%M9+JX.F(QL5:->VT'+X=T)%C?8TH0!OB6KA/ MXC4[H/"+#WYV*0H\=:B:EP]V'_+X7&U$).57T^M6(ED\./XV8D3:X?K0EO?! MZWH#7(>X9O+&-66F@)6GDG\?ZVS0'-S:FZ)L0Z3-7CUH&X""F--K=;&P&IZ1 M JK!W475TG&JT2FQU MW6Z!:G!J/:4^I:M]#K>HX)*MJ@OVIH?->AU21.]&CV:'$L=U9/!<&3$5MV=> M(W$VG1<):,.+;.8<+N.0\946UQ(\N:EU9=BGI3?H\"@!5F"_G9A]*I-X8'Q7 M7Y^NNRBIGH2/$NSUT!S@K=>4/M%H0SND ICXMM-&$1BD60Y@'N,9JCV7L/:S=(.@+J(U2 ME^;:AX/BY2BUD')[Y- 0HO"5E:VF]^XS+38A5X(MY!F[OY-U=S7?([![09*_ M6\WMUR<&:7)&HL_,@I4?9."C!52[\>)NR]!0@:;[U0GRH>5M3"GCD?KW),F* M9YG$*Y/%[?11.!K>F41!KL/"$H^,OYV84':=Q*$G[.;J,#O. UWP=3ZE MZSCACF&'"-;!2%BQ*QD9VWN,PP%[B%9I4'1;<4 ARD:02@>^P=UR/&P>4[;+ M,<8OG_8/UJW4YV D++67D;%6^X,!T91=2L>MBBO$UE!Q.52#4^SC]WQGV_RG MK;V*C_C%:/GRM_[ ?A+Y3MZ1=F+%Z5HQ>US:#7+HHK 55Y]X*XO+- M6Y*BV M7V?1'@SN,)?,3%2'H&@4787PL I[5/Q_7SZ6F*;+UT"&3[;U,%264K4+U$>\ MP$^2K^5ID'X^3Z@?9/PG\*B\G-)X9-6*%VAMTXJBZ/EEN>O#"JB%D+MXEYET MVK!":WDC3=?%M8+:9$?D7^A#J5-HU"Z4)FKH?/F\IE%*49:=#L41B5 +0.@V M+7GQOCV?5W'R*TD2ID-I)EY]DO*1BB%&( 8M))1=6>Q>?I.$L@,"]7E54B;M MHN39NCPD7.?[9O!$^=K&VYX^ MW;'(U0#)4IH_@DDSMQ5EN=,TS\H*F>EFC)\E\6>:M(I28D#U1QNZ@$S!J<[7 MBOL?RV=&Q9,9W,751FD\![16O"HAM41!.F2)3JD7+PIH<"6EIC>FBG4:Z%5R M:VDC8R6X1O];+&E)B(QG2$/)DN?![_F ;/A1?NCJA]2HU@5^]MF1?T<-[2K:6#N M7&ZD!G67P84RM,1S97'F_6J$NN,=68UF(2A(JZR=EL,U8UHJ60':$$L[B0K= MUK8BRZNC\=<]WEG ?BH@J\B-JA:R$CN]MQ5F'OF>ZGG>S?XZFBWI[CKF;L[^ M)=5U,U<WKS/J+:/@]PUM50JX2T]4GAT63S$T%SW)4*MSO>-"[!W/@".OQ[ZW-'R[ MN([8>)L5ZGL7-4&'5MJP5+L.>E@9^[4^\IB64TIF/%*2(Z61T-][V,YB.[M+C ME NL*V0Z>[>=<>#$41>:C(K;S#N=3B\2=-31],['PG.2+J_"^,N^3P$)ZVW& M^CD FG$Q\,8]UN J*R%T> MU8+]W#C_)> ;%%GE=FG/@L'FK56#GT1A!NV49YM><7P.#H/2=K#+9D9%Z-I^60-\^ J MRIEUP.E\L'HAC7#VZ4I"$E7!A;MDRMW3'M:9*1].D\/,6^78XZT;I.B4[L?6 M_>-A888I9?,)O*Q<.9/(/_C-)P9Z.O&RX G;94%E=;2:A" UG0MY"&4[J@*2 MLU:4 G&B4C8,C:I7%P#^.N??WHOIY^_N=[MZA\H'0V_CQ4ZJ9+%(Z**HFC.O M3QUKD>C1=&E =?IW:2(WM+R*6E>ASE[KR)L+U6(XS&;%$<\XNYOO2)65V4HRVF-.0R=6G,8(K!7! M!O,>O,F+\G#/^!'E[/2D!69S!HK#UE]J>!@Z&OHWG, M,..HGVW+/_9P!#/B8CR]9VQA'EZ0M9Q)O$^13.-YMJ3-=_&"A%_+0UDUXA6? M"+UA^XY_'64D6O"0;D&4S8U>9W0%W2W!B+3I"LSS 9I%,"YH1H(P[0"Q3F(% M-$TL9Y:$H7CAV6C$+@,#'/'C%1I'O#KQ97&Q_/?7:;&HP5V?LTW*9IFF]:H6 MSP'T&I!10]' M/2[1N_,;?F6E;,,,7&T$3##YX"?\,VG>WUBG<92@(2"GA+/S9<0C"_WI(-=S@ZB\T3PLQT5V7+<6 MY.+Y?F7F_Q,)\S::. 89B5F'"M.R0D16'$M:H-GK*$QODH0_1,D_*:J$-62- M4_+^E2F@6I;#-WGU.=0>HX]%#>LL.PWSN=:_ANRTRO@,1^_N$[HF@5_>$K+/ MU\ _$1DQG[\ M$T*'TL\7P7;5_U!6W+DGV^/+DT'9 37OKAWTEN6$O!FU"70LI\;:'ZKDBC(U M<51*>0!<4$J-KS?:#9YJUB)VM18Z;CM0=2 MQU-)P&*H#6L;,9$!P8@14D%E%>T27EI_H"\%[JM-,$@PR"K*O;\@ M1(2D9+!V*.V@4!]KN!$$EP*.%EH2D40)+K40PKH=U(HNJ91<)1_M*!.L=,"C M3.WR<1IF@A&1;IT""#GQ1S>\CC/W0E$*$F@0='F/JS0J;2(3@8=T:CLD?9\$ M'OTE#IG!+MHZ]B Z,4V7N8O=Q"?!$"6M^I#V-$@_7R645@="7OFR%R&V$!ZO M)-O01$E7EEF"*I^C-W&V$!ZO.-O0U,GK["S.O*!];AYZ$>(1N?&*[A@YY>-+ MNRO-JKWQ86?C'2?@=YMJBL/H%MUC,$%+#(.^!KJ)HX7LLJ=C67FR#C*>%)8# MRNED9:H&5H#1C#94Y@U&G$]$H??JH%:BE*<3G-*EG$3&6I2U.CA[1&]&GYY(GODFK!*K@?CQ" ZCK%:8"S ?B-S1'+R<'^=,HIK M:@O[\0AC@UV @<;C[$ZP?XHVZ8:$'XFWY&^ +:$7C^+VC9&5!"1PJ(M8=1+" MS\_KA*:VX#>_/3X#?S#[$NOOT S\1Y*R(Z3'&V%;(GX\PM@LC0"#$O>_8%F: MGQ+RF4:V3DS]RV,#NSGS$N?OL7"^7 ?>!\:8K7(??G]T+OH1 "7B/^!XYS-F MN]9$> NLY2O6OST^XWTP^Q+J']&,]\.:>/2?EF WOCPV*]*<>74, GN*(V(+>N/;X[,G![.OT&X[=G8] M[R\3D@:QK?UN?'M\>!_,OL*[M1A8QX/^)HN+MPJ3:/ME21/A/;_.>5\VD+LZ M,G:G?BD@E31@[N^/"4?^)@E"6_@;WQZ?YA_,OL*Z]=S9L53/W9>(^I/L/$[A MV[2+:+A;")WO;R6@8:7F"E(1@"4DHN#0!>TL("%B6ITM'+TYCE=K$@4T)0EE MFUZ\62S/XFQ)HH?[7TCD7P0)]3)!)DJ71\<5R4F#Y(23G A(VKX[MB5C>8O^ MU:P58''JKA[XYSOW9%OH=%S6[L0372LI-P= 1#&V XMR55ET$@JB19[MF5Y' ME\]>_D+Z;GX;9W3?:.B26TR>>Z!7_,MFW/[]"P19VJ.J<25J+M_JN7OMK7NU M)TM7K42DFD.]F%5IA-]P:Q1SA:LU#.OV3K_JII$/RO.28Q+5!C]R\8"V 6VR M]B[[7G<:Q')*C.)5$)'(8ROZ$$G8B=IR@7=>EN;4FJJ"N RA(=@0*;>GG%NK M$H56RZ)[]<)38NXI,?>4F(N7F'L>,SV300B,XXXXBT:R&"K&@2>)QV M%!?OXZ;Q8YP%7FHE$H/A1I$I8P(/Z//MG/K!V6:2\6/:$S^FE8OT/DXX:@8" M,AQR!)>#IB#I-'""%-5M''GPTI*-.H8\'0NL-/KB=G -K$Q=R]='L&K:)J^3 M4PRT0HIGX"8W.1K#.&TN9AXUT$8'ZSJWJ30?2<9[A6PO2(;[6+I!R%%P7%\I MY4>8)F ]-2RHUX]YR-C_^?Q$(@))JY%4UT6RXXXGO[+Q M-PFT>#0(NLJO %D^0@3U/&PW=WP'!8-(HV 02:IRW3[9P[&_!S3W5&M=%LH+ M !***%_0C 1AVHE/R96BQ/EUPYG=\:I/7@5WE0- T%'_-*?JNSO0.!"_JX)% M.S[.MKL?_Q'0A(EINAACM>8R8@/\:MA8V XOBWL2M5Z%\DZB+AK$Y"R_0RG" MVD;)Y2V:E5T32E($(5H@343U?6^">_]2!??>Y)X:3'#?]B:X;U^JX+[5OL"V M%9RH$;GXT@>EH;NX>V"_@1OGAS(]6:"MWKH-@$4O).$T_T=' M[^NR$8.$TP5'P%H/2W%<\A"#A'(3])7V]+65C+J7+TP:5B."?GR??TNS,LD( MXPJBE9[;-%-3>6G@IY.7!2NZ?;91;]*KD727) 0GO#J"6E4?'=T?-3VN;$DR ML><41V3::#-A\Z[]R-=F0.W;3^0L'/:@J'>[R.E^BN+'E"8YSD7?(.HQK-EW M2 D1;N-73)8!HFOP[*'V@,5B%\F$J+O ]J#1PE,KFMP[7QV=[HW@[HWZ7NXX M-T6GJZ+35='IJNCE717][;^_>?/J__[Z\9?O_M___:>WWCS_%GWWH__']T^+ MW[;1IXO-EP_?)S]^_]/[?W^:;=/P^R?OCV_"_\S>9@_T/__X_MO/S^^\F^R; M_[JZ>O_PT]NGY[/SW[YY\A^2_SK[Z?YY\6G]GX]^_,=W?ZS__,-WYW]Y#&\7 M'_^Y^NW^;/,?'W^/'^X__.,B_OGA[,/BVG\___'\G_2W;\__^/DOSU.Z69V% M7SXLM\F7X(?M\OW2NYG&/_L??_KRYV0V">+O+S_.;R:_S7ZYF?U$XNN__'#V M\\?9[.'7X/+'VY\_+"[_\?'R\QF=/7K???[RX?'VAOX4_W"SS?[Y]O.W/V3) M7]X^/ 7O_H-1^6?PK\X6W_Q^ M_?WOP:^/Z?+'3_/TIS_^WZOSA^F;-]W7R"GBCQGQA[]CZR&2-;P@EBOWN#4. M!E5Y=Y_W>U!J<#=K8/FV$'(7.G$EXC;4L=+@3S'/8<@>(G9Z"IR^3 TP"\!: M/9(-0^IQ#N_F]VPR7K FX1US)#(2^6QN3060/I55##((#ZLGH6K"JGZ$:RS+ M3U%">>E:RA0I3>^B9JT^+4DJAOBJW"\M3#7Z!%E(LE29D)'R-Q[U+S9T%N^J M,FI)4C'$UR=)%:8:G8ALZJ]X'ONZKWIR*"NW(OWVUR>_%B25+8VL1,D#%H!]:B6YKTDW]&6@ M;AEE50U^G[NY3^ST_[TISO; DE<0^ZJV"%T!Z#2LLBTUE.;N_J$!4F=BMA8@ M,ACTZPJ?6 *OU4/+W&'?)-Z2I&6!=*FQE_GJTF]_56M8A:2Z'5>'(_,'AD;' M([-PB*]/@BI,8?MX27?\/(5X3Q>]M<<1O:_+'!O(0:.YF+-4TOLD7K.3Q)9$ M/G^ML<[+[-&L2YYH->1]2*)L4AOW"$@ZT=! S[4D60<3Y6F?!F7P=$)-03I,(L03HU[>H-F23)/L7U/>FDG7C+(O MU.3$_K6747,L)"F@6L<#--# UL\LU(&[AWX0K09,J$,-. W2 #O@J6=L#!%U M8$ET\01O9,+'_\CFN=JLP#2T.9Z3((1DV56('LP8VNG)29!G6% ;XPT2U.:, MT1I$4Y+291SZUZMU$C\56=MME%Q>;!GXTHWKB3;@T+*U/Q)OR0ZCR;;. M*(JXVBB-4%RMP.'50=HD#)Q-0O,.=<_\)YS%U4+(71*FI:C:0$-I32OE\S+- M@A4O+_\II?-->!,\:=X"F0SHL >&6<#+ BNDEPU2)C#*\BN(.;T5LHM8JN!3 M+S)0H54*,P?/I]&@^)+$5P<2I\#_Q/,VJTW(E_D%72?4*ZZ1V,\AS7&+_,F* M]X/Z(_^]E%-@08.Q-4C'IE49X"0"_2A!.:];"JT'K:3<7N)"KQPM@Y CK!-:YY<6@Y3#?:/%U^!UWG8(L M$-_G@A_.'.WH?,?6"%M;T2)G""VZ;^)HP2L* M&.UI1U]RU-2QR\YQ/'&4>J(2D:(]K%;3<,.-T&6Y[Y>1_.8?9Y3)(_Q)LN6]#Q>K4FT39NS MM*H*6B":?_VHQGM'=HZ.\NU6&ID'RW Y#EOZC>$PZ?=5I[-/'=OOF)B"@TAN M-4X+R)O_\E$?/!JQ.<1 25CB<9UW:.MAY57I!Q)D,7([*@J?HG1-O6 >4%\_ MA54E2.G8>*%>9:I7J];N!"!'I5I>O;WR9J+QVD>_!61GC+Z'@395.FXO=L<\$^ MJFJ0/ZE)NW0TLEO<7M55T=#D=7>PO MHP[<(Z,[*=EWA^"7BN:, !TP6I'TC;[$X0-@/M3 MG&('I]C!*78 >.U9U1]$/2;M MB+AX^H6\JZE@17OV?O!NX.Z1S2WB!?\OG[TE+WEQ%2?]Y&IVX<35&0)?(3K) M1^MUL*/N\1M>+* L1[,K7PI_)A'2 3EZ*$8&/F&TX 4]AP&=%_2DISH6M&%W M\OZ=>/]J=3XY^2CT./J-DF3V)7:D"!7UH1T4\31@A[=.U2U\R3-Y0U^9 MFM,?V*$06?@%Y#BUA$P8N8HW\.4H#4N_BUFJ9#"[C M3Y%?/H*A_N6SQSXZ6?%_]2EP*0\O?K7+T5?V8#Z5YG A3=6%C+SWL;/[&/YJ M;I/EUU/Q_"((-TS7;N(TO:?) _L2M7TN5D%R21+^TG(W7D4"J1N;DIRUG=S7 M09+0.-LR+%=Q=,Y;9>/V9=/GH*]B&:;B%G=G,T"VYS=?NQJA41;XG"OF=.T; MW3+C'&[8*BRZH^\6U/&$SK;B 1#ZNV%R.IRV1\9KL5&8%U.8*&\4Q 1OR0JG MHYR2G*-;K!Y7HUI?ZNAC54U3409O0:2<79P,5/MYM7-%V/0N8%;N@C]F> M.$J;$A4U=[U*=(U?76I*[%#,]*\D20A2TY_FV(XKIEM(Y ;I+(K4YIF2> Q M5^ AB[W/*)(0TQC7^I#@A/*D['*U#N,MI7@2$5%PV+O'1B!"D-2W>TY.,RBQ M0!B>'$K=Y@@,)(A!EXDM#?_$8Y,,LJU=^XC=OLX/=G?5F'=)GBZ-%512$+-? M?\*!,4)'+83ZCA#I2:[AP[6@U&L:;RM#""$<.1V\BR_M&(Q:=Y4RU*]7"B%1#*2>G 0TH48&WS/[:CK4:AD-]HH5>)T70 MBK"1N"O(](D4B"3\,1C?XLZV^X^4MY63+R3)6XUEV^N('?0V^17F7;:DR6Q) MHKMU7@;IEL=(4N:BWFX0!-L?WTZ[SYB[-3T*%#C(DE^:]\#^03W6RV?FF00I MO4\"3^_UFVL>7?:JU%?(04"%U-&VAVE=1UD2L.W=^X6$X*EP_?,_P*W7M1D] ME+ R'#B^-G^U!)0O%$;H>_:A7:"IM.8&"M^NH*&0\BS,2MGF?T#JIS<77<.[1%XGZX8:Q(A54-?;M MFV"NIQ1F(XXDU&*#E?)IA=-+U(-\C5P3TZ,K57/#Q =;QB&;>EJ84>89UG*G M[IGJT"0IJ1Z]E&CE2G(K*S-.O7!B>$9#YTR_H!,^%VC&6UP!JE?5VYM]?&%V M?Z%P*C'56F*JMP4)T'#S5)7J5)7J5)5J\+'\TPVHY1/:WG?Q(=ZB6BOUHYK_ M1\GY4Q;3^,#/1A=L(5^1($&[F>J'<4?EW-SJ=$\Z,;9KUWP.:15O&8VE/F#; M58FR%VBF#Q5"YZU$OSHM9-2)N>Z1^Z_29O>I'>JKV&$9[E_*5(J1&>X#MD^& M&TTA=&Z*G;C8OXS2O];EVF'=I=$ZV-H:H7&)[+!O($>MF)'S&R0!+[W>&[72 M=W!;))6-&RS&>#.DHU)0]T%R<9UN@89]"Z1::*>[G]/=S^GN9[QW/\+C]83X]["X7A]<]W-%U6^>.WI%.EJV(,(P:]4R5\=0*4FDKD1=^;Y\7@<)*5[H#7.S%W%XVNP[R5?G MZ9Z3S5[ [9@V>U/V3YL]EEXH^TBYLK8%E[M9*)^F#\#\:K#\XGV$?A6@BL>W MW-.YT-Y:)9QAO?^1\C?.Y-J^E5(@UTH#H=M- +(Z),< B.N36PNN!Y4BMUT$ M.5?E03L _>#RRGVV8&7Y2S$R;E&?*SF/^JW$1X?N,@/5UMMD\F&E@-*CV67Y0-4XU'Y"UWG,SI MS->'QE3K .HZK;]Y31:+A"Y(1@?M==O/XZ3_R'I2J3[*55[GQW8&2UKFKKT; MF#QLJ3 M(8C5][OB%EA&NV%=NJ.0BAC@N\OB/9HR5B_>#3NH15E)CK'&#TE12L]H MQ$#*@,V%BIJCB(]$OQK-=U4X*>5C(YV+\B!=DMWI#ZJ0-(DZM/@:\M)%#J-/ M*B.64)+2"UK\]SKB\;8B:A&&\1<2>;3D2\N4F8PW3*F8PZ+QZMFJ9!5S!B:1 M?\,^8K:=B+_I*D)MLZ-(YHYURFL:S ;Q?G<9!6EW]\HMJBC?>51 @EGF9 ZBQ/^QU*9((;?!GM3^K1G-WH*61C"HK.[F2SR/I93P/T MZ+17CVJAJ (G;D[KE_,YY5===,?^E,TW!3BR2T:V/+>K1K,\QHB'G5(OCKP@ M#(JE5M_A-FRL;>/#P$L @J,!!"(UI5]?0""R0 I&Z/ FWC;! YN=6!E"K E) M->3PH_3*T6'I*DYHL(@:G[@(V!>YVQP<^C"]:(:2I4&$RY%41"T/+/=)A[OS M)4\;N8XN(Y+G@CC;7B2,O&3-D&&/=>FEPQ/[Y3D[C05EMP('BG#(@?.@$I+T MCY"&[6=2%#/3X*.*/UYLZ"R>,5*?UG?S?%^[O;O1,1Q$FR!:W*UI6>>E%ST1$AZ70;%!5J/^D[.@ MWY%^$G9L#L@CT^,LV ?_K.XQ=_@>$9DTB%C& 75'M7WL>C1^*=-HP7.'STF2 M;.=QDG=W0KI+TJ$\B*.8H8!%-TU:**M#>B""9C]4ORLC^(U''9%?!O13\;,H MGM2*K1$0++K??"'U!D1H&)DV(D[OV681E=/U.*]Z_KSF4&.U"49P8<7GCNC_ M@_H+9HYF"6&JXF%X2UHDG4=<(!>K$%.T%LE'Y*^C^R3V:)I.:4H9$DLVE0OZ M1,-X738]0Q6OBOQ8UZ\]WCA=@X_XJ/%_2]'%?$#M12W@0R31NN0*=.F)IEG^ MF@A_G>Y)O< U6<-1'VHGG@K2Y]%L8I[6ZH:U1.=A9;?RA::+.CSSS(2A6> M+4DV2>C'.,VF- RH_VD=1V?;;$G/8W_%_I)O]-4#7Q+YS 3Q0*AE(+X"MV1E M2M=Q4M3 F,>,ZW+>HG[VW"W4[@6*F?;\H^"#O7=9V?! =(!\*A+ MO8W0&[6,;-#MMZ'\CM7-8SENJMM.WD3(!Z/CN3?*GO( FM\0\2%N:$^R:I0N MM)O%V\GHPFG#>(5*2M"O,$%*5C^BI-:[AQX8/U>[=2[[K)A*E7,][SUTV9W ;DY.[H0OB;2?7W!>[SWTQ XRE M7W9P-ZJ/L'S*\!I\'D=I' 8^+U!C *S@:T/76]%,P5_X5^R\S%)'73W/H\)& M[<IC8Z_41 VZ MF&*^*L4WAB5-O:P)Q1!.@I9MN&O-&SA3I>)GEWV%5F=41,'A;MNF^$(PT+:$ M/,&\H%36 >:2%B='=I=".S&G:\)V]U !B)4QE-.]C:.XJ2X8$A-0<;MOZ"GM MD91$:*$4)]O?#)X3P MNP;!4:T\'0#5Z9$VHKLB09)WVICX_]X4B_]N_BOAC0O $ZS::8U*8 K8^2 M!8F"/_)#!^%'\-1+@KQ52SP_VZ3L&)+RVWENGZ.L=D!/RTXR5HU+NA(].AVU MAD7@J-F&[KMR(+C81YKK#-6E.+K!Q]&&76P)"/?.5_XF"I,F6?W%;M[1Z2/- MEK&_/[4<_Y;26\),DF9J *-1,[SL7WNCVYD\VJVT,G4 ?JEQ1>HN#]#S/F=' M1DX_[T"A H"CA(/H%9&)545C,"I"FJ2>CD+ +)SDK30K_C TQPXR;LO$4W2 M9; &,K3-\1QF7>&9S@/(H N<-TB V;_#$1T:/*'*'8&K;;(Z8@MBH83H.C-) M)@!K&16; \+5_N$ M]%PNT/D97C$$49PP%JNKC)T$[IGE9]3)@IYM[TD"_^K;A++#QZ4HITPK].%S MUVI/7'FI#Q)MKRB])P%353](J)>%6RT[HC..NZ=O>'$"+?S0\B'$KK! A8 7 MKCY=1R_Z49>L >I8%7'W9/56+>#M?>OR?G&RU@$:YR;KN#L[S\-*4IK_X6$= M@O<3T:'XPFRX$=A(%V#[Z]%T%D]\/T>4A(66G9-UD/$&#D@R-R3^$LVY*?XZ M=6W[?E"[6:U(LHWG#\$B"N:!1Z*LS(\(HL5]' 9>0.OW;A:E*DU(F-VR60YM M55C+@O'UL4>+*'O(='4-; T>+;7 4^0T.DAHHYBICIXHES M?&3S7&U68!K:',^)6RQ9=A6B!S.&?GJ4DR#/L* VQALDJ,T98W7=O4]X[G^V MO0^YD8]\?B;)/=I/*9UOPIM@#AW2T:'HL'959^?%"%DLL>9UE1\/ZRI/>$KL M(G>%SK;[C]R3+?_5A!?VOGQ>!T6Q_'N:!+$/+'PXOES6@ 33$4 QJ4._5ER M0+WDM"G\XIB-!X M5/UH2,O7^RKP98!O_>I=.FN $(:=J:_"FS7.$,IXR:@@;N=Z00^U)M8-N10L MM-I=(HK\QX0:Y-1V%%23GK-PB:;&JN1U@!Y.SHN2,'@1,#W!.:P(!BDVW6PW MR]JSC]EUE+)A9J\)K*5RD)?NSMK)M5$N$,2G BJ" MX':M52Q.#5HWR> 4.WQ)V;K&+A!0CJO=>:88G^=G59F6J1GP\@'?:O#E;49/_'=)Y08NTJ]1+<\F:(8I5CLR B[QL@T/AEO1?I(0K M;+&RI 6L/&1T79M0D>M9&9CKG>."9K-!6')XR0:B#Q9"4.=86VG(.4F7)3G_ MBLVRQA6PX-LH.>M*8R[-5L#4"=)V!?K7ZR+*3L*J T[EZ-TG 7CG-36]4:T_ M#?@T,IJ!@JR\A30OW58HT&64\7X_^PZW_,\]7&UH<3$F?]D::66SQ.HBM<]D M]F6<9#.:K&IOZQKWK):I-^6H_&QQ!"98'HV0B/$**J[5Y3@8)*:K!D';>^0] MEUHEL4\T5TZ_U^)*^Y="[!2:OP<+29K>S?.7(1B-E:1T7!?[T-7+YOLJ*6I( M ? Z(93[" $!YU>O2N5LN'("A*"CKW):X!<1$GDXO(#H* V]2U2[H&42/.6- M*?9!MFF08IBQ5E+.;U5M3%D[>*!71L6-#N0W.**#'7_?-1&:0[EU*C2# M=KJP:%SG]1YWOHTS6NLFTSWD7'6HR0>>1/Y-3*(: :P@M#;9#N]8=\68&\1R M2HQBV=8X6NRI"B+6W3<-2RYZK+QBJPJ-G<86[-[?+)T:$-A&HX 65D]=!VST MXM1YX-1YX-1YH.?. ^JG$"_SR12@.6V#$.MVYO2>ZO2>ZO2>2NL8'C,CFBP8 MI=F2)F1--UG@I=>1MS?/!O%\_='<]$8P;"5@ [L55A.?4J8,D77D;]ARA P MHWMS;B44G7&<50HSE(@6)O"K9+*B":_*NC,%AMTX=M[7Q@'XN?LH#Y?MQ!M-HRQ&.X>Y:K M_6Y2"0-:\90FBS7J,X9YRLNQ[Y^ E/>H^8W++ D6"_#+XZ[*8G04KY/[+Y-3>F:!#[;'2,O6),0=:\ZI/4B-JPC -6/$\U# M$XQ&GD9U-U#U#"RQ6FN6P;+XH-RQGKC30V7\\$I%) /\)ZYOE![3I- MF6MRP9S,:%$4)2_21F_IE_Q/\.\6M8B.U['01;4Z$P,_+RGH%/0K/'KA(6;&_N?4D3+UY10Q=#^N4Q>A=R)"KDX9.GN>U]H!X_7K,S MVO$FB>";MY(;VP:FCV,E0WG);+6&$6?6?%5OR12:Y74/35>VH5I M\ICF3Q:!]4A-KUMP-:%>0!"JAC6&=JGPV@([B)36@-'+S.I3MV\H.XS5:@O9 M"+\8 TEM#P:W/3/<4&9MZ-TZK\ 8+?)1^5N>NWGU0AB<;R5!A_NL6&1UQ=4! M#.6!=$YIPCM9\W)ME\_\.2CTR4Y,PUWH2T<<0E0TGKG:^9U>P@E>T.*_U]%] MD@>EIT_:.,4SC=)0O.MZ#:.O.(?P,)141OR MDE$BI7'5;&W >'%!#*.5CSOH15&;/LH=L&ACFE+.>'V;ZF$W%Q!U&]*UV]1% MV*FKV/;OJ4ZI3QFK[&A9R\YB]K8HYUI4&+$^E)7W?[H4C@ZWBIM2\W%M4F?U MZ>@7SS0=L[]:FEU%5KOV-82M^Z/BTP,VS>ITEBJM^6H-]N!R>K1V>K1V>K2F M+9E3%6$ XZ8N*@P=&C@5%3X5%3X5%5:8M.+1%Z]E%T<\_PS3K EI84FH?\,F MAA+G'<I+ET7 MD%P 0X=?,G7P+Q\EYH;;[-:(_> M%AI"W4,=AMIT;@*VWOT\";V8&8T\FCZHE"??^KGH'?0E<#NQT4E\#U,NJ?DW0YB7R\JB^MI-Q$*B'%UXZD1AD*FV/-9+%(Z((Y>)SF%34M M^=+R]7%NA$I0M"I,=$F#^97PCH'979)?!MUN^#S9>MX]W#\G84C]LVWYN;3\ M(/1BZ\K-^-=C9WG@E<00LG;YS-0T**L2[?ZXXP=\-[7BX86JA1I[=6T-F/C( M_C*YM807> E#&54'S[SP3L8MX*IK=%C)EIVO?!KYZ8&?SO8E:'FV4!I[Q+@5 M176EC@[K\J+(C+J)HT56-MU$*WXMI_4"UF +D)4 Y8&H3BL/:YV-7BI[@"H) MR(,_/3^SS"?!Z]VSXW!Q2T0B7^/%9=?L]2/ $-+7;VR?5^YB?+MF:OEX9]M\ M=-S&KL>4^GMCJ24H<:-6 4 S5AMA':V21G+:3KQF#JG!5CP^?@R*BZ?4!JH M;5V(4L"P7K&("/(?$XKSA%)-S_F+(X72JL1U@!YL;S-MPN!I^GJ"3^1W#&>$#<7?$C#^20%,0J)%OB.F M9]O]9^Z+VO0Y;WL&(Y^7HT-[;(["HMN'ZD+-/\IJ Q<+TOMV#&;!S3::%CFU M]4X4"?PY/N]1. LR;ANO(Y\?3#..:$-H 4GXIHOZ1T1FB_ MY)BA5#2M4>&._MV\ECV,4PM.6*>ENR>:3,(PSM\JW.7YD2BBD=-Q*AI]U[?1/DP.FNY-]\!J ME$!HH&4YF NXZDC*H492$TD-"4Y%Y()X#S7UVB@-MY"/%D[ ]S)UK7@'N%*4 M8PW65)DAHJXG8BV-SB(8M8F23!\E0%5L1'CFZ'C\X1LA 28:)UYC9:^RQ!BY MQR B,O]0HNGR;SOU^K3S/7=*WP(#<&)-L<;B^+>-B46I?;[_Q[L=<@?V5J4^ M8Y0*M?\9I\L->6"LA'1K@*WH>PXV1PB0A1# WOMP-B_80O+8G_1MM2+#X&# MT6FX"!24>G7[.@3YQO")@9-.'SZA;)KMM!RZCYAIK>*B#T*P$<[+>4V0%NO/3O/AA+MR/8.N4\ 95@U\%US]+^,\53;^@*)AT8 M&4Z Q4(%]*!6!P(ZIIJT5-*%3"\Y*KL[?*E),5*7W.SNQA2&84HS=M8 +_ N M)S0"@]H&D[K\)81L2G*\,?E'RM:NCU),1(ODV.0EA4Y9U]+> ZW'MA';)K00 M&H&4VF!25JR$DZ2/ /&SVL;(VU*FD1'XEOH0JA3N-*^=*S@UFY&DQ6; MP;X:*OA%CS;AH=P M0K2!$B-ZI=0IG+OG/9@+FO$QA%142&&5WM21!FOFXF* MVD@W.%&[DI;2D$"%3?;U"N_FO\2\@GO5XB$MKRZAUYHE$V,XI=GBJRX4:1M7 M45U9R&XLBN3#]$->LO2:SR*(_;SB/_2I'('#D7A+*,+1*5W9JR852JGI M7;:DR6Q)HG(:O["U0/UJ&K,X(^$5"1*,+BZ.)O'2];&CB-7%.NU4]N >M7Z, MO*59%>Z^BI,9>>9W[KPX)+//>"T*#-D8@1]C#[%6?="N(L\5[(BI7L6MQ\(H M#H5VX%:";@FF6>]'.+$SYSU&[2SW4>?0EA 9P-JZ?.9;!/0.+2$R"BG( *K2 M&8"K5%ZNUF&\I?2!)D^!1\6[]VV<-XRA10I2FF^]];_SV/=MG/U&LRGUXD6$ M$%O!XW,,1T)$*55Z!?ZLDC]!\WC85LPMSLK7)#H27UH7PDJ&4,]ZS.A7.[83 M4>Z(C\#/-86S$FMK^*[/ZO?7$?N1,MYH:E?:/L^@/![E"+76I-&V[]L]:#@> M45"T7IN;6AGZG@K1Z\*Z2V*53AB@"+V5I2D8VM4*N.$?#F*,2O1ME- <1&61 M$1TUK)N25KQ0:EA(**+4%VFGY;;XDH:F:@@*M_1\*U'PNB-J:3DM0 (I,-2B M\W?,1I#B;H>S="CA?.LN*QJD)WF"/WA;\ N2@O M8)G-GJ0ISR<),GV M*D[R$_8593R0L"EFB9MH-_+P)=@%-O4+'9M5>L3,,2?SDI/,JW?08\^XU-3NMB$ M7*.V^_"4E1]P-)!9A*KEZS8OJX^&TX].2;Z*%N@0AZ;4<.Y<"=EF;$S0 M51 Q9S0@X3XM!2$D):/BLA6,AN+5K8@4*)185%X&D>U/*?,JBBLQYG?0BK^$TKH"I0UIQ5U%;K?? \%*0^T:N20;()'T: 5QVG,S9'N(!1"+\ZW M\8K13(('ZFT2AB45!N9D)W_9EQTF'F 8T'TT0(H6VLH^)^L@(V%>Y.:69BCA M-S$-1TZ^GD>E@ >GI\KEL\=+T14DH<]BC;$=1L?,\#^ 1+,R3;\GIY G)MR3 M)-O6BTS7CE%VV7["8=/)(S,B[&=@]5"2ZY %+ARY6$EIHS!W/W,24G:;UJ0K M[&:VHP&N>K4L^UPV#\6AX7K'OE%[7 YAZ_>$1!S*T[FPY2Q30%D7OSK4CT MG2K&N2G4D#E? 5]C4<9+8':2B7! %U/<9LW MKX:Z.9*+MQBF(!_,';0F;IT7?L0&L2SY0 Y.I)8VI9BWQGVPN=J>;Y*$4;@* M4H^$OU&27$;^!?,T.\$L'=310=00=CDFZHJ,=H:ZU@7 I)R'KMEN'7X<,M'! M";9>XI[J_>8Q#+RK,"9M)PQ=8=1'&[X)$B"@40+1'.D)8\CG3%V%I)O*-T<: MP_9Y,'=E(4-+&\,()#PL[=/GG^@6PJPFVSFN=> Q:'P[,LJ:@W:"^"4.-U%&DNU5$-($0@*'(XYH 1R!H5,DT'8) MY#3.F0>UB!,(P],<;TP.S $2&L7\+"'_E8;A3U'\)7J@)(TCZN?E"MH2.G7! MEXT\)C%(T=$IVF=[>BW*\4"CCF M&+9=*1X:%?&Z85^(&QK]^J@CB$6V0*)31\YR)WA8D3"L2B4"V/_F>&.R^@=( M0!="VQ.Z7-%DP1S:#TG\)5ORT@4D@O![Q...)8@@006V-%E-VDNVR<-AWQAN M#,9>A )P=3!.YMJ;)Y.-'["_3K*,IEG.5>"EGV H4@9 8HN ME(.-PM0<0Z!3YLH6:O[Z+6'RS'G*7ZR>\Q2T9'L>^Q I!NWCC\#\:,&DKEAE M+: 9>;[V&:_!/"@*0X M#-G(X[!+"G0JB;05A;<3R,3W$UZEOO@/YZ^MC9ZN M,$2CCF9U""&I)(!P!CZF]QY%!._'+(+W>Q&TWNUV$L$Y^_$NF<5?VM*_#050 M&W,\!S,!'A7Z+2WL.F&?;T-WR7T2/P61![%92P8>G12.D*E$ 7A0;A"\C]F) M,/RO8 WD-0F''9'W*H:ED@+L09DON4E"26?H&P,-/PK7G'>530C4V)Z-GY>M MN5_&$<11[&BP42CS,005S(#UMQB=\L7H]MW[QUF0=4RW/QIL%% ?0U!!#7OJ MK>A<=P%22KZ[96 M$AIYLXV1QK 8#N9>P=MR>+5$M[/-KX\SBMVU,?$*6+C6ZC425?E:"'QW8XU@ M.SV:?H6R*@59\K#U;V_Y\(\DI7SN_Q]02P,$% @ +#Z!6/9W^;@$XP M+4@+ !4 !D;VUH+3(P,C,Q,C,Q7VQA8BYX;6SL?6MSY+;1[N=S?@6.H/O$B])%G*S0E]GJ M*[2/EEFV_N&;;SY]^O3UG'R3SH,$I_$FF>.4_@+M[Y,.RRY/$DP[_ '=;2+T MWDO0JT-T';MV^_87^M/DT#WH>DV\-O M_O[^\FZ^Q"MO/XC2S(OFE$ :_)"R7U[&Z!O3?&9='C-5 M_K*:-TLS>$\6%M::QD;+>BY#^O,EX:S%,W[.<.1CO^2:=B, (*/"X%[V2WN. MYZT^0PKD."F[9(3_],4FW7_TO/6_9FF*L_1DDR0XRKJ3E1*ZC.;"2Q\8X:(A M8>#HU36M&?62^8E7?+/'H:++[Z9 MQV2C66?[89/M11*O>F22Q:)A??/G0?(?1?"4*0?2%HIY.N*%Y5H+5$NBEX'W M$(1!%N"1EC6'@(NUW65#:H&'=3.W,(#EU(0$,$KM]=[H;SQ86%_Y#=I"$$Q1 M^#U2'[@;W&5$!5D1V)R$9.^[7MQE\?SC[#DP+7V83HMW(W (!4@ ^0!PP3Y# M\0*Q#]$_Z*?_K+#A !F] FOB1#S:0CO6P SI91F'/E%5_C)(A] LTD M4Y_] \[T'WLAO9W7L_S"IOA@A#TPG^2SR%>?XD.9*7YY0#XTHS//(G_T_:^7 MG/$UJ:)!<5F25:N0%_D3WBEE!0TH8_#4U!JO$O"NU]0$&T2/9\]K'*7&E?)N M__:AU>%!B*6X_!KAXG.7VA@HGR9 ^ ,WIRBHBLC+BYVQMC6=970<15'<;O7 G.&,0+3,:_*]&(% M9$:\D61+G'0W$4>0Z15<$SCB >M>ZZYP-MJ>TN[;Q66NQ0$ #/(-"LF?79XH M7"FTA-\9B/$C^PDG#W'UFB4WG;R+66<^':TMY2D]&'!7:'4V>_("\O<0W\Z[C"/CI(3\N*\SX-"'W 1Q=N*ERYLD?@I\ M[!]O/Z38OXBJ.^=LG@5/8[SS*A!VHGQ(,B?0.^:D![0A#1'9K&I[E%>U=:_O M*HI^1]U0F2)-30.@'*8DX7GHFPZ>7@*1"\!3VB*-.%)2=#_4<7AR0NISG!+X)\$ M\PS[] ^SR&__HO'E#5/VEU0A^C*V=KC.K M/5/58,9Y9BT!%##Y;1<$_P.!QO.+UHZ8V\KOO6>>/B:QUO(-,C;] [;2:^HB<_TIPDFZ#-87 M48;I-2$]\=8!V:-F\WF\B;*Q5HP2;;M!)$J\06YK 3GS?/J,04%>-"5@+V+G MN1!W 7 ="+2 K#Q7NOM^T1=1KF_(:IE3=]QQH"D@9/@2(P(AS 6 N+O-:N4E M6Q;,%#Q&P2*8>V1CK?M!94?3V5_[9=J*CQ5/B;Y/#PN\GM+(Q2?+CC:U*DB/#+FQEILG$P! MKE?<%3:M-YGFSGJTD^$!"!=6A,LL1O0FL*.^.5;W1X+96(NKG&H#"F)3]S3O M[@E1&2$01W2U -B 7*]+*V#[>K'CZ.D4IX#4>'CCC5D[2\][+_F(666QD>=0 M2TB\9]*&6-*JT0\N'T5-"V)(1!FO[W=>$+%X('NKOD/2HK%3AA_([#E?8G]# MD$6TG9>X_"%)]Z&/.ST#$H4MXR2[Q\FJL:..!#XA*KY;_*S?IZ<<*\)"^B^R4^]X+D)R_)8[$O%^J&V=+C&C7B/5-_T9_([^;V82H2;!0,!N;;.W@ M3T['%H[5T9PM)0*PN]P(#]2,0C"H/MY#9(&]X= M#9#"0R$%S"*@'<#2+W'N<+6,_#N/'[6A*]O@<6XTC'W\\$J?ICQLOR@+J MFO>$R7E)"Z7D7HZW^)'0HDXVE]21$;UJ'K7OL9=NDMQWC[1:;T 71V>Y$.Q@ MNY-=P8) !QCO&W)C4KLG;4:XR(!D;*XOB E@430^SQ&-:(-)Y&GHDUK+L"(: M]0#D7,;1HQUCBHB2<>.P"$ "1L#,CM&CW,W#3:[8?AFVTL3VC%_Q97[WQD+V M2"^B1N<$WR^3>/.X/(ZSY2RZN_F);'ZG08+GF8$;LRX9"[9B0ZS*W)G+KA$Y M?U#1.:*](R]"I/\\J(%1F/*M>2!F>!?G(9.N7[2DN[3&WT5'NK'U7IPYK$ / MZ%6PZ<,$,N0+A-2S37(.6WM79( ?W@WYC%V!NY/]\F;[P'B%GKY78X 17BV" MQBO[Z+")/])U@:1QB,$3?6,= M2U7G4;!YQ>/0AX*+XXPH/_7W$WG<%(BHB0QHG /NVA MFN#"=N'/LOI+O5O?$$HV-C!S[$I<_A84P$\,P%Z-V; 'L^YN>09@PKGH#9UC M?4>DJK_C;?7/OP0X(3.SW#+C^@@F6$FBKK9?(5?]&W'5AD'Y:O;3).RT:H+F M;KW]\Z)M M59-W'2?T%4?TY.](*9!&0;M\B\QTC909O\?<(<4;M]:'KBQW' <^*R&.4=FQ MUY0BQ1G/L+(KPKVV#-'^KA#=G@_CB>UP!+')U-21X8UGK5%<>Y^KV(Z&5.T! M"5R1(5D^T1LDW63%E&%-\TR/XFA?Y5R?%$*[6) #ZHTU6XS8CQ< PQ#CK[V_SI'/__@6(\&F+,OTEH M49=L>T-F.2/$:'9:EGAR)(M^/SW+=J5>AH"SOVS'S$A5HXD\#DE+M8DWN9G0 M-B*!W1]O1_(EE:%H-YFF!$'I+MO7](B,J/%"+0[M^ESU"8-'?3LHXGHD7Q)M#S/NF,: MDH2]++S(NBU?V;>&(0!1<7%. [R(CFBWMJ4>$;72H0O&9O_X%7##.WFKSU'( MJHHUG%YQ":FIQML?-^6).N@2HTL;Y*KVHVGL:)8 MVX> POAUM8(S+Z&O);3F'(N%'4D_ ,G8U!0@)@3UCVCZ*UI@*Z\HS_1[B9R M=U22=RO)FO0,:48WL5E:QJ%/K@S4$I5MZ5/;6+EGQ,3LOC^(F0'M4'6CW__N MS='AZS^@O'%>SDL-B6[4$#F1MU*R]$^5?OXSS6PO.1]U L*4%1R[7WK1=9[Z MY2IF 8#8O]JL'G!B&LK6^';D-&1M@) >S_Y( V]22B8OG-L(LT9?!E&NWZ=? MN57KK4/82+8D+3$Y2GU@=9!<+[@.&!]V/P?0(XK*\U@RO&9_!D'CTOR MWQE1"+Q'?/:,DWF0XILDF.^8 Z$P3,<\VHU#F<*0@9.H;(**-LRRQ/:!W3/) ME=UR"I/7W NFP,]00]E)Z*7I]>)GCS*<72>WE-0(9BZ8CMWK$,@'L"K8]_1$ M+%J@.$&LS12T#^CC)YZF5U@NHQ;C9V&'<3 MY&)O@!H'2D>O=)Q9V3:(.ZJD/4&YO&A;&R7O=J.EX/P/&D>6TP#=15OU*EB] MWF1IYC')3\MX!O(WRDDREH4,&@5P7#2^VUF.>Z@V3.2FAY=J>>@#GA$+@W#> MAU3(,L:/O-%@2FNPWXSPDNS7:N/36+.=X[;L$+$>W58SL0KED5:UG%G \5*_ MB+(DB-)@/MH=;A0^'96K&6DX&JNWZB#/H?69K%8^&D=:GQP9#%!V;_$3CC8C M)F?=Z=ZB[]@N;= 5AGTV'0\#2"3M9*RMB6?RD+O;CTMS*#!D[: M2YU9-;"GC;27.8GN*8E/-YQG=]9YVY6C@)TF>9X)K_R[4VNQ[/R-D1U/(M5* MDP5>7ISB[R\#@X<##!9$@5L%11V6B*AS$0U4P=$\8%M;X6\ZDCJE1MOR$Z@* M;]"S:-U'Z1%:]S*AK.9:&&B]FBI/ENY+ZD4TCU?XWGL>'9PB2E8=XP6, +C+ M6R#29%(PDY!=$U1]XQY6*ZWJ_2:)GX*47E_U[@&"CNS7.X.9D=#M:]B@JOFT M=/A^H7'4]9XY&5J!X6RQP',:%%31N?4RR +1BZ:^WNQ#JHBA-4F1#-&C!.$9B]&<3*1B;U&V,=-2"=Q.YEX$FVO4^\*"7]L=+<8]GK>\A9Q5$?-R"86#/$VJ%&P\E@2U:J;?N% MQ&3HQK'B1WH7O<4LT6WT.%8$*T3&9D8,B E(+\L_1]7WKE4P69FUGA]%8]:P MM.\H8@QY:8(V%*VY@V15_B_.OT*Q2PUHX=!N3DV4KHUC\% MVI$[FX=B,QDCK=%N[Y:37K2I0_MJ_=4D*@("$FGI!YR!#0+ KQO2U]D3ZW D M71(B8U67!)@0(8-]CO+O)Z-+]LBL@Q5HS$-RJ^4E4<=!RT[GIC'2ZX'0I@^E M'KN[.[N_.F2NAV0_]!T 4]>R#;R M[,1+DBU1",=PJI>C:=\W3(HO"%*D$;OKSND_<-W<;?B^BG1;3BG24Z&Y,;WW MDH\XHUD'ZWR0X]1]%E&RCS$!-P"RZA8HK9JX/<(DA-<$4]^8=5_3\#I. X+* MYK9H^AV-2\/VV<;E H!+^2WZ%&1+- ^QE["PFR3^B!/71YU09*TG-'#$^D?= M38+77N 7Q@VRNS'3QYCHD:'HH+ZU!%M@?3K6$I56+W;BY9:PCB[EI(*0M(3; MA83DYD._9%BS?QM0<[51<;GHP9(W)PH&6>OT478>I\X=2832@F%C9H]BR+M; MQDEVCY/5!4MTP6QQ8YCBN70<[$<@,Y#MC'ZZ3[I=H:#^N%VTU6DYE3XA=NSO MX.!-6Z5_V.%^P]_"F8!Q%].?^4I\/[?&1QI.GV77=S$9T'./1O MXB#*JBNAE)='7Q^V%!X99D#7V;(56:F(M5O3=HT*(VZT:!4A5=X-,G.@!Y!)7:RGYP84">:-V\U#8RY=,W<:D(9[]7?%\%M+1 M?G$LMOYM8<$S[>JQT[N#V^H."Z"OW^[/[H/_P/AA6.;LN4CN+_&X)H[%J:LN2=; 'R/(&E>.^ MF!U?7%[<7YS=H=G5*;J[OS[YVU^N+T_/;N^J8E@_?KBX_\7IJ:(J^%;U5I49 M,H#,<5U@QK\00Z,10]HG7?!7@J]O)/J^= U#C4 T/+'4IPE[2#V MHMNSU3J,MQ@7$=?C85-$S,%I*^8(!B##6NJ%7A(43]4/15/'41IR\MR!6M\4 MZ!ZB1==W7DC02G,1I33-QZC8 FC9=\46L=.#JWGUO6M_8AGY<; D&+4Q.U^Y M$6['@5,/,1=/V4*.H.L LRF5^MD6[:-Y_KWK\U%.F+!=B3M^%T_:O5P)C7X3 M,NV9D8%&M\0SU[ MX.$$[(&'+\(>>-@4K&@@N@HCL+]<$49MGO(->DZVA3ZNY [[*;WJ"40I<;[L MC-SXL[O^.=_F3/*H_]P$Q@Q_U[^!'P^+R;;WA MB%]M[#[;JC[2-!N4CS*8-70;GZ_T#"/Q\*(=T[# 9'/)GW;&B!+E4;!N(>(P M 8I=ZR;B0 M 8FZ4!?E6)/#UAY:>Z6W\9=!A$[C,/22M*XV^Y73'4I-]# .A9.D;,'%3FAPE#CSH,#0V4_5[S; M"U\\/.E\)J(98+_D=7Z1IALK2[\@Y" J$V!%<;T'K-'4T-067Q^2&@-W4CQ) MS)/"\MX1QF3V75UQ#"K4SNNZ42C3PMIN4IO" F_PH[C*X[KEU)8Z1Z1] -N= MA\DL^AW&%%8^3T"36?[#161P([@,?MT$/BO*'4SS'JP>"RE>'>XA.%VM _G&TA\B7Z[RX2[AE7;[Z=N_MX>NBRX/#UWL' MK]]R#C^5?AW??R&X[=89[(AL6.W+HCM+UCT9B@XV6@FVI%:'M$W/+;Y4['FR M4V-@EQW9D">BY"!1).L@\T+#F(*H.(D\X_,"!6-47R.:BF^?*$[SO('K"!^QX%KA M&((1:P/G/L%>NDFV#)0%/ADT#4,'IN- $P>9@0KY%-^7.Q&Y[^TDH'2 G%[) M-;$C'K&#!TPA0]SD@2T9%(>!X\5K3@0#'BIO<>8%$?;/O"0BYT@ZF\\WJPVK M^WB*%\'<>&H5"8+6W:_Z>8*C],H/D9]_Z;K,IZPXVX4^I<:O6[:QXU;ZJHTI M6=?>5Q-P[7WU(EQ[7S6E+!K(X.",$W*2T=0;17KBL:HI]=-S&IP!<05%;U5Y MOJ@BD,>,=Y(5N P+Z),J-RQ . E.XS1$G(GSL+&6GZ=(="(U2@+O<$0HA#05 MA;\*HH#V2E\H"CJ&%W\?-=NO4CW\ (N^:)5G*&FU<^I&*RG*)KQDQJ^/K5N< M8L(_K0MTBI]P&*]IVM=QD"6FY4 /%; #EI[/VS!<^74KUWJHA!#;*FC?T'6U M3W[/E\&<5>&@52&27?,[H)#*]60Y$; 44XK80?LHS#O(RV8D3=N[;>5627Z5 MOBL_+<9N-=_JW6J^G<"MYML7<:OYMB-E8"#:MQJ:ER"O36WA2B,FYJI "LB1 M,!-%7I6\4:?<<<"YE" [*2G$8W=5)$7(%??ZTE,S_C,1R-#T,GGGXZUJZ_>2 M!FV)Q3J9%=HC_8'7B6;E"-K=143FD?S&L-Q!,M8O$1 G8)V0_,]=5+B 19^T MFA@1#G2 ;S>OCNB'*,%>2'U_WGE!=!FGIE\X)8FZL'+*L099/ K M%$=HU5-EU@7FU.3=5W$6F!D7]D]Y]L!Z:RYU!AMR.3"I9\O57)-GCE> C:VG MWH7TF4KK<(C)NNCG.J(92:\75W&&TUL\Q\$3)6W:9-U#S;K)6LP/L'G74D!T M!Z>XBTA#E%0-7?O024JU9;V6F(HQ-H5'^IP^4$:\?5I)2)^-B+2B]_@VH^_T M[';?39V_0+4O)L;AC]LS#@/LCMW :JK&L)7"Z40=0?P3L5 M2$E#:: -:K?/TWR)C8RADHH+FP' BP*6=K>AB>!F1W0BY#3';"BK]?=ZJLKW M$U!5OG\1JLKW_:K*]X-4E9\Q+8))>GO"B?>(KS8T[/MZT0GH&4E[42;O8O-0 M91) 5MD-\O)^4,0ZHI73N\%@(@W(Q;ZCBY/FAJ0UC]IO:K+4QE"?U&@[>%I7 M8M DGJDREE-QK8%IX4,'SFV-S2"4BP-][-A;5>KV$P,H6$>@3T$E, ZBZ M+9J:^0'F2M9GOKY.-PDY0VX()W&>#BG_-2%(N'L*YL;C]-5H.]##E1B47P,W M^IN]L^(>JA#IU/M0FD9559R[FF[JU93V+2>MO5V)@$7X#F9V1"CSMW/7F[D. M5,!=7'FF-35VT;)B'K$6M^N#P%/1Z%VO0KAM3A10YRH MSH/,6)CN'MW"@NR^7$^=WF/$*9DRTFWP%/@X\M-;S/)#W,>%HC.+_,YB =>* MU.9LE*"MIU3CG -@STD@OZ1!=NT\#4D6FP&][0U\#'A5&[IQ@6A;R44K-"=) MJZ1?+SY$0693.^_2GIAVWF$0C&GU\6K-LHHW]__IHG\0,F0W?_[L#2KLV*64 M*X&.4 P1=U( 4IJ],4 \ ?O*,*!(@%HTG9H%:.LYYZC]PS09S:ZMF<,',*D" M8'7%VWZN@2$8:"0?T)[*,< +WUF'HU?0MVW[B":?8R 8VH*G!>A^7,@ANF=N MAQA#;O&:@&3II;SM?PS%0DS0^@-E/T]0U:VB!05OUDY^ZMI>IR[@CD+0/R,C M/:"4+L'8/XE7-"4!J^9C\9X&,#"QRQJ?2U$%]/T'^C6:-SZ?INXJ 0/92YE@ MED:YF?'IO4O,1[-KLS&IVYJ 444H3VO/'8 /Z:M9W]QIZKDGU+ ?AEZNB30J M(E0FO696B)/C]TJN'OJ]6W;PT&84>CII]$C?O%4C_%F4>#"9.R_I,G J],^]:6PHDI+JQ\KNH:5SO;C"&?5QN4EB^I+J M'V\_$ 7O(JKRC<]HG5*6P&6D^#4-!AQJ_J MPN6;I3X>FA<)S>G2O2.WW-1O,1UF$&+"1)Y&CB8>N8_=PGP4%MU&5Q@:!5BA MK2)%[RE)20Q%96@Y^2W]-_-8W-#[..L%@#9/"T;T1S59Q MD@6_%0?7+0V3BA=$4K,TQ9+WH)XN;&NJ8G8@)#<:494DH')H[C*=T1B^ M%$ADP=QE@9=#K?E-68G)=>81U:D]T(NQ.%F2B< 7T;D7)+F?\.)N298M >JJ M-GS)70CENK*>BT2.+T@%9XVIMK @S=$3;9^'*),>]FD7#:NH6WN"DB3K"Z/\ M[%C,@*_(&F]10Y+CB>NSDY5&"C6 " MT((E*$(6,#%FZS"5]86*RCS<,E]*Y9B #FW[4LJSIEB;:;_LI2S1M%O<8-0+QX6W@KR;C="51J]NR)RZS>%3G/^W M8?@H4EF,9/M3(&P?4O+,"0_1=,?ZQNP!;*<+ ^\A"''JQ03#LKBZ/ )UWUG3=$Z;YL7 M=*\NU%X*=:="[[X)]TY?S(*6Q99)IHF0ZLNH2(<-1#X#F]9<.4WLH MB*A.X2$[>&U?",$9?TE_+G?#K3W]<(>N;6=J:\$H/&L:P M.GWKIA%E%B$3,FE+'\3ZBKPZ@*XV"IK(U9NG 5:078+7"_(;?T,7"-.R;'F.5.]_H73'> M3."*\>9%7#'>-$4M&HCA*\9Y$'EDA;B[8H@8F,X50\"EY!5C4?8P[2N&!!XD MKAA]TV7BBE&GCI9,NF7TQ)2A;M]I0)%#*77.5)+G/185Q/3"E#UKLD[B!?F& MKHIYG#KRY1L(+NALEIU_39<$/JEV_^3:E/^"J-_8WHKH9<*I2BG/IUK*T!>7 M]WP8@OIA+S6]QC34MWH:ZML):*AO7X2&^K9?0WVK7X"DT]?A@9Y #P_L;2\0 M!WWR="[+>G)A81;#,/5(=7BH*<]#Y_(\G+X\#R7D>3CX 9Q,'$XS6F7.^!MW MHVL7OK8U>=%U;DW^SO(A!44#=NAGWK-STR9/-NV'Z9T1ZJ2RZ4+J2'--'SE? MTT?37]-'$FOZ:.":IK ^#^-/5X0[\L_Z:3#R.7?X4W)S"^-TD^"1;$2#V;%^ MLQC*,0!#TMT^2Z#1>)DF6XW0B.1BWS&%G^9>961*]6/GJ &=4,B3.%U$9\]S M%DB1&]AK^_K9F/>>88A M?ROZ@ZK0G4.8G;_=V4CUQDA90'??W76^QOYC1Q+&;99YHL2D'7 M%"VK'MF&F 9WYS:"ZU=&NDE7RF'CBR2G@?P-+K(FM9:(2^0;QE*U'$R*0"_B MX#[QHG2!$_9RWPW>OX_[G9* -:'7LW5+DQ:; .;+O@H?#UY.#HKL/H\D^_@> MA((*S?I3J64.(XL@]-(T6&SS9_[*A-Q>5??QSJO_+*O2"LCJ)8/I6$XL88!E M6'$I>LY!WJS)NZNTT"1WM/_F[[RLD:_"V472('2:JHV1.=?5RINKKYLL@[/X M-/9QV7ZMZC$:#$KMW[Q,*A+;M\N]6U'NW)U;90KU=(X;0B5(TSC9@JNDKJ5' M%*&XR!LLKX\/HV 5O8-8A9T3BCZ%^_.\ZI?JXW&5;[JM;MO&LQ%T5,@>/KUZ M&.^:(5]IVH%?.;<#OYJ^'?A51_#0,#3?ZJZC]S0KT-%K*K+[)::)7;QH.ROR M LW",/=S)E>W1@C;]>)\G7FGG4=RD^7!#EWDQ6J0AVQI.*N 6DB@\A1D+R UI F.&R=\ M_(D6IZ'*+$'S5$I]M=[AP5G0Q,E]45V2]<>YXP]&"X> 29O5VQPU$7ZDU9Y$ MN.DR MYJF@4W]^@5G#J2[J'O#_8.OWW#,//M]V_V#@Y?5X6-,G1*4+1Z('>A M5P?Y)LJ^JW][R'Y[M$?@EJXQB_0)MTXA!HN^"31@VK03;U27]SJ%_?7B9R\A M-RKC 7%B6L;41'D,"AE23%Q:7[*=^OQ+R;,)J/XY&&]_N.\[7'J9TTM5[/9! MW;R(#O0]S)O^NZ/;"J %[1M\"R M9;/NHQEWY*IH:7N0*\VI,06J5/I/B-+P'F?+V+1GHQ1)4T:Y(0I6ERWE M>N>.?2!5I"O6FH"Y&) -.:]RZK.%?YV@+P$K<)5,]\/\JJIU(?X(BJRZ^8%#VF]5,/@521N?PM5 M8]! W5VGQ[L>%L R:'+SY2#^6YU+WBWCMI0;VY':TOL/$=[!D)VG=23?XHP> MQC=>?L_)#^39BH80CZFLB<@:!*:FSB;@#O1NH2W882C4W)RK;A+R!M6WOFG1 M33Q0=+XN=%^?7$P*4K:T.#G2[E0Y*?XTH,E5V=RI:TH(X.AL\M,T8/OD^2+> M8B\,?L/^.R^(:,G1L^=YN/$)87;!OE]ZT3U>K>/$2[87J[47)&-8=@PRY@#I MYK@'UT'>65Y'E]QH>KUI'2P$\^!J+A/#$(@'#="GWY2-I])8]E%V"6%'(3H3+SXN#B(L$6[Z;2D!<5%_J2BNLKQUO, M.%+9O9$8D8M$65P)U@[[)?-9BN1PR 9->TUIMYAT?/9,0T0W0;K,7\!.\8/I MVV$_/3?.$KU\]6D;;.&3'7HW*FWJ@9O*0&BB4V[6#-8LN4DPS1]Q6CQT%646 MJQ>N,9(,:S+A0+76XQ1T$6=-J_)@>:(Y5FPB]S1SGJQC"#;$]2:DITTW% #7OVUPQ2'6I(35'@23(6Q"HNG>!V3 MOFWNCAR2]N]=,FQ![Z(A]E@RS8ET;Z-:CQ1-)_Z=,IS)(' RL=1:K?W>S*E MU,&5I_9!4=$]?=C3XV38D4#/(GBF,4\N[ZLJPJF#DB5&KA=VW+AM7"_(/GZ% ML^L%31971>[1)]7R,+[^A'T:\D\^E *0?N\V]ZAAK((UB.L[:AX<.B@"SP%( M!T.C@N^PN=7/.IAMDHC:'=D-9[&)V/-F^3.-W9^]]R+O$?M%37C"EQ2L]7JV MJ_;I,PK[DY"^6*V)O#7ZLNBO\;NO\L00'CFG6:_T8D*[9=AW:*89A(5&QA[= MZ=3*5U7O^F>K=1AO,3XG \\7R67LR27)[.W$^D[;QQ'DU;NA43T$7+AH19UY MBV8H).VF<:"+1<4YT0638/+62^V+\1RGY&J=8AJJ3_;<4_R$PWA-/QS[(M)' M?B)WXAXV)53,I&C(SG6_;HK"8,X>3EQ[9^@B0WAUD9DWS=Q/Q=S&BSH](IG: M*M=6 !ERH/U0H3\')[8">Q)@;&249 E+. G*W.:1U)!NO84J3I7>&5P0N5Y4 M"2II"I,BY5F=+(I9+94 *->C_34BFQV(J"ZMPQ>F9 ,\'=)='VBHOO38*? M@GB3AMLR+VA"1'.043H;B($^N77BLLK&?0AO/U2KBK]W#$"R* Y(#^D;?[I]LG M=[,B.="[G16]'O8O:^"T$79@O;2$B)N>U;I_.(7U*BV4ZA3H';+I7,:"Q2K% MD&BI=H7@>+&:E\>!OD-,G6\+K-T]RH$L3]=6'G=ES@1%LY4*8KLX*)3%WCPV MU&9(\R:38_Y:$Y_"DT6A4T>GC3R'XA/HVOD.IR[ G5U/<2KU'3K&[LK3-F*0:C:(-IHG^9KSINY/BJE!-G.E=HW M?%.947/(C@(IF(X#/0MDIJ\JT!3V^%Z)@)M_NVYWT/%8>#X M)F5>& <&-9S*E2/3%@4O@UA;%-/0@!',W68N%TNJ_?P"CE+3#^?2BX#3?T-B)*/.*.,$@\J)Y0%.@DXECCFQ%G@_ 1IZZSE&474X >R U/TCZ]C2!)U M 4HYUJ [9L[U,CTX'8C5)-L$W<*P01#+#P-M);SA[2C,8"FKXY6[0/6J#%M"J+),1I%_1CYY\L(14DJ. MS*QUF(X['K"^:9HGY6#IMW#]O6-#A!TD]F@XIJ=_*BMSDR2D0?ZEA?R;=GE_ MV>NV;WA@G?<\_3;Z%&1+5"7G/F;)N?=/,0%AXOI8I!3F%M90/HE9E.DO$/$?N)T"^NY8??MM,+E5& HT#/WR+0P632R-:"[CD7%C,^-P C[_=DVX+JUG E%U3&C0 M**>EO#?_D#_\I3?>EO8Q?3U P/OG<%N'AP=[OM&Z1%750-=+Q@E<1S[?>X0R MV<5=EE.\Q4\XVKRLQ;W+^V>VN'>&U[.XY_&*IC@E+#CV?G*"5WNKFR>5R:YN MIG"\J#6=<_R9K60V*&#]_HR],%L6I3J*'/4\Y?:S6\DM;-I;O[4L=$O:=*][ MWVG>M[]S?M_^;OKW[>^:&!$.8TBYU"I+/2W&^I 1,-6O+/1=-=O6;RWDCR%[9*O(\Z^ MMDLF[V5SK,4DIF5= Q&R(^'\V -H!W"6$F83D_U3,$#1K@%_$9&[$CX-G@*B M2_BC;=$[9*P#"N($+:=0MW*J"36YH\;+\H"&L[_A,GJ6\3)*L^,<(L?O8152;ZDR0_0J^;"+1C, M30,7T7KC]LRQ"NOFP65/BOIK_A0GP1.3;\G;MB$^)CS#*U:&H@,G80FVH AA MBOPGAOQ5W8(<:"W@NU'A%<3;1*[L9&AG[8AI_H5Q57H^#=L[.9<+R F+%A&= MA*(C):=6H@UPF/I;4ZT2T5XOHC1+-KG2,_HE$"3H,.@;XDGB&)\>L.1ER[\) M"B?#B%'S^E.$_5E&*Y&.9M%LTK"],7&Y$&U,N\8IFJ\QS1#34B9CW.1(C6_9 MW!VTB:?.42\Z(!F'=G#UNWZ\6GL1K:O@)1C=+Y-X\[A$QW%&8YC1W0 M(*\R-CAJO2H^><0L7+A%]'9\YP9G*X7M))['5!W]ISAB'D_2EDX=?JU M=>3I,@C6IRMZ*DJN4],E+CJC@(M(=XV03_*WHD-7;N)#!5\9*77G4 ^JI2&T M806EBDC6MH!*H5.R*^O%I>3X@E)_5(;S16V!(/@+>=J:4^RI2;*"F\+LZ!LB MO"BEV$VI'TX50-B(*Q[?"4V/!QG7F8Z2$] R+:5#V8%0%3Y":+?.'^\ZA-8^\U*.%13N+F(R*03 MW?.6=,S2VOLW.*%E +S'<7$D)&S?/4V>.>BP9)^ALB6Z;0'..=QDY S#KW<^ M--TB=S;)=TF)#G\0&FX0F(OK'V0C1;477$I9U/)*$F7L#AZ5YE M*\A5?1I_@>@0 MZ]#02%_LC!\,T!AVUG:ER-8W_W'W;!Y!Z]?K?IY$_E0_M>\O3N C+T;!Q@Z- MVURP]/=2EUY>.]?!TM]//UCZ^Z:(A<-0WRZ [EYKRO.U59>^B=Q1,[8+"![P*YI0\58I=*?]?;Z ]_F=1_L#37EJA$. C[4)5J' M=2A.D*KR#R#XC>86\L;Y%O)F^EO(&XDMY(V1+<3(OB'<+!QL%=K[ [@G.-L0 ME'>!OJ5O1H%XJ[GZWSI?_6^GO_K?2JS^MT-6?^E*/V3Q]_5AU?.JAYE>G^,I MZ0*2PJFP(3-V[7=_SM5RM-@(,2WKQ@4A.[UV!5;;KJQ-7):T@RK9.3(^2 F7 M&VT(3LF0U!W5B[]J4".+#[!4V-$$;RX3/1C@7ZFJ(P!]YIQ?DJ,>!9.QR(T" M0[YGBRE9:#[T[28,.W^Z"@RO&RX)!P]]/#X &+-/G:?Q%,FF"29P8+I/?!9J MO8$EV2:0O0T Q7U,2]6OZG1MZ733M?%@(JP^-D@OO,)9'G=,@T;5*\X*NN3>,":-Y-. M8.J.;.N75_$_7]O\LW- M,,1ZB#E0%L4<*1YF*2^WK&O R0FX%5C7/R=:K^?YRSP-5MZ-8KZ/^R_<4,"Q M:J?V0X\5.81 5W7#"WW/XKY[N8-@9$UYUV').C.G"1VV82KH'"+NPK;N+V0$P4S="(6E%S1@[.Y1#QP(9"35\#'J'KY,!NP!> M2/KR-W/LGV[('E9E^9#"24\7MG$B9D<L5R>]W)3>>4$T\)3A M=N'NE.&QTW_*/))6TSQE1!+BG#+@\$T9C7:3HHQM->K0FT0FNUVNAADB)V$X M@@0KM!QQYT';+^XFB=:1O'_K9R\I3:R(8G. &[+N&[,/[V M+$%Q2C"KV=+FSQZ)M"F2K/'RJ/#W H0KL6URL87NSB,[ MKS$7CI>6%0/,1>N T*.H& []I7+6YR-[7UZAS[D@)5_Y=3)BC^YM4\59R Z^W29M4$KYX;;)!NR M6373,V-8DHP\\4X5SMW6T6C9OY]Q\+@D=^H9N=)[CT+5'DJQI-V[ M[=Q+NHQ*J/1WF]7*2X+?,%PLW'N(-QG*EKBH_[?]_>_>'!V^_D.**G;0S@W4 M09:WH5"ILST-FNT!KXMM] MO"5*RJ8H9'=<%F[!<'[X!Q17,&=_3-&7082VV$O2KURJ2+IX@>^^DO.I;=L3 M4J/O]33[.\VY7V3;MXEP'OG)(9S#I"S"_:(I(KUC$-INC=*Z^)!&-#1_ ZS5 MQD;9MV/!< MZ&F\._9PI1L,U-9Z;!K " "1:V@+LJU"]LQ]I2"*AF?FR6*$JO4< NY/-T'- M^AU4H#GY=$J'$U2B'AB@(96IV#Q'Q49)PW;V#RX7DNC ^=>3>H/:D14,DN90 M]2W959+BL780#@$7.TB7C?[4TSE(F*[108J+-(B@J%JY#/D#':ZJCJ6<.GC6 MZ(' %>A]-E<[MU['$B.Y<'NE%/M27PQ$N7YV'\ MZ6ZS7H>8^CMY83-/KYW\N&I<.'!>TF15RDQ=]X-HYXCVWC)3W^*0^=C=QUUK MM-MDMUKHX:>U59]7,S>2,N1K5,VS(F(_)Q2?D5[M[K47%]W2/%.XZ!B13707O2CDN/8Y +(!,#71 M/G22!SSO\1Q>ZX2C1;WKDQ*M5')V$7CI:@@E=+IP^WBJQ M*F%]I6%#F\PKD[\7W>6 O>$ UNUKK19<^*^UZA.IB_99E 4^[9WLMW7I@K/G M>;@A&M0Y&6I#"%W&9BOJ%6\8^V9XLFXO,,*VL-:E7RR L-RQT_8"< !_H_AI M+@9SLSDH;R=>X"3!_EU&%MIXR3KY5)RD*N;S CT48Q_C%2ORDE='R0+Z[ZH3 MQ'IQFR56*,%VBBIXZ-I:*.MK&8<^F?B\+C!-KCU^0F)YNK:?M:0Y@Q2$1OLB MH!CE_;#,0C(X=*0IJ$*AI1LHS=H ;_!*!^%3_-E+$H_;D("3]N7[E&HP/OL*K,W&ZSKE4/3CV4NQ3!0)'*=,@9I32 M(W.,/-[6GQ2FB=DG+_%SOBZB-$LVS%[!LM??+[WH>LVB#Z]B5F:/%=Y,@B@- MYF/4W;7/OYMH#?#(%W.\AW*EO.HFKYGM.$#$$;;;\2OH8W&;@,[4(($HJVP&-"-%]*('=.^3M,:FW5-J.D>- MWA'-G?N9[CH#5I"='4D7")H5V;4'0G;.G./.B"[2=(/]]KX#Y;T:C;K=I):C MC0-8X_D?]TI=/D\#Q"@T\@#95>?MH*E.C37JC-M>3/)ZRLZ>O>,+KM K(\7N;S'P/?PK<"X4+5*HDC!T,RWG MO4MHV]W"0,!J4NO1=I9F)>Y43RN9&Z5UQ&M)N$*O^GP-SO+ 5L/#[H*Y)8<1 M.7*RXD%Q%OD[O_D0!5E:&O8MI8(8@56G#R[&AR/Q)E-WEK\K(K;YI=TW&K?O M,Z.!$GC"&4<4DWOE>.LC4RR-%UPP(!X-6[AU@_V'>Z M>BVCUHZ1E".@ 3Y90[73-C<[>@+[XZF7X7,O2";U>JO)_8MY<]$;7T\2ZTK/ M92W1J;=%M&E^O>NN^!>UY(?!V7I&E]L'@-N?>#8B.^O> M?. M?#7&']NPM9X3<1O=8AFZG35N24;ZKACMRT1G2V+Z6L&0BWNS#D/6#^#!+,MD M562*<]X+US71_ MJFU:N3.1\]B \= WWG6UGGKC[Q@2>=-'&@LO WMA[,AC1O\'*P/G=Z!")V(I M'6)N:3F[V-Z[#7+NX%'1WNB4=_II>IDY1+32&C8T(&7IBS MF&@LRDL3#/]Z21Z?"B@SYB76*P5=![%25DTZT@Y!042S3Z52:\H((>M>U2:X M'GZ 23F>65] )J%3+11C$SZ:5:#O@#R/$\()S83_(M5.5?9?H.ZI.$39];O( MNU5105^B_JF);Z-*J(X$76BBE,\ 9[5_MP-EM(\'VR[:(X]'8[5^3EJI).*, M*:8RTAC+*[5OESA[7@=%K?.7>!*KLO\"3V+%(X6C7(KR\'26 MIA+7G;UH]W-5\)I1'M3;W3]$ M G4="J>P[T%>RX<3"QDP.+"7&U!G8OBR"@S\G,^2*&WI&_97+V%+FL2LCQ? M9PP3VC%^M_@)1QN<%W#)._XYR)8GFS2+5S@9*Y)/FJP#RZ,L;V 1%M;7Q& M *@U/W:L&HBEU 2,8(2:"#E.XH_L0*:U_X(TI8=Y 4/#,!%1LH\5 3< 8!H? MNMUN)$36Q$S?2#6!4Y;5/8^3]SAYQ,DM#NG6?!*GF>D=1DS+^@N0D!T /3/_ M*4CC9(L6N!D>YZ)FG8S@6I7K>H<[X/7C*B:7 #+CY+*0;V@LO9=A_ !$[.\Z M?$:@0'OZ-Z=0$0NGB1'!P#3W%[9;90QXY%I)57=RYN%H'N!T_/J&BL1MFXC5 MV!.=9WDG96G#NAO7 ;QZTF\B4F..]$VE.>;OO>?QH2DDY<*<*&((2AC-FB#2 MQCW29$37Q%7O< WDIZ(VN#BBT+U>5/2H92U*\3&.\"+(+"6F4N?$OC^./K,2 M5H@:JN@FB8D.1]3G:61@U@8)/P&5WN3I1E&>8W*1]<+90\HLRJT1 M05)P+8U*8K2:Q;+(AI-@+\6G./_O140?L/,WJ#",/]'L8@5=J:U"I3_K(=(* MS,'Z$VN)@@@]E6V15S9V5DQ&0XQU80W%6=&KKY1Y&2;7@4ORB=KAPV]I:\.! M60#+V)-OV;6.SD;HL-R*<,KKJ#IP;-KJ='N[:A&P>T[UD+:N,*MP)WF$.3_ MY,0+GV82LZ!=42J"-[066:63K;\WJWN3-%L#3S0'&YBR_#I'FMRD:&]TP&UM M++L39_MR9G*2VJQX5WCT9='F*[=J>(_LN(8G:&\:9G,Z6RPPS3"-*SJW!*&W MF XB" .&7DM&)PU67$1T#N!7PO!4==HT0=%^';\^FT ,WP*E.8VZ/ELRY&9- M_6!#^MJV/C:\ DQP9/]-TP#7D(O.UW=?HZH%*KI@B\"QQXY![#37@JFIU#3F MR9!OZ2W5=]BTQ\<@5AP1R"8D]/_F MK!VUEV!&Y26@7XP15,.IV'[X'LPQ@.:R#?(W&&4QRD@SM%GG)< HQDE3AR\7QN!0Y^HU,I$Z>3F5 M*9>+J] X"6VB<.6E=QE/DCFLS9.UG W>_ @D%T.]OY=*/^F*O>C%3 4J%HLS MK6=D6.FO&3D!#'!95SF;3C%1P1)V.,W2%&=I]R7 H8HDPYWUYTG# X!>,*OE M535!,\YST\0U*05\Z:I7LG,\) 5690/N$*/7_,![($QE 4XM/4"H<>'T[4&) M58EGA[(_9F+*>V2'3J-/MQGEAD&%__*@/HE:WD==,BH>2'!KV_:S%#TY )">%2O40CU/3R-[I]'J-:3K@Z)&&\IYX2;)=Q E-K6':IJY" MV86U1($_*#(E)_IBL:)C@UE$RQ:UW3'& 5H.*0EU5GV'C1O-'&<.&-$I F7CJF) MUO4)Y#%T0S3PJ% ]YI0E.1.+9%?6O=SE^ +@6GR(?N^MUG] Y<<3TAF$\H(5 M"'@.M#,/[9+X"_8?R9EPGW@$K'.6G&OLS9='TG8HC@Q34(++^A/$R%?MUR8C"5Q((0LC)S94ZO;5SQRI=439LX&UAV]NLWJ7F,_>]%'>+?UL@18SUA)53=WZJ<@+M.63(CE\[6JBE<_+ M+J6+:!$G*[;A'F^+/X[O::7&A5-/*R56)3RM2KS>)/&"'(2Y(H?NEUZ&9@E& M[^.48CD,R*;Z81U'Z'B+LB5&)[&_8A^P6V-='X%:4.CMACH#3"5"7 MC?!1" J+G8-@!=A5&_ /G']OM0CJ^96(!JD M]E7@G1=$]!"_CNX\>O+-YO-X0R['MWB.@R?JBFP8-A($K;O&]?,$EO5)L!<& MOV$_]_\DBE,4TYC9JJ%;Y4A>NDV@24Z'KCM:Y4G*W%^4K,% 4\M1>GPNH,VF M\A#>]?:Q?AJ))[XZD 3#TQ5Y]XP[TE0RCIPK&4?35S*.))2,HZ'U>CP*V5J$]DK8N'<*C:>6]^W039]CW. MEK%?>R_<%H=H??"D+"< MO,QJF=(>]PF-%?E;V:?+%TIM5+1SJ^K,VH"(9Z+ ;U8;]KATBM?D&A[4QMLSI__+0-\4\L"(N<9K^ M@!I$D-^@DELX&]V[7!.FT=5<*D9G6=/?C8H"XSK^D:[(RA?F0^0'*;L>T^ N MZDQ.^-D87RIZ/+C17K1X%2P#M*91"42%SH^%LKU357H0)IH UY\L_==_;I3A M+$GH&4P7R_&V_J0HQSJCD;ZY G81D1ODAGG0Y'ENR-E]O6:."C^1\PL3W>P& M)T'LF[X(VF+;@1YE:VQ0W,5F]8 3JG#=DL^3@":X0WD0+Z.2[J&\'[?75\NX M;=V&;0IH2&X;73X+;L[C9(&#;$-P/K5E+.#0S3DWPDB ]7FV6H?Q%I,K4=X2 M+?*FV-]#]=IEQ%P9F"T T,AZ[)E[^X=JP=#9\SI(<@?4B2X\'HK%@V ;&S MG5,]L?!/TZC'K"%38!QR7(D;%*"%QYLTB.CSXOS739 &S$3S'E,+ MEVDCI"X;MI,LZ#(*0+-L@$[BU4,0Y2K;/_(F_W0=@S(4&^UXM0'SIGZ9*"J? MUXY3/P7S(*)N@C'Y^"1.UCP8@]7N^_NQG?U>@J?^S&>T[DC1%K'&B+;^VCD M5:77J'4O-RN:F^5[[-$@^+S_]89MP*SH&TY6HVR+$@2M!T7U\P1&O+#=C7[' M19B#'4Y>H,V]3'(&!MPZ=BG<),$<_Q333#0A\W6V@#4^3?M9^:3X@LP@U6== MQ$T ;D*QBA 'SX&AG>TV2#^>)QB7+LG4Z&<%=0+"[J$',P=>8]./^[0%*INP MNO%3W?[ZI2X"9<_L&#YS3ZD:B2/?&C(%A-TC$V8.\F H&J"R13I54/8+7.9L M!B;&$"B9>P/;E*U L4/./0!W61)6@&'?5OE=F(Y*KZ/G_YKZD6$6$.4MR0_SWF;ENI/[";;$'(BQ0N6*ODV@\'NQGK.] MER4IS!0M4=G4]2U*369<^,"3H>5GT^SZQV<:LZD+G'9KEXI)BQ,IG!0MW%YZ MY.3!!45WQ$/5DO=>2B9\'GK:>.CVX.[$Z? BA8I&J^D]NH$"X@*$/P$&#IV_ M)=Y''.G>99J-W:&CR8;,+@7V-V1VP "6?K8/[.6VDK'KOM'1I" M=EB1P@1M@UBCB9TB@%RXN. -W(3)XYX<3FN/^S(J=<%MMG:I6;0XD;S:LA83 MPP17'L"5=G?$0S6+N[4WQW_7A$*KL;L3H\F&% SR!M,[,7C"X.*@,V(#)\:I MEWD/23#_J'MD=#IP>DW=Y48*&'6CJ1E%(>EPX<$=^^ +*:UL$B>^+CI:K5T> M&RU.Y&"1MYC8L<&5!Q\/G1$/MI,O$R\-8ET5HM7:J0K1Y$1.A;2XL3.@_M' M.34Q5GA2F!HME?;6PPLONB!(I6GZ<'IY>5)#6 %:,OW8WGTD>(*\;UE+5#=% MI"UJ[$X3N \I2*Z.!I2<$<,J!L'M0SQ<4 <:DG)W9HPHGP.]M3Y;87(-IOU' M\1,K]G8;/\19,$^UEKQ"=Y;MY?*<00E9B@Y0W0,JNQ!O [91IB[3"FR*LZ1K M:Z>'5:/0TRP[]X*$)5XNCK ;FFT[5GFG4^S2ZH5)C3!S5"=TB.*- MK3(6.I)>TG0>ASQ0#(X:$E&R'S DX 9 T8^;F :HK6E@34HM21Y+1(=67O(1 M9RGZDO6!#K^:1B21A&";041]\Z$9F<;K]L@:O(XF!:\C(;SN@L+MA4UWS,CNNK()HE8 MP1;2[7GPS$JWC*.-P(1L)R&$60&P535@@%H432:B=O0*L'7JB8>N;JA)D^Q? M[X,H6&T44KB11@W(D)]JN'3[L_A@VB$.[37Y-\Y==\#)IR+G#T;C 8-UY#V; M%7&K/]LB;A('CY/GZ8B8-_F5B#N#&9 XK^%><8H?LCL\WR0LB_(H1T(?-=OG M0@\_0FMM[F^S3HH,U2AEF7HF<4)("K5Y3,C,A'Z)BI\]6MMJ'#6VW;=-)RXN M!P!FBF]2E,5H33A8DLL#5517<00BQXV6RI55$RK=X1J_+4C8+CI<\*P5Q4?3 M6)7J$WLP8,G5!6A9"K%1EAZ?ANU-G,L%G-F^+,N;KSJ/E>7]7].X( IEUD0* M/&1]P)0E&L>#"X^"]6S,'":$Z9=?P(XMD%RK,A4P$IR3_X_F M@:?BJP^UM>Z##3 "%?TIOD;5YQ/PA>N10UWY1S!4+SBX^!']\L MO63E*2 ;&S70PAB S1@T\]1_CW*&SC?!Z2$4<% .&)]OYTT#@.?EJ)1\]?9 M;>8B"&.'!_C65WWHWN\0GO&F0PYO9*I+G9H>-73P@Z0[CL#?O;0_13#N LX\T$$DIX#IZP(151 MDR!W[;^(R$5I0\G19/NR@%6J-2@@-<)AQH.G#"]@%A'8_?KR6T@ P $&'?TLJ2]=?=C4@#/_"2[9U'>V87Z1'V%)B.'4VIEP_(?<_+@9+7+'"K/4G+K%5S M3SA@7?>PO! X*V%/MR5:PYYE33 /'!$E*XJ2!".@+D1;H*H)*MNX58H49-@$ M4M_X=5UW2LM-?QJJB[SE>:@X+T.S_:0G\6KM1=MSC&^\P*<:6X+G6;B5LB+*].,N Q#( M$Z1$X3#$"5J3;R>1=;!7-IP<0.(Q:QY^?"L"!YJF7RVEZ=I^^);F3'OS'"DM*'CJZ6"C%NV"LD9T;5:L!J-#UZ*?0IN'*7Y#99ZJ#VR2^WQ MMO[DQMNRNPIUICI[7@<)^YALMT'LFP:H,;YW4/-MB+: MPP^D?M)617(*M*#MT)>CS&-C,^@ M6PYP->8VM'T7YC$!O35YS^@!1YA\B];5QRXKPXFFOKKY@B/4O.K2"(S: M@L M#W^V6&"6U&6TZZX:;0>JH!*# \QV3O8=+#J=$99UX91 K2Q#KU+PF+'?<_RIRO/LJPGZ;EJO*/X\3]NLQWO!,LN?B1=KP&/HV;:*DIJPE>R3)._G* MM6HZ%LXZ+WRF)WK0PAI%U:@[=@5FD>YPTLA[P4RM.1@1*P31?+:K_^;V :\K MJ ZFVCJ#91-XFP.>?5N098Q(P$LDYW[RLS_ >-TVE#3W*B3[-: ,&?JS1FT%#"^#< MF^,9>V48%=D-,M8-WA G(!"#:!ZLO9#S^N(>?UUYP<#:&>H ^W2C.H^7T22/ MVU,O,ZW. $3LF]KXC$CN6ZNB"?(=.\6+9<;W2>Z,5]L991V3:^MEX#T$(4L) M.IO/DPWV2[NP\18?&I5"/D0) M]L+@-^R_\X+H,D[-YUKL(6??O-3'$@"F^D,4DJ^U,8J M\\DU;ISL4G"0/:'#A-S.XSP3&BB>MAV2/[P!*C7K9):F.+M8K;T@8>\MY!Q[ M-*Y'BRC9WV,$W$"(J;Y#\_Q#UP\?$K)KHJ=OR)I;RR4F7>+K-7/]CQY9!==[ MG*RN%R=QE"7>W+0M6X*@]8VGGR=1\5Y$^E\YWH+DQ=BNURLU[@$;%.MR%OFW MS$7U[)DZ*YF^9?%IV [XYW(!VB')-H3S3U+GR!%(J%/,>L-T4CW"T MJY--0F>) /:*C"+_P3"B^JC9WH)Z^!%M1L5S@MNW,DGI-=$D,V3][8EW/M[B M%;G1-4]+"PH2AZ@+B[4<:V#]<%8\?%64C2X0EZ*0HT--1(."9=VG10&SHFVQ MOL>K=9QXR3://VS:+PW#3T3)_D5/P(UZ)>*],ER II.EF1?Y!,@V8-8D-Q&L-5@"/>3X((OKEE!\RE3 QA%S+^)V)T81 M=LP&?[T@,T>?^. W..#!A-_2EL(%LP 54"N^S7T%FM$BTWE(ZY=(]78"#]U\ MW,)E0$#GYUD)V4K#9 1C9!#4X<"VAJ_!(^0_D+&BC>PU=TH>Y\3-;*C":I8F]#IIT,=-FP#5Y= M1L&\KJ09V5#S=JZM^4/!T/).&#)1^GBN%!GF@M-80?D_4[: S(=Y2I-UX#,C MRYOP+D*_4C[X'<%8%0--V"I-EFZT<=U7$3G6O/^83G?60\P!(,4 M1VB3$V8KBT[_^'61=4NV4P)/HA6Q5#U1HUJ&Z2-;2,J%84_$$ "J*YQ5AV_A M^85]QY=;&1$VT=0[;+TJ3K/'QP0_$OV:]GH.)[$#[K:"YE8ON# ?4&!7V0#- M20NTP% *6MNWVGZ!5%?;GD'KYW4+O32]7OSLT20=V75R&SPNLZL-S:Q'=K+* M;^S$"T/L'V^+[]+B0],;T%!N7.Q1 WF6\G(N0SH^%8TG=5B:05#K-#4PI697 MQ-DS66]!$7I2_;&B:%S!T^)A,NCOXQ3 ?-FLB%R:YDUD$#QZ02XU<\;"=WV\ M6F?E]<=2F0*8JO.07H Q"4NE>WU"4\2B"%_1= SPA3FE)=YQY*<[]W*BUY@& MGH"2@_@#F!O0 \;'>$4P-F^FE'6T[TF(K06FGM$.*+=RBA?>)LPNX^B1>F?0 M7XV62@>FY62W MD1("A?Q+M>>8ZVIE[9[6Y(XA&;V(;&VG0<(*0D#4:*L]W$ M+S^;S)8BW$ &Y9;([T@G'N&%WA6D[!R[;6P7X=JA+S:>SLO/')HQ@$FN;!>\ M =']_X__9W\?_>/G]S]]]\]__'V^WCS_$GWWUO_M]=/C+]OHP^GFT[O7R=O7 M?SOZ]X?[;1J^?IK_=A#^-?LFN\-__>WUJX_/A_/+[."_S\^/[O[VS=/S\7[\L/[K@Q__]MUOZV_??'?R_4-X]?C^[ZM?;HXW__7^U_CN MYMU?3N,?[X[?/5[X1XNW)W_'O[PZ^>W'[Y]O\69U''YZM]PFGX(WV^71WOUX[O' ML[^\/_MXC.\?YM]]_/3NX>H2_RU^<[G-_O[-QU=OLN3[;^Z>@L/_(E3^'MQ= M_=>_,_^;:/'KSN;(<0)L)R.-UOZJDE- MQ[19<5P"50X=/8&))=A^\A(,?FBJC%N\KA)Q,#*598:M\]DF6\8)#3&]CX]Q M_;'QS-2#>+'N9#"$6]A&2$M9HZ3^LG#RF38(#&'&61$:+71#L:997!:^LX1/:G(?#I!_PTI.GGW_&"UN);\=* M/P.1L:XD0)S .6KSC%J2OC*._+U$(MSUYP)'/T!+N*O/[IV^JXZ)(>!.\Q MV0']4:Q^4B2=H@M@"G+Q+VOOTDH]TZG:KB)9$&JBF= '7<-#L&V\IN%R*+6)T7802$\:>;4 ^ <*V_J N^Z_DE/C.;#QW&W-%6S6,%/,76Y+C/Y MI&6]*L, U63"6:U=-3X!W.9?HW7\"2D6ARI+FY8O MTRE+.72_]*)K]K25_D38I!G.\XR<]W'FA>=>D(P1C.5H$$YN\$Z&"I4>?PZR)2W20S:G M\1S?%=FP?1'0912\A);=%9ZF12S&)]H4AUUSLAL%;2A*^+[U&C.H?ZG8(V59#+L6#_HJ'#IBZ\16?)!("NA!(!R.7G4+?:]WAY7QPG>I'*[-)PU<\- MPSG.W.LE@G0MIO*S[$!MG%2* !'GFU-?.L6=[8>[T;C?9@3)%07CU<3+V6H= MQEN,[W#R%,PQ7VF]BEG &_:9?IHRC;/Y=VKQNXJS7S M+Q,_1O0MS##DQN/3 MNCEDM*$(4J:7G] R(%4?96Y1\.76Q6(8'9#-]32N*(9DJ S9W['/9VF<;5V2 MJ OKAQQK(M],], <GMS)=$#11JS5)>ADC M=CM.Z5JH$LK&:7KB)A:I"L&Q4;=2=,-S].AV*7W*(@QT)V9Y%_23H,#>^O MVFS8S]6HQZ@H#!IY$5$7:/GU+KB=E]$>!H]V0.* J1M2NVV'+/G'"?DYR%HD MQZB_I43:04BL/'?0P[+WC.:L2;X)EVU<1_&K2UP(U+Z)&6 Y.%LL,$WUB//Z M8832+8$^M4Q$\R ,F*92D4_K3%:F[76Z;-C>?W49A7S2*\\=ZD.G&J[0Z'1LIP-F;8!SJ#>.LB\\$,4,%5FE*L9GX9M7'*Y$"39F^??3Z/< MCU!,+6]-<)3Z&#E[GF-Z_+.>36]KK;Y=W,E;'("9F^@W$\@QP15%:QOIC&: M[U)(;4>YT;MU@TJ8/N6^D["I9?>9ZB^1+ MI D6SK"&!*KD6VJ^QY;XVN;_/]:F)T?3@?NC#%^097@B1ZR2/%LNDM*#U_2% M.Z',TX+6='N[#=*/N?6"_LNTB4% R4DL*<0-'#Q:MV!'7SLEIINHT3[A[82) M"L>L":'W7O(1%YI@F1<[1ZAA! D(V=;[858 ]-0-4-W"J66T7VQ-[/0,>$AI M)?I6EVUO0H]5**:18&NZYXU[VDF3=5):28XW,$5,WIQIZU5;IUA3%?).(CGY MV1A0X0:3\=!")Z?X"8Y$ M'4C-@RK@\DHJU<7Q/$[*!/L9?Z>#*N&(N["=,%;,#E04IVJ$%G&"RF:NE'4% MT=0UK>,/FD=#LW),5)4+GC#=%L=1MW0XL)[34IU'T(FH]CIN]N7\ MZJB/@_[(_/Z)TE?LJO#\]RQ=$JZ/['$U.WFZML$JS1GDO4ES3[ .4"XXM(_N MEG&2[=.\].@J+KS@FFF.Z"^=JG[*,&BB5FW&U+%:^(NNXS3(4AJ)?!*24Y_L MYL=)_!$G0J""7L6RO5FM6"?-%IBX/V_/ M?1O.@!/; N7'H,*\JNX26L,B': MCZ*7.$UQ7K(X'7??$U&R;U\3< ,@+/_6K4%-0EK-[:EOD-KQ[$\XVN BLI+E MQAH5.?WTW'AP]' %WD-9.]=ZF[00V[=.F3%K;T:MS)5CH0D@8G\+XC,".6&7 MF6_O6MD@7:B(1JME^B1'&^DN MW,[\>$W32U3VL[N,7%UI1(C.I4N]5VL[C1Y_H&Z3]X.\O"/DU2;4M.S*81DN M;>E6US*]F=*W4EWA3PTWKB2.R#_GS,Z0VC!6*9-WH8FK,@EYZ+/P&>HY$>%/ M3>2N6UVB*,[0%F"'7QT7*9U9D_O6CY?(ZO%P*2M#A1L;HNHG.6D^XN4-E"U0U0?_(&_W3)>SZ15*!J&?8 MVI#(^TB7P;K*0Z\&"K@#ZSE$1-P(P%&W054C'CPN=8_Y*9@' M49!MW\?D@Y,X62M@ VIK'18 (U 5BN)KQ#Y']/NO)[%9],BB0H)HN%H@R!]: M'\F&<[_$B;?&FRR8IQ?1O+XX*\!"OC>KQXHT6\*B.[0]:G:P1[:4^=>H[H0# M)=M 4I9G!2VU2=([DVH:C0=^^KZOA3%^'XZ0Q66F'T^[C@Z3V(TDQ<2!#CP+ MQA]/")V'>)AH#L2RF3=D$_%E\QE(YD#7Z62V(K>8N1==1%'\Y%'/J]OX(::; MQN7EB=;QH=:C=0=1%>X@?]&B#U1W@LI>]A#I1WR:.-@+M*1<.Y )MJ G!J?^O40VZCIET@%D9Y1ZRD:=P1V.+UN MEQ)4@(2HO3TW@#Y6P)!1V@)=HZI-[A(P@?-+0BX5,/H&KO'PV^CW9B V^.V= M8(/+BA@;-Y/%AE N.]B !ZZ+C5OLX]4Z#RY]7"J9RX"FEA'!YP)\BRT_1OG7 MTU YQ$)HO+."0QVV-9R"Q6B5=XG>KJP;S.3X$N\>IZUK:_].X@!#:I+D M9D?+W%;T?V@08;U]V?43D>2J!V#[AZH0J51@4-\7AU+L9WK; M( SM#'&,?ME,8N5W)[5>W3OC,%72EV5:O;W[P).EZ;J .[2L.S0+V>DO$IB? M$'G1+Z>K7TF4@G*!G G0U6__&J?+C7>WI+GOM@K[ J^=7;6"PP$ A?Q+5'PZ MB?<4P;17.P43*#YO9,.;A+;1)XHZ M?X!HO .*?81>FEXOF.Y*2'B!Z<3]' (CF%%#P:[1Y0#R]*$?4K6DL%OE'SN] MCL#B:27:Y(]0^S[+*GG1X^J>)F T#(B=SDWO&B(DM$F+JKOE#_/L,Z?RYTNB ME6BI.Z8AB:#+WBZ#"%^0?YI.!\XA8'D[Z'+0#P3Z*6+?.M<]80EQ4=$>I/:. M0)-@9EN:RBN.2*^CG!1\&H8OKR)D!*GA5!*K9) X$@'U-,H M#.*S.>D\9!2S\]RQM++T-]+R&-AGNH;-H%E@MD20NW5=!":D*T M Z8:W9[BS O"]&Z^Q/XFQ/&B2N26QHMLB?.*D 5QWXO\R\!["$*F1G-T'#C& MRBA-&ZK/&(P+(K@:9-"7!:&O:-K @AC5KNNT@DS9)A113K+$O,^R"C:H=C0Q M!Q>UD0#7#!LS+B/]S;SL^9P&,.'+X(F&PV9$VO0)/"<^EH:H1-KF[4&%,4BE M'+@, #W4P8&@ Y#FV: \F0,N-:?X(;N(TBS94(WXREN-HY" 9&R"%&("3+/Y MD*'Z^SU$6W!4#DWBYBPARM8=NF\.-*,=NMW6L130J0JY $GV94W3E&1( M#4*-'J CT+I;D9H0:Y6/K)8E M;9\7JMLTEX!^#5>,1(2(@CSF2_AS_G561L@M(U2&J>W1\(;<) M4FYY@+'DHYE&=R2^QKKAC\ZNQ;-G[+$87K;.M2?;D+6P?$UI;>TK[!@G)8^" M.^.$[&62Y32N[Y)U!]QCR+VA CP^H.$;,4^<>.L@\\+@-X9..F=9<6$=:QM7 MHVW>75#.?B'!FQ(&>R^C3BT;"BC@FSIDITO7;[6F5&3@3&F"F_0R]B*Z(9\' MD1?-R69+\S('3W2)C&MJ4^/"%8B5N)2 <]G?'DMC19/9T#Z9WE#UBNINN_NL M4Y!K(8RG:=@?M:3? M5T-1/$U:,0Q5C_&B6/)>F-_KVMX0L"<%[VLO*=GVO:SZ4L%%R#I7EAX&W8RN M?Q511XJ2E=)_8M=MHM\1"6I)6"OM*S[RLF:+*;@DN5H"M=.2$T!,?K]0>\1U MPYF5APUWXYORSN'<".M^03C907B&VF$:\A7.3G$2Y,E2&2,E$UN./9D9D#]$ M\4.*$Z:O,W,]+;Y)AAT&N5EYS ?2L=AU\=XRTEAZ]PURY<09JDGG&P#ZLJ+^ M5;WN::J^D@/$6-A#328*YX,V&U,(.[,%<.Z]84S)&G"(,,_>Z.^L8[+LZ X^ MXI!D?+=W%8=L2$"QDL\BG MD7-K]GPWED^=#$6[BTZ"(U$Y6N;)NPE9T15=315$.W M9**X)5:T4D$U>[-D*MHA*XBN#M(LF)--M.G"XA@8@ 3*/%"[X])TV*H?H& D MC?KLV4/6U3NGF"T 266C/<2:L:MXU7!B3Y=RXN:_54I,CO%3;BS55(*@3<>D M?G;TL,=3\*9TR@EU,\E)T4UO>4DV?8Y=YVZS6GE)\!O^<4/(!AE3""^B19RL MF%KG/<2;+%MBFKS B[9IE1XK[T_^J69,^A8,(F./ =+HV!>@8;2BC)JD48,V M8L19N&M!_O>_>W-T^/H/:3-56TYE F\L%E!:V4+'EJ9>O-HX7*D]D8S-@QU] MQ\909"+KC"[1V4.:)=X\SW1) 1UZFG4/5U$)EOSY[7N.(W+OCDTV2D",\ MKVE>L!!'PX]-!2KN%YL\LWJG(/LS*@B@+$8%"9330#41MY'19F'3MT 49]WV M$C!R(BE2LA:7;81=B;,E9,C'-?+G!?+7.?+_?WOOVALWDB2*_I4$%AC80+FW M[9Z9GL%\TL/JHWML24K[*H)%C M\S[=TRRIZ7I9'$V1&C]=[/,P8 1"9 HB//5']P<=^U=!PF/ M>\6CDQWE)G= GL&%;5^A3SB,:7/.5L3W8_>D'7K8)=ID>N5UNDZS'1B1VI8/ M)ZM=Z)PN:!T>25 MY1E(PF$NF(B[RG9KL+LOOQ;BE^0SK9^+]=QJ*X[>1'BPPSA23P_K-/D/ M[W'@FB[H/>M:C<O M[-OS6U*625[?EO?IT_-I>FO89@JZY2P+<75EDF-(41(^:A8M-SQ8B'1J,J)_ MS(UTBJ?:,E' %]F\BO%[:!:%#-W\0&P<:84=/.+0/VB&Q3!V'IVBI(LPQY:$U>!_?IQAZZ_TZ' MVVP3#L?JB7TF#EL?_ZUH5Q[\E37._=V\K28,?)S<_*#)CO?V9_0[.VBN+76L MHV4E?J07$UE3T'?2.O]W\CK:< CW)AK.)Z[Q_7WW\VCN*21+QTG$(K=P=[-!P'SGFZ+$M(NM#"H\[W\ MXXG;NGFO((IWTWMY/D*,^)PTP/0@/>[?5%_,*S][]"8Q-(P;1JS'M&%MFW1&-MPQ7.[L1U_2C-^ 4 M#O/@B"D%T1:!T7("2HW:) M8X(@3ZY['8;-U?:),,4?!:YJXLC$ ^=IN^;V:\ZDQ>=T>[1MTH<8;%_T M)C9LA.:K.92V,5!?<1W#:&*<[6WYE.2RC0C3"BYIM2I3+NL7F_-=Q>Z?"HIV M0O'ZO+ZDKS0KMD+F$VJ"O['I.#,%"Q@_RG)->TV#S15<#3J(90H^_YN8@>A3 M:$IO_,#RH^Z@1F<]'ODC'8QQ9J/CS18R4/UHJS[5.<&%P^_MA)@M.\=EP+1X M 5Y/85]L'M*G/-VD*ZA")/J?,%GVKLC255L7>H1K8CS8@ 4+QJ_.:/KA@+@N MWH(B+2RB@-GN_.#&R\D\;VV2TR@XI=K J*E&6ONG@0[7YWW2^HZZ5[$;>-;[ MU6)'GT[-B4+(U=W#V8JI>%4*=_KH2]0R/)0OR;P$4PGWNP>BC;!<>\$[,3B9 MT;9+L&,]+5( !3KNOG* "/B"VE4C"R4IA6Z<*I(_XK,6PJ[0F$6K,+'(6?#C8[5OL0'UB@-)S4=;04U=KJ3M> MG'PC9+3'@YQY-5K43C0XM#^EXK^"=M<(U/$M;5CZYA MW%:*;JSPXUK'=65&^\@"9DW+BG[RO=-/DW M*>EY4M$U%&"@><4]-6>0LODD.FZ?[]MO9&DBGF/"_Q_H;^Q"A\X.)RLI=)(E MAFP*<@H$3)6+8 "!$5B02!1)_73[JROGGXC&$ZY^"(!9IC7(K=?Y.GU-U[LD M^RVMGWF51*C.^YQNE\5'*.Z^/UKTTM@90YR ">LR;&P.!1P[+9SH@7 3>:QB MI*809OH]G_!P8GA 8(/?;I;L9%3)BAMU3W)KNR<,>@<[EV,RA21ZMLXG>AKM M8CP!C2#")JU$PT#B].ZMO)382IYA\!>9E\FQ!>:!H;,GK6L ;[ MQN"?S\QFZ&!$8WZQ(3PI]G0(<)RASS8^G+79LHJ1>V$FICH/MECV!/;F3'IT MN C.'F/PB3S0\C4%9];M1OJUDNPZK^IR)\K5,W 5_J>3O%%'75I H>F8ZS;% M>*D!1!LQ"\WP%/M)?RF/3MR)0:?W]&F7P1_W$UQZZ-"0GCML 48/B/HX?DB] MG>B:!\.(WW0O6@_D6&>9<7@XGYAI"1Z,Q][,Z,RWN;"LN![]I*V+%;]7N-". M$;\-@+\J2EF-M*KIM_J<[;D_3,$86M+ IBA5959VS\-(\@A#(QY&.TX#GOB0 MX-AZIP]?RAU=7^6.3M5[J^8FBS#\TL:F/?H9_/W<."Y+2&GU?0 M9BV1<+E5JF4?*1AH B2%(3]$S!6>3!&$UP?1]LA/DWLK/#V5]"FI*>_N1ND= M+2$E,WDR'T",3]$M9D941EP MPH'T?)C0=*EL@]JO\XOSSVG.0T.,I\O&)/:*-8U"TP8L^Y$PP/$.TV0:^'/7 MCYJAWS'C<@]@<<6'QA1+'%CY,ZW'FM"OV\4SQ&-=YU=)6OZ:9#MZN_E4Y$]U M)\''R",^&([6A@TGKS">]XIG$-X!".T 1F66#Y)#EOF3)OB9\EF:^6B-8%L5 M^@J@/]XSTB<"](LOH2MSC M=V6:K])MDMWNZJIF*C23VMT:P:J! /_:*ABD:(%$-9^X,!PRS(LDP2])'F-3 M\55!HI.6E%9\3LH_: T_MTU738Q;/E-0XAKF*:CPKYS!U$O5,(&?YD0D9IZ]:Z8_"?F?[,-N3*PW@"@]G%J4:3K1P.YW-E,*1$ M8*87C@,.CJ!,Z%-Z2>D+75]"Q#7-UU6CPSS0DFVE6^'89#_=>63B^)W@-9^1 MK-64NL)8\;G(+3>'RG_5%KBW;0+W9F =."8=D?US;"9%4'4NY2J6 MR3=AD@(#L+*U05O;BZ0L]U=%R1OV7#%,RB0S;:E[RKA?\4"#M=H%=?)-V/$J M86)O[7C0,W<%T,'P)QHM;03\B&;92?1 ML9DJL9X(7J+93_.N5@+# MFJYW*W&CU/1E6Y10,6V=;MA RL%PJ_!6+)-?3)E<:.P;QX>8[@UCX4'4'?(I M31[3#-)]X*RO4CYF['V0*2#LURV4V3 .Q='&,@M1PDL.VZ)*ZPJRM"XRFC#% MX^F\+/Z@):^KMU^Z(@H4 /*502 K"8(\3LQY7("UT6Y_1L76QK\,M?[>I="4)J6JPK3[Z*.;AZ1K^2I(T; MV7;F@;OWD=WC8BIN4.&3@:P/LT75P8])I\$V.3X3HNVD])4V\<#W"==-&679 M#252!NBJ!!_JY8ZIJHU92<@@-[>?V'MS6S_3M\=UO523QH@N89+WC MS_>JM<<)P(1!YL]T ; )4[HHV6WGL)V.22S#ICH^/T(_*Z/Q$*N%]"?V'<-B MVC:2VT1DMD(,!X,4\0TZF J'[P^&J%-G;22:1M=)W+,%%PVZ<5&,*-/%1CV_N="0:)C)-=M>-C.@1\\!OPS)\H$63! MX>+N2KI-TK46\WE15,9 AH9K"@"YSHD$T2D?#4 BOLJ^>'IPST:@&9RX7Y4] M[4R9TQP&V:Z-OV$H.WV(:2ZN_64$MAZ,=% J_#.HEH@MC4PR0(M),I369 VZ#?M+ MDS/")+:+"\#1N]2FFVOBL8;1N_OOGQU(-L^4#"1Y('-/XA DNL>"&<\:!# ME"/9A*Y!3;TDWT.&!'O$H6(9V_QUMG?SR#@TZIEQKL[") =P!5'R N*R>?#*3/B=F@[8W_A M6NQ$Y5KYB/WA&[V"[8\8=_4!5''NC?$DCG)Y>-N[;-L C(@*#)%P2 .(:) ( M@(HJ1H_!&67R2(H%Y^HG6E72-\LVVVM:[*ILKXIWE.!BNUW5Q2,M/_SXX<.R ML.7S-GI1JNE%/%&0%(]9^B34(QXR M[/7@IAC",]'OD!CZ?2+SBCN^&Q32PT MT^:&*>;W$/=#U]S7(7[+]JO]_;_IA1NWL>/@;T04(;C\81+E92K5/$@*5?"- M<21B#7;+49D00>CZ!URR8!F!YK( M><5>?Q4>#15YV>VY*_?6X&(M\JON&*Z:"'*P@TA(@TCAT+QQXSE@E"]I8I@L MU-J6A2SBL&2L 9G.GIWOQ;--^@TL3QS0##AF0-'(+BM)(IZP9:%\O&Q#/5 DN>=XQ=-*J*LJ]IMEV):$VCXO)087,0;?*FRW0CNF@G_6F MY<0Q&;1H*;G9,.7ZUI,95JS)]I.("EM&Q7*I)7]A+R5 F7Y_3U3-30@CE#3+83W4* M0C?TSVM..R6[6L3"<_4TY?>#6-Z";&&!7(VA:HGD3?VSJ359\ M%?N'[PE-7FLOI(JLH")]NDFY "<"<6-RUH3VD(UV H5_59KU-!GXW#,M:BFT M5R)?K?$5T9BD52G@F4Q-R8EM^]3 \Q(YMVD4WA8N>E,M&F>+3E-JO Q-SW3U77^\9O(2^AG['_\5M.\LB:R=05S,"]3 M"0RK>$ 5P*@2_'C\!UR>2L+@)W?\0BUVD&,P^SO@-E85>2(5(PCQL)B\SO8R M(:O-V7J BN05^V9&:< -4EO6G) @PVAHM$!JZ!B[!6+8N'ID/,:/" M / US3)(YMTF>S[/+E]#ZF47GPU-((^U@O$0[2*&[C*A(,-8$<18D8H1GRT< M\L+9BPA@>-)5D:F8UA2"#LK8K^ 4WB-[?_H6BG-#6M9K#NOY__?\L??\K/:[ MF?'C-KQK T60]B6/H#&Q=V,&+4H(BPF1(&/?7Q;,$*XYZ1#G-JHH0_CY+%]? MTE>:%<+H*LJ\VTL*MM7ZBZH&U8O?'FORYOU;GC3([=.0&B%F@!.\@@!T=CU) MJXJ*]DI2*&C&Y+-U6JW ++Y7Q2_^R(NO&5TS;8[7.(%C_%QLF7P'AO5JQZ#J M7XC[9,<-Q;"$M<"(9W5P<-NR@%I%L)2*MYNBB_8O*UKQ:Z:FJ^<\_:\=^QO[ M%P/S"&$>',ACP6ZOA%3I4YYN&")P\[RPH:^B<263.L&2_RVM5+D.-9L$_P_X M^'/[/IEB^!7X@ U#1?Q M]\GK9=N 8\BN9Y&^6_$.UN*J%FZ+/R7;HOI'!:1?D/6.Q_.(BWP+-?4! M-G=^0+&)\DF4JFNP!GO;NMU[,/>_Z*JN%K"EY,,DKG/89KST0,/65?&RW=40 M,U1LZJ_LH8$2!$!>4D[!WK$IS(!%;PF.:BXW,2[:_4\13B*B*?>ROS\DK*"L, M-ELT#&+_E%5;=E7,F"?[/8#<9NYK(\)3@RU*5N1235+<3XXX><;M*5M@S(Y7 M/3P]6892)[P6B"U-M?:12Y2;:W28C8F1[YK60;(<'<+9*%*%/RT\>6PC9!R9 M@UUX3'B5$=$0!\7;/LI_0^S!V>##R1L)4/O=6_5\ MO@BPZCKGO:1^^--_?%O_ X@0F_,3R()L@_V>5@]T_4NH[<;54R)299: MV73V+^Z!7'8+W_,.D$YC,?MJQW1/+E1F105OK-0$VY)7\*]N&7KX#5J*/F(@ MT%'(--@I1R1^C%ND77Y;KA621: ,1"^;QF^_*("P"QJ0A,/D=3.&Z4BBA:K! MSQ!ODXRDAV5C3*)L:.F!.\#.V?J@E L\;:(< ?2D?.)ZSOF^_43&J9Y!-5^( M,:KW6B-A4;R-'099O>FFX-M^D)WU\1LM5ZDL0&[<3C G>81)N9JB%M;8K))V MA<-R651.84F+B/!$12;U<*?.@?7_E^UWD:]H3]UT[F=NRI5M8R.^JW.@Y-PV MM<[?"!+A5.09;@++ 17L&]9X3>O7\^->W+[RN^8&AXE)#A74A;>"\KGU-AS< MZ;".*1:(RAPV<$6Z#UI"+B0H$?N* MY:?X-&\,SK#Q!!CRKZ.;-S983GJE/!JV!F7[=YDL#)^)#'# M&RZ^Y"5-LO3?=/U+DN:W>3?RVAUU\,1&$4@Z3X0'HH4'84'LV0!G!%HA-CQ[ M[;@.^.A#FN!7<[LH:/(WGE]OH"GB6YUC.U^.Q6,7AJJ%76;*A->1>:#KY7MC M>.MG"E*A41L1Q20OWQ,- &D@$ Z""!B132I^B [ERS$$.H$MK8./Y-RN>O>4 M)-MA21_/['DU#EXY.9+PH:0=&^D>]$5-Y],XX_&W4"Z.@+*N0XWUAAU""8S7TRD:[/[T;PB,W:-J-.>@ M&,]_E!#X]:I@S*7K[FG:);_O:&U%%R4>BE^4&/W;<*5^=NMCQ6LGJT'/3!X2 M8]Y]^/'#3^_9_W[X5JW_PQ-*(*');S5 ,%L,V^UF("D1-78.,6H.5B&Q:#9" MA'R?#S6^_\HC,*#$%1,QX&);%O K&8/!45.952,\+>_X=$1?$CGK>EKT[^2Z M"%_8@LBEL2>&+XZ'RJOE@? -OUX0;8D+TBRR[RJ,_?)$XP_V?$7>+('UO-8V MYUG/HQVP(+)H!U*\([**9\0*8[B#!$>W2]K8(=I2*E5SO>9=\I),-)FY2+9I MG61AH%4K)6."/1GM]+<@CW11,K[P2$4I, 8M^_T\D M#'I]'T3DD +C;?X9C!@??@;)=OE,94\IE==WEF5"^N8R=\*37:'9T.9J6YU5 M4GN&D "0LOZLRU9HS?Z<:+,1R :7\RDSW9JP&94Z(U289E*03=FT[*^DF1CZ ME?*I$2$U?/W_4]!R(-F>D&.:.#Q%C;H2WHM$+F#YG-1G)?W,"^:SA;4U@V[S MLWMPO,')8 8\,BQ*AZ*V>&+]M#AFDD:TP 4/F#S$#41.:L)3"6$ M;\*.9CL;X=/-2N\[WMY"5,0CL22HD'9)'^LVXKFM[:+:BCB"=& X:<VN+*#JT?I\_X5?RDWBW-FJ3E_Y MS>UZ5,&0"Z"(@@4Z^QL QV3LMUI&8@N2_*Z 1K;ECZ<"QN.IM QR7C4GJT]] ML=;;BNE4JK=A"\C#+QTSXF,LX@;W]%C*A567A;BE;2U4'1;O,';R8JBZG36C MJBR"5<#[L9M!K 39_4V1RUIS)CKW,K 7C0:Q7Y!V=%3B.W'#^.%)D+!^RX&3 M1M,X++4W$-_5 AR2,8T_#E1PV<(#^] A,YT[\5+55&3*($_JU Q4YMXWW4>D M@<&M^QP*T<#$E@W]$49#:D:2*YAS6._%_C^3?7)3?+5'JFG=Z*]S D/8=?=U M( +$[$'?P6/PTCLP#NFJ.U,5W'!3G:.BE-/T*<='=D_X(8F*!B/(TWF/IAB5 M('*_5TEFHK7(!BF@*N"S'@\+#XPF,)QHXXTNTD"&O MMK0]=P@? Y84X1")*> 843'ZG\UX![9T]<0L;6^,DC"U<;.2-+5U>8F9 _S# M"OWZ0[TJ7J@J2^PEF< 7HR #XFJAIGPL+OG,9SCVPVO5.+(T>R&#<3OR&YH MH<((NZ&3EN&$A?N$;I+\.E_O()J55I\^7;0[T6XJ%$-).Y9T!O<5@^#!]F[, M!E*"-S5"Z@J]DD@BR1P:X,$#>KNK>7LAZ2Y:F<[BH$)@FZLN!0H-TH*[YU9Q M3^ HM+'#-X%NX<[=Q\V&PN&GXK9G+^]]PI/9&&'2+!6I W0%O> I[X*\+'?T MRY8MOV;?W=Q^,IW*!K!\"KE\ K!)%SA1T D#3Y8%@0G(ERU(_GP.PB:)&M9] M,(D&Q_M(1 ]FHIF87XYMBR9C&V 1!4P36&$+M/!( S#:_1TQ03^TD5M.OI>5 MD,VIHN(S(K^+*MOVUHRJ>!A:@16[,GWEO0P:=X:,N1""]G9G\2"HH;I_1QM- M^/#8QFD/#'&-SY,P0=D%2?@5I':S]SG_^ U\4;NT>H8E09GP1R.S8"!Y\TGE MO7>'@HP#@V-JY$[,,"9YDB/P705N#,AGHV4EJB*ZU$#QU8*=Y4#PY8CL7#$(3\*=!3,,^/CQQDJ,P*Q:EORB MW8LH?:Z,W-/:U@!&C5#9MBH"7@Z+>VS,Z&"L<2$?,C#]"DXKSYX0"Q&N6+J^ M*LI[RG3&BO(<"J-(W8Y7*K2" #D'1,(022=5Q*!Q7SP'TO,X H4TB6AA$$WD M;.M)-YTC;=1"CTQN1\:6YNQX80?*AQ)!93A5 H%G"U0\/0FZ,]QN5/K 1]Z7 MC6MF8GO!GXUNEJ9JA 9O0;31O %&]!B1B5AC'#V(@$%9?0?M+M.U],9?M$%B MAJ ?WF55?KT@%[TXN3B1/4,$#$$\)DP#2P_@3CC+U_ ?$&U>DXP[L.N+I"SW M3$&PYF-S9PS$6/$?M/$+:'&I0/23I2,PQ@M+C%$CR!/RO>H&@SOY<7&C3P MY=%=@.#14(# U#*$5SJ_3.JV89@QU^%8Y2EXW+=8S&+8BTOU,!&A.I'W23BJ M&X-^ O(\\./<1-!SB4S6QH B0J[4C3:EX$(T^,T;06D^(1%.[#".>Y(DC U3 M1@$+!]]U#AM%;, L*[Y"_7/NYX.TYF*59"9F*0 0!=V ( T,Z3WEJ>4 )IH# MS1O1@>(_DD1A#=#"HO>9,IEAW?KR[K4ZOJ(X[&5:;8M*K-%B\12 B%[O1<$B M/;>"@AA5-!Z+/G8HIY$P+)L-H5-BN9W0J8GA9PTD+?PL\N/LCS/&U;$4"ZH M]0O+7N=WHA<]7N1T3-W=%/+)15_[>[VCM@9N;J5X'=BCBM,D"@9]5]L 5O"U M%.5Z3#Z1'!([:M"(!?)(6O$->;H^)F4.Y455"/UEFNUJLS])?=YF#2R('!+3 M&F? GW ; A'\(>;"C'=T*_\3^;:5CP!4A;,%>.) -"Z^1@0\45T*[5PO(/*=E\P31-]H*6_!\JA*RDZ_=C2ELO2 <,T>!$E1_'X&MS3_C3*V#N M@A:LG=0B]HQI*QX/D/J

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�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�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

  •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ea0202511-10k_domin_htm.xml IDEA: XBRL DOCUMENT 0000012239 2023-01-01 2023-12-31 0000012239 2023-06-30 0000012239 2024-03-26 0000012239 2023-12-31 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-12-31 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2023-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2023-12-31 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-12-31 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-12-31 0000012239 srt:MinimumMember 2023-12-31 0000012239 srt:MaximumMember 2023-12-31 0000012239 domh:FPSMembershipInterestsMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-12-31 0000012239 domh:FPSMembershipInterestsMember 2023-12-31 0000012239 domh:FPSPurchaseAgreementMember 2023-12-31 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:VicinityMotorCorpMember 2021-10-25 2021-10-25 0000012239 domh:VicinityMotorCorpMember us-gaap:CommonStockMember 2021-10-25 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000012239 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0000012239 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000012239 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0000012239 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000012239 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0000012239 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000012239 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0000012239 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0000012239 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2023-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-12-31 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInUnusualMachinesMember 2023-12-31 0000012239 domh:InvestmentInUnusualMachinesMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-12-31 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-12-31 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-12-31 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-12-31 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-12-31 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-12-31 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-12-31 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-12-31 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-12-31 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-12-31 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2022-01-01 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2021-12-06 2021-12-06 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2021-12-06 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-10-20 2023-10-20 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-10-20 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowIncInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowIncInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-12-31 0000012239 domh:ConvergentInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:ConvergentInvestmentMember 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2022-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000012239 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000012239 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000012239 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000012239 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000012239 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000012239 domh:SeriesORedeemableConvertiblePreferredStockMember 2022-02-24 0000012239 domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-02-24 0000012239 domh:SeriesOPreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:SeriesOPreferredStockMember 2022-02-24 0000012239 us-gaap:PreferredStockMember 2022-02-24 0000012239 us-gaap:PreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:SeriesPPreferredStockMember 2022-02-24 0000012239 domh:SeriesPPreferredStockMember 2022-02-01 2022-02-24 0000012239 domh:RedemptionRightsMember 2023-06-30 0000012239 2023-01-01 2023-06-30 0000012239 domh:SeriesOPreferredStockMember 2023-06-30 0000012239 domh:SeriesPPreferredStockMember 2023-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 2022-01-21 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 2023-03-06 2023-03-06 0000012239 domh:SeriesDConvertiblePreferredStockMember 2023-12-31 0000012239 domh:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2022-12-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000012239 domh:BusinessCombinationMember 2023-12-31 0000012239 domh:SooYuMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember us-gaap:RestrictedStockUnitsRSUMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember 2023-06-27 2023-06-27 0000012239 domh:SooYuMember us-gaap:CommonStockMember 2023-12-19 2023-12-19 0000012239 domh:SooYuMember 2023-12-19 2023-12-19 0000012239 domh:JoshuaShipleyMember us-gaap:CommonStockMember 2023-12-19 2023-12-19 0000012239 domh:JoshuaShipleyMember 2023-12-19 2023-12-19 0000012239 srt:DirectorMember us-gaap:CommonStockMember 2023-12-31 0000012239 srt:DirectorMember us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-12-31 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2021-12-31 2021-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2023-12-31 0000012239 us-gaap:WarrantMember 2023-12-31 2023-12-31 0000012239 2021-12-31 2021-12-31 0000012239 us-gaap:OperatingIncomeLossMember 2023-01-01 2023-12-31 0000012239 domh:DominariSecuritiesMember 2023-12-31 0000012239 domh:DominariFinancialMember 2023-01-01 2023-12-31 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-12-31 0000012239 domh:ConsolidatedMember 2023-01-01 2023-12-31 0000012239 domh:DominariFinancialMember 2022-01-01 2022-12-31 0000012239 domh:LegacyAIkidoPharmaMember 2022-01-01 2022-12-31 0000012239 domh:ConsolidatedMember 2022-01-01 2022-12-31 0000012239 2023-10-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure 10-K true 2023-12-31 --12-31 2023 false 001-41845 DOMINARI HOLDINGS INC. DE 52-0849320 725 5th Avenue 22nd Floor New York NY 10022 (212) 393-4540 Common Stock ($0.0001 par value per share) DOMH NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 12149343 5934917 688 Marcum llp New York, NY 2833000 33174000 13547000 7130000 7687000 898000 564000 301000 13000 3177000 7474000 2000000 28142000 50656000 344000 1129000 1100000 24150000 23103000 3335000 919000 458000 458000 57558000 76236000 1036000 447000 51000 1260000 77000 421000 82000 22000 1607000 1789000 3028000 680000 4635000 2469000 0.0001 0.0001 50000000 50000000 5000000 5000000 3825 3825 3825 3825 0.0001 0.0001 5000000 5000000 834 834 834 834 0.0001 0.0001 0.0001 0.0001 100000000 100000000 5995065 5485096 5934917 5017079 262187000 262970000 60148 468017 501000 3322000 -208763000 -185881000 52923000 73767000 57558000 76236000 2039000 23838000 11683000 3000 830000 -6000 1833000 23835000 14346000 -21796000 -14346000 36000 64000 716000 687000 630000 -5952000 -3248000 -780000 2560000 -1086000 -7761000 -22882000 -22107000 4109000 -22882000 -26216000 -4.38 -4.91 5229477 5334075 4659 5275329 265633000 -264000 -163774000 101595000 11000 11000000 11000 11000000 -1504000 -1505000 1504000 1505000 -4109000 -4109000 -11000 -11000000 -11000 -11000000 468017 3058000 3058000 238244 1472000 1472000 22812 -5665 26000 26000 -22107000 -22107000 4659 5485096 262970000 468017 -3322000 -185881000 73767000 1179468 2977000 2977000 -25000 236630 939000 939000 644499 3760000 644499 -3760000 -22882000 -22882000 4659 5995065 262187000 60148 -501000 -208763000 52923000 -22882000 -22107000 359000 -188000 83000 13000 2621000 -793000 -61000 1833000 2977000 1472000 -1180000 -1405000 1049000 -4867000 -3248000 36000 406000 215000 -301000 301000 4137000 376000 66000 -1209000 580000 52000 -88000 31000 -99000 122000 600000 -22232000 -10597000 2000000 34125000 26798000 27574000 28658000 93000 427000 1112000 -3898000 1102000 107000 1833000 75000 15016000 1600000 -7170000 -14598000 17891000 26000 -22000000 939000 3058000 -939000 -7193000 -30341000 -32388000 33174000 65562000 2833000 33174000 686000 179000 143000 1497000 2147000 1439000 899000 3112000 2000000 1112000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. Organization and Description of Business and Recent Developments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Organization and Description of Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 9, 2022, Dominari entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank &amp; Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”).   Pursuant to the terms of the FPS Purchase Agreement, Dominari purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari.  The FPS Purchase Agreement provides for Dominari’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari of 20% of the FPS Membership Interests.   Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari of the remaining 80% of the Membership Interests. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse Stock Split </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.</span></p> 1 2000000 0.20 1400000 0.80 On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). 26000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. Liquidity and Capital Resources</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. Summary of Significant Accounting Policies</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation and Principles of Consolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company’s chief executive officer is the CODM. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Cash</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at four financial institutions in checking accounts. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2023 and 2022, the Company had no cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of highly liquid mutual funds and exchange-traded &amp; closed-end funds which are valued at quoted market prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property and Equipment</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounting for Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, <i>Derivatives and Hedging</i> (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based Compensation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for forfeitures as they occur. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair Value Option - Short-term Note and Convertible Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance in ASC 825, <i>Financial Instruments</i>, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deposits with clearing broker</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits with Dominari Securities’ clearing broker consisted of approximately $6.7 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842, <i>Leases </i>(“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 11 - <i>Leases</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenues under ASC 606 - <i>Revenue from Contracts with Customers </i>(“ASC 606”)<i>. </i>Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - <i>Revenue</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treasury Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury stock is recorded at cost and is presented as a reduction of stockholders’ equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>  </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income Taxes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company’s consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Long-term investments </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently adopted accounting standards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i> (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s consolidated financial statements from the implementation of ASU 2021-08.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effect of new accounting pronouncements not yet adopted</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2022, the FASB issued ASU 2022-03, <i>Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</i>, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03<i>. </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, the FASB issued ASU 2023-01, <i>Leases</i>, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effect of new accounting pronouncements to be adopted in future periods</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation and Principles of Consolidation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company’s chief executive officer is the CODM. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Cash</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at four financial institutions in checking accounts. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2023 and 2022, the Company had no cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable Securities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of highly liquid mutual funds and exchange-traded &amp; closed-end funds which are valued at quoted market prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property and Equipment</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounting for Warrants</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, <i>Derivatives and Hedging</i> (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based Compensation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for forfeitures as they occur. </span></p> P10Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair Value Option - Short-term Note and Convertible Note</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance in ASC 825, <i>Financial Instruments</i>, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deposits with clearing broker</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits with Dominari Securities’ clearing broker consisted of approximately $6.7 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of December 31, 2023.</span></p> 6700000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842, <i>Leases </i>(“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 11 - <i>Leases</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenues under ASC 606 - <i>Revenue from Contracts with Customers </i>(“ASC 606”)<i>. </i>Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - <i>Revenue</i>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treasury Stock</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury stock is recorded at cost and is presented as a reduction of stockholders’ equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>  </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income Taxes</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company’s consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.</p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Long-term investments </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently adopted accounting standards</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i> (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s consolidated financial statements from the implementation of ASU 2021-08.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effect of new accounting pronouncements not yet adopted</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2022, the FASB issued ASU 2022-03, <i>Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</i>, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03<i>. </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, the FASB issued ASU 2023-01, <i>Leases</i>, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effect of new accounting pronouncements to be adopted in future periods</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. FPS Acquisition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank &amp; Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.4 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consideration Transferred</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FPS Acquisition was accounted for as a business combination under ASC 805.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the FPS Purchase Agreement and subsequent amendments and side letters to the agreement 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the consolidated statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair Value of Net Assets Acquired</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 27,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Deposits with Clearing Broker-Dealer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,784</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Wealth management liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total net assets of FPS Acquisition</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 1 2000000 0.20 1400000 0.80 1 3400000 1000 300000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 27,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Deposits with Clearing Broker-Dealer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total assets acquired</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,784</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Wealth management liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total net assets of FPS Acquisition</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 92000 3550000 53000 89000 3784000 273000 25000 62000 360000 3424000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. Investments in Marketable Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Realized loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,180</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,405</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,867</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">762</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">630</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,952</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Realized loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,180</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,405</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,867</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">762</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">630</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,952</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 1180000 1405000 1049000 -4867000 762000 320000 630000 -5952000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. Short-term investments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s short-term investments as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Investment in Vicinity Motor Corp.</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Beginning balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of short-term investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investment in Vicinity Motor Corp. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 25, 2021, the Company entered into a warrant agreement with Vicinity Motor Corp. (“Vicinity”) that entitles the Company to purchase up to 246,399 shares of Vicinity common stock at $5.10 per share. The warrant expires on October 25, 2024. The fair value was determined using a Black-Scholes simulation. The Company recorded the fair value of the Vicinity warrant of approximately <span style="-sec-ix-hidden: hidden-fact-172">$0</span> and $13,000 in the consolidated balance sheet as of December 31, 2023 and 2022, respectively, reflecting the benefit received as part of its purchase of Vicinity common stock through its brokerage account. Gains or losses associated with changes in the fair value of investments in Vicinity warrants are recognized as change in fair value of investment on the consolidated statements of operations. During the year ended December 31, 2023, the Company recorded approximately $13,000 of change in fair value of investment for this investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Option term (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">      0.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s short-term investments as of December 31, 2023 and 2022 ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Investment in Vicinity Motor Corp.</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 13000 13000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Beginning balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of short-term investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13000 13000 246399 5.1 13000 13000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Option term (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">      0.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="text-align: left"> </td></tr> </table> 0.8 1.8 67.2 76.9 5.43 4.47 0 0 0.96 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. Long-Term Investments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in Kerna Health Inc</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kaya Now</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Tevva Motors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in ASP Isotopes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Unusual Machines</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Qxpress*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Masterclass*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kraken*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Epic Games*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Tesspay**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in SpaceX*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Databricks*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Discord*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Thrasio*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Automation Anywhere*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Investment in Anduril*</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,922</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">24,150</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,103</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the value of the long-term investments for the year ended December 31, 2023, is summarized as follows: ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments made in these companies are through both an SPV and direct investments.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Beginning balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Purchase of investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receiving shares in exchange of note receivable extension</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of long-term investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">793</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,150</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The following table presents the Company’s long-term investments as of December 31, 2023 and 2022 ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in Kerna Health Inc</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kaya Now</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Tevva Motors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,794</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in ASP Isotopes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Unusual Machines</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Qxpress*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Masterclass*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Kraken*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Epic Games*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Tesspay**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in SpaceX*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,674</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Databricks*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Discord*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Investment in Thrasio*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Automation Anywhere*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Investment in Anduril*</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,922</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">24,150</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,103</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments made in these companies are through both an SPV and direct investments.</span></td> </tr></table> 2140000 4940000 4940000 1500000 1972000 2794000 2794000 1300000 1075000 1033000 1000000 1000000 1000000 1000000 170000 170000 170000 597000 597000 597000 3500000 3500000 3500000 1240000 2679000 2500000 3500000 4867000 3674000 1200000 842000 1200000 476000 476000 476000 300000 300000 300000 476000 476000 476000 476000 476000 476000 20922000 24150000 23103000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Beginning balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Purchase of investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receiving shares in exchange of note receivable extension</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of long-term investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">793</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,150</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 23103000 75000 179000 793000 24150000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. Notes Receivable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s notes receivable as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Notes receivable, at fair value</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 9pt">Convergent convertible note - current</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">12/2/2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">   8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,064</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Raefan Industries LLC Investment</td><td> </td> <td style="text-align: center">12/31/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">751</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,114</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">American Innovative Robotics Investment</td><td> </td> <td style="text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - current portion</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,177</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Notes receivable, at fair value - non-current portion</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,129</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stated <br/> Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal<br/> Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest<br/> Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Short-term convertible notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Convergent Investment</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">01/29/2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">  8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">307</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,307</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Short-term notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Raefan Industries LLC Investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">6/30/2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4,730</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Total</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Long-term notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">American Innovative Robotics Investment</td><td> </td> <td style="text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convergent Therapeutics, Inc. Investment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal balance of the Convergent Convertible Note was approximately $1.0 and $2.0 million as of December 31, 2023 and 2022, respectively. The Company recorded an interest income receivable of approximately $13,000 and $0.2 million on the Convergent Convertible Note as of December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded principal repayment of $1.0 million and $0, interest receivable repayment of approximately $0.3 million and $0, and an unrealized gain on the note of approximately $6,000 and $0 on the Convergent Convertible Note for the years ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raefan Industries LLC Investment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 6, 2021, the Company purchased an 8% promissory note (“Raefan Industries Promissory Note”) issued by Raefan Industries, LLC (“Raefan Industries”) in the principal amount of approximately $2.0 million pursuant to a Note Purchase Agreement with Raefan Industries.  On December 6, 2022, the Company, Raefan Industries and Mr. Jeffrey Cooper entered into a Consolidated, Amended and Restated Promissory Note agreement (the “Raefan Amended Note Agreement”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 20, 2023, in consideration for extending the maturity date of the Raefan Amended Note (See Note 8 – <i>Notes Receivable</i>) to December 31, 2024, Raefan Industries agreed and had delivered to the Company 357,143 shares of TessPay at $0.5 per share of common stock. The Company reduced approximately $0.1 million of principal and interest receivable balance of Raefan Amended Note and recorded an income of approximately $35,000 for receiving TessPay shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded an interest income receivable of approximately $0.4 million and $26,000 on the Amended Note as of December 31, 2023 and 2022 and an unrealized loss on the note of approximately $3.3 million and $0 for the years ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>American Innovative Robotics, LLC Investment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded interest income of approximately $89,000 and $67,000, and an unrealized gain on the note of approximately $6,000 and $0 on the Robotics Promissory Note for the year ended December 31, 2023 and 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kaya Now Inc. Investment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the year ended December 31, 2023.</span></p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s notes receivable as of December 31, 2023 and 2022 ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Notes receivable, at fair value</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 9pt">Convergent convertible note - current</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">12/2/2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">   8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,064</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Raefan Industries LLC Investment</td><td> </td> <td style="text-align: center">12/31/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">751</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,114</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">American Innovative Robotics Investment</td><td> </td> <td style="text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Notes receivable, at fair value - current portion</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,177</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Notes receivable, at fair value - non-current portion</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,129</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stated <br/> Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal<br/> Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest<br/> Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Short-term convertible notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Convergent Investment</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">01/29/2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">  8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">307</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,307</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Short-term notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Raefan Industries LLC Investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">6/30/2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4,730</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Total</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Long-term notes receivable</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">American Innovative Robotics Investment</td><td> </td> <td style="text-align: center">04/01/2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2024-12-02 0.08 1006000 58000 1064000 2024-12-31 0.08 1363000 751000 2114000 2027-04-01 0.08 1106000 22000 1129000 3177000 1129000 2023-01-29 0.08 2000000 307000 2307000 2023-06-30 0.08 4730000 437000 5167000 7474000 2027-04-01 0.08 1100000 1100000 0.08 1800000 2023-01-29 250000 1000000 2000000 13000 200000 1000000 0 300000 0 6000000000 0 0.08 2000000 357143 0.5 100000 35000 400000 26000 3300000 0 89000 67000 6000 0 500000 0 0 10000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. Fair Value of Financial Assets and Liabilities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured as of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-align: left">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,547</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,547</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,177</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured as of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at <br/> December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/> prices in <br/> active<br/> markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other<br/> observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant <br/> unobservable<br/> inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level 3 Measurement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Short-term investment at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in fair value of investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Short-term investment at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in fair value of investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Short-term investment at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Notes receivable at fair value, current portion at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,984</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Accrued interest receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Reclassify from convertible note receivable to notes receivable at fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,147</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Purchase of notes receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Change in fair value of short-term investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,858</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Conversion of note receivable to marketable securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(899</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, current portion at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Collection of principal outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,254</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Principle reduced due to receiving shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(143</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, current portion at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,177</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, non-current portion at December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Purchase of notes receivable</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,100</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, non-current portion at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized gain on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, non-current portion at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,129</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note Receivable at fair value </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b>  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors.</span></p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured as of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-align: left">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,547</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,547</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,177</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,129</td><td style="text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured as of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at <br/> December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/> prices in <br/> active<br/> markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other<br/> observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant <br/> unobservable<br/> inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Marketable securities:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Equities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,130</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">     -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Total marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Short-term investment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Notes receivable at fair value, current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Notes receivable at fair value, non-current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13547000 13547000 13547000 13547000 3177000 3177000 1129000 1129000 7130000 7130000 7130000 7130000 13000 13000 7474000 7474000 1100000 1100000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Short-term investment at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in fair value of investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Short-term investment at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in fair value of investment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Short-term investment at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Notes receivable at fair value, current portion at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,984</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Accrued interest receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Reclassify from convertible note receivable to notes receivable at fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,147</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Purchase of notes receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Change in fair value of short-term investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,858</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Conversion of note receivable to marketable securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(899</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, current portion at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,474</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Collection of principal outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,254</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Principle reduced due to receiving shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(143</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, current portion at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,177</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, non-current portion at December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Purchase of notes receivable</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,100</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes receivable at fair value, non-current portion at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Unrealized gain on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued interest receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Notes receivable at fair value, non-current portion at December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,129</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 419000 -406000 13000 -13000 6984000 600000 2147000 500000 -1858000 -899000 7474000 -1000000 -3254000 -143000 100000 3177000 1100000 1100000 6000 23000 1129000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. Property and Equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net, consists of the following as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated<br/> Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 50%; text-align: left">Leasehold improvements</td><td style="width: 1%"> </td> <td style="width: 25%; text-align: center">Shorter of the remaining lease term or estimated useful life</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">    50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">    -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Machinery, equipment and computer software</td><td> </td> <td style="text-align: center"> 1 to 15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> 3 to 5 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Total</td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(83</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $83,000 and <span style="-sec-ix-hidden: hidden-fact-206">$0</span> during the years ended December 31, 2023 and 2022, respectively.</span></p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net, consists of the following as of December 31, 2023 and 2022:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated<br/> Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 50%; text-align: left">Leasehold improvements</td><td style="width: 1%"> </td> <td style="width: 25%; text-align: center">Shorter of the remaining lease term or estimated useful life</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">    50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">    -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Machinery, equipment and computer software</td><td> </td> <td style="text-align: center"> 1 to 15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> 3 to 5 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Total</td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(83</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Shorter of the remaining lease term or estimated useful life 50000 P1Y P15Y 169000 P3Y P5Y 208000 427000 83000 344000 83000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22<sup>nd </sup>Floor Premises”). The Company currently uses the 22<sup>nd</sup> Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date”). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22<sup>nd</sup> Floor Premises on the Commencement Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on February 1, 2023. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tables below represent the Company’s lease assets and liabilities as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use-assets</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,335</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">   919</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,028</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,449</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">762</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company recorded approximately $0.8 million and 0.1 million of lease expense to current period operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">668</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">    73</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">773</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">140</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Year Ended<br/> December 31,<br/> 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows - operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">  231</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">960</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Year Ended December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">747</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,279</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,449</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P7Y 12874 13502 P7Y 49368 51868 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tables below represent the Company’s lease assets and liabilities as of December 31, 2023 and 2022:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use-assets</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,335</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">   919</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,028</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,449</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">762</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 3335000 919000 421000 82000 3028000 680000 3449000 762000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table> P6Y6M P7Y1M6D 0.10 0.10 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company recorded approximately $0.8 million and 0.1 million of lease expense to current period operations.</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">668</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">    73</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">773</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">140</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 800000 100000 668000 73000 668000 73000 105000 67000 773000 140000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases were as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Year Ended<br/> December 31,<br/> 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows - operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">  231</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">960</td><td style="text-align: left"> </td></tr> </table> 396000 231000 2780000 960000 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">$</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Year Ended December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">747</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,279</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,449</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P5Y 747000 685000 685000 685000 766000 1160000 4728000 1279000 3449000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12. Net Loss per Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2023, and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,168</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,722</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,001,307</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">499,552</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2023, and 2022 are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444,796</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,168</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,722</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,001,307</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">499,552</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 34 34 444796 444796 136309 420168 54722 1001307 499552 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13. Redeemable Convertible Preferred Stock </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series O and Series P Redeemable Convertible Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Offerings”), (i) 11,000 shares of the Company’s Series O Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series O Preferred Stock”), and (ii) 11,000 shares of the Company’s Series P Redeemable Convertible Preferred Stock, par value $0.001 per share (the “Series P Preferred Stock” and together with the Series O Preferred Stock, the “Preferred Stock”), in each case, at an offering price of $952.38 per share, representing a 5% original issue discount to the stated value of $1,000 per share of Preferred Stock, for gross proceeds of each Offering of $10,476,180, or approximately $21.0 million in the aggregate for the Offerings, before the deduction of the placement agent’s fee and offering expenses. The shares of Series O Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The shares of Series P Preferred Stock will have a stated value of $1,000 per share and will be convertible, at a conversion price of $1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The Series O Preferred Stock and the Series P Preferred Stock are being offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-238172) (the “Registration Statement”) filed under the Securities Act of 1933, as amended (the “Securities Act”). The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The closing of the Offerings occurred on March 2, 2022. In connection with this transaction, the Company received net proceeds of $21.0 million, which was deposited in an escrow account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Offerings, the Company has entered into an engagement agreement (the “Engagement Agreement Agreement”) with H.C Wainwright &amp; Company, LLC, as placement agent (“HCW”), pursuant to which the Company agreed to pay HCW an aggregate cash fee equal to 8% of the aggregate gross proceeds raised in the offerings and issue HCW common stock purchase warrants to purchase up to 103,528 shares of common stock in the aggregate at an exercise price of $21.25. The warrants were recorded as a component of stockholders’ equity in accordance with ASC 815.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After (i) the earlier of (1) the receipt of stockholder approval and (2) the date that is 90 days following the Original Issue Date (the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock) and (ii) before the date that is 120 days after the Original Issue Date (the “<span style="text-decoration:underline">Redemption Period</span>”), each Holder shall have the right to cause the Company to redeem all or part of such Holder’s shares of Preferred Stock at a price per share equal to 105% of the Stated Value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, the Preferred Stock were recorded separately from stockholders’ equity because they are redeemable upon the occurrence of redemption events that are considered not solely within the Company’s control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2022, the Company redeemed for cash at a price equal to 105% of the $1,000 stated value per share all of its 11,000 outstanding shares of Series O Preferred Stock and its 11,000 Series P Preferred Stock. The total redemption amount was $23.1 million. As a result, all shares of the Series O Preferred Stock and Series P Preferred Stock have been retired and are no longer outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023 and 2022, the Company recognized approximately $0 and $4.1 million in deemed dividends related to the Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable preferred stock and stockholders’ equity, respectively.</span></p> 11000 0.001 11000 0.001 952.38 0.05 1000 10476180 21000000 1000 1 11000000 1000 1 11000000 21000000 0.08 103528 21.25 1.05 1.05 1000 11000 11000 23100000 0 4100000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14. Stockholders’ Equity and Convertible Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by an executive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Treasury Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the year ended December 31, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. During the year ended December 31, 2022, the Company repurchased 468,017 shares at a cost of approximately $3.1 million or $6.53 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D-1 Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity for years ended December 31, 2023 and 2022 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">341,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">   -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.87</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,528</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">21.25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">4.15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">444,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">29.25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">3.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">444,796</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">29.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.20</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Confirmation of Mutual Understanding</span> - In March 2022, pursuant to a Confirmation of Mutual Understanding (the “Confirmation”), all parties to the Confirmation acknowledged and confirmed a scrivener’s error set forth in warrants to purchase shares of the Company’s common stock (the “Warrants”) dated March 10, 2020, April 15, 2020 and March 2, 2021. Pursuant to the Confirmation, all parties, which were involved in the original execution of the warrants, agreed that clause (v) of the definition of Fundamental Transaction in Section 3(d) of the Warrants, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">“<i>the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the Company’s outstanding equity securities, including with respect to the election of directors (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)</i>”. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Awards</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 19, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,287,129 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $2.6 million. Pursuant to the Grant Agreement, the Company withheld 657,079 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 19, 2023, pursuant to the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Joshua Shipley was granted 33,003 shares of the Company’s common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately $67,000. Pursuant to the Grant Agreement, the Company withheld 13,300 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $27,000 and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the Company also issued an aggregate of 136,309 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company issued an aggregate of 238,244 shares of the Company’s common stock to members of the Company’s Board of Directors and an employee for services rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of restricted stock awards activity for the years ended December 31, 2023 and 2022, is presented below: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding: 0in; text-indent: 0in"> </td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td> <td colspan="2" style="padding: 0in; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0in">Number of<br/> Restricted<br/> Stock Awards</td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td> <td colspan="2" style="padding: 0in; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0in">Weighted<br/> Average<br/> Grant Day<br/> Fair Value</td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2021</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in 0in 0in 0.125in; width: 76%; text-indent: 0in">Granted</td><td style="padding: 0in; width: 1%; text-indent: 0in"> </td> <td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 9%; text-align: right; text-indent: 0in">238,244</td><td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 1%; text-indent: 0in"> </td> <td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 9%; text-align: right; text-indent: 0in">6.13</td><td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Vested</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">(230,176</td><td style="padding: 0in; text-align: left; text-indent: 0in">)</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">6.14</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2022</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in">8,068</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in">5.90</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Granted</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in">1,315,777</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in">2.27</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Vested</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">(1,187,536</td><td style="padding: 0in; text-align: left; text-indent: 0in">)</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">2.30</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2023</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 4pt double; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 4pt double; text-align: right; text-indent: 0in">136,309</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 4pt double; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; border-bottom: Black 4pt double; text-align: right; text-indent: 0in">2.26</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $2.7 million and $1.4 million for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of option activity under the Company’s stock option plan for year ended December 31, 2023 and 2022 is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,203</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">548.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">      -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(167,381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">73.70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">302.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,882</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(857</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">9,719.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">420,168</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.80</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,929</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation associated with the amortization of stock option expense was approximately $0.2 million and $13,000 for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.5 million.</p> 644499 644499 25000 3000000 236630 900000 3.97 468017 3100000 6.53 644499 3800000 1379685 0.0001 convertible into 10 over 1,373 of a share of Common Stock. 5000000 5000000 3825 3825 3825 3825 0.0001 convertible into 10 over 1,373 of a share of Common Stock. 5000000 5000000 834 834 834 834 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity for years ended December 31, 2023 and 2022 is presented below:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">341,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">   -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.87</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,528</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">21.25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">4.15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">444,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">29.25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">3.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">444,796</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">29.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.20</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 341268 31.68 P3Y10M13D 103528 21.25 P4Y1M24D 444796 29.25 P3Y2M12D 444796 29.25 P2Y2M12D 0.50 1033591 2700000 503876 1300000 1287129 2600000 657079 1300000 33003 67000 13300 27000 136309 238244 A summary of restricted stock awards activity for the years ended December 31, 2023 and 2022, is presented below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding: 0in; text-indent: 0in"> </td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td> <td colspan="2" style="padding: 0in; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0in">Number of<br/> Restricted<br/> Stock Awards</td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td> <td colspan="2" style="padding: 0in; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0in">Weighted<br/> Average<br/> Grant Day<br/> Fair Value</td><td style="padding: 0in; font-weight: bold; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2021</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in 0in 0in 0.125in; width: 76%; text-indent: 0in">Granted</td><td style="padding: 0in; width: 1%; text-indent: 0in"> </td> <td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 9%; text-align: right; text-indent: 0in">238,244</td><td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 1%; text-indent: 0in"> </td> <td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; width: 9%; text-align: right; text-indent: 0in">6.13</td><td style="padding: 0in; width: 1%; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Vested</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">(230,176</td><td style="padding: 0in; text-align: left; text-indent: 0in">)</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">6.14</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2022</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in">8,068</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in">5.90</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Granted</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-align: right; text-indent: 0in">1,315,777</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; text-align: right; text-indent: 0in">2.27</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0in 0in 0in 0.125in; text-indent: 0in">Vested</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">(1,187,536</td><td style="padding: 0in; text-align: left; text-indent: 0in">)</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0in">2.30</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0in; text-indent: 0in">Nonvested at December 31, 2023</td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 4pt double; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; border-bottom: Black 4pt double; text-align: right; text-indent: 0in">136,309</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td><td style="padding: 0in; text-indent: 0in"> </td> <td style="padding: 0in; border-bottom: Black 4pt double; text-align: left; text-indent: 0in">$</td><td style="padding: 0in; border-bottom: Black 4pt double; text-align: right; text-indent: 0in">2.26</td><td style="padding: 0in; text-align: left; text-indent: 0in"> </td></tr> </table> 238244 6.13 230176 6.14 8068 5.9 1315777 2.27 1187536 2.3 136309 2.26 2700000 1400000 200000 A summary of option activity under the Company’s stock option plan for year ended December 31, 2023 and 2022 is presented below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,203</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">548.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">      -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(167,381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">73.70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">302.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Employee options forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,882</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Employee options expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(857</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">9,719.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Outstanding as of December 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">420,168</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.80</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,929</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left"> </td></tr> </table> 28203 548.35 P8Y2M12D 170587 5.95 P0Y3M18D 167381 41.9 216 73.7 31193 302.97 P7Y10M24D 395714 3.42 P9Y4M24D 5882 5.95 857 9719.07 420168 5.8 P9Y3M18D 84929 15.16 P8Y9M18D 200000 13000 500000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 15. Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underwriting</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">   -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advisory fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">140</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,039</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underwriting</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">   -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advisory fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">140</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,039</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 594000 1096000 209000 140000 2039000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Proceedings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than as described above and ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consists of the following ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended<br/> December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,820</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,618</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation allowance</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,820</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,618</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and local</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td> <td> </td> <td> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231"> </div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232"> </div></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,012</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,825</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,825</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Provision (Benefit)</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended<br/> December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Statutory Federal Rate</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Taxes, Net of Federal Tax Benefit</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.36</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.58</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Permanent Differences</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.54</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.11</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State rate change in effect</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.18</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.95</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMT credit benefit</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-235; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-236; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease due to true up of State NOL</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.11</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.69</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease due to change in Federal NOL and other true ups</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.67</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Valuation Allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29.85</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38.15</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Benefit</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023 and 2022, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net-operating loss carryforward</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,124</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,241</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,754</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,358</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents &amp; Licenses</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,061</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,898</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction Costs</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research &amp; Development</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,937</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,207</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liability</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,202</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment portfolio and other</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,879</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,445</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred Tax assets</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,166</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,443</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(55,946</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,115</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Tax Asset, Net of Allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,220</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">328</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liability:</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,163</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(328</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December 31, 2023 and 2022. As of December 31, 2023, the change in valuation allowance is approximately $6.8 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company has approximately $40.7 million federal net operating loss carryovers (“NOLs”), which expire from 2033 through 2037, and $68.5 million of federal NOLs which will never expire. The Company has approximately $152.3 million of state and city NOLs, which expire from 2035 through 2043. As of December 31, 2023, the Company also had federal research and development tax credit carryforwards of $0.2 million which may be available to offset future income tax liabilities and begin to expire in 2042.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the U.S. NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. If the Company experiences an ownership change, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. The Company determined an ownership change occurred on September 10, 2013, and any NOLs generated prior to this date are therefore limited by Section 382. Any carryforwards that will expire prior to utilization due to this limitation were removed from deferred tax assets, with a corresponding reduction of the valuation allowance. The Company has not yet determined if any additional ownership changes occurred after September 10, 2013. Any past or future ownership changes may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023 and 2022, no liability for unrecognized tax benefit was required to be reported. The Company’s policy is to record interest and penalties related to income taxes outside of its income tax provision and classify as interest and penalties in general and administrative expense in the statement of operations. As of December 31, 2023 or 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s statement of operations. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files U.S. federal and state income tax returns (New York, New York City, Virginia, and Texas). As of December 31, 2023, the statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for all years since 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. There are no audits pending in any of the above-mentioned jurisdictions during 2023 and 2022. The Company believes that its income tax positions would be sustained upon an audit and does not anticipate any adjustments that would result in material changes to its consolidated financial position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December, 2023, the FASB issued 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09) which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Public business entities must apply the ASU’s guidance to annual periods beginning after December 15, 2024. The Company may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted. The Company has chosen not to early adopt this standard.</p> The income tax provision consists of the following ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended<br/> December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,820</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,618</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation allowance</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,820</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,618</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and local</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td> <td> </td> <td> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231"> </div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232"> </div></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,012</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,825</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in valuation allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,012</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,825</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Provision (Benefit)</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> </table> 3820000 3618000 3820000 3618000 3012000 4825000 3012000 4825000 The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended<br/> December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Statutory Federal Rate</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Taxes, Net of Federal Tax Benefit</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.36</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.58</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Permanent Differences</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.54</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.11</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State rate change in effect</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.18</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.95</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMT credit benefit</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-235; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-236; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease due to true up of State NOL</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.11</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.69</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease due to change in Federal NOL and other true ups</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.67</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Valuation Allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29.85</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38.15</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Benefit</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.21 0.21 0.1536 0.1358 -0.0054 -0.0011 -0.0418 0.0295 -0.0011 0.0069 -0.0167 0.0004 -0.2985 -0.3815 0 0 As of December 31, 2023 and 2022, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net-operating loss carryforward</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,124</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,241</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,754</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,358</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents &amp; Licenses</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,061</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,898</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction Costs</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research &amp; Development</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,937</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,207</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liability</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,202</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment portfolio and other</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,879</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,445</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred Tax assets</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,166</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,443</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(55,946</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,115</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Tax Asset, Net of Allowance</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,220</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">328</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liability:</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,163</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(328</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 33124000 26241000 9754000 8358000 8061000 9898000 209000 23000 1937000 2207000 1202000 272000 2879000 2445000 57166000 49443000 55946000 49115000 1220000 328000 57000 1163000 328000 6800000 40700000 68500000 152300000 200000 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 18. Regulatory</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of December 31, 2023, Dominari Securities had net capital of approximately $4.9 million, which was approximately $4.7 million in excess of required minimum net capital of $0.2 million.</p> 4900000 4700000 200000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 19. Related Party Transaction</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $75,000 and $1.0 million during the years ending December 31, 2023, and 2022, respectively. These fees were included in general and administrative expenses in the consolidated statements of operations.</p> 75000 1000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 20. Segment Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “<i>Summary of Significant Accounting Policies.</i>” While assets are primarily held within the Legacy AIkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Legacy<br/> AIkido<br/> Pharma</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,039</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,039</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,839</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(13,711</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(8,085</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(21,797</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,248</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,248</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,315</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,086</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(13,482</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(9,400</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(22,882</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Legacy<br/> AIkido<br/> Pharma</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenue</td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: 0in; padding-left: 0in">General and administrative</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">157</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,526</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,683</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Loss from operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(157</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(14,189</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(14,346</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0in; padding-left: 0in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,952</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,952</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Change in fair value of investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Total other (expenses) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Net loss</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(157</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(21,950</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(22,107</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 2 The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Legacy<br/> AIkido<br/> Pharma</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,039</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,039</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,839</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(13,711</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(8,085</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(21,797</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,248</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,248</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total other (expenses) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,315</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,086</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(13,482</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(9,400</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(22,882</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Legacy<br/> AIkido<br/> Pharma</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenue</td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: 0in; padding-left: 0in">General and administrative</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">157</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,526</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,683</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Loss from operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(157</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(14,189</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(14,346</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0in; padding-left: 0in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,952</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,952</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0in">Unrealized loss on note receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Change in fair value of investments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Total other (expenses) income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Net loss</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(157</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(21,950</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(22,107</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 2039000 2039000 15750000 8088000 23839000 3000 3000 -13711000 -8085000 -21797000 36000 36000 229000 487000 716000 630000 630000 -3248000 -3248000 -780000 -780000 229000 -1315000 -1086000 -13482000 -9400000 -22882000 157000 11526000 11683000 -2663000 -2663000 -157000 -14189000 -14346000 64000 64000 687000 687000 -5952000 -5952000 2560000 2560000 -7761000 -7761000 -157000 -21950000 -22107000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 21. Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Litigation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024 the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities LLC. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. At this time the Company has no reasonable basis to assess or record any potential income statement impact related to this petition. See Note 16 Commitment and Contingencies for further information.</p> false false false false -3.95 -4.91 5229477 5334075 false FY 0000012239 Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. Investments made in these companies are through both an SPV and direct investments.
  •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